Cornea

PRACTICING OPHTHALMOLOGISTS
CURRICULUM 2014-2016
Cornea/
External
Disease
***
Practicing Ophthalmologists Curriculum

Disclaimer and Limitation of Liability
As a service to its members and American Board of Ophthalmology (ABO) diplomates, the American
Academy of Ophthalmology has developed the Practicing Ophthalmologists Curriculum (POC) as a tool
for members to prepare for the Maintenance of Certification (MOC) -related examinations. The
Academy provides this material for educational purposes only.
The POC should not be deemed inclusive of all proper methods of care or exclusive of other methods of
care reasonably directed at obtaining the best results. The physician must make the ultimate judgment
about the propriety of the care of a particular patient in light of all the circumstances presented by that
patient. The Academy specifically disclaims any and all liability for injury or other damages of any
kind, from negligence or otherwise, for any and all claims that may arise out of the use of any
information contained herein.
References to certain drugs, instruments, and other products in the POC are made for illustrative
purposes only and are not intended to constitute an endorsement of such. Such material may include
information on applications that are not considered community standard, that reflect indications not
included in approved FDA labeling, or that are approved for use only in restricted research settings. The
FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or
device he or she wishes to use, and to use them with appropriate patient consent in compliance with
applicable law.
The Practicing Ophthalmologists Curriculum is intended to be the basis for MOC examinations in 2014,
2015 and 2016. However, the Academy specifically disclaims any and all liability for any damages of any
kind, for any and all claims that may arise out of the use of any information contained herein for the
purposes of preparing for the examinations for MOC.
THE AMERICAN ACADEMY OF OPHTHALMOLOGY DOES NOT WARRANT OR GUARANTEE THAT USE OF
THESE MATERIALS WILL LEAD TO ANY PARTICULAR RESULT FOR INDIVIDUALS TAKING THE MOC
EXAMINATIONS. THE AMERICAN ACADEMY OF OPHTHALMOLOGY DISCLAIMS ALL DAMAGES, DIRECT,
INDIRECT OR CONSEQUENTIAL RELATED TO THE POC.
Any questions or concerns related to the relevance and validity of questions on the MOC
examinations should be directed to the American Board of Ophthalmology.
COPYRIGHT 2014
AMERICAN ACADEMY OF OPHTHALMOLOGY
ALL RIGHTS RESERVED
ii
Practicing Ophthalmologists Curriculum

Authors and Financial Disclosures
The Practicing Ophthalmologists Curriculum was developed by a group of dedicated ophthalmologists
reflecting a diversity of background, training, practice type and geographic distribution.
Jeffrey A. Nerad, M.D., American Academy of Ophthalmology Secretary for Knowledge Base
Development, serves as the overall project director for the acquisition and review of the topic outlines.
The Academy gratefully acknowledges the contributions of the Cornea Society.
Practicing Ophthalmologists Curriculum Panel
Michael H. Goldstein, M.D., Chair
Anthony J. Aldave, M.D., Vice Chair
Deepinder K Dhaliwal M.D.
Nicoletta A. Fynn-Thompson, M.D.
Carol L. Karp, M.D.
Stella K Kim M.D.
Jeanine Suchecki, M.D.
Sonal S Tuli M.D.
Financial Disclosures
The Academys Board of Trustees has determined that a financial relationship should not restrict expert
scientific clinical or non-clinical presentation or publication, provided appropriate disclosure of such
relationship is made. All contributors to Academy educational activities must disclose significant
financial relationships (defined below) to the Academy annually.
Contributors who have disclosed financial relationships:
Anthony J. Aldave, M.D.
Consultant/Advisor: Allergan, Bausch Lomb
Lecture Fees: Alcon Laboratories, Inc., Allergan
Grant Support: National Eye Institute
Deepinder K Dhaliwal M.D.
Consultant/Advisor: Abbott Medical Optics, Avedro
Nicoletta A. Fynn-Thompson, M.D.
Employee: Ophthalmic Consultants-Boston
Equity Owner: Boston Eye Surgery & Laser Center
Michael H. Goldstein, M.D.
Consultant/Advisor: Eleven Biotherapeutics
Equity Owner: Eleven Biotherapeutics, Hemera Biosciences
Stella K Kim M.D.
Consultant/Advisor: Eli Lilly & Company, Seattle Genetics
Contributors who state they have no significant financial relationships to disclose:
Carol L. Karp, M.D.
Jeffrey A. Nerad, M.D.
Jeanine Suchecki, M.D.
Sonal S Tuli M.D.
iii
Background on Maintenance of Certification (MOC)

Developed according to standards established by the American Board of Medical Specialties (ABMS), the
umbrella organization of 24 medical specialty boards, Maintenance of Certification (MOC) is designed as
a series of requirements for practicing ophthalmologists to complete over a 10-year period. MOC is
currently open to all Board Certified ophthalmologists on a voluntary basis; time-limited certificate
holders (ophthalmologists who were Board Certified after July 1, 1992) are required to participate in this
process. All medical specialties participate in a similar process.
The roles of the American Board of Ophthalmology (ABO) and the American Academy of Ophthalmology
relative to MOC follow their respective missions.
The mission of the American Board of Ophthalmology is to serve the public by improving the quality of
ophthalmic practice through a process of certification and maintenance of certification that fosters
excellence and encourages continual learning.
The mission of the American Academy of Ophthalmology is to advance the lifelong learning and
professional interests of ophthalmologists to ensure that the public can obtain the best possible eye care.
The role of the ABO in the MOC process is to evaluate and to certify. The role of the Academy in this
process is to provide resources and to educate.
Background on the Practicing Ophthalmologists Curriculum (POC)
At the request of the ABO, the Academy developed the Practicing Ophthalmologists Curriculum (POC), a
knowledge base that identifies and defines areas of knowledge important to the delivery of quality eye
care as a basis for the content of examinations for the MOC process. The content in the POC is
comprised of the information deemed as the most relevant clinical information for a practicing
ophthalmologist.
The ABO has agreed that their Periodic Ophthalmic Review Test (PORT) and closed-book Demonstration
of Ophthalmic Cognitive Knowledge (DOCK) examinations will be based on the POC. The ABO is solely
responsible for creating the PORT and DOCK exams and for certifying MOC candidates. The Academy has
developed study tools based on the POC to assist doctors preparing to meet these MOC requirements.
Organization of the POC
The Practicing Ophthalmologists Curriculum comprises 10 practice emphasis areas (PEA), plus Core
Ophthalmic Knowledge. The ABO has designated the following as practice emphasis areas:
Comprehensive Ophthalmology
Cataract/Anterior Segment
Cornea/External Disease
Glaucoma
Neuro-Ophthalmology and Orbit
Oculoplastics and Orbit
Pediatric Ophthalmology/Strabismus
Refractive Management/Intervention
Retina/Vitreous
Uveitis
iv
In addition to two practice emphasis areas of choice, every diplomate sitting for the DOCK examination
will be tested on Core Ophthalmic Knowledge. Core Ophthalmic Knowledge is defined as the
fundamental knowledge every practicing ophthalmologist must have whatever their area of practice.
Each PEA is categorized into topics presented in an outline format for easier reading and understanding
of the relevant information points by the reader. These outlines are based on a standard clinical
diagnosis and treatment approach found in the Academys Preferred Practice Patterns.
For each topic, there are Additional Resources that may contain journal citations and reference to
textbooks. These resources are supplemental to the topic outline, and should not be necessary for MOC
exam preparation purposes.
Creation of the POC
The POC was developed by panels of practicing ophthalmologists in each of the ten practice emphasis
areas. The panels reflect a diversity of background, training, practice type and geographic distribution,
with more than 90 percent of the panel members being time-limited certificate holders.
The panels ranked clinical topics (diseases and procedures) in terms of clinical relevance to the
subspecialist or comprehensive ophthalmologist. The panelists created outlines for the topics deemed
Most Relevant, based on what an ophthalmologist in a specific practice emphasis area needs to know to
provide competent, quality eye care (i.e., directly related to patient care). These outlines were reviewed
by subspecialty societies and the American Board of Ophthalmology.
Revision Process
The POC is intended to be revised every three years. The POC panels will consider new evidence in the
peer-reviewed literature, as well as input from the subspecialty societies, the American Board of
Ophthalmology and the Academys Self-Assessment Committee, in revising and updating the POC.
Prior to a scheduled review the POC may be changed only under the following circumstances:
A Level I (highest level of scientific evidence) randomized controlled trial indicates a major
new therapeutic strategy
The FDA issues a drug/device warning
Industry issues a warning
***
vi
Anatomy
1. Anatomy and embryology of the cornea ....................................................................................... 1
Diagnostic Tests
2. Slit-lamp biomicroscopy: performance and record-keeping ......................................................... 3
3. Tear film evaluation: static and dynamic assessments; tear break-up time, Schirmer ................. 6
4. Detection of altered structure and differentiation of signs of inflammation affecting the eyelid margin,
conjunctiva, cornea, sclera, and iris ................................................................................................... 10
5. Diagnostic techniques for infectious diseases of the cornea and conjunctiva, including specimen
collection methods for microbiologic testing and diagnostic assessment of the normal ocular flora
........................................................................................................................................................... 12
6. Diagnostic techniques for neoplasia of the cornea, conjunctiva, and eyelid margin, including specimen
collection methods for histopathological testing .............................................................................. 16
7. Corneal pachymetry ....................................................................................................................... 19
8. Corneal esthesiometry ................................................................................................................... 21
9. Ultrasound biomicroscopy for the anterior segment .................................................................... 23
10. Anterior segment ocular coherence tomography (AS-OCT) ........................................................ 26
11. Confocal and specular microscopic imaging ................................................................................ 31
12. Corneal Topography/Placido disc imaging................................................................................... 36
13. Non-Placido disc imaging (retinoscopy, keratometry, keratoscopy) ........................................... 38
14. Scanning-slit topography, 3-D imaging, wavefront analysis, and anterior segment optical coherence
tomography, corneal aberrometry .................................................................................................... 41
15. Universal precautions for minimizing transmission of infectious agents .................................... 46
Ocular Surface Disorders

16. Conjunctivochalasis...................................................................................................................... 48
17. Aqueous tear deficiency, Sjgren syndrome and Mucin deficiency ............................................ 52
18. Filamentary keratopathy.............................................................................................................. 58
vii
19. Meibomian gland dysfunction, rosacea, and seborrheic blepharitis........................................... 62

20. Benign conjunctival masses ......................................................................................................... 67
21. Hordeolum and chalazion ............................................................................................................ 73
22. Exposure keratopathy .................................................................................................................. 76
23. Floppy eyelid syndrome ............................................................................................................... 79
24. Recurrent erosion ........................................................................................................................ 82
25. Persistent corneal epithelial defect ............................................................................................. 86
26. Neurotrophic keratopathy ........................................................................................................... 91
27. Trichiasis and distichiasis ............................................................................................................. 95
28. Ocular surface problems related to contact lens......................................................................... 98
29. Limbal stem-cell deficiency .......................................................................................................... 102
Infectious Diseases
30. Acute conjunctivitis ...................................................................................................................... 107
31. Chronic conjunctivitis ................................................................................................................... 110
32. Herpes simplex virus blepharitis, conjunctivitis, and blepharoconjunctivitis.............................. 116
33. Herpes simplex virus epithelial keratitis ...................................................................................... 120
34. Herpes simplex virus stromal keratitis and endotheliitis............................................................. 125
35. Varicella zoster virus dermatoblepharitis and conjunctivitis....................................................... 130
36. Varicella zoster virus epithelial keratitis ...................................................................................... 135
37. Varicella zoster virus stromal keratitis ......................................................................................... 139
38. Adenovirus conjunctivitis and keratoconjunctivitis ..................................................................... 142
39. Staphylococcal blepharitis ........................................................................................................... 146
40. Chronic blepharitis ....................................................................................................................... 149
41. Bacterial conjunctivitis in children and adults ............................................................................. 153
42. Bacterial conjunctivitis of neonates ............................................................................................. 157
viii
43. Adult chlamydial keratoconjunctivitis.......................................................................................... 161

44. Bacterial keratitis ......................................................................................................................... 164
45. Fungal keratitis ............................................................................................................................. 173
46. Acanthamoeba keratitis ............................................................................................................... 178
47. Microbial scleritis and sclerokeratitis .......................................................................................... 183
Immune-Mediated Disorders
48. Conjunctival inflammation with scarring ..................................................................................... 187
49. Allergic conjunctivitis ................................................................................................................... 190
50. Vernal keratoconjunctivitis .......................................................................................................... 193
51. Atopic keratoconjunctivitis .......................................................................................................... 198
52. Contact lens-induced conjunctivitis ............................................................................................. 202
53. Stevens-Johnson syndrome ......................................................................................................... 205
54. Ocular mucous membrane pemphigoid ...................................................................................... 209
55. Thygeson superficial punctate keratitis ....................................................................................... 212
56. Marginal corneal infiltrates associated with blepharoconjunctivitis........................................... 215
57. Peripheral keratitis ....................................................................................................................... 218
58. Nonulcerative keratitis................................................................................................................. 221
59. Ulcerative keratitis ....................................................................................................................... 223
60. Peripheral ulcerative keratitis associated with systemic immune-mediated diseases ............... 228
61. Mooren ulcer ............................................................................................................................... 232
62. Episcleritis .................................................................................................................................... 235
63. Scleritis ......................................................................................................................................... 239
Neoplastic Disorders
64. Ocular surface squamous neoplasia: corneal intraepithelial neoplasia, conjunctival intraepithelial
neoplasia, and squamous cell carcinoma .......................................................................................... 244
65. Sebaceous gland carcinoma of the eyelid margin and conjunctiva ............................................. 248
ix
66. Primary acquired melanosis of the conjunctiva........................................................................... 250

67. Melanoma of the conjunctiva ...................................................................................................... 253
68. Conjunctival lymphoma ............................................................................................................... 257
Corneal Dystrophies
69. Corneal epithelial basement membrane dystrophy/degeneration ............................................. 260
70. Corneal dystrophy of Bowman layer 1 (CDB 1; Reis-Bcklers dystrophy) and corneal dystrophy of
Bowman layer 2 (CDB 2; Thiel-Behnke dystrophy) ............................................................................ 263
71. Meesmann corneal dystrophy ..................................................................................................... 266
72. Granular and lattice corneal dystrophies .................................................................................... 269
73. Macular corneal dystrophy .......................................................................................................... 274
74. Fuchs endothelial dystrophy ........................................................................................................ 277
75. Posterior polymorphous corneal dystrophy ................................................................................ 280
76. Keratoconus ................................................................................................................................. 283
77. Pellucid marginal corneal degeneration ...................................................................................... 286
Congenital Anomalies
78. Corneal congenital syndromes and anomalies ............................................................................ 288
Degenerative Disorders
79. Pterygium and pinguecula ........................................................................................................... 292
80. Salzmann nodular degeneration .................................................................................................. 296
81. Band keratopathy......................................................................................................................... 299
82. Pigmentation of the conjunctiva and cornea............................................................................... 303
83. Postinflammatory, post-traumatic, and postsurgical corneal opacity ........................................ 306
Toxic and Traumatic Injuries

84. Chemical (alkali and acid) injury of the conjunctiva and cornea ................................................. 309
85. Toxic medication injury of the conjunctiva .................................................................................. 314
86. Toxic medication injury of the cornea ......................................................................................... 317
87. Subconjunctival hemorrhage ....................................................................................................... 320

88. Conjunctival laceration ................................................................................................................ 323
89. Conjunctival foreign body ............................................................................................................ 326
90. Corneal foreign body ................................................................................................................... 329
91. Traumatic corneal abrasion ......................................................................................................... 332
92. Corneal and corneoscleral laceration .......................................................................................... 336
93. Corneal perforation...................................................................................................................... 339
94. Corneal edema ............................................................................................................................. 344
95. Postsurgical corneal edema ......................................................................................................... 349
96. Surgical injury of Descemet membrane and corneal endothelium ............................................. 355
Procedures for the Cornea and Ocular Surface

97. Punctal occlusion ......................................................................................................................... 359
98. Tarsorrhaphy ................................................................................................................................ 362
99. Conjunctival biopsy ...................................................................................................................... 365
100. Pterygium excision ..................................................................................................................... 367
101. Bandage contact lenses ............................................................................................................. 371
102. Application of corneal tissue adhesive ...................................................................................... 374
103. Anterior stromal puncture ......................................................................................................... 377
104. Corneal epithelial debridement ................................................................................................. 380
105. Corneal biopsy ........................................................................................................................... 383
106. Superficial keratectomy ............................................................................................................. 387
107. Amniotic membrane transplantation ........................................................................................ 390
108. Repair of corneal laceration and suture closure of corneal wound .......................................... 394
109. Management of descemetocele and corneal perforation by bandage contact lens, tissue adhesive
or reconstructive graft ....................................................................................................................... 398
110. Donor selection criteria contraindicating donor cornea use for corneal transplantation ........ 403
xi
111. Penetrating keratoplasty ........................................................................................................... 406

112. Endothelial keratoplasty ............................................................................................................ 413
113. Anterior lamellar keratoplasty ................................................................................................... 419
114. Allograft rejection ...................................................................................................................... 427
115. Conjunctival limbal autograft..................................................................................................... 431
116. Keratolimbal allograft (KLAL) - cadaveric donor, living-related conjunctival limbal allograft (lr-CLAL) living related donor ............................................................................................................................ 434
117. Keratoprosthesis ........................................................................................................................ 439
Miscellaneous
118. Clinical trials in cornea external disease .................................................................................... 447
xii
Anatomy and embryology of the cornea

I.
II.
Describe relevant aspects of corneal embryology

A.
Week 5 of gestation: surface ectoderm forms corneal and conjunctival epithelium
B.
Mesenchymal cells from the neural crest of the surface ectoderm extend under the epithelium
from the limbus to form corneal endothelium
C.
At week 6 of gestation: mesenchymal cells of neural crest origin begin forming corneal stroma
and sclera
D.
At birth, infant's globe is 80% of adult size
E.
Distensible postnatal sclera and cornea become more rigid during first 2 years of life
Describe relevant aspects of corneal anatomy

A.
11-12mm horizontally, 10-11mm vertically
B.
nutrition: glucose from aqueous humor; oxygen from tear film and limbal vessels (peripheral
cornea)
C.
very high density of nerve endings (extend from long ciliary nerves and form subepithelial
plexus)
D.
Epithelium
1.
Thickness: 50 microns
2.
Stratified squamous epithelial cells optically smooth
3.
Limbal stem cells (found in palisades of Vogt) are source of continuous proliferating basal
epithelial cells
4.
Basement membrane is secreted by basal epithelial cells
E.
Bowman layer: acellular compact layer of anterior stroma (8-12 microns thick)
F.
Stroma
G.
1.
Made up of about 200 regularly arranged flattened collagen lamellae (mainly collagen types I, V
and VI) and proteoglycans synthesized by keratocytes
2.
Keratocytes are sparsely distributed, form an interconnected network, and are generally quiescent
unless exposed to injury
3.
After injury, some keratocytes undergo apoptosis and others transform into activated keratocytes
or myofibroblasts
4.
Anterior stromal collagen lamellae are short, narrow sheets with extensive interweaving
5.
Posterior stroma has long wide, thick lamellae extending from limbus to limbus
6.
Water content 78%
Descemet membrane
AAO 2014-2016
H.
1.
Basement membrane of the corneal endothelium
2.
Increases in thickness from 3 microns at birth to 10-12 microns in adults
Endothelium
1.
Closely interdigitated cells arranged in a mosaic pattern of mostly hexagonal shapes
2.
Cell density is typically 2400-3200 cells/mm2 in adults
3.
Human endothelial cells do not proliferate in vivo
4.
Cell loss results in enlargement and spread of neighboring cells to cover the defective area
5.
Pump function is critical to keep cornea compact and transparent. Both Na+ K+ ATPase and
carbonic anhydrase are important in this process
Additional Resources
1.
AAO, Basic and Clinical Science Course. External Disease and Cornea: Section 8, 2013-2014.
AAO 2014-2016
Slit-lamp biomicroscopy: performance and

record-keeping
I.
Describe the instrumentation and technique

A.
Instrumentation
1.
Viewing arm (corneal microscope)

a.
b.
2.
3.
4.
B.
Magnification depends on eyepieces and objective lens changer settings

i.
Magnification numbers on knob apply to one set of oculars
ii.
For higher power oculars, magnification increases by proportionate amount
Eyepieces
i.
Adjust dioptric power to compensate for observer's refractive error and/or

accommodation and for any instrument misalignment
ii.
Eyepiece settings and calibration can be confirmed using focusing rod
Illuminating arm
a.
Illumination arm swings in an arc on a co-pivotal axis with the corneal microscope to allow
coaxial alignment with a parfocal and isocentric light beam
b.
Beam length generally available with pre-set increments and with continuous-length
adjustment; beam width varies from open spot to narrow slit
c.
Light filters may include grey filter, cobalt-blue filter, and red-free filter; heat absorption
screen often part of lighting system
Base
a.
Allows both corneal microscope and slit illuminator to be horizontally and vertically mobile,
controlled by joystick
b.
Arresting lock or lever for stabilization
Patient positioning frame
Illumination methods
1.
Diffuse and direct illumination

a.
b.
Diffuse illumination
i.
Gives overview of eyelids, ocular surface, and anterior segment of eye
ii.
Use full height and broad width
iii.
Light diffuser may be used for photography
Direct focal illumination and slit illumination

i.
Allows detection and localization of structures, including differences in refractive

3
AAO 2014-2016
index
c.
2.
ii.
Use medium to narrow beam width to illuminate a parallelepiped of transparent tissue

and use very narrow slit beam to illuminate an optical section
iii.
Use shortened beam to evaluate Tyndall flare effect in the anterior chamber and to
detect cells in the convection currents of the aqueous humor or in the tear film to
detect slow tear turnover or presence of inflammatory cells
Tangential illumination
i.
Shine light across anatomical surface, such as cornea or iris
ii.
Observe shadowing effects
Indirect illumination, retroillumination, and sclerotic scatter

a.
b.
Indirect, proximal illumination and lateral illumination

i.
Purposely focus or reflect the illuminator's light beam at a different, though adjacent
site as the corneal microscope
ii.
Useful to highlight abnormalities that have a refractive index similar to their

surroundings and that are difficult to discern by direct illumination
iii.
Abnormalities visualized by light scattered from its irregular surface or glowing by

internal reflection
iv.
Three-dimensionality may be enhanced by oscillatory movements of light beam
Retroillumination
i.
Direct retroillumination
i)
ii.
Indirect retroillumination
i)
iii.
3.
Used to examine illuminated abnormalities against a darkened background

(e.g., microcystic epithelial edema against dark pupil)
Fundus retroillumination
i)
c.
Used to examine darkened abnormalities against an illuminated background

(e.g., keratic precipitates against illuminated iris)
Used to examine darkened (e.g., posterior subcapsular cataract), illuminated

(e.g., keratoconus), or transilluminated (e.g., focal iris atrophy) against "red
reflex" background
Sclerotic scatter
i.
Used to detect subtle corneal abnormalities that distort the total internal reflection
property of the normal cornea
ii.
Detect scattering of light while shining light onto limbus
Specular reflection
a.
Used mainly to examine corneal endothelium (second Purkinje light reflex), although can
also examine corneal epithelium and lens epithelium
AAO 2014-2016
C.
b.
Monocular viewing
c.
Estimate endothelial cell density, evaluate endothelial cell pleomorphism and

polymegethism, and detect abnormal areas of nonreflectivity (e.g., guttate changes and
pseudoguttata)
Devices used with the slit-lamp biomicroscope

1.
2.
3.
4.
5.
Linear measurement tools

a.
Length and width reticules of the illuminating arm
b.
Eyepiece micrometer of the viewing arm
Applanation tonometer
a.
Falsely high measurement of intraocular pressure with increased corneal thickness
b.
Falsely low measurement of intraocular pressure with corneal thinning
c.
Misleading estimation of intraocular pressure with high astigmatism
Gonioscopy tools for examining the anterior chamber angle

a.
Goldmann single-mirror gonioscope
b.
Koeppe goniolens
c.
Four-mirror gonioprism
d.
Zeiss four mirror lens
Lenses for examining the vitreous cavity and posterior segment

a.
Hruby lens
b.
Goldmann fundus contact lens
c.
Three-mirror contact lens
d.
Condensing lens for indirect ophthalmoscopy
Optical pachymetry for measuring corneal thickness
1.
AAO, Basic and Clinical Science Course. Section 3: Optics, Refraction and Contact Lenses
2013-2014.
2.
Leibowitz HM, Waring GO III, eds. Corneal Disorders: Clinical Diagnosis and Management. 2nd
ed. Philadelphia: Saunders; 1998:34-81.
AAO 2014-2016
Tear film evaluation: static and dynamic

assessments; tear break-up time,
Schirmer
I.
List the indications/contraindications

A.
B.
Indications
1.
Keratoconjunctivitis sicca
2.
Evaluation of ocular discomfort
3.
Evaluation of intermittent blurred vision
4.
Neurotrophic keratopathy
5.
Exposure keratopathy
6.
Preoperative evaluation for refractive or cataract surgery
Contraindications
1.
II.
Inability to cooperate with testing

A.
Slit-lamp biomicroscopic examination

1.
Measure tear meniscus height

a.
B.
Below 0.3 mm is abnormal
2.
Observe for presence of debris, mucus in the tear film using slit beam
3.
Observe rate of disappearance of dye, such as fluorescein
Vital stains
1.
2.
Fluorescein
a.
Available as .25% solution with an anesthetic, 2% non-preserved unit-dose eyedrop, and

impregnated paper strip
b.
Moisten a fluorescein strip with a drop of non-preserved saline and touch the inferior
palpebral conjunctiva
c.
Observe using cobalt blue light
d.
Measure location and intensity of staining
e.
Stains areas where epithelial is missing
Rose bengal or Lissamine Green
AAO 2014-2016
a.
Available in impregnated strips
b.
Moisten strip with a drop of non-preserved saline and touch the inferior palpebral
conjunctiva
i.
C.
D.
c.
Observe using white light
d.
Measure location and intensity of staining
e.
Stains areas of devitalized epithelium (missing mucin layer)
Tear break-up time

1.
Tear break-up time should be measured prior to the instillation of any eyedrops
2.
Moisten a fluorescein strip with a drop of non-preserved saline and touch the inferior palpebral
conjunctiva
3.
Observe using cobalt blue light
4.
The patient is asked to blink, then hold the eye open without blinking
5.
Time from the last blink until the tear film thins and "breaks up"
6.
Take at least three readings
Schirmer
1.
2.
Without anesthetic
a.
Any tear present is removed from the lower fornix by gentle blotting
b.
Whatman #41 filter paper strip (5 mm wide and 35 mm long) is placed across the lower lid
at the outer 1/3 of the lid margin
c.
The patient is advised not to squeeze the eyelids together
d.
After 5 minutes the strips are removed and the amount of wetting measured
e.
If no tear production at 5 minutes, consider nasal stimulation
With anesthetic
a.
III.
Be sure to maximize amount of dye in tear film to avoid false negatives
Same as above except a drop of topical anesthetic is first placed into the eye, and then
removed by gentle blotting
Describe the considerations in interpretation for this diagnostic procedure

A.
Vital stains
1.
Fluorescein
a.
Detects disruptions of intercellular junctions
b.
If abnormal, consider pattern of staining

i.
Diffuse
i)
Keratoconjunctivitis sicca (severe)

7
AAO 2014-2016
ii.
iii.
iv.
v.
ii)
Viral conjunctivitis
iii)
Trauma
iv)
Toxicity
Inferior staining
i)
Lagophthalmos
ii)
Blepharitis
iii)
Trichiasis
iv)
Interpalpebral
i)
ii)
iii)
Dry eye syndrome
Superior
i)
Superior limbic keratoconjunctivitis
ii)
Foreign body under upper lid
iii)
Trichiasis
3 and 9 o'clock
i)
2.
B.
C.
Contact lens
Rose Bengal or Lissamine Green

a.
Stains epithelium devoid of surface glycoproteins (mucin)
b.
Interpalpebral staining- dry eye syndrome
Tear break-up time

1.
Normal tear break-up time is over 10 seconds
2.
If rapid tear break up time- evaporative type dry eye
3.
Consider lipid deficiency or mucin deficiency
Schirmer test
1.
Normal values
a.
With anesthetic: over 10 mm
b.
Without anesthetic: over 15 mm
2.
Test with anesthesia measures basal level of tear production
3.
Test without anesthesia measures reflex and basal level of tear production
4.
Test widely available
AAO 2014-2016
5.
Test is very operator dependent
6.
Poor reproducibility
7.
Low value suggests aqueous tear deficiency
1.
AAO, Basic and Clinical Science Course. Section 8: External Disease and Cornea, 2013-2014.
2.
AAO, Focal Points: Dry Eye, Module #5, 2006.
AAO 2014-2016
Detection of altered structure and

differentiation of signs of inflammation
affecting the eyelid margin, conjunctiva,
cornea, sclera, and iris
I.
Describe the instrumentation and technique (See Scanning-slit topography, 3-D

imaging, wavefront analysis, and anterior segment optical coherence tomography,
corneal aberrometry)
A.
External examination
1.
Observation under room light
2.
Focal illumination
3.
Palpation of eyelid tumors and adenopathy
B.
Slit-lamp biomicroscopy, using diffuse, focal, retro, specular, indirect, and sclerotic scatter forms
of illumination
C.
Ultrasonic or optical measurement of corneal thickness
D.
Specular microscopy of corneal endothelium
E.
Anterior segment imaging

1.
Ultrasonic biomicroscopy
2.
Scheimpflug analysis
3.
Scanning slit
4.
Optical coherence tomography
F.
Anterior segment angiography
G.
Confocal microscopy
H.
Additional instruments may be of value under special circumstances

1.
Indirect ophthalmoscope with a +20 condensing lens focused on the anterior segment and ocular
adnexa when unable to perform slit lamp evaluation
2.
The operating microscope and/or portable slit lamp biomicroscope during a sedated or general
anesthesia evaluation
I.
Meibography to visualize meibomian glands
II.
Describe the considerations in interpretation of this diagnostic procedure

A.
Detection of altered structure and differentiation of signs of inflammation: Diagnostic

considerations
10
AAO 2014-2016
1.
Eyelid
2.
Conjunctiva
3.
Cornea
4.
Sclera
5.
Iris
1.
11
AAO 2014-2016
Diagnostic techniques for infectious

diseases of the cornea and conjunctiva,
including specimen collection methods for
microbiologic testing and diagnostic
assessment of the normal ocular flora
I.

A.
B.
II.
III.
Indications
1.
To determine the microbiologic (viral, bacterial, fungal, or protozoal) etiology of an infectious

process of the cornea and conjunctiva, in order to aid in the selection or modification of
appropriate anti-infective agents for treatment
2.
To determine the normal ocular flora of a patient
Relative contraindications
1.
Severe thinning of the cornea by the infectious process that might result in perforation of the globe
by the specimen collection
2.
In conditions where obtaining the specimen might cause further dissemination of the infectious
process
List the alternatives to this procedure

A.
Diagnosis based on clinical appearance
B.
Broad-spectrum treatment

A.
Specimen collection
1.
Eyelid margin specimen

a.
Microbial cultures are obtained by swabbing the abnormal area with a sterile applicator
moistened with thioglycollate broth followed by direct inoculation of appropriate culture
media and slides
b.
Viral eyelid vesicles or pustules can be opened with a sterile small-gauge needle or a sharp
pointed surgical blade
c.
Material for cytology is smeared onto a glass slide and fixed in methanol or acetone for
immunofluorescent staining
12
AAO 2014-2016
d.
2.
3.
4.
Conjunctival specimen
a.
Sterile Dacron swabs moistened with thioglycollate broth are used to collect surface
conjunctival cells
b.
Swabbed material can be plated onto solid media, smeared on slides, and inoculated into
the broth tube
c.
Conjunctival biopsy may also be performed with forceps and scissors
Corneal specimen
a.
Corneal infiltrates can be scraped using a sterile spatula, e.g., Kimura platinum spatula,
needle, jeweler's forceps, or surgical blade, or swabbed
b.
Specimens may be immediately inoculated onto room temperature microbiologic media in

rows of C-shaped streaks or placed into transport medium
c.
Contamination and false positives must be avoided by not allowing the blade or swab to
touch the eyelids
d.
Viral specimen can be obtained with a swab, and then inoculated into chilled viral transport
medium
e.
Corneal biopsy can be performed with a 2-3 mm trephine to create a partial-thickness

incision; forceps and scissors are then used to excise a lamellar piece of cornea
f.
The specimen is divided for histopathology and microbiology
Contact Lenses
a.
5.
C.
Consider also swabbing/scraping contact lenses or contact lens cases if applicable.
Tear Specimen
a.
B.
Collected vesicular fluid can be inoculated into chilled viral transport medium for culture
isolation or polymerase chain reaction (PCR) testing now rather widely available in hospitals
Immunochromatography to detect Adenoviral infection
Isolation techniques
1.
Bacteria and fungal culture plates and broth are examined periodically to detect visible growth
2.
Microorganisms are identified by chemical staining and reactions, and may be tested for
antimicrobial susceptibility
3.
Acanthamoeba may be identified by trophozoite trails on blood agar, but optimally on non-nutrient
agar with an overlay of killed E. Coli
4.
For viral and chlamydial infections, an appropriate tissue-culture cell line is selected for inoculation
and examined for the development of cytopathic effects and cellular inclusions
Culture media and stains

1.
Aerobic bacteria
a.
Media: blood agar, chocolate agar, thioglycollate or thiol broth
b.
Stain: Gram, acridine orange
13
AAO 2014-2016
2.
3.
4.
5.
6.
IV.
Anaerobic bacteria
a.
Media: anaerobic blood agar, phenyl ether alcohol agar in anaerobic chamber, thioglycollate
or thiol broth
b.
Stain: Gram, acridine orange
Mycobacteria
a.
Media: blood agar, Lowenstein-Jensen agar, Middlebrook agar
b.
Stain: Gram, acid-fast, lectin
Fungi
a.
Media: blood agar (25C), Sabouraud's agar with antibacterial agent (25C), brain-heart
infusion (25C)
b.
Stain: Gram, acridine orange, calcofluor white, Gomori's methenamine silver, wet mount
(potassium hydroxide preparation)
Acanthamoeba
a.
Media: non-nutrient agar with bacterial overlay, blood agar, buffered charcoal-yeast extract
agar
b.
Stain: acridine orange, calcofluor white, Giemsa, PAS
Viruses
a.
Cell culture
b.
PCR testing of fluids or scrapings
c.
Electron microscopy
d.
Enzyme immunoassay
e.
Serologic testing to detect circulating antibodies

A.
B.
C.
False-negative cultures
1.
Inadequate specimen
2.
Recent antimicrobial treatment
3.
Poor survival in transport media
False-positive cultures
1.
Contamination with normal ocular flora
2.
Contamination during inoculation or transport of culture media
Criteria used in laboratory for nonviral infection may differ to include

1.
Sparse growth on a single culture medium
2.
Growth on two or more media
14
AAO 2014-2016
3.
Growth on at least one culture medium of the same organism identified on the smear
4.
Confluent growth at inoculation sites on at least one solid culture medium
5.
Anaerobic growth in an anaerobic culture medium
6.
Amoebic trails on culture plate, with microscopic confirmation of trophozoites from culture
1.
2.
AAO, Focal Points: Applications of New Laboratory Diagnostic Techniques in Cornea and External
Disease, Module #9, 2002.
15
AAO 2014-2016
Diagnostic techniques for neoplasia of the

cornea, conjunctiva, and eyelid margin,
including specimen collection methods for
histopathological testing
I.
II.
List the indications

A.
Suspected malignant lesion
B.
Cosmetically undesirable or uncomfortable lesion
C.
Lesion interfering with vision
Describe the pre-procedure evaluation

A.
B.
History
1.
Age of onset, including congenital or acquired
2.
Growth pattern, including speed of growth, color changes, ulceration, and bleeding
3.
Risk factors, including sun or chemical exposure, pre-existing lesion, previous injury, or systemic
disease
Clinical examination
1.
Distinguish epithelial from subepithelial lesions
2.
Distinguish cystic from solid tumors
3.
Determine presence of inflammation
4.
Evaluate pigmentation
5.
Evaluate with Rose Bengal to define size of conjunctival lesion
6.
Determine movability versus adherence to underlying structure
7.
Determine extent and focality versus multifocality of lesion
8.
Consider likely origin of cells producing neoplasia

a.
Epithelial or epidermal cells
b.
Melanocytes
c.
Cells of the substantia propria, including lymphocytes
9.
Assess regional lymph nodes
10.
Presence or absence of abnormal vessels extending to the lesion
16
AAO 2014-2016
III.
IV.

A.
Periodic observation
B.
Sequential photographs

A.
Exfoliative or impression cytology
B.
Incisional biopsy to remove a representative portion of the lesion
C.
Excisional biopsy to remove entire lesion
D.
V.
VI.
1.
Superficial debridement to remove superficial lesion of the epithelium
2.
Shave biopsy to remove superficial lesion of the epidermis
3.
Complete excision of deeper lesion
Preparation of biopsy for histopathological processing

1.
Minimize crush artifact during excision
2.
Apply specimen onto moist carrier or paper, keeping specimen flat with epithelial side up
3.
Indicate orientation, such as by snipping corner of absorbent mount, making a penciled drawing to
map location of biopsy, or tagging a margin of the specimen with a suture
4.
Frozen section for intraoperative decision-making
5.
Place specimen into fixative solution for histopathological processing
6.
Consult with the pathologist regarding appropriate studies
List the complications of the procedure, their prevention and management

A.
Structural alteration during healing, including distortion and scarring
B.
Lesion recurrence
C.
Inadequate material for adequate histopathological evaluation

A.
B.
Determine cell type involved in neoplasia

1.
Histopathological examination
2.
Flow cytometry
Distinguish histopathological features of neoplasia

1.
Benign
2.
Dysplastic
a.
Abnormal or precancerous growth of cells

17
AAO 2014-2016
b.
3.
C.
D.
Cellular atypia is a set of histopathological features involving cellular polarity; number, size,
and shape of nuclei; and number of mitoses
Malignant
a.
Invasion of dysplastic cells beneath the basement membrane into adjacent tissue
b.
Metastatic spread with secondary centers of neoplastic growth
Correlate clinical appearance with histopathological findings

1.
Gelatinous lesion may have acanthosis (thickening of epithelial layer with increased mitoses of
basal epithelial cells)
2.
Papilliform lesion may have hypertrophy (increased size of cells) and hyperplasia (increased
number of cells)
3.
Epidermalization and leukoplakia may have hyperkeratosis (excessive formation of keratin) and
dyskeratosis (abnormal formation of keratin)
Use diagnostic results to determine need for further therapy, including surgery, cryotherapy,
radiotherapy, or chemotherapy
1.
2.
3.
Shields CL, Shields JA. Tumors of the conjunctiva and cornea. Surv Ophthalmol 2004;49:3-24.
4.
AAO, Focal Points: Ocular Surface Neoplasia, Module #1, 2007.
18
AAO 2014-2016
Corneal pachymetry
I.

A.
II.
Indications
1.
Diagnosis and management of glaucoma, glaucoma suspect, and ocular hypertension
2.
Preoperative planning for keratorefractive surgery
3.
Corneal thinning disorders - diagnosis, ongoing assessment
4.
Endothelial dysfunction - ongoing assessment, preoperative planning for patients with visually
significant cataract, following corneal transplants

A.
Ultrasonic pachymetry
1.
B.
Followed by applanation of cornea in area to be measured
C.
Scheimpflug imaging (e.g., Pentacam, Galilei)
D.
Scanning-slit (e.g., Orbscan)
E.
F.
Optical pachymetry, focusing technique

1.
III.
Topical anesthesia
Measure distance between focused images of anterior and posterior surfaces (e.g., specular
microscopy)
G.
Perpendicular alignment of measuring instrument to cornea is essential
H.
Employ universal precautions, particularly for contact procedures (See Universal precautions for
minimizing transmission of infectious agents)
List the complications of this procedure, their prevention and management

A.
Corneal abrasion
1.
Prevention
a.
2.
IV.
Careful applanation
Management (See Traumatic corneal abrasion)

A.
Falsely elevated readings if instrument is not perpendicular to cornea, or, for central corneal
thickness (CCT), not centered properly
19
AAO 2014-2016
B.
Consistent pachymetry values (at least 3 measurement values)
C.
Compensating for intraocular pressure readings based on CCT
D.
Evaluation for corneal refractive surgery based on corneal thickness
E.
Corneal thickness should be compared with the appearance of the corneal endothelium
1.
V.
For example, in the preoperative evaluation of cataract patients with concomitant corneal
endothelial dysfunction, increased corneal thickness should be correlated with corneal endothelial
changes on slit-lamp biomicroscopic examination because patients with evidence of corneal
decompensation from Fuchs endothelial dystrophy may benefit from corneal transplantation
Describe appropriate patient instructions

A.
Explain relationship between corneal thickness and disease process
1.
2.
Price FW Jr, Koller DL, Price MO. Central corneal pachymetry in patients undergoing laser in situ
keratomileusis. Ophthalmology 1999;106:2216-20.
3.
Seitzman GD; Gottsch JD, Stark WJ. Cataract surgery in patients with Fuchs corneal dystrophy;
expanding recommendations for cataract surgery without simultaneous keratoplasty.
Ophthalmology 2005;112:441-6.
4.
Arce CG, Martiz J, Alzamora JB, et al. Sectorial and annular quantitative area pachymetry with the
Orbscan II. J Refract Surg 2007;23:89-92. Review.
20
AAO 2014-2016
Corneal esthesiometry
I.

A.
Indications
1.
Determine the presence of abnormal corneal sensation in the presence of suspected disease
2.
Monitor return of corneal nerve function
3.
II.
During the recovery from disease
b.
Postoperatively
Estimate prognosis prior to contact lens wear, corneal surgery

A.
III.
a.
Cotton tipped swab

1.
Qualitative, gross assessment
2.
No topical anesthetics for 24 hours prior to testing
3.
Wisp of cotton fiber from tip of swab brought in from side to avoid startle reflex
4.
After touching central cornea of each eye, patient responds as to which eye is more sensitive, and
examiner observes the interocular difference in blink reflex and verbal response
B.
Dental floss
C.
Cochet-Bonnet aesthesiometer
1.
More objective, quantitative
2.
No topical anesthetics for 24 hours prior to testing
3.
Handheld "mechanical pencil" like device with 6 cm long adjustable nylon monofilament for testing
4.
Longest extension of filament (6 cm) exerts 11 mg/mm2 pressure, shortest extension (1 cm) exerts
200 mg/mm2 pressure when applied perpendicularly to cornea
5.
Perception of touch at full extension (6 cm) indicates normal corneal sensation
6.
Tip progressively shortened in 0.5 cm increments until patient can feel corneal touch
7.
Record length at which filament is first felt to quantify level of corneal sensation

A.
Corneal abrasion
1.
Prevention
a.
Careful applanation of wisp of cotton, dental flex or nylon filament

21
AAO 2014-2016
2.
IV.
V.
Management (See Traumatic corneal abrasion)

A.
Accuracy depends on consistency in testing same area of cornea each time
B.
Confirm values by increasing and decreasing filament length by 0.5 cm from recorded
measurement
C.
Insure tip of monofilament is perpendicular to corneal surface
D.
Recognize expected variances in corneal sensation

1.
Ocular sensitivity greatest in central cornea, except in elderly where peripheral cornea can be
more sensitive
2.
Long term contact lens wearers can have significant decrease in corneal sensation
3.
Topical medications (glaucoma medications) can decrease corneal sensation
4.
Penetrating keratoplasty grafts are anesthetic initially and never recover full sensation
5.
Endothelial keratoplasty corneas will have reduced corneal sensation only at the area of the
wound, similar to cataract surgery patients
6.
Radial keratotomy reduces corneal sensation
7.
Laser refractive surgery such as photorefractive keratectomy (PRK) and LASIK reduce corneal
sensation

A.
Explain relationship between corneal sensation and disease process
1.
2.
Krachmer J, Mannis M, Holland E, eds. Cornea: Fundamentals, Diagnosis and Management. 2nd
ed. St. Louis: Elsevier Mosby; 2005.
3.
Brennan NA, Bruce AS. Esthesiometry as an indicator of corneal health. Optom Vis Sci
1991;68:699-702.
4.
Rao GN, et al. Recovery of corneal sensitivity in grafts following penetrating keratoplasty.
22
AAO 2014-2016
Ultrasound biomicroscopy for the anterior

segment
I.
List indications and contraindications

A.
Indications
1.
To provide an image of the anterior chamber (AC) angle when gonioscopy is not possible (e.g.,
with a cloudy cornea or hyphema)
2.
To qualitatively and quantitatively image and assess up to 4-5 mm in depth the normal anatomy of
the
3.
a.
Anterior chamber angle structures
b.
Cornea
c.
Ciliary body
d.
Anterior choroid and sclera
e.
Pars plana
f.
Zonular apparatus
g.
Posterior chamber
h.
Anterior crystalline lens
To qualitatively and quantitatively image and assess abnormalities of the anterior segment
associated with
a.
Evaluation of pigmented conjunctival lesions, nevi, for presence of cysts
b.
Evaluation of conjunctival melanoma for sclera invasion and depth
c.
Scleral invasion of squamous tumors
d.
Iris and ciliary body tumors and cysts
e.
Traumatic angle damage and recession
f.
Cyclodialysis clefts
g.
Ciliary effusions
h.
Phacomorphic angle-closure
i.
An anterior or posterior chamber intraocular lens position
j.
Retained AC or posterior chamber foreign bodies or lens fragments
k.
Filtration blebs and glaucoma drainage devices
l.
Zonular dehiscence due to trauma or exfoliation syndrome
m.
Acute and chronic angle-closure
23
AAO 2014-2016
B.
II.
IV.
An open globe (relative, can be done gently through the lids)
2.
Inability to remain supine for examination
Complete anterior segment examination with slit-lamp gonioscopy, if possible, to allow for
clinical comparison and correlation with subsequent ultrasound biomicroscopy findings
List alternatives to the procedure

A.
Slit lamp biomicroscopy to assess tumors on the conjunctiva, with mobility of tumor
B.
Gonioscopy with a standard 4 mirror gonioscopy lens or 3-mirror retinal lens before and after
pupil dilation, with attention to the angle anatomy, ciliary processes, peripheral lens, zonules and
anterior, peripheral retina
C.
Anterior segment optical coherence tomography (OCT) for 2 dimensional imaging of the cornea,
AC angle, and anterior lens surface

A.
V.
1.

A.
III.
Contraindications
Ultrasound biomicroscope
1.
Optical cross-section of the eye in 2 dimensions
2.
B-mode imaging system at 5-10 frames per second
3.
25 and 50-MHz transducer
4.
4-5 mm depth tissue penetration
5.
0.08-0.2 axial resolution
B.
Place patient supine
C.
Anesthetize the cornea
D.
Insert eye cup with methylcellulose for coupling
E.
Control ambient illumination and patient fixation and accommodation of the fellow eye for
standardization of pupil size and angle anatomy
F.
Examiner comfortable with hand steadied on patients forehead
G.
Orient probe perpendicular to structures of interest for best image

A.
Corneal abrasion
B.
Corneal infection
C.
Make sure imaging probe (which can come to within 2 mm of the cornea) does not contact the
24
AAO 2014-2016
cornea during examination, adequate gel
VI.

A.
Scleral invasion of conjunctival tumor may be difficult to ascertain
B.
Resolution of tumor low compared with OCT
C.
Accommodation, pupil position and patient fixation of the fellow eye may affect the angle
anatomy.
1.
Pavlin CJ, Sherar MD, Foster FS. Subsurface ultrasound microscopic imaging of the intact eye.
2.
Pavlin CJ, Harasiewicz K, Sherar MD, et al. Clinical use of ultrasound biomicroscopy.
Ophthalmology 1991;98:L287-95.
3.
Pavlin CJ, McWhae JA, McGowan HD, et al. Ultrasound biomicroscopy of anterior segment
tumors. Ophthalmology 1992;99:1220-28.
4.
Hiroshi I, Liebmann JM, Ritch R. Quantitative assessment of the anterior segment using
ultrasound biomicroscopy. Curr Opin Ophthalmology 2000;11:113-39.
5.
Bianciotto C, Shields CL, Guzman JM et al. Assessment of anterior segment tumors with
ultrasound biomicroscopy versus anterior segment optical coherence tomography in 200 cases.
Ophthalmology 2011; 118:1297-1302.
25
AAO 2014-2016
Anterior segment ocular coherence

tomography (AS-OCT)
I.

A.
Indications for OCT

1.
Assessment of corneal pathologies, iris pathologies and angle configuration
2.
Assess depth of corneal pathology prior to lamellar surgery

a.
3.
Corneal pachymetric mapping

a.
4.
Evaluate ocular surface tumors

a.
Help differentiate ocular surface squamous neoplasia (OSSN) from other entities
b.
Evaluate for cysts in pigmented lesions such as conjunctival nevi
Assess tear film
6.
Measurement of angle and central and peripheral anterior chamber depth

a.
Population screening: non-contact exam, relatively quick procedure
b.
Pre iridotomy and post iridotomy and/or iridoplasty
c.
Possible new dark room provocative test for angle closure suspect eyes to evaluate the
need for potential treatment
Assessment of conjunctival filtration blebs and glaucoma implants for function/scarring or patency
and assessment of non-penetrating glaucoma surgical procedures
Contraindications
1.
C.
Assess corneal configuration and focal thinning/thickening
5.
7.
B.
Depth of scarring, dystrophy, prior LASIK flaps
Lack of patient cooperation
Advantages
1.
Non-contact, comfortable technique
2.
Seated position of patient
3.
Rapid image acquisition
4.
Some devices provide image of scan localization
5.
High resolution, cross sectional images are reproducible and accurate
6.
Ability to image an eye immediately preoperatively and postoperatively without contact with the
eye
7.
Easy for technician to acquire skill in examination technique
26
AAO 2014-2016
D.
II.
III.
8.
Avoids potential mechanical distortion of the anterior segment of the eye and change in angle/iris
anatomy
9.
Can provide "optical biopsy" in some cases for differentiating ocular surface squamous neoplasia
from pterygia and other entities
10.
Can follow tumor resolution when treating OSSN with medical therapies such as mitomycin, 5
fluorouracil, and interferon
11.
May help detect early recurrences of OSSN and map disease
12.
Can be used intra-operatively or post Descemet stripping endothelial keratoplasty to assess

donor/host apposition
13.
Can assess potential depth of corneal pathology prior to phototherapeutic keratectomy, automated
lamellar keratoplasty etc.
14.
Dynamic investigation of anatomical angle variation and occludability with changes in illumination
intensity
15.
Potential for large scale, population screening at the primary care setting, in areas where angle
closure glaucoma is highly prevalent
Disadvantages
1.
High cost of the device
2.
Limited depth of penetrance (especially in spectral domain OCT)
3.
Shadowing often occurs due to keratinization, or depth > about 400 m
4.
Cannot determine atypia as seen with histopathology
5.
Tumors in locations such as caruncle, inferior or superior fornix difficult to image
6.
Cannot image structures behind the iris such as the ciliary body, ciliary processes, lens equator,
zonules, and lesions or tumors in these areas
7.
Inability to perform dynamic compression to discriminate appositional from synechial angle closure
8.
Potential for over diagnosis of angle closure by AS-OCT compared to under diagnosis by
conventional gonioscopy

A.
Select the appropriate patient for the imaging
B.
Describe the procedure to the patient
C.
Adequate fixation is required, ability to move eye to evaluate lesion in not near limbus
D.
Select the appropriate illumination for the study
E.
Anesthesia is not necessary
F.
Lid manipulation may be necessary
Device characteristics
27
AAO 2014-2016
A.
Non-contact, optical technology to image the eye with the patient in the upright and seated
position (unlike ultrasound biomicroscopy [UBM])
B.
Provides real-time, in vivo, cross sectional images (tomography) of the ocular anterior segment
(more detailed than UBM)
C.
Enables detailed visualization of cornea, bulbar conjunctival surface, iris, anterior chamber angle,
and anterior lens surface, but not ciliary processes, due to light attenuation by pigment
epithelium (not as deep as UBM)
D.
Employs low coherence interferometry to compare the time delay of tissue reflections against a
reference reflection, with image correction for the effect of refraction at the cornea air interface
E.
Instrument scans a beam of light laterally to create a series of axial scans (A-scans) which are
combined into a composite image
F.
A-scans contain information on the strength of the reflected signal as a function of depth
G.
Time-domain (TD) OCT

1.
2.
H.
Visante OCT (Carl Zeiss Meditec, Inc., Dublin, CA, USA FDA approved October, 2005)
a.
Axial resolution of up to 17 m and transverse resolution of up to 60 m
b.
Scan width of 16 mm and depth of up to 6 mm
c.
Images 4 meridians and 8 angles simultaneously in 0.5 seconds
d.
Requires lid manipulation to image superior angle
e.
High intra and interobserver reproducibility
f.
Better than FD-OCT for anterior chamber (AC) biometry of AC depth, angle-to-angle width,
iris profile and angle anatomy
Slit-lamp biomicroscopy OCT (Heidelberg Engineering, GmbH, Dossenheim, Germany)

a.
Axial resolution of less than 25 m and transverse resolution of 25-100 m
b.
Images only 1 meridian and 2 angles simultaneously
c.
Requires manual beam rotation to image non-vertical meridians
d.
Software calculates central corneal thickness, central AC depth, volume of the AC, and the
inter-spur distance
Fourier-domain (FD) OCT

1.
RTVue (Optovue, Inc., Fremont, CA, USA FDA approved September 2007)
a.
Axial resolution of up to 5 m (>3 times higher than TD-OCT)
b.
Spectrometer with a high speed line camera captures 26,000 A scans per second (13 times
faster than TD-OCT)
c.
Better for corneal and conjunctival pathologies, biometry to map corneal thickness, and
assess internal corneal structure than TD-OCT
d.
Higher speed reduces motion artifact and produces higher resolution, more detailed images
than TD OCT
e.
Can image Schlemm's canal, Schwalbe's line and the trabecular meshwork better than
28
AAO 2014-2016
TD-OCT
IV.
V.

A.
Slit-lamp biomicroscopy to evaluate tumors, corneal pathologies
B.
Conventional slit-lamp gonioscopy with a gonioprism and clinical grading of the angle by the
Shaffer, Scheie or Spaeth classification systems
C.
Ultrasound biomicroscopy
D.
Corneal topographic slit-lamp device
E.
Confocal biomicroscopy
F.
Histopathologic biopsy for tumors
Describe the technique

A.
Position the patient comfortably at the device
B.
Maintain proper fixation to image the appropriate angle/meridians of interest
C.
Adjust ambient illumination for most appropriate imaging
D.
Optimize the scan image
E.
Select the scan acquisition protocol
F.
Select the scan analysis protocol
G.
VI.
1.
Display raw image and averaged image in devices able to do this
2.
Measure depth/thickness when appropriate
Archive and/or print the scan image for appropriate interpretation of the scan results for clinical
assessment and billing purposes

A.
None known
VII. Describe the considerations in interpretation of this diagnostic procedure

A.
Acquisition of a good quality scan
B.
Accurate interpretation of the qualitative and quantitative scan results
C.
Comparison of scan results with findings from clinical biomicroscopy
1.
2.
Ramos JL, Li Y, Huang D. Clinical and research applications of anterior segment optical
29
AAO 2014-2016
coherence tomography - a review. Clin Experiment Ophthalmol 2009;37(1):81-9.

3.
Bianciotto C, Shields CL, Guzman JM, et al. Assessment of anterior segment tumors with
ultrasound biomicroscopy versus anterior segment optical coherence tomography in 200 cases.
Ophthalmology 2011;118(7):1297-302.
4.
Shields CL, Belinsky I, Romanelli-Gobbi M, et al. Anterior segment optical coherence tomography
of conjunctival nevus. Ophthalmology 2011;118(5):915-9.
5.
Kieval JZ, Karp CL, Abou Shousha M, et al. Ultra-high resolution optical coherence tomography
for differentiation of ocular surface squamous neoplasia and pterygia. Ophthalmology
2012;119(3):481-6.
6.
Shousha MA, Karp CL, Perez VL, et al. Diagnosis and management of conjunctival and corneal
intraepithelial neoplasia using ultra high-resolution optical coherence tomography. Ophthalmology
2011;118(8):1531-7.
7.
Vajzovic LM, Karp CL, Haft P, et al. Ultra high-resolution anterior segment optical coherence
tomography in the evaluation of anterior corneal dystrophies and degenerations. Ophthalmology
2011;118(7):1291-6.
8.
Nolan W, See JL, Chew PTK, et al. Detection of primary angle-closure using anterior segment
optical coherence tomography in Asian eyes. Ophthalmology 2007; 114:33-39.
9.
Radhakrishnan S, See J, Smith SD, et al. Reproducibility of anterior chamber angle

measurements obtained with anterior segment optical coherence tomography. Invest Ophthalmol
Vis Sci 2007; 48:3683-3688.
10.
Wolffsohn JS, Davies LN. Advances in anterior segment imaging. Curr Opin Ophthalmol 2007;
18:32-38.
11.
Nolan W. Anterior segment imaging: ultrasound biomicroscopy and anterior segment optical
coherence tomography. Curr Opin Ophthalmol 2008; 19:115-121.
12.
Ramos JLB, Li Y, Huang D. Clinical and research applications of anterior segment optical
coherence tomographya review. Clin Experiment Ophthalmol 2009; 37:81-89.
13.
Jancevski M, Foster CS. Anterior segment optical coherence tomography. Semin Ophthalmol
2010; 25:317-323.
30
AAO 2014-2016
Confocal and specular microscopic

imaging
I.

A.
Indications
1.
Corneal endothelial cell imaging

a.
Determination of endothelial cell density

i.
b.
2.
3.
Cataract surgery
ii)
Secondary intraocular lens implantation
Identification of endothelial pathology (such as guttae)
a.
Fungal
b.
Protozoal
Diagnosis of non-infectious keratitis

Corneal dystrophies
i.
Fuchs endothelial dystrophy (confocal and specular microscopy)
ii.
Corneal stromal dystrophies (confocal microscopy)
b.
Interface opacities following lamellar corneal surgery
c.
Corneal intraepithelial neoplasia
Contraindications
1.
II.
i)
Diagnosis of infectious keratitis
a.
B.
Prior to intraocular surgery
None, although imaging may not be successful in setting of limited patient cooperation

A.
Patient history
1.
Infectious keratitis
a.
2.
Decreased vision, pain, conjunctival injection
Non-infectious keratitis
a.
Corneal dystrophies
i.
Decreased vision
ii.
Pain (in the presence of epithelial edema)

31
AAO 2014-2016
b.

i.
B.
Examination
1.
a.
2.
Corneal opacity
Non-infectious keratitis
a.
b.
Corneal dystrophies
i.
Corneal stromal opacities
ii.
Corneal endothelial abnormalities (guttae, endothelial bands, etc)

i.
III.
Asymptomatic or decreased vision
Debris under LASIK flap or between donor and host corneas (Descemet stripping
endothelial keratoplasty) or donor cornea and host Descemet membrane (deep
anterior lamellar keratoplasty)

A.
B.

1.
If stromal opacification prevents endothelial cell imaging with specular microscopy, confocal
microscopy can be used
2.
Specular reflection performed with slit lamp
Diagnosis of infectious keratitis

1.
2.
C.
Fungal
a.
Corneal scraping for culture and sensitivities
b.
Corneal biopsy
Protozoal
a.
Corneal scraping for culture and sensitivities
b.
Corneal biopsy
Diagnosis of non-infectious keratitis

1.
2.
Corneal dystrophies
a.
b.
Molecular genetic analysis

a.
b.
LASIK surgery
32
AAO 2014-2016
i.
IV.

A.
Confocal microscopy
1.
Technique
a.
2.
3.
B.
Uses spatial filtering techniques to eliminate or reduce out-of-focus light, thus minimizing
image degradation, when performing serial optical sectioning of the cornea
Types of confocal microscopes

a.
Slit scanning
b.
Laser scanning
Procedure
a.
Topical anesthesia for contact confocal microscopy
b.
Positioning of the patient's head
c.
Patient fixation
d.
Automated scan and analysis
Specular microscopy
1.
Technique
a.
2.
3.
V.
Lifting flap and removing opacities for further analysis
Based on imaging of the light reflected from an optical interface, such as the corneal
endothelium and the aqueous humor
Types of specular microscopes

a.
Widefield scanning slit
b.
Scanning spot confocal
c.
Contact
d.
Non-contact
Procedure
a.
Topical anesthesia for contact specular microscopy
b.
Positioning of the patient's head
c.
Patient fixation
d.
Automated scan and analysis

A.
Confocal microscopy
1.
Corneal epithelial abrasion
33
AAO 2014-2016
B.
VI.
a.
Prevention - Use of viscous artificial tear prior to application of applanator
b.
Treatment - Topical antibiotics +/- bandage soft contact lens
Specular microscopy
1.
Non contact - No complications associated with performance of the procedure
2.
Contact - Corneal epithelial abrasion (see above)

A.
Confocal microscopy
1.
Image quality:
a.
2.
Dependent upon:
i.
Operator experience
ii.
Patient cooperation
iii.
Degree of corneal opacification
Image interpretation:
a.
Dependent upon
i.
b.

i.
ii.
B.
Reader experience
Provides
i)
Endothelial cell density (see below)
ii)
Pachymetry
Does not provide

i)
Coefficient of variation (see below)
ii)
Average cell size
iii)
% hexagonal cells (see below)
Specular microscopy
1.
Image quality:
a.
Dependent upon:
i.
Degree of corneal opacification

i)
2.
Unable to visualize endothelium in cases of corneal opacification
Image interpretation
a.
Dependent upon:
i.
Reader experience - less than confocal microscopy
34
AAO 2014-2016
b.

i.
ii.
Mode
i)
Automated - appropriate when endothelial mosaic well-visualized
ii)
Manual - appropriate when endothelial cell borders not well visualized or

endothelial mosaic interrupted by guttae
Endothelial cell density

i)
iii.
Normal adult endothelial cell density is 2400-3200 cells/mm2
Endothelial cell morphology - cell shape and size

i)
ii)
Coefficient of variation - Average cell size divided by the standard deviation of

the average cell size
(i)
Normally < 0.30
(ii)
Polymegathism - increased variation in cell size, which is an indication of

poor cell function
Percentage of hexagonal cells

(i)
Should approach 100%
(ii)
Polymorphism (Pleomorphism) - increased variability in cell shape. Less

than 50% hexagonal cells may be an indication of poor cell function
1.
2.
Kumar RL, Cruzat A, Hamrah P. Current state of in vivo confocal microscopy in management of
microbial keratitis. Semin Ophthalmol. 2010;25:166-70.
3.
Tu EY, Joslin CE, Sugar J. The relative value of confocal microscopy and superficial corneal
scrapings in the diagnosis of Acanthamoeba keratitis. Cornea 2008;27:764-772.
4.
Wang Y, Le Q, Zhao F, Hong J, Xu J, Zheng T, Sun X. Application of in vivo laser scanning

confocal microscopy for evaluation of ocular surface diseases: lessons learned from pterygium,
meibomian gland disease, and chemical burns. Cornea. 2011 Oct;30 Suppl 1:S25-8.
35
AAO 2014-2016
Corneal topography/Placido disc imaging

I.

A.
Indications
1.
2.
B.
a.
Refractive surgery
b.
Corneal surgery
Postoperative management
a.
Refractive surgery
b.
Penetrating keratoplasty
c.
Post-cataract surgery astigmatism
3.
Evaluation of corneal ectasia, including keratoconus
4.
Irregular astigmatism
5.
Evaluation of cornea scars (trauma or previous infection)
6.
Contact lens fitting
7.
Evaluation of unexplained decreased vision
Contraindications
1.
II.
Preoperative management

A.
Computerized corneal topography: Placido disc

1.
Digitally captures keratoscopic images and analyzes with computer
2.
Placido disc-based computerized topography
3.
a.
Collects reflected data points from the concentric rings and creates a map of the cornea
b.
Uses color-coded map to present the data with warmer (red and orange) colors
representing steeper curvature of the cornea and cooler (blue and green) colors
representing flatter curvature.
Maps that can be obtained

a.
Power maps
b.
Simulated keratometry
c.
Probability of having keratoconus, etc.
d.
Elevation maps
36
AAO 2014-2016
e.
III.
Corneal wavefront maps

A.
Computerized corneal topography: Placido disc

1.
Useful in detecting irregular astigmatism or multifocal corneas- irregular corneal reflex, scissoring
reflex
2.
Useful for contact lens fitting and intraocular lens power calculation
3.
Critical screening tool for refractive surgery
4.
Identifies changes in astigmatism over time or after surgery
5.
Identifies corneal ectasias
6.
Identifies contact lens induced warpage
7.
Useful in postoperative management of corneal transplant patients
8.
Helpful in determining etiology for unexplained decreased vision or unexpected post-surgical

results including: under corrected aberrations, induced astigmatism, decentered ablations,
irregular astigmatism, etc
9.
Requires skill to interpret test results
10.
Quality and reproducibility of images is operator dependent and dependent on quality of tear film
11.
Non-standardized data maps; user can manipulate appearance of data by changing scales; colors
may be absolute or varied (normalized)
12.
Other limitations: misalignment may lead to error
1.
2.
AAO, Focal Points: Computerized Corneal Analysis, Module #5, 1996.
3.
Arce CG, Martiz J, Alzamora JB, et al. Sectorial and annular quantitative area pachymetry with the
Orbscan II. J Refract Surg 2007;23:89-92. Review.
4.
Cairns G, McGhee CN. Orbscan computerized topography: attributes, applications, and

limitations. J Cataract Refract Surg 2005;31:205-20. Review.
37
AAO 2014-2016
Non-Placido disc imaging (retinoscopy,

keratometry, keratoscopy)
I.

A.
Indications
1.
2.
B.
a.
Refractive surgery
b.
Corneal surgery
c.
Cataract IOL calculations
a.
Refractive surgery
b.
3.
4.
5.
6.
Post-trauma
7.
Contraindications
1.
II.

A.
Retinoscopy
1.
Takes advantage of the eye's natural optics to determine refractive error and to assess corneal
curvature
2.
Shine retinoscope in patient's eye while patient fixates on distance target
3.
Reflex is neutralized using appropriate lens powers yielding information on sphere and
astigmatism
4.
Quality of reflex is noted and is useful in assessing for irregular astigmatism

a.
5.
B.
Non-linear or multiple reflexes are seen in irregular astigmatism
Decreased light reflex may also indicate cataract or other optic pathway obstruction (i.e. vitreous
hemorrhage)
Keratometry
38
AAO 2014-2016
C.
III.
1.
Measures central corneal curvature when the cornea is symmetrical
2.
Takes advantage of the reflective qualities of the front of the corneal surface
3.
The front of the cornea acts as a convex mirror whose reflection generates a virtual image of a
target
4.
Keratometer empirically estimates corneal power by reading four points of the central 2.8-4.0 mm
zone
Keratoscopy
1.
Presents an illuminated series of concentric rings and views the reflection from the corneal surface
(handheld Placido disc, collimating keratoscopes)
2.
Allows measurement of central cornea and parts of cornea more peripheral (which can't be
measured with a keratometer that doesn't have a topogometer attachment)
3.
Images can be stored on film (photokeratoscopy) or video (videokeratoscopy)

A.
Retinoscopy
1.
Useful in detecting irregular astigmatism or multifocal corneas- irregular corneal reflex, scissoring
reflex
2.
Useful for:
3.
B.
C.
a.
Children
b.
Non-cooperative patients
c.
Mentally challenged patients
d.
Patients with significant language barrier
More qualitative than quantitative
Keratometry
1.
Useful for contact lens fitting and intraocular lens power calculation
2.
Useful in IOL calculation formulas
3.
Useful in detecting irregular astigmatism - irregular keratometric images
4.
Most useful for central cornea measurements
5.
Not useful for changes outside the central cornea (radial keratotomy, keratoconus)
Keratoscopy
1.
Has all of the uses discussed above
2.
Gives readings of peripheral cornea
3.
Requires skill to interpret test
4.
Dependent on tear film
39
AAO 2014-2016
5.
Its use has been superseded by computerized corneal topography
1.
40
AAO 2014-2016
Scanning-slit topography, 3-D imaging,

wavefront analysis, and anterior segment
optical coherence tomography, corneal
aberrometry
I.

A.
Indications
1.
2.
B.
a.
Refractive surgery
b.
Corneal surgery
c.
Preoperative cataract surgery planning
d.
Intacs surgery
e.
Phakic intraocular lens (IOL) surgery
a.
Refractive surgery
b.
c.
Lamellar corneal procedures affecting cornea curvature
3.
4.
Evaluation of cornea scars (trauma or previous infection)
5.
6.
7.
Contraindications
1.
II.

A.
Computerized corneal topography: scanning-slit

1.
Computerized corneal mapping device
2.
Maps created
a.
Anterior corneal elevation map

41
AAO 2014-2016
B.
b.
Posterior corneal elevation map
c.
Simulated keratometry map
d.
Corneal pachymetry map
3-D imaging: Computerized corneal topography/Scheimpflug camera

1.
Computerized cornea mapping device and anterior segment camera

a.
2.
The cornea is imaged e.g., by a rotating Scheimpflug camera which measures thousands of
elevation points to create a 3D image of the anterior segment
Multipurpose instrument
a.
Anterior and posterior corneal elevation maps and topography
b.
Corneal pachymetry maps (limbus to limbus)
c.
3-D anterior chamber analysis (AC depth/chamber angle, chamber volume)
d.
Lens density (quantification of light transmittance of crystalline lens and IOL's)

i.
C.
D.
IOL calculation software for post LASIK, PRK and RK patients
Wavefront analysis
1.
Optical aberrations produced by each individual's eye are as distinct as fingerprints and wavefront
imaging allows the physician to measure aberrations beyond sphere, cylinder, and axis
2.
Wavefront sensing devices measure the cumulative sum of optical aberrations induced by each
structure in the visual pathway
3.
The most common wavefront sensing devices utilize the Hartmann-Schack method (Autonomous,
VISX, Bausch and Lomb)
4.
Light rays from a single (safe) laser beam are aimed into the eye and the light rays reflect back
from the retina in parallel rays
5.
Aberrations inside the eye cause the light rays to change directions and a wavefront sensor
collects this information in front of the cornea
6.
Other methods for wavefront sensing: Tscherning and Tracy - measure wavefront as light goes
into the eye
7.
All wavefront systems give detailed report of higher order aberrations mathematically, the
aberrated wavefront can be described by Zernicke polynomials to quantify spherical aberration,
coma, etc. or using Fourier analysis can be isolated into individual components of a compound
waveform, concentrating them for easier detection or use
Anterior segment optical coherence tomography (OCT)

1.
Measures the delay of light (typically infrared) reflected from tissue structures
2.
Its principle is similar to that of ultrasound in which the round trip delay time of the reflected wave
is used to probe the target structure depth
3.
Because light travels fast, it is not possible to measure the delay at a micron resolution, so a
low-coherence interferometry is employed to compare the delay of tissue reflections against a
reference reflection
42
AAO 2014-2016
E.
4.
Images are obtained by use a light beam laterally, creating a series of axial scans (A-scans), after
which it combines these A-scans into a composite image
5.
Each A-scan contains information on the strength of a reflected signal as a function of depth
6.
OCT resolution is very high, ranging from 2 to 20mm, making it ideal for imaging and measuring
small eye structures
Wavefront corneal aberrometry

1.
2.
III.
Pre-operative assessment
a.
Determines origin optical aberrations (corneal or lenticular)
b.
Provides the ability to follow aberrations in scotopic and photopic conditions
c.
Evaluate the effects of cataracts and internal aberrations
Intra-operative assessment
a.
Analysis is taking during surgery
b.
Measures optical aberration in aphakic or pseudophakic state
c.
Assists in intraocular lens (IOL) selection or position

A.
Scanning-slit corneal topography: (Orbscan)

1.
Identifies regular and irregular astigmatism
2.
Anterior elevation maps useful for evaluating anterior ectasias, guiding astigmatism treatment,
glare symptoms, haze symptoms, unexplained decreased vision, central islands
3.
Posterior elevation maps useful for evaluating posterior ectasias, glare symptoms, haze
symptoms, unexplained decreased vision
4.
Pachymetry map useful in giving measurement of corneal thickness throughout the cornea
5.
Identifies changes in astigmatism over time or after surgery
6.
Identifies contact lens induced warpage
7.
Useful in postoperative management of corneal transplant patients
8.
Critical screening tool for refractive surgery
9.
Allows clinicians to detect subtle variations in power distributions of the anterior corneal surface
10.
Helpful in determining etiology for unexplained decreased vision
11.
Helpful in explaining unexpected post-surgical results including: undercorrection, aberrations,

induced astigmatism, decentered ablations, etc.
12.
Reproducible data
13.
Operator dependent and misalignment may lead to sampling error
14.
Non-standardized data maps; can manipulate appearance of data by changing scales; colors may
43
AAO 2014-2016
be absolute or varied (normalized)
B.
C.
15.
Tear film dependent
16.
Higher cost compared with Placido based computerized corneal topography
17.
Pachymetry requires an acoustic adjustment factor
3-D imaging: Computerized corneal topography/Scheimpflug camera (Pentacam, Galilei, others)

1.
Provides similar functions as listed in scanning-slit corneal topography (items 1-12)
2.
Rotating image process helps better identify central cornea and correct for eye movements
3.
Higher cost compared with Placido based computerized corneal topography and scanning-slit
corneal topography
4.
Provides equivalent K readings for IOL calculations and includes formulas to calculate IOL powers
in post RK and post-laser surgery patients
5.
Helps plan phakic IOL surgery by imaging and calculating the anterior chamber dimensions
6.
Keratoconus detection program useful in determining what size penetrating keratoplasty button to
use due to peripheral corneal thinning
7.
Scheimpflug images can be use to evaluate placement of INTAC segments, evaluate DSAEK
lenticle apposition to the cornea, and document relative depth of cornea scars
8.
Densitometry software provides cataract grading system
Wavefront analysis
1.
Only technology currently available which is able to measure and quantitate higher order
aberrations
2.
Information from the wavefront is fed directly into the excimer laser computer to treat patient's
refractive errors and higher order aberrations ("custom cornea," wavefront guided laser ablations)
3.
Should be useful for all situations where computerized corneal topography is helpful (see above)
4.
Currently, the ideal wavefront for optimal vision is not known.

a.
D.
Current systems attempt to eliminate all higher order aberrations
5.
Clinical uses for wavefront technology are currently being defined
6.
Expensive instrumentation
Anterior segment OCT

1.
Anterior chamber angle assessment
2.
Accurately maps corneal thickness in clear and opacified corneas
3.
Allows precise depth measurements of corneal opacities, LASIK flap thickness, and the degree of
epithelial hyperplasia
4.
Images corneal degenerations, scars and dystrophies allowing for pre-operative planning (ablative
procedures versus lamellar or full thickness procedures)
5.
Images anterior segment tumors, and monitor iris cysts, iris nevi, and iris melanomas
44
AAO 2014-2016
E.
6.
Images intrastromal corneal ring segments (INTACS), providing accurate positioning and depth
assessment
7.
Images post-operative DSAEK patients and can provide information on dislocations, partial
detachments, retained Descemet membrane, and other anterior segment abnormalities which may
not be clearly visible in post-operative corneas that are edematous
8.
Provides objective measurements of donor and host corneal thickness after DSAEK which can be
used as markers for clinical improvement
9.
In PK with femtosecond laser applications, can identify top hat, mushroom, and zigzag-shaped
incisions, alignment of donor and host cornea and depth of sutures
Wavefront corneal aberrometry

1.
Measuring solely corneal aberrations may assist in improving refractive procedure selection
2.
Preoperative knowledge of corneal aberrations assists in optimal IOL selection and calculations
3.
Intra-operative analysis aids with implantation of presbyopia-correcting IOLs to achieve

emmetropia
4.
Intra-operative analysis demonstrates proper axis placement of astigmatism correcting IOLs
5.
Intra-operative analysis on patients with previous laser vision correction aides in IOL selection
making it less of a challenge
1.
2.
Cairns G, McGhee CN. Orbscan computerized topography: attributes, applications, and

limitations. J Cataract Refract Surg 2005;31:205-20.
3.
AAO, Focal Points: Wavefront Analysis, Module #10, 2005.
4.
Lawless MA, Hodge C. Wavefront's role in corneal refractive surgery. Clin Experiment Ophthalmol.
2005 Apr;33(2):199-209.
5.
Ramos JL, Li Y. Huang D. Clinical and research applications of anterior segment optical
coherence tomography-a review. Clin Experiment Ophthalmol 2009;37:81-9.
6.
Konstantopoulos A, Hossain P, Anderson DF. Recent advances in ophthalmic anterior segment

imaging: a new era for ophthalmic diagnosis? Br J Ophthalmol. 2007 Apr;91(4):551-7.
45
AAO 2014-2016
Universal precautions for minimizing

transmission of infectious agents
I.
II.
III.
IV.
Handwashing
A.
Single most effective means of avoiding risk of transmitting infections
B.
Wash hands between patient exams and after procedure involving contact with tears
C.
Methods
1.
Alcohol-based hand rubs
2.
Soap and water, with complete drying
Gloves
A.
Use gloves if blood or blood-contaminated fluid is present
B.
Use gloves if examiner's hand have cuts, scratches or open sores
C.
Change gloves after contact with each patient
D.
Use cotton-tipped applicators to minimize direct contact
Eyedropper bottles
A.
Avoid direct contact of bottle tip with tears or conjunctiva
B.
Discard bottle if tip does contact the ocular surface
C.
Date bottles when opened
D.
Consider individual sterile strips impregnated with dye if available
Disinfection of instruments and lenses

A.
B.
Tonometer prisms
1.
Wipe clean and then disinfect in diluted bleach, hydrogen peroxide, ethanol, or isopropanol
2.
After soaking, rinse tip and wipe dry before re-use to avoid corneal de-epithelialization that might
be caused by residual disinfectant
Contact lenses
1.
For rigid gas-permeable or hard contact lenses, use hydrogen peroxide or chlorhexidinecontaining disinfectant system
2.
For soft contact lenses, use hydrogen peroxide or heat disinfection system or multipurpose
solution
46
AAO 2014-2016
3.
C.
Surgical instruments
1.
V.
For diagnostic lenses (e.g., goniolens), wipe with alcohol or immerse in diluted bleach then irrigate
and dry before re-use
When there is contact with high-infectivity tissues in patients with confirmed or suspected
Creutzfeldt-Jakob disease, use single-use instruments or decontaminate or destroy reusable
instruments
Recommendations for infections among health care personnel

A.
Health care personnel with viral keratoconjunctivitis or purulent conjunctivitis should avoid
providing direct patient care for the duration of symptoms
B.
Personnel with draining skin lesions infected with Staphylococcus aureus or infections with
group A streptococci should be restricted from direct patient care until they have received
appropriate therapy
1.
Basic and Clinical Science Course. Section 8. External Disease and Cornea, American Academy
of Ophthalmology, San Francisco, 2013-2014.
2.
Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the
Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA
Hand Hygiene Task Force. MMWR 2002;51(RR16):1-44. http://www.cdc.gov/mmwr/preview
/mmwrhtml/rr5116a1.htm (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5116a1.htm)
3.
Information Statement: Infection Prevention in Eye Care Services and Operating Areas and
Operating Rooms. American Academy of Ophthalmology, San Francisco, August 2012.
http://one.aao.org/clinical-statement/infection-prevention-in-eye-care-services-operatin
(http://one.aao.org/clinical-statement/infection-prevention-in-eye-care-services-operatin)
4.
World Health Organization Infection Control Guidelines for Transmissible Spongiform

Encephalopathies Report of a WHO Consultation 1999. http://www.who.int/csr/resources
/publications/bse/whocdscsraph2003.pdf (http://www.who.int/csr/resources/publications
/bse/whocdscsraph2003.pdf)
5.
Centers for Disease Control: Guidelines for Infection Control in Health Care Personnel: 1998.
http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/InfectControl98.pdf (http://www.cdc.gov/ncidod
/dhqp/pdf/guidelines/InfectControl98.pdf)
47
AAO 2014-2016
Conjunctivochalasis
I.
Describe the approach to establishing the diagnosis

A.
B.
C.
D.
Describe the etiology of this disease

1.
Age related process
2.
Thought to be due to elastotic degeneration and collagenolysis that leads to laxity of the
adherence of the conjunctiva to the underlying connective tissue
3.
Suggested that enzyme accumulation in the tear film due to delayed tear clearance may lead to
degradation of the conjunctiva
Define the relevant aspects of epidemiology of the disease

1.
Occurs more frequently with age
2.
Prevalence low prior to age 30
3.
Prevalence may be higher in patients with autoimmune thyroid disease
List the pertinent elements of the history

1.
Tearing
2.
Tired feeling eyes
3.
Pain
4.
Blurred vision
5.
Foreign body sensation
6.
Irritation
Describe pertinent clinical features

1.
E.
Loose conjunctival folds interposed between the inferior globe and the lid margin of the lower
eyelid
a.
Folds may be located temporally, centrally, and/or nasally
b.
If the chalasis is nasally located it may cause punctal occlusion and delayed tear clearance
2.
Folds may be single or multiple, and may be lower than, equal to, or higher than the tear meniscus
3.
Localized injection of the redundant conjunctiva may be seen
Describe appropriate testing and evaluation for establishing the diagnosis

1.
Slit lamp examination
2.
With fluorescein or Rose Bengal stain discreet areas of staining may be present on the redundant
bulbar conjunctiva, the adjacent lid margin, and tarsal conjunctiva. These features may help
distinguish symptoms due to conjunctivochalasis from other causes
48
AAO 2014-2016
II.
III.
IV.
Define the risk factors

A.
Age
B.
Thyroid disease
List the differential diagnosis

A.
Entropion
B.
Ectropion
C.
Punctal stenosis
D.
Nasolacrimal obstruction
E.
Lid laxity
F.
Tear film abnormalities
G.
Aqueous tear deficiency
H.
Meibomian gland dysfunction
I.
Conjunctival edema, chemosis, lymphangiectasis
J.
Describe patient management in terms of treatment and follow-up

A.
B.
C.
Describe the natural history, outcome and prognosis

1.
Conjunctivochalasis is common with age
2.
It may be asymptomatic in which case no treatment is required
3.
Symptoms such as intermittent epiphora, dry eye type symptoms, and exposure related pain and
irritation can occur and require treatment
4.
Medical therapy may improve symptoms. If not, surgical intervention may be indicated
Describe medical therapy options

1.
Ocular lubricants
2.
Topical corticosteroids
3.
Topical antihistamines
4.
Patching at bedtime with ointment to protect the exposed conjunctiva
Describe surgical therapy options

1.
Most surgical methods include excision of the area of conjunctivochalasis
2.
A crescentic excision of the inferior bulbar conjunctiva 5mm away from the limbus followed by
closure with absorbable sutures may be performed
a.
Fibrin glue can be used in lieu of sutures to reduce suture related granuloma formation and
inflammation
49
AAO 2014-2016
b.
V.
3.
Suture can be placed to tighten the conjunctiva
4.
Transconjunctival cautery can be applied
List the complications of treatment, their prevention and management

A.
B.
VI.
Amniotic membrane can be placed over the defect created after the crescentic excision of
conjunctiva. This can be sutured or glued into place
Complications
1.
Recurrence
2.
Conjunctival scarring
3.
Cicatricial entropion
4.
Retraction of the lower fornix
5.
Motility restriction
6.
Corneal complications
Prevention and management

1.
Conjunctival area of excision should be limited as much as possible to avoid these complications
2.
Use of amniotic membrane may reduce the likelihood of these complications
Describe disease-related complications

A.
Delayed tear clearance may lead to an increase in ocular surface irritation, inflammation and pain
B.
Epiphora secondary to blocking access to lid puncta
VII. Describe appropriate patient instructions

A.
Appropriate use of topical therapy
B.
If indicated, proper instruction on patching at bedtime
1.
2.
Erdogan-Poyraz C et al. Delayed Tear Clearance in Patients with Conjunctivochalasis Is

Associated With Punctal Occlusion. Cornea 26:290-293, 2007.
3.
Yokoi N. Clinical Impact of Conjunctivochalasis on the Ocular Surface. Cornea 24(Suppl.

1):S24-S31, 2005.
4.
Meller D, Tseng SCG. Conjunctivochalasis: Literature Review and Possible Pathophysiology.

Survey of Ophthalmology 43(3): 225-32, Nov-Dec 1998.
50
AAO 2014-2016
5.
Meller D et al. Amniotic Membrane transplantation for symptomatic conjunctivochalasis refractory

to medical treatments. Cornea 19(6): 796-803, 2000.
51
AAO 2014-2016
Aqueous tear deficiency, Sjgren syndrome

and Mucin deficiency
I.

A.

1.
Decreased aqueous tear production due to

a.
Localized lacrimal gland disease

i.
Idiopathic inflammation
ii.
Trauma
iii.
Infiltrative disorders
iv.
v.
b.
i)
Lymphoma
ii)
Amyloidosis
iii)
Sarcoidosis
Scarring with obliteration of lacrimal ducts and atrophy of lacrimal gland

i)
Mucous membrane pemphigoid
ii)
Stevens-Johnson syndrome
iii)
Trachoma
iv)
Radiotherapy
Absence of the lacrimal gland: congenital or surgical
Autoimmune disorders affecting the lacrimal glands

i.
ii.
Primary Sjgren syndrome

i)
Aqueous tear deficiency (keratoconjuctivitis sicca) and/or,
ii)
Decreased salivary gland flow (xerostomia), and/or
iii)
Lymphocytic infiltration of lacrimal and salivary glands, and/or
iv)
Presence of serum autoantibodies.
Secondary Sjgren syndrome, associated with systemic autoimmune disease (e.g.,

rheumatoid arthritis, others)
i)
Aqueous tear deficiency (keratoconjuctivitis sicca) and/or,
ii)
Decreased salivary gland flow (xerostomia), and/or
iii)
Lymphocytic infiltration of lacrimal and salivary glands, and/or
iv)
Presence of serum autoantibodies.
v)
Systemic autoimmune disease (e.g. rheumatoid arthritis, systemic lupus

52
AAO 2014-2016
erythematosus, progressive systemic sclerosis, and chronic hepatobiliary

cirrhosis)
2.
3.
c.
Medications with anticholinergic effects (e.g., tricyclic antidepressants)
d.
Decreased corneal sensation

i.
Trigeminal nerve dysfunction
ii.
Contact lens wear
iii.
Post-surgical (e.g., laser in situ keratomileusis)
Excessive tear evaporation

a.
b.
Lid/globe congruity disorders
c.
Lid closure and blinking disorders

i.
Bell's palsy and other disorders of cranial nerve VII
ii.
Parkinson disease
iii.
Cicatricial, post surgical and other traumatic causes
Decreased mucin production from chemical or inflammatory destruction of conjunctival goblet cells,
conjunctiva
a.
b.
Goblet cell destruction from conjunctival scarring

i.
Mucous membrane pemphigoid (MMP) (ocular cicatricial pemphigoid (OCP))
ii.
iii.
Trachoma
iv.
Chemical alkali burn
v.
Erythema multiforme major
Goblet cell dysfunction

i.
c.
d.
B.
C.
Vitamin A deficiency
Drug induced mucin deficiency

i.
Practolol
ii.
Echothiophate iodide
Goblet cell loss from surgical trauma, such as suction for microkeratome use with LASIK
Define the relevant aspects of epidemiology of this disease

1.
Dry eye syndrome is common, and more common in women
2.
Prevalence increases with age
3.
More common among people with arthritis

1.
Dryness
53
AAO 2014-2016
D.
2.
Irritation
3.
4.
Burning
5.
Light sensitivity
6.
Blurred or fluctuating vision
7.
Excessive tearing
8.
Symptoms may increase as the day progresses or wax and wane
9.
Dry mouth
10.
Medication use

1.
2.
E.
Tear film
a.
Decreased tear meniscus
b.
Rapid tear film breakup time
c.
Reduced Schirmer test
d.
Hyperosmolarity
Ocular surface
a.
Interpalpebral conjunctival staining
b.
Interpalpebral and/or inferior corneal staining, using fluorescein, rose bengal, or lissamine
green
c.
Relative mucous excess, filaments, and plaques

1.
Tear film break up time less than 10 seconds (See Tear film evaluation: static and dynamic
assessments; tear break-up time, Schirmer)
2.
Schirmer Test
3.
Aqueous tear deficiency: laboratory testing usually not necessary, although tear assays (e.g., tear
osmolarity, lysozyme and lactoferrin) are available
4.
Sjgren syndrome (e.g., dry eye and dry mouth)

a.
Anti-Ro (SS-A) antibody
b.
Anti-La (SS-B) antibody
c.
Antinuclear antibody
d.
Rheumatoid factor
5.
Consider salivary or lacrimal gland biopsy if abnormal glandular enlargement
6.
Impression cytology of the conjunctiva

a.
Look for decreased conjunctival goblet cell density
54
AAO 2014-2016
II.
III.
IV.

A.
Hormonal effects (e.g. menopause in women)
B.
HIV infection
C.
Certain human leukocyte antigen (HLA) types
D.
Connective tissue disease
E.

A.
B.
C.
Toxicity of topical medications/preservatives
D.
Factitious keratoconjunctivitis
E.
F.
Mucin tear deficiency
G.
Lipid tear deficiency
H.
Blepharitis

A.
Define medical therapy options

1.
Tear replacement therapy

a.
Preserved artificial tears in milder cases
b.
Preservative-free artificial tears when frequent application is necessary
c.
Gel or ointment in severe cases
d.
Artificial tear pellet , prescription lubrication
e.
Oral secretagogues
f.
Autologous serum tears
2.
Reduce medications contributing to dry eye or ocular surface irritation
3.
Reduce evaporation
a.
Room humidification
b.
Side shields to eyeglasses, moisture chamber goggles
c.
Avoid drafts
d.
Adjust work tasks (e.g. lower computer screen to reduce interpalpebral fissure width)
55
AAO 2014-2016
4.
5.
Suppress ocular surface inflammation

a.
Topical cyclosporine
b.
Topical corticosteroid
Vitamin A deficiency treatment

a.
b.
Adults and children older than one year

i.
200,000 international units (IU) (oral or IM) daily for 2 days, repeat in two weeks
ii.
100,000 IU (oral or IM) every 4-6 months
Pregnant women and children less than one year

iii.
c.
Infants
iv.
6.
B.
Oral immunosuppression for active MMP, Sjgren, autoimmune disorders
Increase tear retention

a.
2.
VI.
50,000 IU prophylactic dose
Define surgical therapy options

1.
V.
100,000 IU every 4 to 6 months
Punctal occlusion: plugs or cauterization
Decrease tear evaporation

a.
Correction of eyelid position abnormalities or lagophthalmos
b.
Tarsorrhaphy

A.
Loss of epithelial integrity: punctate epithelial erosions or large epithelial defect
B.
Microbial keratitis
C.
Sterile corneal ulceration
D.
Corneal thinning, neovascularization, scarring, or perforation
E.
Corneal calcific deposits and band keratopathy
F.
Fornix shortening, symblepharon, lid malposition
G.
Loss of vision

A.
Proper administration of topical medications
B.
Appropriate frequency and timing for use of topical lubricants
C.
Advantages/disadvantages of different lubricants

1.
Preserved vs. non-preserved
56
AAO 2014-2016
2.
D.
Viscosity, retention on the ocular surface, and blurring
Obtain care for dry mouth and oral complications of xerostomia
1.
AAO, Basic and Clinical Science Course. Section 11: Lens and Cataract, 2013-2014.
57
AAO 2014-2016
Filamentary keratopathy
I.

A.
B.
C.

1.
Filaments are composed of degenerated epithelial cells and mucus in variable proportions
2.
Seen in various corneal conditions which have in common an abnormality of the ocular surface
and altered tear composition

1.
Common symptoms include: foreign body sensation, ocular pain (may be severe), photophobia,
blepharospasm, increased blink frequency, and epiphora
2.
Symptoms tend to be most prominent with blinking and alleviated when the eyes are closed

1.
Filaments stain with fluorescein and rose bengal dyes, facilitating identification
2.
Filaments range in length from 0.5 to several millimeters, and are relatively strongly attached to
the cornea
3.
Often a small, gray, subepithelial opacity will be present beneath the site of corneal attachment
4.
Any underlying epithelial defect will stain with fluorescein prominently
5.
The location of the filaments may provide a clue as to the cause

a.
Superior cornea
i.
b.
c.
Interpalpebral distribution
i.
Associated with keratoconjunctivitis sicca, pharmacologic dry eye, or exposure

keratopathy
ii.
After cataract extraction, filaments may be found superiorly
Graft-host junction
i.
6.
Associated with superior limbic keratoconjunctivitis, ptosis, or other causes of

prolonged lid closure
Filaments after cornea transplantation typically reside on the graft or at the graft-host
interface or at the base of the suture on donor side
Evidence of a predisposing condition

a.
Ptosis
b.
Lid lag
c.
Incomplete lid closure
d.
Punctate epithelial erosions associated with dry eye syndrome
e.
Epithelial irregularity or epithelial defect
58
AAO 2014-2016
II.

A.
Any condition associated with irregularity (including desiccation) of the ocular surface
1.
2.
3.
4.
5.
III.
IV.
Dry eye syndrome

a.
b.
Medication-induced
c.
Posterior blepharitis (tear film instability)
a.
Cranial Nerve (CN) VII palsy
b.
Altered mental status with decreased blink rates
Ocular trauma (including surgery)

a.
Epithelial abrasion/erosion
b.
Contact lens overwear
c.
Cataract extraction
d.
e.
Glaucoma filtering surgery
Prolonged occlusion
a.
Ptosis
b.
Prolonged patching
Ophthalmic disorders
a.
b.
Epithelial keratitis (e.g., herpes simplex virus (HSV) keratitis) and epithelial erosions (e.g.,
toxicity)

A.
Dendritic lesions, such as HSV dendritic epithelial keratitis
B.
Loosened sutures
C.
Corneal abrasion
D.
Non-adherent mucus or foam

A.
59
AAO 2014-2016
1.
Mechanical removal of filaments
2.
Bandage contact lens (for relief of discomfort; may increase number of filaments
3.
Management of dry eye syndrome
4.
a.
Preservative free artificial tears
b.
Punctal occlusion
c.
d.
Autologous serum drops
Mucolytics
a.
5.
B.
V.
Topical sodium chloride (e.g. Muro 128 drops and ointment)

1.
Repair of contributory lid malposition
2.
Tarsorrhaphy if secondary to severe dry eye syndrome
3.
Superior conjunctival resection or cauterization if secondary to superior limbic keratoconjunctivitis

A.
Mechanical removal of filaments - epithelial defect with secondary infection

1.
B.
Prescribe topical antibiotics after filament removal
Mucolytic treatment - toxic keratopathy

1.
VI.
N-Acetylcysteine
Discontinue use

A.
Major symptoms are ocular surface irritation and pain, and decreased vision
B.
Filaments are an indicator of ocular surface disease

1.
Complications are not typically secondary to the filaments, but the underlying disease process

A.
Once underlying process is effectively treated, filaments will resolve
B.
Removal of filaments/use of mucolytics may be successfully employed when filaments present,

but are not definitive treatments, as filaments will recur
C.
Continue with aggressive topical lubrication (if not possible to eliminate underlying process)
60
AAO 2014-2016
1.
61
AAO 2014-2016
Meibomian gland dysfunction, rosacea,

and seborrheic blepharitis
I.

A.
B.
C.
D.
Describe the etiology of the disease

1.
Meibomian gland dysfunction is a result of progressive obstruction and inflammation of the gland
orifices
2.
Seborrheic blepharitis is a chronic inflammation of the eyelid, eyelashes, forehead and scalp skin
3.
Rosacea is a skin disease characterized by dysfunction of meibomian glands and/or other

cutaneous sebaceous glands of the skin of the face and chest

1.
The prevalence increases with increasing age. It mainly develops in patients between ages 30 and
60 years but can affect all age groups including children
2.
Slight female preponderance

1.
Burning, gritty, sandy, foreign body sensation
2.
Crusting of the eyelids (especially in seborrheic blepharitis)
3.
Chronic eyelid margin redness
4.
Conjunctival injection
5.
Blurred (occasionally) or unstable vision from tear-film disturbances
6.
Eye pain and photophobia (occasionally)
7.
Recurrent chalazia
8.
In rosacea, additional elements may be reported

a.
Facial rash
b.
Flushing episodes

1.

a.
Affects posterior eyelid margin
b.
Increased opaque secretion in meibomian glands
c.
Foamy secretions
d.
Pouting, metaplastic meibomian gland orifices
e.
Telangiectasias of the eyelid margin
62
AAO 2014-2016
2.
3.
f.
Meibomian gland drop out (meimography)
g.
Abnormal meibum after expression of glands (with slight pressure on lid margin with Q tip or
finger)
h.
Bulbar and tarsal conjunctival injection
i.
Papillary conjunctival reaction
j.
Atrophy of Meibomian gland acini
k.
Episcleritis
l.
Corneal punctate epithelial erosions
m.
Corneal marginal infiltrates
n.
Corneal vascularization
o.
Evidence of systemic rosacea in some individuals
p.
Lipid-tear deficiency
Rosacea
a.
Malar rash and telangiectasias of facial skin and eyelid margin
b.
Papules, pustules, hypertrophic sebaceous glands
c.
Rhinophyma
d.
Meibomian gland dysfunction, distortion
e.
Excessive sebum secretion
f.
Bulbar and tarsal conjunctival injection
g.
Marginal corneal infiltrates and sterile ulceration of cornea
h.
Episcleritis
i.
Iridocyclitis
j.
Corneal neovascularization and scarring
k.
Atrophy of meibomian glands late in disease
l.
Lipid tear deficiency and aqueous tear deficiency
Seborrheic blepharitis
a.
Affects primarily anterior eyelid margin
b.
Oily or greasy eyelid crusting
c.
Increased and turbid meibomian gland secretions
d.
Mild conjunctival injection
e.
f.
g.
May have evidence of seborrhea elsewhere on the body
63
AAO 2014-2016
h.
II.
III.

A.
Staphylococcal blepharitis
B.
Lice infestation
C.
Masquerade syndrome (eyelid neoplasm - rare, but should be considered in chronic unilateral
blepharitis)
D.
Discoid lupus
E.
Demodex blepharitis

A.

1.
Daily eyelid hygiene (warm compresses, eyelid massage, and eyelid scrubbing) with commercially
available pads, using clean washcloth or Q-tip soaked in warm water +/- dilute baby shampoo
2.
Artificial tears
a.
3.
4.
5.
IV.
V.
May be associated with staphylococcal blepharitis or meibomianitis
If aqueous tear deficiency or lipid-induced tear film instability present
a.
For acute exacerbations
b.
If marginal corneal infiltrates or progressive corneal neovascularization
Antibiotics
a.
Oral tetracyclines e.g. doxycycline, minocycline, tetracycline in adults
b.
Oral erythromycin in children
c.
Topical macrolides e.g. azithromycin
Topical metronidazole for skin involvement

A.
Complications of topical corticosteroids, if used (including glaucoma and cataract)
B.
Corneal toxicity and allergic reactions to topical antibiotics, if used
C.
Side effects related to systemic tetracyclines, if used

A.
Corneal ulceration
B.
64
AAO 2014-2016
VI.
C.
Corneal scarring
D.
Corneal thinning and perforation (rare)
E.
Eyelid ulceration, trichiasis, madarosis
F.
Atrophy of Meibomian glands and lipid-layer tear deficiency

A.
Chronic nature of these conditions
B.
Importance of daily eyelid hygiene
C.
Instruction on proper eyelid hygiene
D.
Instruction on medications and their side effects
E.
Instructions regarding follow-up
1.
2.
Bron AJ, Benjamin L, Snibson GR. Meibomian gland disease. Classification and grading of lid
changes. Eye. 1991;5:395-411.
3.
Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol. 1996;40:343-368.
4.
Zengin N, Tol H, Gunduz K, et al. Meibomian gland dysfunction and tear film abnormalities in
rosacea. Cornea. 1995;14:144-6.
5.
Barnhorst DA Jr, Foster JA, Chern KC, et al. The efficacy of topical metronidazole in the treatment
of ocular rosacea. Ophthalmology. 1996;103:1880-3.
6.
Frucht-Pery J, Sagi E, Hemo I, et al. Efficacy of doxycycline and tetracycline in ocular rosacea. Am
J Ophthalmol. 1993;116:88-92.
7.
Asbell PA, Stapleton FJ, Wickstrm K, Akpek EK, Aragona P, Dana R, Lemp MA, Nichols KK. The
international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee.
Invest Ophthalmol Vis Sci. 2011;52(4):2065-85.
8.
Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O'Brien T, Rolando M, Tsubota K,

Nichols KK. The international workshop on meibomian gland dysfunction: report of the
subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol
Vis Sci. 2011;52(4):2050-64.
9.
Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, Yee R, Yokoi N, Arita R, Dogru
M. The international workshop on meibomian gland dysfunction: report of the diagnosis
subcommittee. Invest Ophthalmol Vis Sci. 2011;52(4):2006-49.
10.
Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international
workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of,
and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011;52(4):1994-2005.
11.
Green-Church KB, Butovich I, Willcox M, Borchman D, Paulsen F, Barabino S, Glasgow BJ. The
65
AAO 2014-2016
international workshop on meibomian gland dysfunction: report of the subcommittee on tear film
lipids and lipid-protein interactions in health and disease. Invest Ophthalmol Vis Sci.
2011;52(4):1979-93.
12.
Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland
dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the
meibomian gland. Invest Ophthalmol Vis Sci. 2011;52(4):1938-78.
13.
Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, Foulks GN. The
international workshop on meibomian gland dysfunction: report of the definition and classification
subcommittee. Invest Ophthalmol Vis Sci. 2011;52(4):1930-7.
14.
Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, Lemp MA, Sullivan DA. The
international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol
Vis Sci. 2011;52(4):1922-9.
15.
Nichols KK. The international workshop on meibomian gland dysfunction: introduction. Invest
Ophthalmol Vis Sci. 2011;52(4):1917-21.
66
AAO 2014-2016
Benign conjunctival masses

I.

A.
B.
C.
D.

1.
Benign lesions occur as a result of over proliferation of cells
2.
Others may occur due to accumulation or deposition of substances in the conjunctiva
3.
There can be changes in lymphatic channels of the conjunctiva
4.
And infection and inflammation may result in benign lesions

1.
May occur at various ages
2.
No sex predilection

1.
Length of time the lesion has been present
2.
Color, location, topography of lesion
3.
Single or multiple lesions
4.
Unilateral or bilateral
5.
Other lesions in non ocular locations
6.
Presence of systemic disease
7.
Presence of pain, swelling, ptosis, discharge, redness, tearing, irritation
8.
History of prior lesion removal, either benign or malignant
9.
History of prior ocular surgery
10.
Recent changes in the appearance of the lesion(s)
11.
Pertinent family history

1.
Benign Nevi
a.
Focal unilateral lesion may be flat or elevated
b.
Most commonly brown, may be tan, amelanotic
c.
Intralesional cysts in 50%
d.
Occur near the limbus, bulbar conjunctiva, plica, caruncle Rarely in the fornix or tarsal
conjunctiva
e.
Typically noted in the first two decades of life, stable, unlikely to develop into malignancy
i.
May increase in size and pigmentation at puberty and during pregnancy

67
AAO 2014-2016
f.
2.
Conjunctival papilloma
a.
b.
3.
4.
May be junctional (intraepithelial), subepithelial, compound
Pedunculated
i.
Seen in children and younger patients
ii.
Associated with Human papilloma virus (HPV 6, 16)
iii.
Fleshy, multilobular growth with fibrovascular core
iv.
Typically arises in the inferior fornix, may develop on the tarsal or bulbar conjunctiva,
or the semilunar fold
v.
vi.
Multiple lesions may occur and may be extensive in immunocompromised patients
Sessile
i.
Seen in adults
ii.
Usually located at limbus
iii.
Flat base, glistening with red dots (strawberry-like)
iv.
Unilateral, solitary
v.
May spread onto cornea
vi.
Possibly related to UV exposure
c.
Pyogenic granuloma
d.
Red, raised lesion often pedunculated
e.
Develops rapidly over days to weeks
f.
May result from inflammation, ocular surface surgery, infection, chalazion, foreign body
Capillary hemangioma
a.
Red, protuberant vascular growth
b.
May occur in infancy associated with cutaneous or orbital lesion
c.
Adults can develop a primary conjunctival hemangioma

i.
Thought to be a variant of pyogenic granuloma
ii.
Similar to cherry hemangiomas found in the skin
Lymphangiectasia
a.
Dilated lymph channels seen as sausage like clear or hemorrhagic conjunctival cystic
lesions
b.
Chemosis, focal or diffuse
c.
May have history of eye irritation, tearing
d.
Associated with local venous hypertension (thyroid eye disease, orbital apex syndrome,
68
AAO 2014-2016
cavernous sinus thrombosis, carotid-cavernous fistula), increased vascular permeability

(allergy), local lymphatic scarring
5.
Lymphangioma
a.
6.
7.
Prominent mass of lymphatic channels

i.
Lymphangiectasia of tumorous proportions
ii.
May be continuous with orbital lesion
b.
Can be clear or have intralesional hemorrhage (chocolate cysts)
c.
Multiloculated, cystic in appearance
d.
Unilateral
e.
Clinically apparent in first decade
f.
Consists of irregular cyst like channels with clear fluid or blood
Benign reactive lymphoid hyperplasia

a.
Salmon-pink colored lesion
b.
Typically found in adults
c.
Rarely reported in children (associated with Epstein-Barr virus)
d.
Irritative (periocular inflammation, chalazia, conjunctivitis, chemical injury) or antigenic

stimulus (from microorganisms, allergens, drugs)
e.
15-25% associated with development of systemic lymphoma
Primary localized conjunctival amyloidosis

a.
Avascular, non-inflamed, soft yellow or salmon colored deposits
b.
Nodular, fusiform or polypoid in shape
c.
Palpebral conjunctiva, superior fornix and tarsus most commonly involved
d.
Ptosis, ophthalmoplegia may occur.
e.
May be asymptomatic or have pain, swelling, recurrent hemorrhages
f.
Young to middle aged adults
g.
Amyloidosis may be localized to one organ or may be systemic.

i.
8.
9.
It may be primary (idiopathic) or secondary (to some chronic disease) and familial or
nonfamilial
Epithelial Inclusion cyst

a.
Single cystic mass or multiple cysts may be seen
b.
Bulbar, fornix
c.
May occur spontaneously, following inflammation, trauma, surgery
Inflammatory granulomatous lesions
69
AAO 2014-2016
10.
11.
12.
13.
E.
II.
Nodule of the bulbar or palpebral conjunctiva
b.
Single or multiple small tan, yellow nodules can resemble follicles
c.
d.
Infectious (parasitic, fungal, cat scratch disease) or non infectious (foreign bodies,
rheumatoid arthritis, sarcoidosis)
Juvenile Xanthogranuloma
a.
Unilateral, yellow mass, may be vitelliform
b.
More commonly located at limbus
c.
Typically seen in children, may present in adults
Dermoid
a.
Well circumscribed solid yellow-white lesion (choristoma)
b.
Present at birth
c.
Usually located at inferotemporal limbus
d.
Fine hairs may be present
e.
Can be associated with Goldenhar syndrome
f.
Dense fibrous tissue, may contain hair, sebaceous glands
Dermolipoma
a.
Occurs superotemporally
b.
Pale yellow dermoid
c.
Contains adipose tissue
d.
Differentiate from orbital fat prolapse
(See Pterygium and pinguecula)

1.
Most lesions can be diagnosed based on clinical appearance
2.
In cases where it is unclear, biopsy (excisional in small lesions, incisional in larger lesions) is
performed

A.
III.
a.
Varies by lesion

A.
Malignant lesions such as melanoma, lymphoma, leukemia, squamous cell carcinoma,

sebaceous cell carcinoma, Kaposi's sarcoma
70
AAO 2014-2016
IV.
B.
These benign lesions make up their own unique differential diagnosis
C.
Allergic conjunctivitis, episcleritis, conjunctivochalasis
D.
Conjunctival pigmentation: Associated with skin complexion (also called benign epithelial
melanosis or racial melanosis);Primary acquired melanosis; Secondary acquired melanosis;
melanoma

A.

1.
Varies by lesion
a.
B.

1.
Some lesions can be observed

a.
2.
3.
Observation with slit lamp drawings and/or slit lamp photos every 6-12 months as indicated.
(ex. Nevus, dermoid, pinguecula, inclusion cysts)
Some may respond to topical corticosteroid

a.
C.
Some lesions may regress, some may remain stationary, and others may progress to
malignancy. There may be systemic associations, systemic evaluation should be performed
when indicated
Lymphangiectasia, pyogenic granuloma
Papilloma
a.
May be treated with topical interferon
b.
Oral Cimetidine may reduce recurrence with Papilloma

1.
Excisional biopsy is performed for small and intermediate sized lesions that may be symptomatic
or suspected to be malignant.
a.
Examples: Steroid-resistant pyogenic granuloma, limbal dermoid, epibulbar osseus

choristoma, lymphangiectasia, Molluscum contagiosum, and because they are rare,
pigmented nevi of the fornix and tarsal conjunctiva should be biopsied
b.
Excisional biopsy should be performed on lesions that exhibit a change in appearance
c.
If the defect cannot be closed primarily, an amniotic membrane graft may be inserted, or a
pressure patch used until the epithelial defect is healed
d.
If malignancy is suspected and with papilloma (due to its high rate of recurrence), a
no-touch' technique should be performed with a wide excision around the lesion.
Cryotherapy may be indicated as well (nevi, papilloma). Cautery may be indicated for
lesions such as lymphangioma.
i.
Caution should be taken when excising pedunculated papilloma due to possibility of

virus dissemination with multiple recurrences
71
AAO 2014-2016
V.
VI.

A.
Complications of topical corticosteroid
B.
Surgical excision
1.
Infection, bleeding, scarring, recurrence
2.
Prevention and management complications

a.
Meticulous surgical technique
b.
Treat infection with topical antibiotics

A.
Minimal in most benign lesions
B.
Some may grow over the cornea and reduce vision
C.
There may be malignant transformation
D.
Complications related to the systemic disease process

A.
Return for an evaluation if the lesion changes in appearance or new symptoms occur
B.
When indicated, advise that systemic evaluation be performed
C.
Review complications of medical and surgical treatment
D.
Review postoperative instructions as indicated
1.
72
AAO 2014-2016
Hordeolum and chalazion

I.

A.

1.
2.
B.
2.
Inspissation and infection of sebaceous glands
b.
Anterior lid (glands of Zeis, lash follicles): external hordeolum or stye
c.
Posterior lid (Meibomian glands): internal hordeolum
d.
Staphylococcus aureus is most common pathogen
Chalazion
a.
Inspissation of Meibomian or Zeis gland
b.
Extrusion of sebum into adjacent tissues produces sterile granulomatous inflammation
Hordeolum
a.
Rapid onset, painful, tender
b.
Typically resolve in 1-2 weeks
c.
May produce purulent discharge with rupture
Chalazion
a.
Slow onset or previous hordeolum
b.
Either painless or mild soreness
c.
Resolution in weeks to months or no resolution
d.
May drain externally
e.
Occasional blurred vision due to astigmatism from pressure on globe

1.
2.
D.
a.

1.
C.
Hordeolum
Hordeolum
a.
Tender, red nodules near lid margin
b.
Surrounding edema, erythema may indicate preseptal cellulitis
Chalazion
a.
Nontender nodules at lid margin or in region of tarsus
b.
Redness of overlying skin
Describe appropriate laboratory testing for establishing the diagnosis

1.
Cultures unnecessary in most cases
73
AAO 2014-2016
2.
II.
III.
IV.
Histopathologic examination of material from recurrent chalazia to rule out neoplasia

A.
Rosacea
B.
Chronic blepharitis

A.
Preseptal cellulitis
B.
Basal cell carcinoma
C.
Squamous cell carcinoma
D.
Sebaceous carcinoma
E.
Keratoacanthoma
F.
Papilloma
G.
Inclusion cyst

A.
B.

1.
Warm compresses and massage of lesions
2.
Topical antibiotics ineffective in treating hordeola and chalazia, but may be of value in treating
accompanying staphylococcal blepharitis
3.
Systemic antibiotics active against Staphylococcus aureus for accompanying preseptal cellulitis
4.
Systemic tetracyclines for treatment of chronic accompanying meibomitis, rosacea

1.
Intralesional corticosteroid injection (0.1-0.2 mL Triamcinolone 10mg/mL)
2.
Incision/excision and drainage

a.
V.
Curettage for larger lesions

A.
Medication
1.
Allergy
a.
Prevention
i.
b.
Obtain history of medication allergies
Management
74
AAO 2014-2016
i.
B.
Incision/excision and drainage

1.
Horizontal scarring of tarsal plate

a.
Prevention
i.
b.
2.
b.
Prevention
i.
Aseptic technique
ii.
Prophylactic antibiotics
Management
i.
Topical, systemic antibiotics
Damage to lacrimal drainage apparatus

a.
Prevention
i.
Careful attention to technique, avoid excising lesions overlying punctum, canaliculus
Intralesional corticosteroid injection

1.
VI.
Plastic repair of tarsal plate
Infection
a.
3.
Vertical incision along Meibomian gland
Management
i.
C.
Cessation of medication, corticosteroids if necessary
Skin depigmentation

A.
Distortion of lid margin, with secondary exposure keratopathy
B.
Pressure on globe, with secondary astigmatism
C.
D.
Rarely, orbital cellulitis (higher risk in children)

A.
Proper use of medications, warm compresses
B.
When to seek further care
1.
AAO. Basic and Clinical Science Course. Section 8: External Disease and Cornea, 2013-2014.
75
AAO 2014-2016
I.

A.

1.
2.
B.
C.
Inadequate eyelid closure (lagophthalmos)

a.
Cranial Nerve (CN) VII palsy, including Bells palsy
b.
Decreased blinking (e.g., Parkinson disease)
c.
Ectropion
d.
Eyelid deformity
i.
Congenital
ii.
Acquired
i)
ii)
e.
Trachoma
f.
Blepharoplasty
g.
Altered mental status
h.
Drug abuse
i.
Unconsciousness
Proptosis
a.
Thyroid eye disease (thyroid orbitopathy)
b.
Orbital pseudotumor
c.
Retrobulbar tumor

1.
Dryness, irritation, foreign body sensation, burning
2.
Tearing
3.
Blurred vision
4.
Photophobia
5.
Redness
6.
Symptoms worse on awakening (nocturnal lagophthalmos)
7.
History of eyelid surgery

1.
Incomplete eyelid closure and/or proptosis
76
AAO 2014-2016
II.
III.
IV.
2.
Dilated conjunctival vasculature
3.
Punctate epithelial erosions
4.
Epithelial defects of varying size
5.
Lesions preferentially involving inferior third of cornea and conjunctiva, in exposure area and
usually conjunctiva below the limbus
6.
Bells phenomenon

A.
Decreased blinking associated with visually attentive tasks
B.
Low humidity

A.
B.
C.
Toxicity of topical medications/preservatives
D.
Factitious keratoconjunctivitis

A.

1.
Treatment of underlying disease
2.
Tear supplementation with frequent preservative-free lubricants
3.
Ointment at bedtime
4.
Reduce evaporative tear loss
5.
B.
a.
Goggles, moisture shields
b.
Taping lid shut at bedtime
c.
Humidifier
Treatment of any concomitant dry eye (See Aqueous tear deficiency, Sjgren syndrome and Mucin
deficiency)

1.
Punctal occlusion
2.
Surgical correction of eyelid position, such as tarsorrhaphy, lateral canthal sling, medial
canthoplasty or gold weight insertion
3.
Orbital decompression for proptosis
77
AAO 2014-2016
V.

A.
B.
VI.
Topical lubricants
1.
Complications: epithelial toxicity of preservatives
2.
Prevention and management: preservative-free lubricants
Surgical
1.
(See Punctal occlusion, Tarsorrhaphy)
2.
Gold weight: infection, shifting, extrusion, inflammation response to gold, induced astigmatism.
Prevention and management: Use sterile technique. Remove gold weight. Treat infection

A.
Corneal scarring
B.
Microbial keratitis
C.
D.
Corneal perforation

A.
B.
Use of moisture shields, taping of lids
C.
D.
1.
78
AAO 2014-2016
Floppy eyelid syndrome

I.

A.
B.
C.
D.
II.
III.

1.
Laxity of upper, or less commonly, lower eyelid and tarsus
2.
Upper eyelid everts with minimal manipulation
3.
Chronic ocular irritation and inflammation, which may result from ocular contact with the pillow or
bedding or exposure during sleep
4.
Chronic eye rubbing with secondary lid laxity

1.
Ocular discomfort and redness
2.
Symptoms may be worse upon waking

1.
Papillae on the upper palpebral conjunctiva
2.
Mucous discharge
3.
Mild to severe punctate corneal epitheliopathy
4.
Severe cases may demonstrate corneal vascularization
5.
Symptoms and clinical findings may be asymmetric or unilateral if the individual sleeps in one
position

1.
Manually test ease of upper lid eversion
2.
Manually test upper lid lateral laxity

A.
Obesity
B.
Obstructive sleep apnea
C.
Face down sleep position

A.
Vernal conjunctivitis
B.
Giant papillary conjunctivitis
C.
Atopic keratoconjunctivitis
D.
Infectious conjunctivitis
79
AAO 2014-2016
E.
IV.
Toxic keratopathy

A.
B.

1.
Tape eyelid closed at bedtime
2.
Wear eye shields or goggles while sleeping
3.
Sleep upright in recliner

1.
V.

A.
B.
C.
D.
VI.
Eyelid tightening procedure
Tape allergy
1.
Change type of tape used
2.
Discontinue use
3.
Use goggles with elastic band
Postsurgical infection
1.
Aseptic technique
2.
Antibiotics
Postsurgical corneal exposure

1.
Lubricants
2.
Surgical revision
Recurrences common unless underlying disease/obesity addressed

A.
Ocular surface irritation
B.
C.
Secondary infection
D.
Corneal scarring
E.
Decreased vision

A.
Explain etiology of upper eyelid eversion leading to ocular surface exposure and how to prevent
B.
Describe how to use tape or goggles at bedtime
80
AAO 2014-2016
C.
Describe surgical option of eyelid tightening procedure
1.
2.
Kersten RC. Cornea. 2nd ed. Philadelphia, PA: Elsevier Mosby; 2005: Chapter 34.
81
AAO 2014-2016
Recurrent erosion
I.

A.
B.
C.

1.
Poor adhesion of the corneal epithelium because of underlying abnormalities in the corneal epithelial
basement membrane and its associated filament network
2.
Predisposing condition
a.
Previous corneal trauma, such as a fingernail scratch
b.
Corneal epithelial basement membrane disease
c.
Stromal dystrophy, such as lattice corneal dystrophy
d.
Irregular corneal surface, such as Salzmann nodular degeneration
e.
Previous corneal surgery, such as photorefractive keratectomy

1.
Prior history of a traumatic corneal abrasion
2.
Prior history of corneal epithelial basement membrane disease
3.
Prior history of ocular surface or corneal disorder (e.g., dry eye, exposure, corneal edema, corneal
dystrophy, or corneal degeneration)
4.
Symptoms: sudden onset of eye pain, usually at night or upon first awakening, accompanied by
redness, photophobia, and tearing; episodes vary from 30 minutes to several days
Describe the pertinent clinical features

1.
The cornea will show areas of positive or negative staining if the last episode was recent. The patient
may have an intact epithelial surface by the time of exam or present with frank corneal epithelial
defect
2.
Pooling of fluorescein over the affected area even with no frank epithelial defect
3.
Subtle corneal changes such as epithelial cysts
4.
Loosely attached corneal epithelium to the underlying basement membrane in either eye
5.
Heaped up or edematous epithelium in area of erosion
6.
May have signs of corneal epithelial basement membrane dystrophy (map-dot-fingerprint dystrophy)
D.
E.
Previous sudden, sharp, abrading injury (fingernail, paper cut, organic material) to the corneal
surface which has not been treated aggressively at the time of initial occurrence
F.
Preexisting corneal epithelial basement membrane dystrophy (See Corneal epithelial basement
membrane dystrophy/degeneration)
G.
Corneal edema
H.
Corneal dystrophy or degeneration
82
AAO 2014-2016
II.
III.

A.
Corneal abrasion (See Traumatic corneal abrasion)
B.
Corneal epithelial erosion associated with other corneal dystrophies
C.
Exposure keratopathy (See Exposure keratopathy)
D.
Neurotrophic keratopathy (See Neurotrophic keratopathy)
E.
Nocturnal lagophthalmos
F.
Herpes simplex virus epithelial keratitis (See Herpes simplex virus epithelial keratitis)
G.
Keratoconjunctivitis sicca (See Aqueous tear deficiency, Sjgren syndrome and Mucin deficiency)
Describe patient management in terms of treatment and follow up

A.
Management of epithelial defect

1.
Pain control
a.
2.
B.
Encourage epithelial healing

a.
Patching and topical antibiotic until epithelium healed
b.
Bandage contact lenses and antibiotic eyedrops until epithelium healed
Prevention of subsequent erosion

1.
Lubrication
a.
Petrolatum, mineral oil or hypertonic ointments (5%NaCl or dextran) or drops while asleep
b.
Artificial tears 4-6 times each day
2.
Protection by bandage soft contact lens has been used
3.
Reduction of proinflammatory medications

a.
4.
C.
Cycloplegic agent, topical nonsteroidal antiinflammatory drug, and oral analgesics may have
some role
Possible benefit of topical corticosteroid and/or oral doxycycline
Control of concomitant ocular surface condition, if present, such as:

a.
Dry eye syndrome
b.
Rosacea blepharitis
c.
d.
Corneal dystrophy or degeneration
Surgical interventions
1.
Anterior stromal micropuncture (See Anterior stromal puncture)
2.
Corneal epithelial debridement with polishing of Bowman's layer (diamond burr) (See Corneal
epithelial debridement)
83
AAO 2014-2016
3.
D.
Excimer laser phototherapeutic keratectomy
Follow-up
1.
Acute phase
a.
2.
Chronic phase
a.
IV.
B.
VI.
Follow-up in 1-2 months

A.
V.
Close follow-up depending on clinical response
Medical treatment
1.
Topical irritation and persistent discomfort
2.
Blurred vision
Surgical treatment
1.
Change in refractive error or induced astigmatism
2.
Increased discomfort

A.
Eye pain
B.
Sterile keratitis
C.
Microbial keratitis
D.
Corneal scarring
E.
Salzmann nodule

A.
Proper use of topical antibiotics in the acute stage
B.
Chronic nature of the disease which can be controlled medically, and in more severe forms
surgically
1.
AAO, Basic and Clinical Science Course. Section 8, External Disease and Cornea, 2013-2014.
2.
Aldave AJ, Sonmez B. Elucidating the molecular genetic basis of the corneal dystrophies: are we
there yet? Arch Ophthalmol. 2007 Feb;125(2):177-86.
3.
Weiss JS, Mller HU, Lisch W, et al. The IC3D classification of corneal dystrophies. Cornea.
2008;27:S1-S42
4.
Hykin PG, Foss AE, Pavesio C, et al. The natural history and management of recurrent corneal
84
AAO 2014-2016
erosion: a prospective randomised trial. Eye 1994;8:35-40.

5.
Ohman L, Fagerholm P. The influence of excimer laser ablation on recurrent corneal erosions: a
prospective randomized study. Cornea 1998;17:349-52.
6.
Hykin PG. Foss AE, Pavesio C, et al. The natural history and management of recurrent corneal
erosion: a prospective randomised trial. Eye 1994;8:35-40.
7.
Ramamurthi S, Rahman MQ, Dutton GN, et al. Pathogenesis, clinical features and management of
recurrent corneal erosions. Eye 2006;20:635-44. Review.
8.
AAO, Focal Points: Surgical Techniques for Ocular Surface Reconstruction, Module #12, 2006.
9.
AAO, Focal Points: Therapy of Recurrent Erosion and Persistent Defects of the Corneal Epithelium,
Module #9, 1991, p.3-4.
85
AAO 2014-2016
Persistent corneal epithelial defect

I.

A.

1.
Generally related to some underlying disease process that compromises epithelial regeneration
and/or the reformation of a normal basement membrane complex
2.
Common causes
a.
b.
3.
B.
i.
Herpes simplex virus (HSV) epithelial keratopathy
ii.
Herpes zoster ophthalmicus (HZO)
iii.
Diabetes mellitus
Limbal stem cell insufficiency

i.
Chemical injury
ii.
Congenital aniridia
c.
Chronic cicatricial keratitis (ocular mucous membrane pemphigoid, Stevens Johnson

Syndrome)
d.
i.
Eyelid malposition
ii.
Proptosis
e.
Toxic keratopathy
f.
Anesthetic abuse
g.
Neuroparalytic disease
i.
Cranial nerve (CN) VII palsy
ii.
Cerebellar pontine angle neoplasia
Medications (e.g., topical aminoglycoside antibiotics, antiviral agents, NSAIDS) and preservatives
(e.g., benzalkonium chloride) that impair epithelial healing
Define the pertinent elements of the history

1.
Nonhealing epithelial defect despite treatment
2.
Key to determine underlying cause
3.
Review ophthalmic medications with particular attention to preservatives
4.
Infection
5.
Allergic conditions
86
AAO 2014-2016
C.
II.
III.
6.
Trauma
7.
Ocular surgery
8.
Eyelid conditions
9.
Dry eye symptoms
10.
Equally important to elicit history of non-ocular conditions such as:

a.
Dermatologic disorders
b.
Neurological disorders
c.
Systemic disorders (e.g., collagen vascular disease and nutritional disorders)

1.
Often a round or oval epithelial defect located in inferior half of cornea
2.
Frequently have elevated, rounded edge or scalloped borders
3.
May be associated with underlying stromal inflammation
4.
Frequently have corneal hypesthesia
5.
If left untreated
a.
Can progress to vascularization and corneal opacification or scarring
b.
May progress to necrosis and thinning of the stroma, leading to perforation

A.
Undiagnosed, untreated, or undertreated ocular or systemic conditions
B.
Poor medication or treatment compliance
C.
Presence of any of the causes listed above

A.
Local, non-immune-mediated
1.
Postinfectious (bacterial, viral, fungal, amoebic)
2.
Traumatic (chemical, thermal, radiation burn)
3.
Postsurgical (diabetes patient, refractive procedure, anterior segment ischemia)
4.
Epithelial and basement membrane complex disorders (e.g., epithelial basement membrane
dystrophy)
5.
Abnormal eyelids or eyelashes
6.
a.
Ectropion/entropion/trichiasis
b.
Exposure/lagophthalmos/floppy eyelid syndrome
Neurological disorders
87
AAO 2014-2016
7.
B.
a.
Neurotrophic keratitis (HSV)
b.
Neuroparalytic keratitis (Bells palsy)
Dermatologic disorders
a.
Acne rosacea
b.
Psoriasis
Local, immune-mediated
1.
2.
Mooren ulcer
3.
Marginal keratitis
4.
Postsurgical
a.
C.
D.
Systemic, non-immune-mediated
1.
Nutritional disorders (e.g., keratomalacia)
2.
Psychiatric disorders (e.g., mucous fishing syndrome)
Systemic, immune-mediated
1.
2.
E.
Lacrimal disorders
a.
b.
Sjgren syndrome
c.
Graft-versus-host disease
Collagen vascular disorders

a.
b.
c.
Relapsing polychondritis
d.
Rheumatoid arthritis
e.
Systemic lupus erythematosus
f.
Polyarteritis nodosa
g.
Wegener granulomatosis
Allergic disorders
1.
IV.
Suture reaction

A.
88
AAO 2014-2016
1.
Remove the offending stimulus or aggravating drugs
2.
Treat the underlying condition
3.
Culture (as indicated)
4.
Lubricants, hypertonics, ophthalmic viscosurgical devices (viscoelastics) (avoid preservatives)
5.
Pressure patch
6.
Bandage contact lens
7.
Anti collagenolytics
a.
B.
V.
Sodium citrate/medroxyprogesterone/tetracycline
8.
Immunosuppression (e.g. cyclophosphamide)
9.
10.
Epidermal and nerve growth factors and retinoids (off label use)

1.
Debridement of devitalized tissue
2.
Punctal occlusion
3.
Tissue adhesive
4.
Tarsorrhaphy
5.
Conjunctival resection
6.
Tenon-plasty
7.
Mucous membrane graft
8.
Amniotic membrane graft/patch
9.
Keratoepithelioplasty or limbal allograft
10.
Limbal autograft
11.
Conjunctival flap
12.
Lamellar or penetrating keratoplasty
13.
Keratoprosthesis

A.
1.
2.
May exacerbate underlying or undiagnosed infectious process

a.
Differentiation based primarily on history and clinical findings
b.
May exclude other viral or bacterial processes with appropriate cultures
May limit repair processes and permit collagenolytic debridement of the stroma
89
AAO 2014-2016
a.
B.
Immunosuppressives
1.
VI.
Continued intensive use of corticosteroid should be continued beyond 10 to 14 days only

with close observation until reepithelialization is complete
Adverse reactions include but are not limited to:

a.
Bone marrow suppression
b.
Nephrotoxicity
c.
Hepatotoxicity
d.
Secondary infections and malignancies
e.
Hemolytic anemia

A.
Progressive, and sometimes rapid, stromal thinning
B.
Vascularization and scar formation
C.
Superinfection
D.
Corneal perforation

A.
Treatment compliance and close follow-up are key to successful treatments
1.
2.
Focal Points: Therapy of Recurrent Erosion and Persistent Defects of the Corneal Epithelium,
September 1991.
90
AAO 2014-2016
I.

A.

1.
2.
3.
B.
D.
a.
Trauma, including surgical injury (e.g., trigeminal rhizotomy)
b.
Neoplasm
c.
Herpes zoster ophthalmicus (HZO)
d.
Herpes simplex virus (HSV) keratitis
Topical ophthalmic medications

a.
Chronic topical anesthetic use/abuse
b.
Beta blockers
Central nervous system compromise of trigeminal nerve function (rare)

a.
Cerebrovascular accident
b.
Aneurysm
c.
Demyelinating disease (multiple sclerosis)
d.
Dysautonomias
e.
Congenital insensitivity to pain

1.
C.
Dysfunction of the ophthalmic (first) division of the trigeminal (fifth) cranial nerve (CN):
Varies with etiology

1.
Age at onset (infancy in familial dysautonomia)
2.
Past medical history
3.
Past ocular history (chronic-recurrent HSV keratitis)
4.
Family history (familial dysautonomia)
5.
Blurred vision

1.
2.
Decreased tearing
3.
4.
Non-healing epithelial defects, sterile ulceration
5.
Poorly responsive to topical lubricants
91
AAO 2014-2016
E.
6.
Central, inferior paracentral cornea most often involved
7.
HSV keratitis
III.
IV.
Punctate epithelial erosions with fluorescein staining
b.
Chronic epithelial regeneration lines
c.
Trophic ulcers
d.
Thickened, rolled, gray edges, oval shape
e.
Minimal rose bengal staining of edges
f.
Intense fluorescein staining/pooling in base
8.
HZO
9.
Zosteriform rash

1.
II.
a.
Neuroimaging if suspected tumor, cerebrovascular accident, demyelinating disease

A.
Decreased blinking associated with visually attentive tasks
B.
Previous HSV or HZO
C.
Low humidity
D.
Topical ophthalmic medications

1.
Preservatives, especially benzalkonium chloride
2.
Trifluridine
E.
Beta-adrenergic antagonists
F.
Diabetes mellitus

A.
B.
C.
Toxicity of topical medications/preservatives (toxic ulcerative keratopathy)
D.
Factitious keratopathy
E.
Anesthetic abuse

A.

1.
Treatment of underlying disease
92
AAO 2014-2016
B.
V.
Tear supplementation with frequent preservative-free lubricants
3.
Reduce evaporative tear loss

a.
Goggles, moisture shields
b.
Humidifiers
4.
Treatment of any concomitant dry eye (See Aqueous tear deficiency, Sjgren syndrome and Mucin
deficiency)
5.
6.
Anti collagenolytic agents (such as tetracyclines, medroxyprogesterone) in more severe cases

1.
Punctal occlusion
2.
Lateral or medial tarsorrhaphy
3.
Correction of eyelid abnormalities, lagophthalmos
4.
Amniotic membrane graft/patch

A.
B.
VI.
2.
Topical lubricants
1.
Complications: epithelial toxicity of preservatives
2.
Prevention and management: preservative-free lubricants
Surgical (See Punctal occlusion, Tarsorrhaphy)

A.
Corneal scarring
B.
C.
D.
Corneal thinning, perforation

A.
Careful avoidance of trauma, risk factors
B.
C.
Proper frequency and timing for use of topical lubricants
D.
E.
93
AAO 2014-2016
1.
2.
AAO, Focal Points: Neurotrophic Keratitis, Module #2, 2003.
94
AAO 2014-2016
Trichiasis and distichiasis

I.
Describe the approach for establishing the diagnosis

A.

1.
Trichiasis
a.
2.
Acquired misdirection of eyelashes that curve toward the ocular surface
Distichiasis
a.
Accessory eyelashes growing posterior to the normal row of eyelashes

i.
ii.
Acquired distichiasis
i)
Extra eyelashes emerge from meibomian glands
ii)
Aberrant eyelashes emerge from tarsus
Congenital distichiasis
i)
B.
C.
II.
Extra row of eyelashes emerge from meibomian glands

1.
Presence and severity of foreign-body sensation and discomfort
2.
Previous treatment for abnormal eyelashes and previous eyelid surgery
3.
Previous ocular surface inflammation or disease

1.
Location and number of misdirected eyelashes
2.
Ocular surface erosion and inflammation

A.
B.
Chronic inflammatory conditions of the eyelid and conjunctiva

1.
2.
3.
Chemical burn
4.
Rosacea blepharoconjunctivitis
5.
Trachoma
6.
Distichiasis can be familial or part of a hereditary syndrome
95
AAO 2014-2016
III.
IV.

A.
Entropion
B.
Epiblepharon
C.
Ectodermal dysplasia

A.
B.
V.

1.
Lubricants
2.
Bandage soft contact lens to protect ocular surface
3.
Treatment of associated ocular surface disorder

1.
Mechanical epilation of misdirected eyelashes
2.
Electrolysis or electrocautery (hyfrecation) or laser destruction of eyelash follicles
3.
Cryotherapy
4.
Incisional procedure
a.
Eyelid splitting along the gray line with excision, electrocauterization, or cryotherapy of the
hair follicles
b.
Resection of abnormal eyelash follicles without or with mucous membrane grafting and
without or with tarsal rotation and tarsotomy
c.
Surgical correction of concomitant entropion or other abnormal eyelid position

A.
B.
C.
D.
Mechanical removal
1.
Broken eyelashes
2.
Regrowth of aberrant eyelashes
Electrolysis
1.
Treated eyelash may not fall out
2.
Cryotherapy
1.
Loss of adjacent, normal eyelashes
2.
Eyelid margin thinning and hypopigmentation
3.
Surgical incision
96
AAO 2014-2016
1.
VI.
Eyelid notching

A.
Conjunctivitis
B.
C.
Corneal neovascularization, inflammation, and opacity
D.
Bacterial keratitis

A.
Eyelash regrowth may occur
1.
2.
AAO, Focal Points: The Management of Trichiasis, Module #4, 2001.
3.
AAO, Focal Points: Management of Cicatricial Entropion, Trichiasis, and Distichiasis, Module #12,
1993.
97
AAO 2014-2016
Ocular surface problems related to contact

lens
I.

A.
B.
C.
Describe the etiology of the disease (See Contact lens-induced conjunctivitis)

1.
Direct mechanical trauma from contact lens
2.
Immune-mediated response to mechanical trauma
3.
Hypersensitivity reaction, allergic reaction (i.e., thimerosal)
4.
Hypoxic response with metabolic epithelial damage
5.
Toxicity from contact lens solution (i.e., hydrogen peroxide, benzalkonium chloride, etc.)
6.
Limbal stem cell deficiency

1.
Redness
2.
Itching, irritation, mucoid discharge
3.
Pain
4.
Blurred vision

1.
Conjunctival changes
a.
2.
Papillary reaction on the superior tarsal conjunctiva, giant papillary reaction, conjunctival
injection
Corneal changes
a.
Peripheral corneal neovascularization
b.
Corneal infiltrates
c.
Subepithelial infiltrates
d.
Corneal haze
e.
Central epithelial edema (Sattler veil) - more commonly with hard contact lenses
f.
Epithelial erosions
g.
Microcystic epitheliopathy - most commonly with extended-wear soft contact lenses
h.
Superior epithelial arcuate lesion
i.
Advancing wavelike epitheliopathy
j.
Dimple veil - air bubble beneath gas permeable lens may cause indentation of cornea
98
AAO 2014-2016
k.
3.
II.
III.
IV.
Corneal scarring, especially apical in keratoconus
Mild iritis

A.
Extended contact lens wear
B.
Overnight contact lens wear
C.
Lower oxygen permeability
D.
Poor compliance with lens hygiene, wearing schedule
E.
Smoking while wearing contact lenses

A.
B.
Bacterial conjunctivitis, including chlamydia
C.
Allergic conjunctivitis/keratitis
D.
Toxic conjunctivitis
E.
Staphylococcal marginal keratitis
F.
Microbial keratitis, especially bacterial

A.

1.
2.
Acute
a.
Stop contact lens wear
b.
Topical antibiotics (typically topical fluoroquinolone), if infection suspected (See Bacterial

keratitis)
c.
Consider topical corticosteroids, usually low dose (if significant corneal inflammation
present) and there is no evidence of infection
d.
Refit with a flatter contact lens in a patient with tight lens syndrome after acute symptoms
resolve
Chronic
a.
Decrease contact lens wearing time
b.
Refit patient with a different type of contact lens (i.e., daily disposable soft contact lens or a
rigid gas permeable contact lens)
c.
Improved contact lens hygiene
d.
Rarely, treatment for significant contact lens induced stem cell deficiency may require
99
AAO 2014-2016
surgical intervention (i.e. limbal stem cell graft)

3.
V.

A.
B.
C.
VI.
Follow-up in 3-7 days depending on severity of presentation
Complications of topical corticosteroids

1.
Glaucoma
2.
Cataract
3.
Worsening of infection
Complications of topical antibiotics

1.
Allergy
2.
Resistance

1.
Use topical corticosteroids judiciously
2.
Use corticosteroids concurrently with antibiotics

A.
Microbial keratitis
B.
Loss of vision
C.
Corneal scarring
D.
Contact lens intolerance
E.
Corneal warpage

A.
Emphasize importance of compliance with therapy and follow-up
B.
Patients should be counseled to call if increasing pain develops or the vision changes
C.
Importance of proper contact lens hygiene should be stressed
1.
2.
AAO, Focal Points: Corneal Complications of Contact Lens, Module #2, 1993.
3.
Sankarigurg PR, Sweeney DF, Holden BA, et al. Comparison of adverse events with daily
disposable hydrogels and eyeglass wear: results from a 12-month prospective clinical trial.
Ophthalmology. 2003;110:2327-34.
100
AAO 2014-2016
4.
Nilsson SE. Seven-day extended wear and 30-day continuous wear of high oxygen transmissibility
soft silicone hydrogel contact lenses: a randomized 1-year study of 504 patients. CLAO J.
2001;27:125-36.
5.
Polse KA, Graham AD, Fusaro RE, et al. The Berkeley Contact Lens Extended Wear Study. Part
II: Clinical results. Ophthalmology. 2001;108:1389-99.
6.
Fusaro RE, Polse KA, Graham AD, et al. The Berkeley Contact Lens Extended Wear Study. Part I:
Study design and conduct. Ophthalmology. 2001;108:1381-8.
7.
101
AAO 2014-2016
Limbal stem-cell deficiency

I.

A.
B.
C.
D.

1.
Aniridia
2.
Congenital erythrokeratodermia or ectodermal dysplasia
3.
Keratitis associated with multiple endocrine deficiencies
4.
Neurotrophic (neural and ischemic) keratopathy
5.
Chronic limbal inflammation
6.
Dysplastic, neoplastic lesions of the limbus
7.
Rosacea blepharitis
8.
Atopic disease
9.
Chemical injuries, including toxic topical medications, preservatives
10.
Thermal injuries
11.
Mechanical (surgical) injuries
12.
Immunologic destruction (chronic graft vs. host disease)
13.
Cicatricial conjunctivitis (Stevens-Johnson Syndrome, Trachoma, mucous membrane pemphigoid)
14.
Contact lens related

1.
Varies with etiology
2.
Uncommon disease except in patients with chronic inflammatory, neurotrophic, or genetic

conditions causing loss or absence of corneal stem cells

1.
Decreased vision
2.
Photophobia
3.
Tearing
4.
Blepharospasm
5.
Recurrent episodes of pain (epithelial breakdown)
6.
History of chronic inflammation with redness

1.
Dull and irregular reflex of the corneal epithelium which varies in thickness and transparency, late
fluorescein staining
102
AAO 2014-2016
E.
II.
2.
Chronic conjunctival hyperemia
3.
Chronic keratitis with chronic staining
4.
Conjunctivalization/vascularization of the corneal surface
5.
Demarcation line visible between corneal and conjunctival epithelial cell phenotype (conjunctival
epithelial cells stain with fluorescein)
6.
Persistent epithelial defects
7.
Melting and perforation of the cornea in advanced and severe cases

1.
Careful clinical and slit-lamp biomicroscopic examination
2.
Additional testing may include

a.
Impression cytology - Examination for goblet cells, indicating presence of conjunctival

epithelium on the corneal surface
b.
Epithelial debridement - Examination for goblet cells and immuno histochemistry looking for
presence of cytologic markers associated with conjunctival epithelial cells (cytokeratin 13
and 19)
c.
In vivo laser scanning confocal microscopy: alterations in normal anatomic findings

A.
Intrinsic diseases that can be associated with partial or total stem cell deficiency include
1.
Pterygium
2.
Limbal tumors
3.
Aniridia
4.
Mucous membrane pemphigoid (ocular cicatricial pemphigoid)
5.
Chronic limbitis
6.
Chronic herpes simplex epithelial disease
7.
8.
Congenital erythrokeratodermia or ectodermal dysplasia
9.
Neuroparalytic keratitis
10.
Atopic disease
B.
Chemical or thermal exposure
C.
Multiple surgeries or cryotherapies
D.
Contact lens wear
E.
Extensive microbial infection
F.
Chronic use of tropical medication
103
AAO 2014-2016
III.
IV.
G.
Dry eye
H.
Systemic chemotherapy
I.
Allogenic bone marrow transplant

A.
B.
Medication induced toxic keratitis
C.
Allergic reactions
D.
Acute herpetic eye disease
E.
Contact lens induced toxic keratitis

A.

1.
Patients with partial stem cell deficiency

a.
2.
B.
Patients with total stem cell failure

a.
Progressive conjunctivalization of the cornea with loss of transparency
b.
Possible corneal thinning, melting, perforation

1.
2.

a.
Asymptomatic patients with partial and peripheral conjunctivalization of the corneal surface
may not require intervention except close follow-up for of progression
b.
Treatment of the underlying problem (e.g., dry eye, blepharitis, rosacea)
Patients with total stem cell deficiency

a.
3.
C.
If underlying disease process is halted prior to severe corneal conjunctivalization, visual

outcome is quite good
Surgical therapy options as described below
Treatment of associated conditions (e.g., dry eye, meibomian gland dysfunction, corneal
exposure)
a.
Nonpreserved artificial tears and ointment
b.
Punctal plugs
c.

1.

a.
If the visual axis or most of the corneal surface covered with conjunctival epithelium,
104
AAO 2014-2016
mechanical debridement of conjunctival epithelium may allow adequate corneal epithelial

healing to occur from the remaining functioning limbal epithelium
b.
2.
Amniotic membrane transplantation and mechanical debridement
Patients with total stem cell deficiency

a.
Conjunctival limbal autograft if only one eye is affected and the fellow eye is completely
normal
b.
Conjunctival limbal or keratolimbal allograft when both eyes are affected; aggressive
systemic immunosuppression for at least 12 months is essential
i.
3.
V.
c.
Oral mucosal autograft
d.
Keratoprosthesis
Correction of any lid abnormality or ocular surface issue that may contribute to ocular surface
failure (Trichiasis, entropion, symblepharon)

A.
Complications of systemic immunosuppression

1.
Susceptibility to infection
2.
Renal and hepatic toxicity
3.
Cardiovascular events (myocardial infarction and cerebrovascular accident)
4.

a.
VI.
This may be followed by keratoplasty
Involvement of transplant specialists in management of these patients

A.
Discomfort, photophobia, and chronic inflammation
B.
Corneal neovascularization and loss of corneal transparency
C.
Corneal melt
D.
Corneal perforations

A.
Chronic nature of the disease with limited treatment options needs to be explained to patient
B.
In patients on systemic immunosuppression due to allografts, possible complications associated

with the therapy as well as the importance of regular follow-up with transplant specialists to
monitor for signs of toxicity is essential
105
AAO 2014-2016
1.
2.
Dua HS, Saini JS, Azuara-Blanco A, Gupta P. Limbal stem cell deficiency: concept, aetiology,
clinical presentation, diagnosis and management. Indian J Ophthalmol 2000 Jun;48(2):83-92.
Review.
3.
Puangsricharern V, Tseng SC. Cytologic evidence of corneal diseases with limbal stem cell
deficiency. Ophthalmology 1995 Oct;102(10):1476-85.
4.
Tseng SC. Significant impact of limbal epithelial stem cells. Indian J Ophthalmol 2000
Jun;48(2):79-81.
106
AAO 2014-2016
Acute conjunctivitis
I.

A.

1.
Person-to-person
a.
b.
Direct
i.
contact with eye secretions from the infected individual
ii.
Sexual transmission
Indirect
i.
2.
3.
B.
C.
Contact with fomites contaminated with infectious secretions
Auto-inoculation
a.
From organisms colonizing patient's own nasal and sinus mucosa
b.
Acute conjunctivitis associated with chronic inflammatory lid disease i.e., dermatoblepharitis
and/or staphylococcal marginal blepharitis
Environmental
a.
Seasonal allergies
b.
Toxic/allergic conjunctivitis triggered by topical medication or other substance

1.
Viral and bacterial conjunctivitis preferentially affects populations living in close quarters, such as
schools, nursing homes, military housing and summer camps
2.
Infectious conjunctivitis generally more common in children and young adults
3.
Epidemic viral keratoconjunctivitis may also be contracted in eye care providers' offices

1.
Watery, purulent, mucoid, or stringy discharge
2.
Epiphora
3.
Crusting and mattering of eyelids and eyelashes
4.
Eye redness
5.
Eyelid swelling
6.
Blurry vision
7.
8.
Recent upper respiratory infection
9.
Recent exposure to individual with red eye
107
AAO 2014-2016
D.
10.
Recent visit to eye care provider
11.
Contact lens use

1.
Conjunctiva
a.
b.
2.
III.
i.
hyperemia with or without chemosis
ii.
petechiae or hemorrhage
Tarsal
i.
papillae or follicles may develop depending upon cause
ii.
pseudomembranes and membranes in severe infections
Cornea
a.
II.
Bulbar
3.
Watery, serous, mucoid, or purulent discharge depending upon cause
4.
Preauricular adenopathy
5.
Periocular dermatitis or lid vesicles

A.
Viral conjunctivitis or blepharoconjunctivitis
B.
Bacterial conjunctivitis
C.
Allergic conjunctivitis
D.
E.
Exacerbation of lid disease with spillover conjunctival inflammation

A.
Supportive treatment with cool compresses and artificial tears
B.
Determine need for collection of conjunctival scraping for cytology, culture or PCR amplification
C.
Topical antibacterial agent for suspected bacterial conjunctivitis
D.
Systemic antibacterial agent for gonococcal conjunctivitis or chlamydial conjunctivitis
E.
Topical or oral antiviral agent for suspected herpes simplex virus conjunctivitis
F.
Topical corticosteroids only for severe conjunctival membranes or subepithelial corneal

infiltrates decreasing vision during adenovirus conjunctivitis
G.
Infectious precautions
108
AAO 2014-2016
IV.
List the complications of treatment, their prevention, and management

A.
Ocular surface toxicity from topical antibiotics, antivirals, and preservatives
B.
Antibiotics (topical and systemic)
C.
1.
Allergic reaction
2.
Bacterial resistance
1.
V.
VI.
Potentiation of infection, elevated IOP, cataract formation

A.
Conjunctival scarring and symblepharon formation
B.
Corneal infiltrates and corneal scarring
C.
Peripheral corneal vascularization

A.
Precautions to avoid spreading the infection to the fellow eye or other people
1.
Frequent hand washing
2.
Avoid touching the eyes
3.
Use separate towels and washcloths
B.
Instructions to discontinue contact lens wear until conjunctivitis resolves
C.
Instructions as to when to return to school or work (usually after at least 24 hours of treatment
with topical antibiotics in bacterial conjunctivitis, and longer in viral conjunctivitis, which may be
contagious for 10-14 days)
D.
Instructions as to when to expect resolution of symptoms
E.
Discard contact lenses, case, and contact lens solution
1.
2.
AAO, Preferred Practice Patterns Committee, Cornea and External Disease Panel. Conjunctivitis
Preferred Practice Pattern, 2008.
109
AAO 2014-2016
Chronic conjunctivitis
I.

A.

1.
Inflammation of the conjunctiva lasting longer than four weeks
2.
May be subdivided into

a.
Chronic papillary conjunctivitis

i.
Bacterial blepharoconjunctivitis
ii.
iii.
iv.
Superior limbic conjunctivitis
v.
Chronic dacryocystitis or canaliculitis
vi.
Foreign body (unilateral)
vii.
viii.
Mucus-fishing syndrome
ix.
x.
b.
c.
Hay fever
ii)
Perennial conjunctivitis
iii)
iv)
Atopic conjunctivitis
Giant papillary conjunctivitis (GPC) (See Contact-lens induced conjunctivitis)
Chronic follicular conjunctivitis

i.
Chlamydial conjunctivitis
ii.
Molluscum contagiosum
iii.
iv.
Trachoma
Membranous conjunctivitis
i.
d.
i)
Ligneous - systemic plasminogen deficiency
Cicatrizing conjunctivitis
i.
Mucous membrane pemphigoid (See Ocular mucous membrane pemphigoid)
ii.
Stevens-Johnson syndrome (See Stevens-Johnson syndrome (erythema multiforme

major))
110
AAO 2014-2016
e.
f.
iii.
Chemical burn (See Chemical (alkali and acid) injury of the conjunctiva and cornea)
iv.
Trachoma
v.
Chronic glaucoma medication use
Granulomatous conjunctivitis
i.
Cat-scratch disease and other causes of Parinaud oculoglandular syndrome
ii.
Sarcoidosis
Masquerade syndrome (unilateral)

i.
B.
C.
Meibomian gland carcinoma

1.
Watery, purulent or mucoid discharge
2.
Itching, burning, foreign body sensation, ocular discomfort
3.
Blurry vision
4.
Matting of the eyelashes and crusting of eyelids
5.
Eye redness
6.
Eyelid swelling

1.
2.
Chronic papillary conjunctivitis

a.
Variable features depending on the cause
b.
Mild to moderate purulent or mucopurulent discharge
c.
Eyelid edema or ulceration
d.
Conjunctival chemosis and injection
e.
Tarsal conjunctival papillae
f.
Punctate epithelial keratopathy
g.
Corneal stromal infiltrates (rare)
h.
May have associated blepharitis or eyelid lesion in masquerade syndrome
i.
Corneal phlyctenules
a.
Small to giant conjunctival papillae
b.
Mucoid or ropy discharge
c.
Conjunctival injection and chemosis
d.
Punctate epithelial keratopathy and vascularization
e.
Corneal ulceration (shield ulcers) and scarring
111
AAO 2014-2016
3.
4.
5.
6.
D.
Chronic follicular conjunctivitis

a.
Tarsal conjunctival follicules
b.
Watery or mucoid discharge
c.
Preauricular adenopathy with chlamydia
d.
e.
f.
Subepithelial corneal infiltrates and corneal vascularization with chlamydia
Membranous conjunctivitis (ligneous)

a.
"Woody" conjunctival membranes
b.
c.
Eyelid edema and ptosis
d.
Persistence and progression after surgical removal
Cicatrizing conjunctivitis
a.
Symblepharon, subconjunctival fibrosis, and foreshortening of the fornices
b.
Entropion, distichiasis and trichiasis
c.
Mucoid discharge and conjunctival pseudomembranes
d.
e.
f.
Corneal vascularization and scarring
g.
Keratinization of the ocular surface
h.
i.
Systemic findings in mucous membrane pemphigoid and Stevens-Johnson syndrome
j.
Altered tear film
Granulomatous conjunctivitis
a.
Conjunctival nodules that progress to pustules and large vegetations
b.
c.
Mild conjunctival discharge
d.
Preauricular, cervical and submaxillary adenopathy
e.
Associated systemic symptoms: fever, malaise, etc.

1.
Conjunctival scraping for

a.
Giemsa stain (intracytoplasmic inclusions in Chlamydia and eosinophils in allergic

conjunctivitis)
112
AAO 2014-2016
2.
3.
II.
III.
IV.
b.
Immunofluorescent antibody test (Chlamydia)
c.
Bacterial culture and susceptibility
d.
Viral cultures
Conjunctival biopsy for

a.
Complement and Ig deposition along BMZ (mucous membrane pemphigoid)
b.
Histopathology (masquerade syndrome, granulomatous conjunctivitis)
Serology for
a.
Antibodies to Bartonella henselae (Cat scratch disease)
b.
Plasminogen antigen and activity (membranous conjunctivitis)
Define risk factors

A.
Variable depending on cause
B.
Direct contact with infected individual eye secretions in bacterial and viral conjunctivitis
C.
Sexual transmission in chlamydial disease
D.
Zoonosis exposure: cat contact in cat-scratch disease, etc.
E.
Personal or family history of atopy in atopic keratoconjunctivitis
F.
Use of topical or systemic medications in cicatrizing disease
G.
History of sleep apnea for floppy eyelid syndrome
H.
Contact lens wear (GPC)

A.
B.
Meibomian gland dysfunction and rosacea
C.
Factitious conjunctivitis
1.
Anesthetic abuse
2.
Foreign objects: feces, dental plaque
3.
Secondary gain/ malingering/ psychiatric disorders
D.
Episcleritis/ scleritis
E.
Exposure
F.
Benign folliculosis of childhood
G.
Thyroid eye disease
Describe the management in terms of treatment and follow-up
113
AAO 2014-2016
V.
VI.
A.
Treatment depends upon underlying cause
B.
Oral antichlamydial agent for adult chlamydial conjunctivitis
C.
Topical antibacterial agent for bacterial blepharoconjunctivitis
D.
Eyelid lesion excision for molluscum or other inflammatory nodule
E.
Topical antihistamine, mast-cell stabilizer, corticosteroid, and/or cyclosporine for ocular allergy
F.
Topical plasminogen (ligneous conjunctivitis)
G.
Systemic medications for zoonoses
H.
Systemic immunosuppressants for immune-mediated cicatrizing diseases
I.
Discontinuing topical medications in case of medicamentosa
J.
List complications of the disease
K.
Conjunctival scarring and symblepharon
L.
Trichiasis and tear deficiency
M.
N.
Corneal ulceration and scarring
List complications of treatment, prevention, and management

A.
Corneal toxicity from topical antibiotics
B.
Allergic reaction to topical antibiotics
C.
Bacterial resistance to topical antibiotics
D.
Complications of topical corticosteroids, if used (cataract, glaucoma)
E.
Side effects related to systemic medications

A.
Precautions to avoid spreading the infection to the other eye or other people, if conjunctivitis
infectious in etiology
1.
2.
Use separate towels and washcloths, and wash hands frequently
3.
Duration and mode of contagion
B.
C.
Instructions as to when to expect resolution of symptoms
D.
E.
F.
Treatment of partner in sexually transmitted diseases
114
AAO 2014-2016
1.
2.
AAO, Focal Points: Antibiotic Use in Corneal and External Eye Infections, Module #10, 1997, p.11.
3.
Watts P, Suresh P, Mezer E. Effective treatment of ligneous conjunctivitis with topical plasminogen.
Am J Ophthalmol. 2002;133:451-455.
4.
Heidemann DG, Williams GA, Hartzer M. Treatment of ligneous conjunctivitis with topical plasmin
and topical plasminogen. Cornea. 2003;22:760-762.
115
AAO 2014-2016
Herpes simplex virus blepharitis,

conjunctivitis, and blepharoconjunctivitis
I.

A.
B.

1.
Usually secondary to herpes simplex virus (HSV)-1
2.
Initial infection in naive individuals occurs due to exposure, often in childhood, through contact with
oral secretions containing virus
3.
Initial infection is followed by centripetal migration to sensory ganglia resulting in latency state
(ciliary or trigeminal ganglion)
4.
Replication may occur in the ganglion and travel through the sensory nerves to present as a
primary infection - usually subclinical
5.
Also presents as recurrent ocular infection years after the initial infection due to reactivation of
latent disease in the ganglion

1.
33% of world population infected
2.
99% of trigeminal ganglia affected by age 60
3.
HSV-1 and HSV-2 reside in ganglia

a.
C.
D.
Local factors control expression
4.
Primary HSV infections usually unrecognized
5.
Asymptomatic viral shedding in secretions is usual mode of transmission
6.
Symptomatic patients are more infectious due to greater viral load
7.
Increasing role of HSV-2 in ocular disease

1.
History of previous ocular herpes or cold sores
2.
Triggers for reactivation including

a.
Sun exposure
b.
Recent illness
c.
Recent ocular surgery
d.
Stress
3.
Red eye
4.
Skin lesions
116
AAO 2014-2016
E.
1.
Primary HSV blepharoconjunctivitis if clinically manifest is clinically indistinguishable from

recurrent disease
2.
Vesicles on skin or eyelid margin

a.
Raised clear vesicles
b.
Progress to blistered, crusted lesions
3.
Follicular conjunctivitis
4.
Bulbar conjunctival ulceration
5.
Presence of a pre-auricular lymphadenopathy
6.
Can be bilateral in 10% of cases
Describe appropriate testing and evaluation for establishing a diagnosis

1.
Clinical signs and symptoms usually establish diagnosis as testing may have poor sensitivity as
well as increased expense
2.
Cytology
a.
3.
4.
Antigen detection tests

a.
Immunofluorescence
b.
Enzyme-linked immunosorbent assay (ELISA)
Tissue culture
a.
Swab from vesicle, conjunctiva, or cornea
b.
Requires viral transport media (chill with ice)
5.
Polymerase chain reaction (PCR) detection of HSV DNA collected from fluid or scraping (vesicle
base or conjunctiva)
6.
Serologic testing
a.
II.
III.
Scrapings from active skin vesicles or conjunctiva demonstrate intranuclear eosinophilic

inclusion bodies and giant cells
Of very little use
Define the risk factors (primary disease as well as recurrence)

A.
Possible genetic predisposition
B.
Environmental triggers such as sun exposure, recent illness, recent ocular surgery
C.
Virulent strain of HSV-1
D.
Immunocompromised patient

A.
Varicella zoster virus (VZV)
117
AAO 2014-2016
IV.
B.
Adenovirus
C.
Other causes of recurrent follicular conjunctivitis (e.g., chlamydia, molluscum)

A.
V.
Define medical therapy options - shorten course of disease

1.
Topical antiviral, such as trifluridine 1% solution, or ganciclovir 0.15% gel
2.
Oral antivirals
Acyclovir
b.
Valacyclovir
c.
Famciclovir

A.
Complications of treatment
1.
2.
B.
C.
VI.
a.
Topical agents
a.
Epithelial toxicity
b.
c.
Contact dermatitis
Oral agents - avoid use in patients with renal impairment

1.
Limit use of topical antiviral to treatment of active disease
2.
Consider use of oral antivirals - tolerated well
Treatment of children can be complicated by tearing which dilutes the drops and can render
treatment ineffective
Describe disease related complications

A.
Recurrence with keratouveitis - epithelial or stromal keratitis (concurrent or sequential)
B.
Autoinoculation resulting in herpetic whitlow due to herpetic infection of a break in the skin
surface (e.g. from thumb sucking with a herpetic oral infection)
C.
Risk of transmission to others

A.
Stress importance of compliance and need for follow up
B.
Awareness of symptoms that may represent toxicity
118
AAO 2014-2016
C.
Awareness of symptoms that may represent worsening of disease
D.
Many times a self-limited condition
1.
2.
3.
4.
Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease
Study Group. N Engl J Med. 1998;339:300-6.
119
AAO 2014-2016
Herpes simplex virus epithelial keratitis

I.

A.

1.
Usually secondary to herpes simplex virus (HSV)-1, sometimes HSV 2
2.
Initial exposure often in childhood through contact with oral lesions and secretions - primarily
subclinical
3.
Centripetal migration to sensory ganglia resulting in latency state (ciliary or trigeminal ganglia)
4.
Reactivation of latent virus periodically
5.
Centrifugal migration to the cornea via sensory nerves

a.
B.
C.
D.
Replication of viral DNA and viral proteins in the epithelial cells, followed by viral
reassembly and release, resulting in cell-to-cell spread and producing characteristic
dendritic epithelial keratitis.

1.
33% of world population infected
2.
Approximately 500,000 people in the U.S. with a history of herpes simplex eye disease
3.
Approximately 20,000 new cases of ocular herpes occur in the U.S. annually, and more than
28,000 reactivations occur in the U.S. annually
4.
HSV latent in nearly 100% of trigeminal ganglia by age 60
5.
6.
Asymptomatic viral shedding is usual mode of transmission.
7.
Symptomatic patients are more infectious due to greater viral load.
8.
Epithelial keratitis accounts for 59% of herpetic eye disease
9.
Usually unilateral, but can be bilateral in 1-10%. Bilaterally more common with risk factors of
immunosuppression or atopy
10.
Stress is suspected but not proven underlying factor for activation

1.
History of previous ocular herpes or cold sores
2.
Close family member with a history of frequent cold sores
3.
Risk factors for HSV epithelial reactivation include sun exposure, recent illness, recent ocular
surgery with topical steroid use, immunosuppression
4.
Photophobia, throbbing pain, lack of foreign body sensation

1.
Punctate epithelial keratitis
120
AAO 2014-2016
a.
2.
3.
4.
5.
E.
Dendritic epithelial keratitis

a.
Linear lesion with dichotomous branching and terminal bulbs at the ends of branches as
opposed to feathered or tapered ends in pseudodendrites
b.
Characteristic staining with rose bengal or lissamine green
Geographic epithelial keratitis

a.
Scalloped, pleomorphic epithelial ulceration
b.
May have peripheral branches similar to dendrites
c.
Borders stain with rose Bengal or lissamine green
d.
Often associated with use of topical corticosteroids or seen in immunocompromised host
Conjunctivitis
a.
Unilateral follicular conjunctivitis that differentiates it from adenoviral conjunctivitis as that is

usually bilateral
b.
May be associated with periocular vesicles that make the diagnosis straightforward
HSV ocular infections in children present special problems

a.
Children are difficult to examine
b.
Crying may dilute the drops
c.
Corneal scarring may lead to amblyopia

1.
Clinical signs and symptoms usually establish diagnosis as testing may have poor sensitivity as
well as increased expense
2.
Cytology
3.
4.
a.
Scrapings from active skin vesicles
b.
Intranuclear eosinophilic inclusion bodies and giant cells
Tissue culture
a.
Swab from vesicle, conjunctiva, or cornea
b.
Requires viral transport media (chill with ice)
Fluorescent antibody testing of corneal swab

a.
II.
Often seen in early stages of recurrence
Smear on slide
5.
Polymerase chain reaction (PCR) detection of HSV DNA from fluid or scrapings
6.
Serology not especially helpful
Define the risk factors (primary disease as well as recurrence)
121
AAO 2014-2016
III.
A.
B.
C.
Virulent strain of HSV-1
D.
Previous episodes of HSV keratitis

A.
Varicella zoster virus (VZV) epithelial keratitis
B.
Toxic epitheliopathy
1.
Topical medications
2.
Preservatives
C.
Acanthamoeba keratitis (early stage)
D.
Epithelial regeneration lines

1.
E.
IV.
Corneal abrasion and erosions
Other rare causes of dendrites or dendritiform lesions include

1.
Thygeson superficial punctate keratitis
2.
Adenovirus keratoconjunctivitis
3.
Epstein-Barr virus epithelial keratitis
4.
Tyrosinemia type II
5.
Drug deposits

A.

1.
2.
3.
B.
Topical antivirals
a.
Trifluridine drops 5-9x/day for 10 days until reassessed for improvement. Watch for toxicity
b.
Gentle wiping debridement (cotton-tipped applicator)
c.
Ganciclovir gel 5 times a day
Oral antivirals - acyclovir, valacyclovir, famciclovir

a.
Oral antivirals have efficacy equivalent to topical agents
b.
The Herpetic Eye Disease Study showed no benefit from adding oral acyclovir for 3 weeks
in improving outcome of epithelial disease or preventing stromal disease when used
concurrently with topical trifluridine
An active epithelial corneal infection (dendritic or geographic ulcer) is a relative contraindication for
topical corticosteroid use
Describe follow-up
122
AAO 2014-2016
V.
Patients are often seen at 1 week interval for assessment
2.
Active keratitis should resolve in 7-14 days - residual punctate epithelial erosions can remain for
weeks
3.
If keratitis appears active

a.
Consider further debridement with culture
b.
Consider switching medications

A.
B.
VI.
1.
Complications of topical treatment

1.
Epithelial toxicity
2.
3.
Lacrimal punctal occlusion
4.
Contact dermatitis

1.
Limit use of topical antiviral drops to treatment of active epithelial keratitis
2.
No evidence to suggest treatment should be continued in the presence of inactive keratitis or with
taper
3.
Toxicity from topical drops is related to duration of treatment
4.
Consider use of oral antivirals in cases of significant toxicity

A.
Delayed epithelial healing
B.
Stromal scarring
C.
Stromal keratitis
D.
Neurotrophic cornea

A.
B.
Awareness of symptoms that may represent toxicity
C.
Awareness of symptoms that may represent worsening of disease (stromal keratitis)
1.
123
AAO 2014-2016
2.
Disease, Module #9, 2002, p.5-7.
3.
AAO, Focal Points: Herpes Simplex Virus Eye Disease, Module #2, 1997.
4.
Predictors of recurrent herpes simplex virus keratitis. Herpetic Eye Disease Study Group. Cornea
2001;20:123-8.
5.
Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and
stromal keratitis. Herpetic Eye Disease Study Group. Arch Ophthalmol 2000;118:1030-6.
6.
A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with
herpes simplex virus epithelial keratitis. The Epithelial Keratitis Trial. Herpetic Eye Disease Study
Group. Arch Ophthalmol 1997 Jun;115:703-12.
7.
Young RC, Hodge DO, Liesegang TJ, Baratz KH. The Incidence, Recurrence and Outcomes of
Herpes Simplex Virus Eye Disease in Olmsted County, Minnesota, 1976 through 2007: The Impact
of Oral Antiviral Prophylaxis Arch Ophthalmol. 2010; 128: 1178-1183.
124
AAO 2014-2016
Herpes simplex virus stromal keratitis and

endotheliitis
I.

A.

1.
Usually secondary to herpes simplex virus (HSV)-1, sometimes HSV 2
2.
Non-necrotizing (interstitial) stromal keratitis and endotheliitis (disciform keratitis)
3.
a.
Likely represents humoral immunologic response to viral antigens resulting in cytotoxicity
b.
The role of live virus and latent infection is not well-defined although HSV has been isolated
from aqueous humor during HSV stromal keratouveitis
Necrotizing stromal keratitis

a.
B.
C.

1.
2.
Asymptomatic viral shedding occurs sporadically with no clearly defined stimulus
3.
Approximately 20% of patients with epithelial disease develop stromal keratitis

1.
History of previous ocular herpes, particularly previous stromal keratitis
2.
Triggers for reactivation may include
3.
D.
Likely represents live viral infection of keratocytes with concomitant severe immune
response, occasionally with granulomatous inflammation around Descemet's membrane
a.
Sun exposure
b.
Fever
c.
Recent illness
d.
Ocular surgery
e.
Stress
Duration and severity of symptoms: photophobia, pain, decreased vision

1.
Non-necrotizing stromal keratitis

a.
Stromal inflammation, often with associated stromal edema and endothelial pseudoguttata
b.
May be focal or multifocal
c.
Overlying epithelium intact
d.
May be accompanied by anterior chamber reaction with keratic precipitates
125
AAO 2014-2016
2.
3.
II.
III.
IV.
Endotheliitis
a.
Granulomatous keratic precipitates with associated overlying corneal edema
b.
Minimal stromal inflammation
c.
May be associated with mild anterior chamber reaction
d.
May have increased intraocular pressure (IOP) presumed due to associated trabeculitis
Necrotizing stromal keratitis

a.
Dense stromal inflammation with necrosis and occasional ulceration that can resemble
microbial keratitis
b.
Variable anterior chamber reaction that may be intense with hypopyon
c.
May be complicated by HSV geographic epithelial keratitis or neurotrophic epithelial defect

A.
Atopy, immunosuppression, and malnutrition may predispose to bilateral and/or chronic HSV
keratitis
B.
Role of modifiable environmental triggers uncertain
C.
Strain of HSV-may play a role in keratitis severity
D.
Prior stromal keratitis is a predictor of recurrent stromal keratitis
E.
Epithelial keratitis

A.
Viral keratitis due to varicella zoster virus, Epstein-Barr virus, mumps, measles or vaccinia
B.
Infection-related keratitis associated with stromal inflammation due to syphilis or Lyme disease
C.
Inflammatory keratitis associated with Cogan syndrome or connective tissue disease
D.
Microbial keratitis, including bacterial keratitis, fungal keratitis, and Acanthamebic keratitis

A.

1.
2.
a.
Initial frequency and dosage according to keratitis severity
b.
Taper very gradually over weeks to months as indicated
c.
Some patients may need a minimal dose of steroids indefinitely to keep the keratitis
quiescent
Antiviral
a.
Oral agents are used concurrently as prophylaxis against epithelial keratitis

126
AAO 2014-2016
B.
b.
Oral agents should be considered in therapeutic doses for necrotizing keratitis prior to
initiation of steroids
c.
Duration of treatment has not been standardized

1.
Indicated in the following disease-related complications

a.
b.
c.
C.
Tarsorrhaphy
ii.
Amniotic membrane graft
iii.
Conjunctival flap - consider in eyes with poor visual potential
Corneal perforation
i.
Cyanoacrylate gluing
ii.
Tectonic penetrating keratoplasty
Secondary scarring, lipid keratopathy, or persistent edema

i.
ii.
Deep anterior lamellar keratoplasty
1.
Patients are seen periodically depending on keratitis severity
2.
Taper topical steroid therapy as patient shows clinical improvement
3.
HSV ocular infections in children present special problems

a.
Children are difficult to examine
b.
Crying may dilute drops, and oral medications may be preferred
c.
Corneal scarring may lead to amblyopia
Role of long-term prophylactic oral acyclovir in patients with severe or recurrent HSV keratitis

A.
VI.
i.
Define follow-up
4.
V.
Persistent epithelial defect
Complications of corticosteroid treatment

1.
Exacerbation of active epithelial keratitis
2.
Progressive corneal thinning
3.
Secondary superinfection (microbial keratitis)
4.
Elevated IOP
5.
Cataract formation
127
AAO 2014-2016
A.
B.
Stromal scarring
C.
Lipid keratopathy
D.
Corneal neovascularization
E.
Corneal thinning and perforation
F.
Endothelial dysfunction and corneal edema
G.
Elevated IOP
H.
I.

A.
B.
C.
Importance of prophylactic oral antiviral in patient with a known history of HSV ocular disease
who undergoes ocular surgery
1.
2.
Herpetic Eye Disease Study Group. Predictors of recurrent herpes simplex virus keratitis. Cornea.
2001;20:123-8.
3.
Herpetic Eye Disease Study Group. Oral acyclovir for herpes simplex virus eye disease: effect on
prevention of epithelial keratitis and stromal keratitis. Arch Ophthalmol. 2000;118:1030-6.
4.
Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for iridocyclitis caused by
herpes simplex virus. Arch Ophthalmol. 1996;1065-72.
5.
Wilhelmus RK, Gee L, Hauck WW. Herpetic Eye Disease Study. A controlled trial of topical
corticosteroids for herpes simples stromal keratitis. Ophthalmology 1994;101:1871-82.
6.
Barron BA, Gee L, Hauck WW. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for
herpes simplex stromal keratitis. Ophthalmology 1994;101:1871-82.
7.
Predictors of recurrent herpes simplex virus keratitis. Herpetic Eye Disease Study Group. Cornea
2001;20:123-8.
8.
Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and
stromal keratitis. Herpetic Eye Disease Study Group. Arch Ophthalmol 2000;118:1030-6.
9.
Young RC, Hodge DO, Liesegang TJ, Baratz KH. The Incidence, Recurrence and Outcomes of
Herpes Simplex Virus Eye Disease in Olmsted County, Minnesota, 1976 through 2007: The Impact
of Oral Antiviral Prophylaxis Arch Ophthalmol. 2010; 128: 1178-1183.
128
AAO 2014-2016
129
AAO 2014-2016
Varicella zoster virus dermatoblepharitis

and conjunctivitis
I.

A.

1.
Varicella (chickenpox)
a.
2.
B.
Results from varicella zoster virus (VZV) transmission from respiratory secretions and
cutaneous lesions (more common)
Zoster
a.
Reactivation of latent VZV (in sensory neural ganglia)
b.
Due to endogenous reactivation in patients with declining cell-mediated immunity to

varicella zoster virus
c.
Complications of shingles due to a combination of:

i.
Viral infection
ii.
Immune reaction
iii.
Vasculitis
iv.
Neural involvement
v.
Scarring

1.
Approximately 90% of individuals over 15 have been infected with VZV (typically before the age of
3)
2.
Approximately 20% of adults experience zoster at some point in life
3.
Zoster most frequently affects the following dermatomes:

a.
Lower thoracic and upper lumbar distribution: most common dermatome
b.
Ophthalmic branch of cranial nerve V is the site of recurrence in 15% of all cases of zoster
(herpes zoster ophthalmicus)
4.
No sexual, seasonal, or racial predilection
5.
Ocular involvement in about 50-70% of patients with herpes zoster ophthalmicus
6.
The widespread, recent use of the varicella vaccine for children over 12 months of age
(recommended by the American Academy of Pediatrics) may have a significant impact on the
future development of varicella and zoster
7.
If administered prior to the onset of infection, the zoster vaccine reduces the incidence, severity,
and duration of subsequent herpes zoster and reduces the incidence of postzoster neuralgia (also
called postherpetic neuralgia) among older adults
130
AAO 2014-2016
8.
C.
D.
The zoster vaccine is recommended for all immunocompetent patients over 60 years old.

1.
Prior history of chickenpox
2.
Viral prodrome (fever, malaise)
3.
Tingling (pain and burning) in area supplied by the trigeminal nerve
4.
Vesicular rash on face
5.
Lid edema
6.
Acute neuralgia

1.
2.
Varicella (chicken pox)

a.
Typically develops during childhood
b.
Usually, mild, self-limited disease, does not recur
c.
Fever, malaise, cutaneous exanthem that lasts 7-10 days
d.
Rash begins as macules and progresses to papules, vesicles, and pustules, mild ocular
involvement
e.
Rash is generalized
f.
Lesions more frequent on face and trunk
g.
h.
Vesicles on eyelid margin or bulbar conjunctiva
i.
Punctate or dendritic epithelial keratitis may occur concurrently with the skin lesions
j.
Stromal keratitis, endotheliitis, uveitis, and elevated intraocular pressure are rare, but may
cause significant morbidity if they occur
Zoster
a.
Cranial Nerve (CN) V branches into the following nerves: ophthalmic (most commonly
involved), maxillary, mandibular
b.
Ophthalmic nerve branches into the following: frontal (most commonly affected in herpes
zoster ophthalmicus), nasociliary, and lacrimal nerves (least commonly affected)
c.
Hutchinson sign
i.
Vesicles on the tip of the nose (nasociliary involvement, 76% chance of ocular
involvement)
d.
Painful, vesicular dermatitis localized to one dermatome, respecting the midline
e.
Zoster dermatitis involves deeper layers of the skin than does chickenpox
f.
Eyelid involvement may result in

i.
Scarring
131
AAO 2014-2016
g.
E.
II.
ii.
Notching of the margin
iii.
Loss of lashes or trichiasis
iv.
Punctal occlusion
Conjunctival changes
i.
Chronic hyperemia
ii.
Follicular reaction
iii.
Conjunctival scarring and symblepharon possible
h.
Corneal changes in about 66% of patients with ocular involvement in herpes zoster
ophthalmicus (See Varicella zoster virus epithelial keratitis, and Varicella zoster virus
stromal keratitis)
i.
Keratouveitis
j.
Sectoral iris atrophy
k.
Episcleritis or scleritis
l.
Cranial nerve involvement
m.
Retinal involvement

1.
Clinical diagnosis primarily
2.
Can culture vesicular lesions
3.
Tzanck smear of vesicular fluid
4.
Polymerase chain reaction to detect HZV DNA
5.
Serology
6.
Consider screening for immunosuppression in younger patients

A.
B.
Varicella
1.
No prior infection or immunization
2.
Direct or airborne exposure to secretions from person with active chickenpox or shingles
Zoster
1.
Increasing age, most patients are 60-90 years old
2.
Immunosuppressed patients (human immunodeficiency virus (HIV), chemotherapy, chronic

debilitated)
3.
Patients with malignancy
4.
Patients undergoing chemotherapy or radiation therapy
132
AAO 2014-2016
5.
III.
IV.
VZV reactivated by unknown stimuli

A.
Impetigo
B.
Contact dermatitis
C.
Atopic dermatitis
D.
Primary HSV infection

A.
Systemic antiviral therapy

1.
Best if begun within 72 hours of onset of skin rash

a.
2.
3.
V.
Some efficacy if therapy started after 72 hours
For acute VZV dermatoblepharitis

a.
Acyclovir 800 mg, 5x/day, 7-10 days
b.
Valacyclovir 1 gram, 3 times a day (TID), 7-10 days
c.
Famciclovir 500mg, 3 times a day (TID), 7-10 days
No benefit to using topical antivirals
B.
Topical antibacterial therapy to prevent superinfection may help, but controversial
C.
Warm compresses to skin lesions
D.
Consider oral corticosteroids in specific situations

1.
Optic neuritis
2.
Cerebral angiitis
3.
Large, hemorrhagic skin bullae
4.
Progressive proptosis with ophthalmoplegia (orbital apex syndrome)
5.
Acute retinal necrosis
E.
Seek consultation from internist or pain specialist for management of post-herpetic neuralgia (if
develops)
F.

A.
Systemic antiviral therapy is generally very well tolerated

1.
Rarely, hepatotoxicity
2.
Systemic dosage should be lowered in patients with impaired renal function
133
AAO 2014-2016
VI.

A.
Postherpetic neuralgia
B.
C.
Trichiasis
D.
Neurotrophic keratopathy (See Varicella zoster virus epithelial keratitis, and Varicella zoster virus
stromal keratitis)

A.
B.
C.
Avoid contact with susceptible individuals

1.
Avoid contact with pregnant women who have not had chickenpox
1.
2.
3.
Colin J, Prisant O, Cochener B, et al. Comparison of the efficacy and safety of valacyclovir and
acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology. 2000;107:1507-11.
4.
Neoh C, Harding SP, Saunders D, et al. Comparison of topical and oral acyclovir in early herpes
zoster ophthalmicus. Eye. 1994;8:688-91.
5.
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to
prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84
6.
Tyring S, Engst R, Corriveau C, et al. Famciclovir for ophthalmic zoster: a randomized acyclovir
controlled study. Br J Ophthalmol. 2001;85:576-81.
134
AAO 2014-2016
Varicella zoster virus epithelial keratitis

I.

A.

1.
Viral infection of conjunctiva and corneal epithelium after reactivation of latent varicella zoster virus
(VZV) in trigeminal ganglion and viral shedding
2.
Innate and adaptive immune response to VZV affect viral reactivation and shedding
a.
B.
C.
D.
Chronic infectious keratitis may occur in patients with human immunodeficiency virus (HIV)
infection

1.
Punctate epithelial keratitis and/or pseudodendrite
2.
Epithelial keratitis occurs in approximately 50% of individuals with ophthalmic zoster

1.
Prior history of chickenpox (patients may not remember)
2.
3.
Tingling (pain and burning) in affected dermatome
4.
5.
Lid edema
6.
Acute neuralgia (93% of patients)

1.
2.

a.
Usually, mild, self limited disease, does not recur
b.
Punctate or dendritic epithelial keratitis may occur concurrently with the skin lesions
c.
Other: subepithelial infiltrates, stromal keratitis, disciform keratitis
d.
Corneal scarring is rare (See Varicella zoster virus dermatoblepharitis and conjunctivitis)
Zoster (See Varicella zoster virus dermatoblepharitis and conjunctivitis)

a.
b.
Punctate epithelial keratitis (occurs early)

i.
Peripheral, multiple, raised, lesions
ii.
Associated with conjunctivitis
iii.
VZV has been cultured from these lesions
Pseudodendrites (occurs after 4-6 days)

i.
Swollen, raised epithelial cells
135
AAO 2014-2016
ii.
c.
d.
Corneal mucous plaques (2-3 months after presentation)

i.
VZV has not been cultured from these lesions
ii.
Polymerase chain reaction has shown VZV DNA
iii.
Possible immune mediated mechanism
i.
E.
Varicella
1.
B.
IV.
Primarily a clinical diagnosis (See Varicella zoster virus dermatoblepharitis and conjunctivitis)

A.
III.
25-50% of patients with corneal involvement develop some degree of neurotrophic

keratopathy

1.
II.
VZV has been cultured from these lesions
Non-immunized status
Zoster
1.
Increasing age (#1 risk factor for herpes zoster ophthalmicus), most patients are 60-90 years old
2.
Immunosuppression (HIV, chemotherapy, radiation therapy)
3.
Malignancy
4.
VZV reactivated by unknown stimuli
5.
Non-immunized status

A.
Herpes simplex virus (HSV) epithelial keratitis
B.
Epstein-Barr virus (EBV) epithelial keratitis
C.
Healing corneal abrasion
D.
Toxic keratopathy
E.
Acanthamoeba keratitis
F.
G.
Unusual causes of dendritiform lesions

A.
Systemic antiviral therapy

1.
Give within 72 hours of the onset of skin lesions, some effect if therapy begun within 7 days of
136
AAO 2014-2016
onset of skin lesions

2.
Oral acyclovir (800 mg 5x/day), valacyclovir (1000 mg tid) or famciclovir (500 mg tid) for 7 to 10
days with dosing reduced as necessary for impaired renal function
a.
V.
B.
Consider topical antibacterial therapy to prevent superinfection
C.
Consider topical corticosteroids to decrease inflammation and immune reaction

1.
May predispose to prolonged treatment and recurrences
2.
Concomitant antiviral therapy is unnecessary
3.
Taper must be very slow to prevent recurrences
D.
Consider oral corticosteroids in specific situations (See Varicella zoster virus dermatoblepharitis
and conjunctivitis)
E.
Debridement of corneal epithelial lesions
F.
Recurrent epithelial lesions may benefit from topical antiviral treatment
G.
Preservative free ophthalmic lubricants
H.
Hypertonic saline ointment or bandage contact lenses may be needed in refractory disease
I.

A.
Systemic antiviral therapy is very well tolerated

1.
B.
C.
VI.
Valacyclovir may be contraindicated in immunocompromised patients as it has been

associated with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in
doses above 8 g a day in these patients
Rarely, hepatotoxicity and nephrotoxicity
1.
May lead to prolonged need for treatment and more frequent recurrences
2.
Cataracts
3.
Glaucoma

1.
Limit use of corticosteroids
2.
Taper medications as appropriate

A.
Corneal scarring and vascularization
B.
C.
Glaucoma
D.
Sectoral iris atrophy
137
AAO 2014-2016
E.
Rarely, corneal perforation
F.
Rarely, vasculitis leading to retinal, orbital, or cranial nerve involvement

A.
B.
C.

1.
Avoid contact with pregnant women who have not had chickenpox
1.
2.
3.
Marsh RJ, Cooper M. Double-masked trial of topical acyclovir and steroids in the treatment of
herpes zoster ocular inflammation. British Journal of Ophthalmology, 1991,75,542-546.
138
AAO 2014-2016
Varicella zoster virus stromal keratitis

I.

A.
B.
C.

1.
Delayed hypersensitivity reaction in corneal stroma producing infiltrates and/or edema
2.
Loss of corneal sensation with neurotrophic keratopathy may exacerbate or prolong stromal
keratitis

1.
Prior history of chickenpox (may not be present if mild)
2.
3.
Tingling (pain and burning) in effected dermatome
4.
5.
Lid edema
6.
Acute neuralgia

1.
2.

a.
Usually, mild, self limited disease, does not recur
b.
Subepithelial infiltrates, stromal keratitis, disciform keratitis may occur but are rare
c.
Corneal scarring is rare
Zoster (See Varicella zoster virus dermatoblepharitis and conjunctivitis)

a.
Hutchinson sign
i.
Vesicles on the tip of the nose (nasociliary involvement, 76% chance of ocular
involvement)
b.
Corneal changes in about 66% of patients with ocular involvement in herpes zoster
ophthalmicus
c.
Anterior stromal infiltrates- isolated or multiple, granular, dry (occurs later than 10 days after
disease onset)
d.
i.
Stromal reaction to soluble viral antigen diffusing into the anterior stroma
ii.
May represent direct viral cytotoxicity
iii.
Classically described as nummular keratitis
iv.
May result in nummular corneal scars but often resolve without scarring if treated with
steroids
Stromal keratouveitis/ endotheliitis (around 2-3 months after onset)
139
AAO 2014-2016
e.
f.
i.
May represent direct viral invasion into the endothelium with resulting immune
response
ii.
Manifests as overlying corneal edema (disciform keratitis)
iii.
Indistinguishable from HSV keratouveitis
i.
Zoster ophthalmicus can result in profound corneal anesthesia
ii.
25-50% of patients with corneal involvement get some degree of neurotrophic

keratopathy
Lipid keratopathy (very late)

i.
g.
D.
III.
IV.
Sclerokeratitis

1.
II.
Leakage from corneal vessels that develop due to chronic keratitis
Clinical diagnosis primarily (See Varicella zoster virus dermatoblepharitis and conjunctivitis)

A.
Herpes simplex virus (HSV) stromal keratitis
B.
C.
Epstein-Barr virus (EBV) stromal keratitis
D.
Corneal transplant rejection
E.
Contact lens overwear
F.
Interstitial keratitis secondary to other causes

A.
Topical corticosteroid eyedrops
B.
No need for oral or topical antiviral "cover" unlike HSV keratitis
C.
Oral antiviral therapy for acute varicella zoster virus (VZV) blepharitis may be of benefit in
decreasing incidence of stromal keratitis
D.
Periodic follow-up is necessary to monitor the response to therapy

A.
B.
Systemic antiviral therapy is very well tolerated

1.
Rarely, hepatotoxicity
2.
Lower systemic dose in patients with impaired renal function
140
AAO 2014-2016
C.
V.
VI.
1.
May lead to prolonged need for treatment and more frequent recurrences
2.
Cataracts
3.
Glaucoma

1.
Limit use of corticosteroids
2.

A.
Loss of vision
B.
Corneal scarring
C.
Rarely, corneal perforation
D.
E.
Glaucoma

A.
B.
C.

1.
Avoid contact with pregnant women who have not had chicken pox
1.
2.
141
AAO 2014-2016
Adenovirus conjunctivitis and

keratoconjunctivitis
I.

A.

1.
B.
Adenoviridae
a.
Simple follicular conjunctivitis without or with punctate epithelial keratitis
b.
Pharyngoconjunctival fever
c.
Epidemic keratoconjunctivitis

1.
Epidemic outbreaks
a.
2.
C.
Transmission via close contact with infected persons (ocular or respiratory secretions) or
contaminated fomites
i.
Populations living in close quarters
ii.
Contaminated instrument/supplies in physicians' offices and physicians waiting rooms
Sporadic cases

1.
2.
3.
Simple follicular conjunctivitis

a.
Self limited
b.
Transient
c.
Mild if any epithelial keratitis symptoms
Pharyngoconjunctival fever
a.
Fever
b.
Headache
c.
Pharyngitis
d.
e.
f.
Mild if any epithelial keratitis symptoms
a.
Majority bilateral
b.
Possible preceding upper respiratory infection
142
AAO 2014-2016
D.
c.
Ocular symptoms 7 to 10 days after exposure to infected person/contaminated fomite
d.
Photophobia, epiphora, foreign body sensation possibly reduced visual acuity (associated
with subepithelial infiltrates)

1.
2.
Acute conjunctivitis
a.
Follicular conjunctivitis: tarsal conjunctival follicles
b.
Bulbar conjunctival hyperemia and chemosis
c.
Petechial hemorrhages
d.
Pseudomembranes/membranes
Epithelial keratitis
a.
b.
3.
ii.
Fine punctate epithelial keratitis
Second week of infection

i.
Coarse deep epithelial granular infiltrates
ii.
Punctate epithelial keratitis resolves
iii.
Possible central geographic erosions
iv.
1.
The diagnosis of adenovirus conjunctivitis is usually based on clinical findings
2.
Laboratory testing may be used as an adjunct to clinical diagnoses when the physician needs to
differentiate adenovirus conjunctivitis from other causes of acute conjunctivitis
Laboratory tests with good sensitivity and specificity include the detection of infectious virus
by cell culture and detection of viral antigen by commercially available immunoassay kit

A.
III.
Minute punctate epithelial opacities
a.
II.
i.
Extraocular
a.
E.
First week of infection
Exposure to infected individual or contaminated fomite

A.
Non-adenoviral viral conjunctivitis

1.
Herpes simplex virus (HSV) blepharokeratoconjunctivitis
143
AAO 2014-2016
IV.
2.
Varicella zoster virus (VZV) blepharokeratoconjunctivitis
3.
Molluscum contagiosum-associated blepharoconjunctivitis
B.
C.
D.
Toxic keratoconjunctivitis

A.

1.
2.
3.
V.
Supportive
a.
Cool compresses
b.
Artificial tears
c.
Topical vasoconstrictor
Pseudomembranes/membranes
a.
Mechanical removal every 2-3 days
b.
a.
b.

A.
1.
May exacerbate herpetic keratoconjunctivitis or bacterial conjunctivitis in case of misdiagnosis or

coinfection
a.
Differentiation based primarily on history and clinical findings

i.
2.
VI.
May exclude other viral or bacterial processes with appropriate cultures
May prolong shedding of adenovirus

a.
Use only for visually significant (photophobia/reduced visual activity) subepithelial opacities
and conjunctival membranes
b.
May use topical cyclosporine in place of topical corticosteroid
c.
May use topical nonsteroidal anti-inflammatory drugs (NSAIDs) instead of topical

corticosteroids for discomfort, if vision unaffected or to wean off topical corticosteroids
144
AAO 2014-2016
A.
B.
Following pseudomembrane/membrane formation

1.
2.
Forniceal foreshortening (more likely to get lacy scar of tarsal conjunctiva)
3.
Symblepharon formation
4.
Aqueous tear deficiency secondary to scarring of lacrimal ductules (very rare)
Following chronic recurrent subepithelial infiltrates

1.
Photophobia or glare
2.
Reduced visual acuity

A.
Avoidance of transmission during period of viral shedding (7-10 days after onset of clinical signs
and symptoms)
1.
2.
Avoidance of direct transmission

a.
Frequent handwashing
b.
Not touching eyes
c.
Leave from work or school while shedding
Avoidance of indirect transmission

a.
Cleaning linens
b.
Not sharing objects with others
1.
2.
AAO, Focal Points: Update on Ocular Allergy, Module #5, 1994.
3.
145
AAO 2014-2016
I.

A.

1.
B.
C.
D.
II.

1.
Burning, itching, foreign body sensation
2.
Crusting of the eyelids, particularly on awakening
3.
Blurred vision (occasionally)
4.

1.
Hard, brittle, fibrinous scales and hard, matted crusts surrounding individual eyelashes
2.
Eyelid ulceration, injection and telangiectases of the anterior and posterior eyelid margins
3.
Poliosis (whitening of lashes), madarosis (loss of lashes) and trichiasis
4.
Papillary conjunctivitis, occasionally with mucopurulent discharge
5.

1.
Eyelid culture and susceptibility
2.
Conjunctival culture and susceptibility, if conjunctivitis present
Define risk factors

A.
Younger age
B.
Certain systemic conditions

1.
III.
Bacterial infection of the eyelids caused usually by Staphylococcus aureus, but occasionally by
coagulase-negative staphylococci
Down syndrome

A.
B.
Meibomian gland dysfunction and rosacea
C.
Infectious blepharitis secondary to other pathogens

1.
Moraxella
2.
Corynebacterium spp
146
AAO 2014-2016
IV.
3.
Demodex
4.
Phthirus pubis
D.
Contact allergy
E.
Atopic dermatoblepharitis
F.
Discoid lupus
G.
Sebaceous cell carcinoma

A.

1.
available pads or using clean washcloth, soaked in warm water +/- dilute shampoo
2.
Topical antibiotic ointment application
3.
a.
Treatment usually empirical, but cultures should be taken in cases that fail to respond to
initial antibiotic therapy
b.
Antibiotic modification depends on sensitivity testing, if cultures performed e.g. MRSA (See
Bacterial keratitis)
Topical antibiotic solution application

a.
4.
Artificial tears
a.
5.
V.
VI.
If aqueous tear deficiency or lipid-induced tear film instability present
a.
6.
If conjunctivitis present
If marginal corneal infiltrates or corneal vascularization or phlyctenulosis present
Consider systemic tetracyclines (doxycycline, minocycline), azithromycin or erythromycin for

extensive or persistent disease

A.
Complications of topical corticosteroids, if used (glaucoma, cataract, etc.)
B.
C.
Allergic reactions to topical antibiotics
D.
Bacterial resistance from chronic use of topical antibiotic ointments and solutions
E.
Potential adverse effects of tetracycline and doxycycline (gastrointestinal upset, photosensitivity,

contraindication in children less than 8 years, contraindication in pregnancy)
147
AAO 2014-2016
A.
Aqueous or lipid tear deficiency
B.
Corneal phlyctenulosis
C.
Corneal marginal infiltrates and ulceration
D.
E.
Corneal scarring
F.
Corneal thinning and perforation (rare)

A.
Possible recurrent or chronic nature of this condition
B.
Importance of daily eyelid hygiene
C.
Instruction on proper eyelid hygiene
D.
E.
1.
AAO. Basic and Clinical Science Course. Section 8: External Disease and Cornea, 2013-2014.
2.
AAO, Focal Points: Antibiotic Use in Corneal and External Eye Infections, Module #10, 1997,
p.9-13.
148
AAO 2014-2016
Chronic blepharitis
I.

A.

1.
Chronic inflammatory condition of the eyelid margins
2.

a.
b.
Anterior
i.
ii.
Posterior
i.
B.
C.
c.
Mixed type
d.
Parasitic blepharitis
i.
Demodex
ii.
Phthiriasis/pediculosis

1.
Burning, itching, foreign body sensation (gritty, foreign body sensation)
2.
Crusting of the eyelids, particularly on awakening
3.
Chronic eyelid margin redness
4.
5.
6.
Diurnal variation in symptoms in some conditions

a.
Worse in the am in staphylococcal blepharitis
b.
Worse in the pm in meibomian blepharitis

1.
2.
Anterior blepharitis
a.
Scales and crusts on eyelids
b.
Collarettes at base of lashes
c.
Misdirected lashes
d.
Madarosis and poliosis
e.
Eyelid ulceration
Posterior blepharitis
149
AAO 2014-2016
3.
4.
a.
Telangiectasias of the eyelid margin
b.
Abnormal tear film, including rapid tear break-up time and increased debris in tear film
c.
Meibomian gland inspissation and distortion
d.
Foamy debris on eyelid margin
Anterior and posterior blepharitis

a.
b.
Papillary conjunctivitis
c.
Corneal marginal infiltrates
d.
e.
Phlyctenulosis
f.
Tear deficiency
Parasitic blepharitis
a.
b.
II.
III.
Demodex blepharitis
i.
Sleeve-like encasement of the eyelash base
ii.
Organisms demonstrable by simple light microscopy of epilated lashes
iii.
Variable ocular surface signs of chronic blepharitis including marginal infiltrates,

keratitis possibly leading to scarring and neovascularization
Phthiriasis/pediculosis
i.
Nits on the shafts of lashes
ii.
Pubic lice at the base of lashes
iii.
Intense pruritus
iv.
Occasional preauricular lymphadenopathy
v.
vi.
Usually sexually transmitted from pubic infestation but may rarely occur from
extension of head lice

A.
Masquerade syndrome (eyelid neoplasm - rare, but should be considered in chronic unilateral
blepharitis)
B.
Allergic or atopic dermatoblepharitis
C.
Toxic blepharoconjunctivitis
150
AAO 2014-2016
A.
IV.
V.
VI.

1.
available pads or using clean washcloth, soaked in warm water +/- dilute shampoo
2.
Topical antibiotic ointment or solution for staphylococcal blepharitis
3.
Artificial tears, if aqueous tear deficiency or lipid-induced tear film instability present
4.
Topical corticosteroid for acute exacerbations or if marginal corneal infiltrates or corneal

vascularization or phlyctenulosis are present
5.
Topical azithromycin drops for antibiotic and meibomian gland therapy
6.
Systemic tetracycline or doxycycline for meibomian gland dysfunction or rosacea (erythromycin in

children)
7.
Tea Tree Oil scrubs and treatment for Demodex infestation
8.
Mechanical removal and/or topical ophthalmic ointment to smother the parasites for phthiriasis

A.
Complications of topical corticosteroids (glaucoma and cataract)
B.
C.
Allergic reactions to topical antibiotics
D.
Bacterial resistance from chronic use of topical antibiotic ointments and solutions
E.
Side effects related to systemic antibiotics

A.
Corneal ulceration
B.
C.
Corneal scarring and thinning
D.
Eyelid irregularity or notch
E.
Trichiasis
F.
Madarosis
G.
Tear deficiency

A.
Chronic nature of condition
B.
Role of daily eyelid hygiene
C.
Instruction on proper eyelid cleansing
D.
151
AAO 2014-2016
E.
1.
152
AAO 2014-2016
Bacterial conjunctivitis in children and

adults
I.

A.

1.
Transmission by direct contact with secretions from a contaminated source or an infected

individual or spread from microorganisms colonizing patient's own nasal or sinus mucosa or other
sites, including genital mucosa
2.
Bacteria infiltrate the conjunctival epithelial layer and sometimes the substantia propria
3.
Alterations in ocular surface defense mechanisms or in the ocular flora can lead to clinical
infection
4.
May be subdivided into:

a.
b.
c.
B.
C.
Hyperacute onset (<24 hrs)

i.
Neisseria gonorrhoeae
ii.
Neisseria meningitidis
Acute or subacute onset (days)

i.
Staphylococcus aureus
ii.
Streptococcus pneumoniae
iii.
Haemophilus influenzae
Delayed onset (days to weeks)

i.
ii.
Moraxella sp.

1.
Purulent or mucopurulent discharge
2.
Matting of the eyelashes and crusting of eyelids
3.
Eye redness
4.
Eyelid swelling
5.
Eye discomfort

1.
Acute purulent conjunctivitis

a.
Pneumococcal and Haemophilus conjunctivitis

i.
Moderate purulent discharge

153
AAO 2014-2016
b.
2.
3.
D.
Eyelid edema
iii.
Conjunctival chemosis and injection
iv.
Conjunctival papillary reaction
v.
Subconjunctival hemorrhage (sometimes)
Staphylococcal conjunctivitis
i.
Usually less severe discharge
ii.
May be associated with blepharoconjunctivitis or systemic dermatologic disease.
Gonococcal conjunctivitis
a.
Transmitted sexually (direct genital-to-hand-to-eye transmission) or from mother to baby

during vaginal delivery
b.
Severe, rapidly progressing conjunctivitis
c.
Massive exudation and purulent discharge
d.
Conjunctival injection and chemosis
e.
Conjunctival inflammatory membrane
f.
Corneal marginal infiltrates, ulceration, and perforation
g.
Enlarged preauricular lymph node
Chlamydial conjunctivitis (See Adult chlamydial keratoconjunctivitis)
Describe appropriate testing and evaluation to establish the diagnosis

1.
II.
ii.
Culture of the conjunctiva

a.
Immunocompromised host
b.
Severe purulent discharge
c.
Cases unresponsive to initial therapy
2.
Consider nasal and throat swab if pharyngitis is present or nasolacrimal system evaluation when
recurrent conjunctivitis is present
3.
Obtain Giemsa stain and/or immunofluorescent antibody tests of the conjunctiva to rule out
chlamydial conjunctivitis in chronic cases

A.
B.
C.
D.
E.
Cat-scratch disease and other causes of Parinaud oculoglandular syndrome
F.
154
AAO 2014-2016
III.
G.
Episcleritis
H.
Dacryocystitis
I.

A.
Describe medical therapy options for acute purulent conjunctivitis

1.
Mild conjunctivitis may be self-limiting, but a topical antibiotic speeds clinical improvement and
microbiologic remission.
2.
Empiric broad-spectrum topical antibiotics four times a day for 5-7 days
Choices include
ii.
Aminoglycoside (gentamicin or tobramycin)
iii.
Combination antibiotic (gramicidin-polymyxin B-neomycin)
iv.
Fluoroquinolone (ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, or moxifloxacin)
v.
Erythromycin or bacitracin ointment.
3.
If a compromised host, severe purulence, or refractory case, then obtain culture
4.
In refractory case with MRSA culture positive non-responsive to the above empiric antibiotics
consider fortified vancomycin four times daily for 5-7 days (See Bacterial keratitis)
5.
Systemic antibiotics reserved for acute purulent conjunctivitis with pharyngitis, for conjunctivitisotitis syndrome, and for Haemophilus conjunctivitis in children
a.
6.
B.
i.
Referral to a primary care physician may be necessary if other tissues or organ systems are
involved
Consider the possibility of sexually transmitted diseases caused by N. gonorrhoeae or Chlamydia

trachomatis in sexually active age groups
Describe medical therapy options for gonococcal conjunctivitis

1.
Systemic antibiotics are necessary
2.
May need to adjust systemic dose for child dosing
3.
If no corneal ulceration, treat with intramuscular ceftriaxone(1 g IM), oral cefixime, or oral
ciprofloxacin on outpatient basis and examine periodically until conjunctivitis is resolved
4.
Due to risk of corneal ulceration and systemic spread, consider treating with IV ceftriaxone for 3 to
7 days
a.
If penicillin allergy present, consider oral fluoroquinolone for 5 days
5.
Consider topical erythromycin, bacitracin, gentamicin, tobramycin or a fluoroquinolone for

conjunctivitis
6.
Irrigation of the eye with normal saline can remove inflammatory material that may contribute to
corneal melting
155
AAO 2014-2016
7.
Follow up until conjunctivitis and corneal ulceration resolve.
8.
If gonococcal conjunctivitis confirmed, treat for chlamydial infection (up to a third of patients may
have concomitant Chlamydial infection)
a.
IV.
V.
Use oral doxycycline, or erythromycin, or tetracycline for 1 week, or one-time dose of

azithromycin
9.
Advise sexual partner(s) to seek treatment
10.
Need to ensure that gonococcal infection and other sexually transmitted diseases are reported to
the local health department

A.
Ocular surface toxicity from topical antibiotics
B.
Allergic reaction from topical antibiotics
C.

A.
Precautions to avoid spreading the infection to the fellow eye or other people
1.
2.
Use separate towels and washcloths and wash or discard after use
3.
Wash hands frequently
B.
C.
Instructions as to when to return to school or work (usually after at least 24 hours of treatment
with topical antibiotics)
1.
2.
AAO, Focal Points: Antibiotic Use in Corneal and External Eye Infections, October 1997, p.10-11.
3.
Hwang DG, Schanzlin DJ, Rotberg MH, et al. A phase III, placebo controlled clinical trial of 0.5%
levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol
2003;87:1004-9.
4.
Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane
Database Syst Rev. 2006;CD001211.
5.
Epling J, Smucny J. Bacterial conjunctivitis. Clin Evid 2005;756-61. Review.
156
AAO 2014-2016
Bacterial conjunctivitis of neonates

I.

A.
B.
C.
D.

1.
Infection of the conjunctiva, usually transmitted from the mother to neonate during vaginal delivery
2.

a.
Neonatal gonococcal conjunctivitis
b.
Neonatal chlamydial conjunctivitis
c.
Other causes of bacterial conjunctivitis in neonates:

i.
Streptococci, including viridans group streptococci
ii.
iii.
Haemophilus influenzae
iv.
Moraxella catarrhalis
v.
Escherichia coli and other gram negative rods

1.
Affects infants in the first several days to weeks of life
2.
Gonococcal conjunctivitis accounts for less than 1% of the cases
3.
Chlamydial conjunctivitis is the most common cause of infectious neonatal conjunctivitis

1.
Initially, watery, bloody drainage from the infant's eyes
2.
Subsequently, thick, copious purulent drainage may develop
3.
Swollen, red eyelids
4.
Maternal history of sexually transmitted disease (sometimes)

1.
Neonatal gonococcal conjunctivitis

a.
Usually bilateral conjunctival injection and discharge 2-5 days after parturition
b.
Serosanguineous discharge for the first several days
c.
Copious purulent exudates may develop later
d.
Corneal ulceration and possibly corneal perforation
e.
Endophthalmitis (rare)
f.
May have other sites of infection such as rhinitis and proctitis
g.
Signs of systemic illness (meningitis, pneumonitis, arthritis-rarely)
157
AAO 2014-2016
2.
3.
E.
III.
a.
Onset of symptoms 5 to14 days after parturition
b.
Copious mucopurulent discharge
c.
Conjunctival injection and membrane formation
d.
No follicular conjunctival reaction
e.
Pneumonitis and otitis media (sometimes)
Other non-gonococcal causes of bacterial conjunctivitis

a.
Onset of symptoms 5 to 8 days after parturition
b.
c.
Purulent or mucopurulent discharge

1.
II.
Neonatal chlamydial conjunctivitis
Recommend Gram and Giemsa stain and culture of conjunctival scrapings in all cases of neonatal
conjunctivitis
a.
Gram negative diplococci in Gonococcal disease
b.
Giemsa stain will demonstrate basophilic, intracytoplasmic inclusion bodies in chlamydia
2.
If clinical diagnosis is not confirmed on culture or scrapings, immunofluorescent antibody tests on

scrapings can aid in confirming diagnosis
3.
Pediatrics consultation for evaluation and management of associated systemic complications

A.
Toxic chemical conjunctivitis from silver nitrate or topical antibiotic applied at birth
B.
Viral conjunctivitis, including herpes simplex virus keratoconjunctivitis
C.
Nasolacrimal duct obstruction
Describe patient management in terms of treatment and follow-up for gonococcal

conjunctivitis
A.
Hospital admission and infectious disease consult
B.
For nondisseminated disease
C.
1.
Ceftriaxone injection (25-50 mg/kg) or cefotaxime (100 mg/kg) IM or IV
2.
Systemic antibiotics if mother has gonorrhea, even if no conjunctivitis present in the neonate
For disseminated disease

1.
D.
Treatment per infectious disease specialist recommendations
Topical erythromycin or broad-spectrum antibiotic several times per day until conjunctivitis
resolves
158
AAO 2014-2016
IV.
V.
VI.
E.
Frequent lavage of conjunctival discharge with normal saline to reduce proteases, debris,
inflammatory cells which may increase the risk of corneal ulceration
F.
Follow-up until conjunctivitis resolves
G.
May need to treat at risk contacts
Describe patient management in terms of treatment and follow-up for chlamydial

conjunctivitis
A.
Topical erythromycin or sulfacetamide several times a day until conjunctivitis resolves is usually
adequate for treatment
B.
Treat systemically with erythromycin to prevent pneumonitis and otitis media
C.
Consult pediatrician for evaluation and management of systemic complications
D.
Follow up until the conjunctivitis is resolved

A.
B.
Allergic reaction to topical antibiotics
C.
Bacterial resistance to topical or systemic antibiotics
D.

A.
Corneal ulceration, perforation, and scarring secondary to gonococcal conjunctivitis
B.
Blindness secondary to gonococcal endophthalmitis (rare)
C.
Otitis media and pneumonitis secondary to chlamydia
D.
Disseminated gonococcal disease: arthritis, meningitis, pneumonia, and sepsis (rarely)

A.
Precautions to avoid spreading the infection to the fellow eye or other contacts
1.
Caregivers should use separate towels and washcloths
B.
Caregivers should wash hands frequently and wear disposable gloves when cleaning the
discharge from the eye
C.
Instructions on importance of follow-up
D.
Instructions on the expected timeline for resolution of the symptoms
E.
Treatment of mother and her sexual contacts
159
AAO 2014-2016
1.
2.
AAO, Focal Points: Antibiotic Use in Corneal and External Eye Infections, Module #10, 1997, p.11.
160
AAO 2014-2016
Adult chlamydial keratoconjunctivitis

I.

A.

1.
Chlamydia trachomatis
a.
2.
Sexually transmitted disease

a.
B.
C.
D.
Obligate intracellular bacterium
Ocular infection via direct or indirect contact with infected genital secretions

1.
Chronic red eye (over 4 weeks in duration)
2.
History of previous sexually transmitted disease
3.
History of sexual activity
4.
History of topical medication use

1.
Preauricular lymphadenopathy
2.
3.
Follicles in the bulbar conjunctiva and semilunar fold often seen
4.
May develop mild keratitis with fine epithelial and subepithelial infiltrates and micropannus
5.
Mucopurulent discharge

1.
Antigen detection tests

a.
Enzyme immunoassay detects antigens in conjunctival smears
b.
Fluorescent antibody staining

i.
2.
Cytology
a.
Conjunctiva (Giemsa staining)

i.
3.
II.
Smears
Look for intracytoplasmic basophilic inclusion bodies within epithelial cells
Tissue culture

A.
History of previous sexually transmitted disease
B.
History of sexual activity
161
AAO 2014-2016
III.
IV.

A.
Adenovirus conjunctivitis
B.
Herpes simplex conjunctivitis
C.
Molluscum contagiosum blepharoconjunctivitis
D.
Ocular surface drug reaction to topical agent(s)/Medicamentosa
E.

A.
V.
1.
Azithromycin 1 g as a single dose (may need to be repeated in 1 week)
2.
Tetracycline 250 mg qid for 3 weeks
3.
Doxycycline 100 mg bid for 3 weeks
4.
Erythromycin 500 mg qid for 3 weeks
5.
Retreatment may be needed
6.
Treat sexual partners concomitantly

A.
B.
VI.
Complications of treatment - associated with medication

1.
Drug allergy
2.
Gastrointestinal distress
3.
Photosensitivity
4.
Vaginal yeast infection in women

1.
Take medication with food
2.
Limit sun exposure

A.
Often resolves spontaneously over several months
B.
May result in corneal pannus and subepithelial scarring
C.
Recurrence with subsequent re-infection
162
AAO 2014-2016

A.
Stress importance of further evaluation to look for co-infection with other sexually transmitted
diseases
B.
Contact sexual partners

1.
Should be treated and be assessed for sexually transmitted diseases as well
C.
Awareness of symptoms that may represent drug reaction
D.
Need to report sexually transmitted diseases to the Health Department
1.
2.
AAO, Preferred Practice Pattern Committee, Cornea and External Disease Panel. Conjunctivitis
3.
Katusic D, Petricek I, Mandic Z, et al. Azithromycin vs doxycycline in the treatment of inclusion

conjunctivitis. Am J Ophthalmol. 2003;135:447-51.
4.
Diamant J, Benis R, Schachter J, et al. Pooling of Chlamydia laboratory tests to determine the
prevalence of ocular Chlamydia trachomatis infection. Ophthalmic Epidemiol. 2001;8:109-17.
163
AAO 2014-2016
Bacterial keratitis
I.

A.
B.
C.

1.
Disruption of epithelial integrity
2.
Bacterial adherence, replication, and stromal invasion
3.
Polymorphonuclear leukocytes (PMN) initiate inflammatory cascade and release other

inflammatory mediators and recruit other inflammatory cells
4.
Production of matrix metalloproteinases and collagenases
5.
Common etiological agents: Pseudomonas species, other Gram-negative rods (Serratia

marcescens), Staphylococcal species, Streptococcal species, non-tuberculosis mycobacteria, and
anaerobes

1.
People of all ages and both sexes
2.
Increased risk with contact lens (CL) wear
3.
Gram negative organisms in refractive CL population
4.
Gram positive organisms in therapeutic CL population

1.
Ocular symptoms
a.
Erythema
b.
Ocular pain
c.
Blurred or decreased vision
d.
Purulent discharge
e.
Photophobia
f.
Lid swelling
2.
Duration of symptoms
3.
Identification of risk factors
4.
Prior ocular history, including:
5.
a.
Prior corneal surgery
b.
Corneal trauma
c.
Preexisting ocular surface disease
Systemic medical problems including

a.
Immunosuppression
164
AAO 2014-2016
b.
D.
Diabetes mellitus
6.
Current ocular medications
7.
History of CL use
a.
Type (daily, 2-week, monthly disposable)
b.
Overnight wear of CL
c.
Poor hygiene and lens care

1.
Epithelial defect
2.
Stromal infiltrate
a.
Severity
i.
b.
Dimensions of ulcer
c.
Depth
d.
Location (central, pericentral, peripheral)
3.
Stromal ulceration
4.
Iritis
5.
Hypopyon
6.
Infectious crystalline keratopathy

a.
E.
Edema with mild-moderate polymorphonuclear neutrophil infiltration to dense white

opacity
Persistent bacterial infection with minimal inflammation may produce intrastromal branching
pattern

1.
2.
Indications for corneal smears and cultures

a.
Aid in selecting antimicrobial therapy, especially if severe or sight-threatening keratitis
b.
History suggestive of atypical pathogen (e.g., trauma with vegetable matter,

immunosuppression, ocular surface disease)
c.
Findings suggestive of unusual pathogen (e.g., raised gray ulcer, satellite or multiple
lesions, feathered edge, keratoneuritis, multifocal infiltrates)
d.
Poor responsiveness to broad-spectrum antimicrobial therapy
Corneal specimen collection

a.
Corneal scrapings or swabbing
b.
Corneal biopsy if scrapings negative in face of progressive disease or deep infiltrate with
overlying normal tissue
c.
Contact lenses, contact lens cases, or solutions can be cultured as they may provide useful
165
AAO 2014-2016
information when the corneal cultures are negative
3.
4.
d.
Prepare smears on glass slides
e.
Inoculate directly to culture media or use transport medium to send to laboratory
Corneal smears
a.
Chromogenic stains: gram, acid-fast (mycobacteria, Nocardia species), Gomorimethenamine-silver (fungi, Acanthamoeba)
b.
Fluorescent stains: acridine orange (bacteria, fungi, acanthamoeba), calcofluor white

(acanthamoeba, fungi)
Corneal cultures
a.
b.
II.
Standard culture media

i.
Blood agar x 2 (one anaerobic and one aerobic) (most bacteria)
ii.
Chocolate agar (most bacteria, especially Neisseria gonorrhoeae and Haemophilus

species)
iii.
Thioglycolate broth (aerobic and anaerobic bacteria)
iv.
Sabouraud's dextrose agar (fungi)
Special culture medium

i.
Lowenstein-Jensen medium (mycobacteria, Nocardia species)
ii.
Middlebrook agar (non-tuberculous mycobacteria)
iii.
Buffered charcoal-yeast extract agar or non-nutrient agar with bacterial overlay

(Acanthamoeba)

A.
B.
Exogenous factors
1.
CL wear (especially extended-wear use)
2.
Ocular trauma (including corneal foreign body)
3.
Previous ocular and eyelid surgery
4.
Previous corneal surgery (including refractive surgery and penetrating keratoplasty) including
loose corneal sutures
Ocular surface disease

1.
Trichiasis
2.
Exposure and related eyelid malposition
3.
Dry eye syndrome and related tear film deficiency states
4.
Adjacent infections (blepharitis, conjunctivitis, dacryocystitis, or canaliculitis)
5.
Atopic dermatitis/blepharoconjunctivitis
166
AAO 2014-2016
6.
C.
D.
III.
IV.
Rosacea
Corneal epithelial abnormalities

1.
2.
Recurrent erosion syndrome
3.
Herpes simplex virus keratitis
4.
Corneal edema (bullous keratopathy)
5.
Systemic conditions
1.
Diabetes mellitus
2.
Malnourishment, including vitamin A deficiency
3.
Obtunded, hospitalized patient
4.
Substance abuse
5.
Mucous membrane disorders

a.
b.
6.
Immunocompromise
7.

A.
Herpes simplex virus necrotizing stromal keratitis
B.
Fungal keratitis
C.
Immune (non-microbial) keratitis
D.
Staphylococcal marginal keratitis
E.

A.

1.
Commercially available antibiotics

a.
Fluoroquinolones (including ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin,

besifloxacin)
i.
Excellent against many gram-negative organisms
ii.
Susceptibility gaps against some gram-positive organisms (streptococcal species

(a-strep, methicillin resistant staphylococcal species (MRSA))
167
AAO 2014-2016
2.
Formulated or fortified antibiotics

a.
b.
3.
4.
Gram-positive activity
i.
Cefazolin (50 mg/ml)
ii.
Vancomycin (25-50 mg/ml) for multiresistant strains
Gram-negative activity
i.
Aminoglycosides (tobramycin, gentamicin) (9-14 mg/ml)
ii.
Extended spectrum cephalosporins (ceftazidime or cefepime) (50 mg/ml)
Recommended initial topical broad-spectrum therapy

a.
Fortified antibiotics with gram positive activity (Cefazolin or Vancomycin) and fortified
antibiotic with gram negative activity (aminoglycoside or extended spectrum cephalosporin)
b.
Monotherapy with fluoroquinolone (only for small, non-vision threatening ulcers)
Adjuvant therapy
a.
Cycloplegic agents (e.g. cyclopentolate 1% or scopolamine 0.25%)
b.
Role of topical corticosteroids

i.
Avoid if causative microorganism is uncertain and effective antibacterial therapy is not

assured
ii.
Consider if individual risk-benefit assessment suggests possible value in:
iii.
c.
5.
Reducing corneal inflammation
ii)
Preventing further stromal ulceration
iii)
Decreasing risk of corneal graft rejection
iv)
Minimizing corneal neovascularization and opacification
v)
Improving reepithelialization
SCUT study evaluated the effect of steroids in bacterial keratitis

i)
Overall no benefit with steroids but no increased risk either
ii)
Ulcers with baseline visual acuity count fingers and central ulcers had better
visual outcomes with steroids
Pain control
Frequency of topical application

a.
6.
i)
Start with frequent dosing (and/or loading dose) and taper depending on clinical response
Frequency of follow-up visits

a.
Depends on initial severity and on therapeutic response
b.
Monitor for signs of improvement

i.
Decreased pain
168
AAO 2014-2016
7.
ii.
Consolidation and sharper demarcation of the perimeter of the infiltrate (with

cessation of progression)
iii.
Decreased density of the infiltrate
iv.
Decreased stromal edema
v.
Resolution of hypopyon
vi.
Decreased anterior chamber inflammation
vii.
Re-epithelialization
Modification of therapy
a.
Consider additional or alternative antibacterial agent if insufficient response or stabilization
b.
Targeted therapy in non-responsive cases when culture results available
c.
Individual decision-making may be guided by results of sensitivity testing

i.
Methicillin Resistant Staphylococcus Aureus

i)
Two forms
(i)
Hospital-Acquired
(a) Found commonly in health care workers or chronically
hospitalized, institutionalized or immunocompromised patients
(b)
(ii)
More commonly multi-drug resistant
Community-Acquired
(a) Increasing percentage of community acquired ocular
infections e.g. perioperative (cataract and refractive surgery),
infectious keratitis, etc.
ii)
iii)
Diagnosis
(i)
Suspect in at risk individuals, communities with a high proportion of

clinical MRSA isolates or in infections responding poorly to therapy
(ii)
Culture if responding poorly to empiric therapy
(iii)
Consider culturing nares in high risk patients to identify asymptomatic

carriers (as part of pre-operative evaluation)
Treatment
(i)
High rate of laboratory resistance to common ophthalmic antibiotics

including fluoroquinolones
(ii)
Topical or intracameral vancomycin is the preferred therapy depending

on the site of infection
(iii)
Alternative systemic drugs include linezolid, daptomycin, tigecycline
(iv)
Alternative topical ophthalmic medications include polymyxin

B/trimethoprim, chloramphenicol, bacitracin
169
AAO 2014-2016
(v)
iv)
ii.
iii.
8.
V.
Consider alternative perioperative antibiotics and/or Infectious Disease

consultation
Pre-operative prophylaxis for high risk patients for ocular surgery

(i)
Polytrim or Vancomycin topically
(ii)
Bacitracin at night
(iii)
Consider ID consult
(iv)
Good draping of lids/lashes
Nontuberculous mycobacteria
i)
Amikacin
ii)
Clarithromycin
iii)
Moxifloxacin, Gatifloxacin
Fluoroquinolone resistant pseudomonas

i)
Aminoglycosides
ii)
Anti-pseudomonal penicillins (ticarcillin)

a.
Reconstructive penetrating keratoplasty
b.
Corneal glue for small perforation
c.
Tarsorrhaphy for non-healing sterile ulceration

A.
B.
C.
Complications of antibiotics
1.
Ocular surface toxicity
2.
Allergy
3.
Drug deposition (ciprofloxacin)
Complications of corticosteroids
1.
Exacerbation of corneal infection
2.
Elevated intraocular pressure
3.
Cataract
4.
Tissue loss
Complications of therapeutic or tectonic penetrating keratoplasty (See Penetrating keratoplasty)

1.
Endophthalmitis
2.
Rejection
170
AAO 2014-2016
VI.

A.
B.
Corneal thinning and perforation
C.
Endophthalmitis
D.
Corneal opacification and neovascularization
E.
Irregular astigmatism with loss of vision
F.
Cataract

A.
Medication instruction
1.
B.
Frequency of use and duration of therapy
Avoid or correct predisposing factors

1.
Appropriate CL hygiene
a.
2.
Advise regarding increased risks associated with extended wear contact lens
Protective eyewear if occupational or sports hazard
1.
2.
AAO, Focal Points: Antibiotic Use in Corneal and External Eye Infections, Module #10, 1997,
p.11-13.
3.
AAO, Preferred Practice Patterns Committee, Cornea and External Disease Panel. Bacterial
Keratitis Preferred Practice Pattern, 2008.
4.
Keay L, Stapleton F, Schein O. Epidemiology of contact lens-related inflammation and microbial

keratitis: a 20-year perspective. Eye Contact Lens. 2007 Nov;33(6 Pt 2):346-53, discussion 362-3.
Review.
5.
Wilhelmus KR, Abshire RL, Schlech BA. Influence of fluoroquinolone susceptibility on the
therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol
2003;121:1229-33.
6.
Panda A, Ahuja R, Sastry SS. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus
cefazol in the treatment of bacterial keratitis. Eye 1999;13:744-7.
7.
Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution
0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial
Keratitis Study Group. Ophthalmology 1996;103:1854-62; Discussion 1862-3.
8.
O'Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the
therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch
Ophthalmol 1995;113:1257-65.
171
AAO 2014-2016
9.
Parmar P, Salman A, Kalavathy CM, et al. Comparison of topical gatifloxacin 0.3% for the
treatment of bacterial keratitis. Am J Ophthalmol 2006;141:282-286.
10.
Charukamnoetkanok P, Pineda R 2nd. Controversies in management of bacterial keratitis. Int

Ophthalmol Clin 2005;45:199-210.
11.
Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong
KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR; Steroids for
Corneal Ulcers Trial Group. Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers
Trial (SCUT). Arch Ophthalmol. 2012 Feb;130 (2):143-50. Epub 2011 Oct 10.
172
AAO 2014-2016
Fungal keratitis
I.

A.

1.
2.
Filamentary fungi
a.
Fusarium
b.
Aspergillus
c.
Acremonium
d.
Curvularia
e.
Alternaria
Yeast
a.
B.
Candida

1.
Climate specific
a.
In warmer and more humid regions, filamentary fungi predominate
b.
Candida species, as part of the indigenous human flora, are present worldwide
i.
C.

1.
History of trauma with vegetative matter or contact lens wear

a.
D.
Its relative frequency as a cause of keratomycosis increases in temperate zones
Agricultural workers
2.
Dirt exposure in the eye
3.
Foreign body sensation, conjunctival injection, photophobia and decreased vision
4.
More insidious onset than with bacterial keratitis with gradually increasing pain
5.
Fungal keratitis tends to have fewer inflammatory signs and symptoms during initial periods
compared to bacterial keratitis
6.
Need to have clinical suspicion to make the diagnosis

1.
Filamentary fungal keratitis

a.
Frequently a gray-white, dry-appearing infiltrate with delicate filamentous or feathery, edge
b.
Multifocal or satellite infiltrates may be present
c.
Endothelial plaque
d.
Hypopyon
173
AAO 2014-2016
2.
a.
Occasionally gray or brown pigmentation
e.
Penetration of fungus through intact Descemet membrane and results in progressive

anterior chamber inflammation
Yeast keratitis
a.
3.
E.
Progression of either filamentous or yeast fungal keratitis

a.
Occasional invasion of the iris tissue and posterior chamber
b.
May result in a dense fibrinoid response in the anterior chamber
c.
May be associated with secondary glaucoma

1.
2.
Corneal scraping for smears and cultures

a.
Potassium hydroxide
b.
Gram, Giemsa, Gomori-methenamine silver, acridine orange, and calcofluor white stains
c.
Sabouraud's agar in addition to blood agar, chocolate agar and thioglycollate broth;
incubation of media at room temperature can facilitate fungal recovery
d.
Polymerase chain reaction
Corneal biopsy if clinical suspicion with negative smear/culture or if vision threatening keratitis with
lack of clinical improvement
a.
Histopathological examination
b.
Homogenization and culture
c.
Superior yield to scraping
3.
Confocal microscopy, looking for filamentous forms or spores in the corneal stroma
4.
Anterior chamber paracentesis, if strong clinical suspicion of fungal invasion into eye and negative
smear/culture of corneal specimen
5.
Sensitivities of isolated fungi to various antifungal agents only available at few centers
a.
II.
Focal dense, creamy suppuration that may resemble keratitis induced by gram-positive
bacteria
Unfortunately, there is poor correlation between in vitro sensitivity and in vivo response to
the antifungals

A.
Trauma to the cornea with plant material commonly associated with filamentary fungal keratitis
B.
Contact lens wear
C.
Corticosteroid therapy- appears to reduce the resistance of the cornea to fungal infection and
potentiate existing fungal keratitis
D.
Compromised immune status (e.g., patients with diabetes mellitus, chronic illness) commonly
174
AAO 2014-2016
associated with yeast keratitis
III.
IV.
E.
Compromised ocular surface (e.g., chronic keratitis, persistent epithelial defect) commonly
associated with yeast keratitis
F.
Use of broad spectrum antibiotics- provides a noncompetitive environment for fungus
G.
Previous corneal surgery

A.
Bacterial keratitis
B.
C.
Mycobacterial keratitis
D.
E.
Sterile posttraumatic keratitis, including corneal burns

A.

1.
Antifungal agents are mostly fungistatic (except for amphotericin B at high doses). Prolonged
topical and systemic treatment is often necessary
a.
b.
Problems with antifungal treatment

i.
Local toxicity
ii.
Poor penetration
iii.
Lack of correlation with in vitro sensitivities and clinical response
iv.
Expense
Yeast keratitis
i.
ii.
c.
i)
Topical amphotericin or voriconazole
ii)
Add oral fluconazole or voriconazole if severe, unresponsive candidal keratitis
Second line
i)
Topical fluconazole or rarely miconazole
ii)
Poor response of candidal keratitis to topical natamycin
Filamentous fungal keratitis

i.
First line
First line
i)
Topical natamycin
ii)
Add oral itraconazole, voriconazole or posaconazole if deep, progressive

keratitis,
175
AAO 2014-2016
ii.
Second line
i)
iii.
2.
Mechanical debridement or superficial keratectomy, especially for superficial fungal keratitis and
for exophytic proliferation during therapy
a.
2.
Debridement increases the penetration of topical antifungals but may increase scarring
Therapeutic penetrating keratoplasty for progressive keratitis despite antifungal therapy

a.
To prevent scleral or intraocular extension
b.
To reconstruct structurally damaged cornea
3.
Anterior chamber washout with antifungal medication if penetration/extension suspected
4.
Partial conjunctival flap, with or without a debulking lamellar keratoplasty
5.
Cryotherapy

A.
Antifungal toxicity, with conjunctivitis and persistent corneal epithelial defect

1.
B.
VI.
Not recommended for patients with fungal keratitis, early or late in the disease.

1.
V.
Beware of natamycin-resistant isolates, including Scedosporium, Paecilomyces, and

Colletotrichum
Corticosteroid
a.
B.
Topical voriconazole, clotrimazole, fluconazole, or amphotericin B
Reduce frequency and/or concentration
Recurrence of fungal keratitis following penetrating keratoplasty

1.
Continue antifungal therapy following surgery
2.
Minimize use of corticosteroid; consider cyclosporine as adjunctive agent following keratoplasty
3.
May consider an optical graft if initial therapeutic graft fails

A.
Intraocular and scleral extension, with fungal endophthalmitis or fungal keratoscleritis
B.
Corneal perforation
C.
Residual corneal scarring and vascularization
D.
Glaucoma

A.
Treatment compliance and close follow-up are key to successful treatments
176
AAO 2014-2016
1.
2.
AAO, Focal Points: Diagnosis and Management of Fungal Keratitis, Module #6, 2002.
3.
AAO, Focal Points: Infectious Keratitis, Module #8, 1992, p.2-4, 10-11.
4.
Bron AJ, Seal DV, Hay J. Ocular Infection: Investigation and Treatment in Practice. St Louis:
Mosby; 1998.
5.
O'Brien TP. Therapy of ocular fungal infections. Ophthalmol Clin North Am. 1999;12:33-50.
6.
O'Day DM. Fungal keratitis. In: Leibowitz HM, Waring GO III, eds. Corneal Disorders: Clinical
Diagnosis and Management. 2nd ed. Philadelphia: Saunders; 1998:711-718.
7.
Prajna NV, John RK, Nirmalan PK, et al. A randomised clinical trial comparing 2% econazole and
5% natamycin for the treatment of fungal keratitis. Br J Ophthalmol. 2003;87:1235-7.
177
AAO 2014-2016
I.

A.
B.
C.
D.

1.
Free-living pathogenic protozoa of the order Amoeba and genus Acanthamoeba
2.
Microbial co-infection may be associated

1.
Low incidence but severe morbidity
2.
Pathogen widespread in nature and in tap water, swimming pools, hot tubs, contact lens cases

1.
Contact lens wear or trauma with soil contamination
2.
Variable symptoms and protracted course

Severe pain, often out of proportion to the clinical signs
b.
May be misdiagnosed and treated as herpes simplex virus (HSV) keratitis

1.
2.
3.
E.
a.
Early stage
a.
Punctate epithelial granularity
b.
Raised epithelial lines
c.
Dendriform epitheliopathy
Intermediate stage
a.
Patchy anterior stromal infiltrates
b.
Radial perineuritis
c.
Minimal or no stromal neovascularization
Advanced stage
a.
Deep stromal infiltrates
b.
Annular or crescentic infiltrate
c.
Ulcerative keratitis, descemetocele, and corneal perforation
d.
Scleritis
e.
Iritis and hypopyon

1.
Smears of corneal scrapings (cysts easier to recognize than trophozoites, which may resemble
mononuclear leukocytes)
178
AAO 2014-2016
2.
a.
Giemsa, silver, gram or acridine orange stain
b.
Calcofluor white (cyst wall fluoresces) stain
Cultures of corneal scrapings

a.
Non-nutrient agar plate with bacterial overlay
b.
Blood agar plate
3.
Corneal biopsy for culture and histopathological examination, especially if smears and cultures are
negative and suspicion is high
4.
Confocal microscopy
a.
II.

A.
Contact lens wear

1.
B.
III.
Soft daily-wear > soft extended-wear > rigid gas-permeable
Exposure to contaminated water or soil

A.
B.
IV.
May identify cysts and trophozoites in vivo
Microbial or viral keratitis

1.
HSV keratitis
2.
Bacterial or mycobacterial keratitis
3.
Fungal keratitis
Toxic or traumatic keratitis

1.
Abuse of local anesthetics (e.g., proparacaine)
2.
Medication toxicity
3.
Factitious keratitis
4.
Posttraumatic sterile stromal keratitis

A.

1.
Medical - usually requires prolonged therapy for six months or longer

a.
Standard therapy
i.
Topical biguanides
i)
Chlorhexidine digluconate 0.02%
179
AAO 2014-2016
ii)
ii.
b.
ii.
C.
i)
Propamidine isethionate 0.1% solution (Brolene)
ii)
Hexamidine diisethionate 0.1% (Desomedine)
Oral
i)
Itraconazole
ii)
Fluconazole
iii)
Voriconazole
Topical
i)
Clotrimazole
ii)
Fluconazole
iii)
Voriconazole

1.
Epithelial debridement, during early infection
2.
a.
Optical keratoplasty (for corneal scarring)
b.
Tectonic keratoplasty (for corneal perforation)
c.
Therapeutic keratoplasty (but high risk of recurrent Acanthamoeba keratitis in corneal graft)
Describe patient follow-up

1.
V.
Topical diamidines
Adjunct therapy - Antifungal azoles

i.
B.
Polyhexamethylene biguanide (PHMB, PHBG, polyhexanide) 0.02%
Patients with active, infectious keratitis should be followed closely during treatment (every day to
once a week, depending on clinical features and clinical course).

A.
B.
C.
Topical biguanides: chlorhexidine or polyhexamethylene biguanide

1.
Stinging and limited epithelial toxicity (reduce frequency of applications or discontinue)
2.
Severe toxic keratoconjunctivitis (avoid higher concentration; avoid preparations containing

detergent)
Topical diamidines: propamidine or hexamidine

1.
Stinging with conjunctivitis and punctate epithelial erosions (reduce frequency)
2.
Contact hypersensitivity (reduce or discontinue)
Topical azoles
1.
Irritation (reduce frequency)
180
AAO 2014-2016
2.
D.
E.
VI.
Drug precipitation on eyelid margin and within epithelial defect (cleanse)
Oral azoles
1.
Drug-induced hepatotoxicity (discontinue)
2.
Other adverse drug reactions, including nausea, and drug interactions, (alter dosage or
discontinue)
1.
Graft failure
2.
Graft rejection
3.
Recurrence of infection

A.
Permanent corneal scarring
B.
Corneal perforation
C.
Progressive infection
D.
Scleritis
E.
Globe atrophy

A.
Good contact lens hygiene

1.
Use appropriate solutions; heat disinfection and two-step hydrogen peroxide are most effective
systems for eradicating amoebic contaminants
2.
Avoid contact lens wear while swimming, showering or bathing in hot tubs
3.
Discontinue contact lens wear if persistent irritation develops and seek medical attention
4.
Always use clean contact lens case, replace case as necessary
1.
AAO, Focal Points: and External Disease, Module #9, 2002, p.8.
2.
AAO, Focal Points: Applications of New Laboratory Diagnostic Techniques in Cornea Infectious
Keratitis, Module #8, 1992, p.1-2.
3.
4.
Bron AJ, Seal DV, Hay J. Ocular Infection: Investigation and Treatment in Practice. St Louis:
Mosby; 1998.
5.
Murray PR, Baron EJ, Pfaller MA, et al, eds. Manual of Clinical Microbiology. 7th ed. Washington,
DC: ASM Press; 1999:1413-1420.
181
AAO 2014-2016
6.
Wilkins JH, Joshi N, Margolis TP. Microsporidial keratoconjunctivitis treated successfully with a
short course of fumagillin. Eye 1994;8:703-704.
7.
Hammersmith KM. Diagnosis and management of Acanthamoeba keratitis. Curr Opin Ophthalmol
2006;17:327-31.
182
AAO 2014-2016
Microbial scleritis and sclerokeratitis

I.

A.

1.
Important causes of infectious scleritis:

a.
b.
Bacteria
i.
Pseudomonas - most common bacterial cause of scleritis
ii.
Staphylococcus
iii.
Streptococcus
iv.
Nocardia
v.
Mycobacterium tuberculosis
vi.
Other Mycobacteria
vii.
Treponema pallidum
viii.
Scleritis secondary to tuberculosis and syphilis is usually associated with systemic

disease
Fungi
i.
c.
B.
C.
Many different species
Viruses
i.
Herpes simplex, virus (HSV)
ii.
iii.
Scleritis secondary to HSV or VZV may be immune mediated (i.e., not an active or
infection), or may sometimes represent an active virus infection
2.
Infectious scleritis occurs more rarely than scleritis associated with systemic immune-mediated
disease
3.
Most common source of scleral infection is the cornea

1.
Symptoms usually more acute (compared with immune-mediated scleritis)
2.
Symptoms may be similar to bacterial keratitis
3.
Very severe pain is typical feature

1.
In cases of microbial scleritis, the cause is usually readily apparent

a.
Adjacent corneal ulcer, scleral buckle, wound infection, foreign body
b.
History of trauma or immunocompromise
183
AAO 2014-2016
D.
Necrosis, conjunctival defect, purulent discharge, acute pain
d.
Scleritis associated with systemic disease (tuberculosis, syphilis, varicella zoster) may
appear identical to "immune-mediated" scleritis
i.
Careful history and systemic evaluation indicated
ii.
Scleritis secondary to tuberculosis and syphilis is usually less acute, non-suppurative,

and non-necrotizing
2.
Mucopurulent discharge may be present
3.
Subconjunctival abscess may be present

1.
II.
c.
Culture material from the involved sclera, cornea, vitreous, or other obviously infected tissues (See
Bacterial keratitis)

A.
Postsurgical
1.
Pterygium excision - risk is higher if patient had Mitomycin C, or beta-irradiation
2.
Scleral buckle
3.
B.
C.
a.
Infections may occur immediately or years after surgery
b.
May have extruded buckle, conjunctival abscess or pain
c.
May be present as uveitis or choroidal abscess
Less common
a.
Cataract surgery (scleral tunnel infection)
b.
Glaucoma surgery
c.
Strabismus surgery
d.
Scleral suture abscess after any surgery
Posttraumatic
1.
Fingernail
2.
Foreign body
3.
Any other trauma (branch, vegetable matter, etc.)
4.
Risk is higher if immunocompromised
Local extension from adjacent tissues

1.
Most commonly from the cornea to the sclera (cornea (keratitis) - most common cause of
infectious scleritis
a.
Usually bacterial (Pseudomonas most common)
b.
Infiltrate spreads to limbus, resulting in limbal inflammation and conjunctival necrosis, and
184
AAO 2014-2016
thereafter to sclera
2.
May complicate infected scleral buckle
3.
Other structures (less common)
b.
Retina
c.
Conjunctiva (conjunctivitis)
d.
Orbit (cellulitis, sinusitis)
e.
Lacrimal sac (dacryocystitis)
Endophthalmitis leading to panophthalmitis
E.
Endogenous (rare, in general less acute and suppurative)

1.
Endogenous (septic emboli, endocarditis)
2.
Includes scleritis secondary to syphilis and tuberculosis
Secondary infection of patients with immune-mediated scleritis (superinfection)

1.
IV.
Choroid
D.
F.
III.
a.
An additional risk factor may be immunosuppression as part of therapy for the underlying disease

A.
Immune-mediated scleritis
B.
Episcleritis
C.
Scleral extension of intraocular inflammation or neoplasm
D.
Orbital cellulitis

A.
Therapy is directed at the causative organism

1.
Topical antimicrobial agents typically used

a.
Base on cultures and smears
2.
Subconjunctival antimicrobial injections often used
3.
Systemic antimicrobial agents usually necessary to achieve adequate medication levels

a.
4.
Specific etiologies (i.e. tuberculosis and syphilis) require systemic therapy
Prolonged therapy may be necessary
B.
Adjuvant systemic corticosteroids may be necessary (depending on inflammation, usually

contraindicated if Pseudomonas or fungi are causative organisms)
C.
Adjuvant cryotherapy may be used for Pseudomonas
D.
Remove any foreign bodies or foreign material (sutures, scleral buckles)
185
AAO 2014-2016
1.
E.
V.

A.
VI.
May also require debridement of necrotic scleral tissue
Prevention and management (See Bacterial keratitis)

1.
2.
Know toxicities of topical and systemic medications and monitor appropriately

A.
Endophthalmitis
B.
Scleral necrosis, ulceration, thinning, and perforation (possible role of scleral grafting)

A.
Emphasize importance of close follow-up
B.
Discuss possible systemic side effects of medications
C.
Discuss natural history of disease
1.
2.
AAO, Focal Points: Scleritis and Episcleritis: Diagnosis and Management, Module #9, 1995.
186
AAO 2014-2016
Conjunctival inflammation with scarring

I.

A.
Describe the etiology of this disease (See Ocular mucous membrane pemphigoid, Atopic
keratoconjunctivitis, and Stevens-Johnson syndrome)
1.
B.
C.
Underlying or predisposing disorder

a.
Autoimmune process (e.g., mucous membrane pemphigoid, paraneoplastic pemphigus,

linear immunoglobulin A dermatosis, Stevens-Johnson syndrome, atopic
blepharoconjunctivitis, chronic ocular graft vs. host disease (GVHD), and lichen planus)
b.
Infection (e.g., trachoma, adult chlamydial conjunctivitis, adenovirus keratoconjunctivitis,

herpetic keratoconjunctivitis, and streptococcal conjunctivitis)
c.
Ocular surface inflammatory condition (e.g., rosacea blepharoconjunctivitis)
d.
Toxicity (topical medications)
e.
Trauma, including chemical injury
f.
History of radiation to the eye area
g.
Genetic disorder (e.g., ligneous conjunctivitis)

1.
Preceding pseudomembranous or membranous conjunctivitis, occasionally with previous

conjunctival ulceration,
2.
Environmental allergies, including asthma and eczema
3.
Use of topical drugs associated with conjunctival scarring, including glaucoma medications, allergy
and adverse reactions to oral medications
4.
Current or previous skin rash
5.
Mucosal symptoms, including mouth or gum inflammation, difficulty swallowing, hoarseness,

obstructive sleep apnea, dysuria, and anogenital lesions
6.
History of allogeneic transplantation or treatment with radiation to the ocular area.
7.
Chronic or recurrent blepharoconjunctivitis, including dry or irritated sensation
8.
History of fever, arthralgia, malaise, and respiratory symptoms associated with conjunctivitis
9.
Living in a tropical, trachoma-endemic area

1.
Conjunctivitis, may show papillary or giant papillary conjunctivitis
2.
Subepithelial fibrosis, often beginning in the inferomedial fornix and semilunar fold areas, leading
to progressive conjunctival shrinkage and symblepharon
a.
Conjunctival scar formation observed as lacy subconjunctival cicatrization, often linear,

paralleling the eyelid margin, associated with trichiasis
187
AAO 2014-2016
D.
II.
b.
With progression, shortening of conjunctival fornix with symblepharon between the bulbar
and palpebral conjunctiva
c.
Severe cases include cicatricial entropion and ankyloblepharon
3.
Conjunctival keratinization, hyperkeratosis
4.
5.
Mucin tear deficiency
6.
Dilated tortuous conjunctival vascular changes
7.
Lagophthalmos with exposure of the ocular surface; abnormal position of the eyelids and
eyelashes including entropion, trichiasis, madarosis, and distichiasis
8.
Corneal findings, may include punctate epithelial erosions, pannus, neurotrophic keratopathy, and
subepithelial opacification
9.
Pertinent nonocular findings

a.
Skin lesions: non-scarring skin bullae of extremities and groin, or as erythematous plaques
of the head; hyper or hypopigmentation
b.
Oral lesions, including bullae of the mouth, nose, pharynx, or larynx; desquamative
gingivitis; and esophageal strictures

1.
Accurate record keeping of sequential slit-lamp biomicroscopic examinations to evaluate

presence, extent, and progression of subconjunctival scarring, fornix foreshortening, and
symblepharon
2.
Schirmer test
3.
Culture
4.
Histopathological evaluation
a.
Cytological evaluation of conjunctival scraping or swabbing
b.
Conjunctival biopsy for severe or progressive disease (See Conjunctival biopsy), including
examination of cellular histopathology and immunopathology (linear deposition of
immunoglobulin G, immunoglobulin A, and/or complement along epithelial base membrane)
c.
Impression cytology of ocular surface
d.
Biopsy of skin lesion or oral lesion

A.
Severe or progressive conjunctival inflammation from autoimmune or infectious disease
B.
Exogenous exposure to inciting agent, including allergen, topical medication, or noxious

chemical reagent
A.
188
AAO 2014-2016
III.
Patient Management
A.
B.
Medical therapy
1.
Aggressive lubrication with drops and ointments
2.
3.
For immune-mediated diseases, topical and systemic immunosuppressive therapy when indicated
4.
For infectious etiology, aggressive topical or oral antibiotic or antiviral therapy
Surgical interventions
1.
Punctal occlusion
2.
Daily lysis of symblepharon formation during active phase of the disease but remains controversial
3.
Epilation of trichiasis
4.
Repair of eyelid deformities
5.
Ocular surface reconstruction with amniotic membrane grafting or mucous membrane grafting
1.
189
AAO 2014-2016
I.

A.
B.
C.
D.

1.
Hypersensitivity reaction
2.
Immunoglobulin E mediated mast cell degranulation triggering inflammatory cascade with the
release of histamine and other mediators, including prostaglandins, thromboxanes, and
leukotrienes
3.
These various inflammatory agents, in conjunction with chemotactic factors, increase vascular
permeability and result in the migration of eosinophils and neutrophils

1.
Ocular itching, redness, and tearing
2.
History of concomitant allergic rhinitis
3.
Seasonal variation
4.
Personal or family history of atopy, including asthma, eczema or seasonal allergies

1.
2.
Chemosis
3.
Eyelid edema
4.
Papillary conjunctivitis
5.
Subepithelial infiltrates may be present

1.
History and clinical findings typically establish diagnosis

a.
Superficial conjunctival scraping

i.
2.
II.
Presence of eosinophils confirms diagnosis, although absence of eosinophils does

not exclude it (for vernal and atopy, eosinophils very rare in epithelial scrapings)
Skin testing by an allergist may provide definitive diagnosis and identify the offending allergen(s)

A.
History of atopy including allergic rhinitis
B.
Seasonal variation
1.
C.
Exposure to the offending antigen
Awareness of common triggers
190
AAO 2014-2016
III.
IV.

A.
B.
Bacterial
2.
Viral

A.
V.
1.

1.
Cool compresses
2.
Refrigerated artificial tears
3.
Topical histamine receptor antagonist
4.
Topical mast cell stabilizers: inhibit mast cell degranulation
5.
Combination agents (antihistamine, mast cell stabilizer, inhibition of inflammatory mediators)
6.
Mild topical corticosteroids for a limited time
7.
Topical vasoconstrictors
8.
Topical nonsteroidal anti-inflammatory drugs (NSAIDs)
9.
Oral antihistamines
10.
Avoid allergen
11.
De-sensitization with Allergist

A.
Possible reaction to medication or preservative (benzalkonium chloride)
B.
Awareness of drug toxicity/contact allergy

1.
VI.
Discontinuation of treatment as indicated
C.
Rebound from vasoconstrictor use may occur
D.
Corticosteroids
1.
Elevation of intraocular pressure
2.
Cataract with chronic use of steroids
3.
Increased risk of infection
191
AAO 2014-2016
A.
Rarely associated with severe vision-threatening complications
B.
Itching, tearing, and injection can be very frustrating resulting in marked discomfort and
decrease in quality of life

A.
Stress awareness of common offending antigens and avoidance of potential triggers
B.
Educate patient regarding chronic nature of disease and reassure patient regarding long term
visual prognosis
C.
Discuss therapeutic options and outline appropriate management
1.
2.
AAO, Focal Points: Update on Ocular Allergy, Module #5, 1994
3.
AAO, Focal Points: Nonsteroidal Anti-Inflammatory Drugs, Module #6, 1997, p. 4.
4.
AAO, Preferred Practice Patterns Committee. Conjunctivitis, 2008.
5.
Mortemousque B, Jacquet A, Richard C, et al. Randomised double masked trial comparing the
efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo
in allergic conjunctivitis induced by a conjunctival provocation test with Dermatophagoides
pteronyssinus. Br J Ophthalmol 2004;88:336-40.
6.
Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the

mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge
model in humans. Clin Ther 2003;25:2539-52.
7.
Daniell M, Constantinou M, Vu HT, et al. Randomised controlled trial of topical ciclosporin A in

steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006;90:461-4.
8.
Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am
2005;18:485-92.
9.
Bielory B, O'Brien TP, Bielory L. Management of seasonal allergic conjunctivitis: guide to therapy.
Acta Ophthalmol 2011:1-9.
192
AAO 2014-2016
Vernal keratoconjunctivitis
I.

A.
B.

1.
Immune-mediated atopic eye disease of children
2.
Hypersensitivity reaction affecting predisposed individuals during childhood until early

adolescence

1.
2.
More prevalent in dry, hot climate countries

a.
Common in Mediterranean area, central and West Africa, South America, Japan, and India
b.
Less common in North America and Western Europe
Young males before 10 years of age more commonly affected

a.
C.

1.
A.
Disease typically lasts 2 to 10 years
History of other atopic manifestation

a.
Eczema or asthma in three quarters of patients
b.
A family history of atopy is found in two thirds of patients
2.
Bilateral symmetrical disease
3.
Seasonal exacerbations
4.
Symptoms
a.
Itching (most specific)
b.
Photophobia
c.
Tearing
d.
Hyperemia
e.
Discharge

5.
Conjunctival
a.
b.
Papillae (2 forms)
i.
Upper tarsal, classic "cobblestone papillae" frequent in Europeans and North

Americans
ii.
Limbal, gelatinous and confluent more common in African Americans and West
Indian patients
Ropy mucous (associated with tarsal papillae)

193
AAO 2014-2016
c.
6.
D.
II.
III.
Corneal (more common in tarsal form)

a.
Punctate epithelial keratitis
b.
Shield ulcer
c.
Pseudogerontoxon - indicative of previous episode of limbal involvement

1.
Diagnosis is most commonly made clinically, without need for laboratory testing
2.
Conjunctival biopsy or scraping may reveal presence of eosinophils

A.
Family history (genetic predisposition)
B.
Habitant of hot dry climate places
C.
Patient characteristics
1.
Young age
2.
Male (but the disease also occurs in females)

A.
B.
Other forms of allergic conjunctivitis

1.
2.
Seasonal allergic conjunctivitis
3.
Perennial allergic conjunctivitis
4.
1.
IV.
Horner-Trantas dots
Bacterial
C.
Viral
D.
Toxic keratoconjunctivitis
E.

A.
Avoidance of allergens
1.
Seasonal removal of affected children from their homes to a reduced allergen climate (not
practical for the majority of families)
2.
Avoid exposure to nonspecific triggering factors (sun, dust, salt water, wind)
194
AAO 2014-2016
B.

1.
2.
Supportive
a.
Cool compresses
b.
Artificial tears (to dilute allergen)
Topical
a.
b.
Mast cell stabilizer/antihistamine

i.
Mast cell stabilizer (cromolyn sodium, lodoxamide, nedocromil, and pemirolast)
ii.
Antihistamines (levocabastine and emedastine)
iii.
Combined mast cell stabilizer and antihistamine (azelastine, olopatadine, and

ketotifen)
Anti-inflammatory
i.
Nonsteroidal antiinflammatory drug (NSAID) (ketorolac and diclofenac)
ii.
iii.
3.
4.
ii)
Higher absorption: prednisolone and dexamethasone
a.
Oral antihistamine (useful if other manifestations of atopic disease are present)
b.
Oral NSAID
c.
Oral corticosteroid in immunosuppressant doses (for vision-threatening disease)
d.
Systemic immunomodulator (e.g., cyclosporine, for vision-threatening disease)
Local
Supratarsal corticosteroid injection

1.
Superior tarsal scarring producing entropion, trichiasis and corneal scarring

a.
2.
Buccal mucous membrane graft
Shield ulcer
a.
V.
Lower absorption (fluorometholone, loteprednol, and rimexolone)
Systemic
a.
C.
i)

A.
Topical mast cell stabilizers

1.
B.
May cause irritation and toxic reactions (replace or discontinue)
Topical antihistamine
195
AAO 2014-2016
1.
C.
D.
1.
May induce cataract, glaucoma and infection
2.
Clinician must pay close attention to initial signs and symptoms, in order to provide early treatment
for these conditions
1.
E.
Major problems
a.
Adrenal insufficiency
b.
Peptic ulcer disease
c.
Psychosis
d.
Cushingoid features
e.
Secondary infection
f.
Aseptic necrosis of the femoral head
g.
Hyperglycemia
Systemic immunomodulators
1.
VI.
Gastrointestinal bleeding, acute renal failure
Oral corticosteroids
1.
H.
Somnolence, dry mouth, anorexia, or constipation
Oral NSAID
1.
G.
May cause irritation and burning
Systemic antihistamine
1.
F.
Headache, burning, dry eyes, dry mouth, somnolence (replace or discontinue)
Internist assistance

A.
B.
Superior tarsal papillae

1.
Pseudoptosis
2.
Conjunctival scarring with entropion and trichiasis, or corneal scarring
Limbal papillae
1.
C.
Corneal scarring, neovascularization, secondary infection
Shield ulcers
1.
Corneal scarring, secondary infection

196
AAO 2014-2016
A.
Avoidance of allergens
1.
Seasonal removal of affected children from their homes to a reduced allergen climate (not
practical for the majority of families)
2.
Avoid exposure to nonspecific triggering factors (sun, dust, salt water, wind)
B.
Compliance with treatment
C.
Understand the natural history of the disease and its potential vision threatening complications
1.
2.
AAO, Focal Points: Atopic and Vernal Keratoconjunctivitis, Module #1, 2001.
3.
AAO, Focal Points: Update on Ocular Allergy, Module #5, 1994, p.2-3.
4.
Anwar MS. The role of aspirin in vernal keratoconjunctivitis. J Coll Physicians Surg Pak
2003;13:178-9.
5.
Tabbara KF, al-Kharashi SA. Efficacy of nedocromil 2% versus fluorometholone 0.1%: a

randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis. Br J
Ophthalmol 1999;83:180-4.
6.
el Hennawi M. A double blind placebo controlled group comparative sturdy of ophthalmic sodium
cromoglycate and nedocromil sodium in the treatment of vernal keratoconjunctivitis. Br J
Ophthalmol 1994;78:365-9.
7.
Sharma A. Gupta R, Ram j, et al. Topical ketorolac 0.5% solution for the treatment of vernal
keratoconjunctivitis. Indian J Ophthalmol 1997;45:177-80.
8.
Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology

1991;98:1679-84.
9.
Kilic A, Gurler B. Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of
vernal keratoconjunctivitis. Can J Ophthalmol 2006;41:693-8.
10.
Sacchetti M, Lambiase A, Mantelli F et al. Tailored approach to the treatment of vernal

keratoconjunctivitis. Ophthalmology 2010;117(7):1294-1299.
197
AAO 2014-2016
I.

A.

1.
Present in individuals with other, non-ocular manifestations of atopy: hay fever rhinitis, asthma,
atopic dermatitis and eczema
2.
Immunoglobulin (Ig) E mediated hypersensitivity reaction
3.
Depressed systemic cell-mediated immunity

a.
B.
C.
Increased prevalence of unilateral, bilateral, and recalcitrant herpes simplex virus (HSV)
keratitis and HSV blepharitis

1.
Non-ocular atopic disorders
2.
Severe ocular itching
3.
Stringy ocular discharge
4.
Perennial symptoms with exacerbations and remissions

1.
2.
Symptoms
a.
Itching
b.
Tearing
c.
Burning
d.
Photophobia
e.
Decreased vision
Signs
a.
Lichenification of skin of the face
b.
Lids
c.
i.
Thickening (tylosis)
ii.
Crusting
iii.
Edema
iv.
Ptosis
v.
Blepharitis
Conjunctiva
i.
Small, medium or giant papillae
198
AAO 2014-2016
d.
e.
ii.
Hyperemia
iii.
"Milky" edema of tarsal conjunctiva
iv.
Stringy discharge
v.
Horner-Trantas dots at limbus
vi.
Cicatrization and symblepharon in advanced disease
Cornea
i.
Punctate epitheliopathy
ii.
iii.
Shield ulcer
iv.
Micropannus
v.
Subepithelial scarring
vi.
Increased incidence of keratoconus and HSV keratitis (unilateral, bilateral or

recalcitrant)
vii.
Pannus
Lens
i.
II.
III.
IV.
Anterior or posterior subcapsular cataracts

A.
Presence of atopic disease
B.
Exposure to environmental precipitants

A.
Vernal keratoconjunctivitis
B.
C.
Contact lens-associated giant papillary conjunctivitis
D.
1.
Viral
2.
Bacterial
E.
Rosacea-associated blepharokeratoconjunctivitis
F.
Medication-associated toxic conjunctivitis

A.
199
AAO 2014-2016
1.
2.
Topical therapy
a.
Antihistamines
b.
Corticosteroids
c.
Cyclosporine
d.
Tacrolimus or pimecrolimus for eyelid skin
Oral therapy
a.
Corticosteroids
b.
Immunosuppressants
i.
c.
B.
V.
Systemic antihistamines
Similar to management as vernal keratoconjunctivitis with additional monitoring for secondary

infection

A.
1.
Medical
a.
2.
3.
Corticosteroids
i.
Cataracts
ii.
Glaucoma
iii.
Predisposition to corneal infections, reactivation of herpetic infection
Prevention
a.
VI.
Cyclosporine
Limit use of topical corticosteroids
Management
a.
Cataract extraction
b.
Glaucoma drops/surgery

A.
B.
Conjunctivitis
1.
Cicatrization
2.
Symblepharon
Cornea
1.
Vascularization
2.
Scarring
200
AAO 2014-2016
3.
C.
Ulceration
Lens
1.
Anterior and posterior subcapsular opacities may develop

A.
Avoid environmental precipitants
1.
2.
AAO, Focal Points: Atopic and Vernal Keratoconjunctivitis, Module #1 2001.
3.
AAO, Focal Points: Update on Ocular Allergy, Module #5, 1994, p.3.
4.
Abelson MB, Udell IJ. Allergic and toxic reactions. The immune response. In: Albert DM, Jakobiec
FA, eds. Principles and Practice of Ophthalmology.. 3rd ed. Philadelphia: Saunders,
2008:1:611-624
5.
6.
Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical

cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998
Sep;105(9):1715-20.
201
AAO 2014-2016
Contact lens-induced conjunctivitis

I.

A.
B.
C.
II.
III.

1.
Chronic conjunctival inflammation related to contact lens wear
2.
More common with soft contact lens wear than with rigid gas permeable contacts
3.
Immune-related response to mechanical trauma of the superior tarsus by the rough surface of a
contact lens or hypersensitivity reaction to the contact lens polymer to the antigens associated
with the contact lenses, or to other foreign material adhering to the contact lens polymer itself or to
other foreign material, such as surface deposits, adhering to contact lenses

1.
Decreased tolerance or inability to wear contact lenses (common)
2.
Redness, itching, irritation, mucoid discharge from the eye
3.
4.
Contact lens decentration, excessive movement, bloody tears, ptosis (rarely)

1.
Papillary reaction on the superior tarsal conjunctiva
2.
Papillary hypertrophy (papillae larger than 0.3 mm); in severe cases, referred to as giant papillary
conjunctivitis (papillae > 1 mm)
3.
Conjunctival injection and mucoid conjunctival discharge
4.
Punctate epithelial erosions on the cornea
5.
Peripheral corneal infiltrates
6.
Corneal neovascularization (initially superiorly and then extending 360 degrees)

A.
Allergic conjunctivitis: seasonal, vernal, atopic
B.
C.
Bacterial conjunctivitis, including chlamydia
D.
E.
Giant papillary conjunctivitis secondary to exposed suture, foreign body or ocular prosthesis
F.
Other causes of superior tarsal papillary conjunctivitis, such as superior limbic

keratoconjunctivitis (SLK) or floppy eyelid syndrome
202
AAO 2014-2016
A.
IV.
V.
VI.

1.
Reduce the amount of or discontinue entirely contact lens wear. Discourage overnight use of
contact lenses
2.
Refit the patient with a different type of contact lens such as a daily disposable soft contact lens or
a rigid gas permeable contact lens
3.
Improve lens hygiene

a.
Use hydrogen peroxide systems for disinfection
b.
Use enzymatic treatment regularly to remove contact lens deposits
c.
Clean and replace contact lens cases on regular basis
4.
Topical mast cell stabilizers and/or antihistamines in mild cases
5.
Brief course of topical corticosteroids in severe cases
6.
Consider refractive surgery in patients intolerant to contact lens wear
7.
Follow-up in 1-6 weeks depending on severity of presentation

A.
Complications of topical corticosteroids, if used (glaucoma, cataract, etc)
B.
Sensitivity to ophthalmic meds and preservatives

A.
Scarring of superior tarsal conjunctiva
B.
Ptosis
C.
Contact lens intolerance
D.
Corneal opacity

A.
Chronic nature of this condition in some cases
B.
Importance of proper lens hygiene
C.
Importance of discontinuation of contact lens wear in persistent cases
D.
Importance of regular follow-up
1.
2.
AAO, Focal Points: Update on Ocular Allergy, Module #5, 1994, p.9.
203
AAO 2014-2016
3.
AAO, Preferred Practice Patterns Committee. Cornea and External Disease Panel. Conjunctivitis
4.
Friedlaender MH. Contact lens induced conjunctivitis: a model of human ocular inflammation.
CLAO J. 1996;22:205-8.
204
AAO 2014-2016
I.

A.

1.
Immune-complex deposition in the dermis and conjunctival stroma

a.
Common inciting agents

i.
ii.
Sulfonamides
ii)
Anticonvulsants
iii)
Salicylates
iv)
Penicillin
v)
Ampicillin
vi)
Isoniazid
Infectious organisms including:

i)
Herpes simplex virus (HSV)
ii)
Streptococci
iii)
Adenovirus
iv)
Mycoplasma
v)
Pneumocystis carinii
Pathologic changes include subepithelial bullae with subsequent scarring
3.
Erythema multiforme major (Stevens-Johnson syndrome) refers to an acute vesiculobullous

reaction of the skin and mucous membranes, and occurs in 20% of patients with erythema
multiforme
Minor only involves skin
List pertinent elements of the history and define the risk factors
1.
C.
i)
2.
a.
B.
Medications including:
More common in
a.
Children and young adults
b.
Females more than males
c.
Patients with acquired immune deficiency syndrome (AIDS), especially if treated for
Pneumocystis carinii pneumonia
2.
History of sudden onset of fever, arthralgia, malaise, and upper and lower respiratory symptoms
3.
History of use or exposure to inciting agent prior to flu-like symptoms
List pertinent clinical features
205
AAO 2014-2016
1.
Appearance of skin eruption with target lesions (red center surrounded by a pale ring and then a
red ring)
a.
II.
III.
Can also have maculopapular or bullous lesions
2.
Mucous membranes of eyes, mouth and genitalia may be affected by bullous lesions with
membrane or pseudomembrane formation
3.
New lesions appear over 4-6 weeks with a 2-week cycle
4.
Primary ocular finding is mucopurulent conjunctivitis; bullae and necrosis may develop
5.
Late ocular complications are caused by cicatrization causing trichiasis, forniceal shrinkage,
symblepharon, tear deficiency, limbal stem cell deficiency, and epithelial compromise

A.
B.
C.
Acute Graft-versus-host disease
D.
Chemical burn
E.
F.
Pseudopemphigoid

A.
B.

1.
Ocular lubrication with drops and ointments
2.
Close surveillance for early signs of ocular infections
3.
Systemic corticosteroids reduce the mortality rate and topical cyclosporine and corticosteroids
may reduce surface inflammation

1.
2.
Early
a.
Application amniotic membrane and topical steroid to the ocular surface
b.
Daily lysis of symblepharons controversial during acute phase because further scarring may
result
Late
a.
Late reconstruction of eyelid sequelae including entropion, trichiasis, fornix foreshortening
b.
Lamellar keratoplasty, tectonic patch graft, and penetrating keratoplasty have poor
prognosis but can be used in progressive thinning and perforation
c.
Keratoprosthesis
d.
Ocular surface reconstruction with amniotic membrane
206
AAO 2014-2016
e.
IV.

A.
B.
V.
Systemic corticosteroids may increase the risk of systemic and ocular infection, and are
associated with numerous systemic complications including:
1.
Gastrointestinal hemorrhage
2.
Electrolyte imbalance
3.
Sudden death
Topical corticosteroids:
1.
Infection
2.
Corneal thinning and perforation (See Bacterial keratitis, Corneal perforation)
3.
Increased intraocular pressure

A.
Conjunctival cicatrization resulting in:

1.
Conjunctival shrinkage, fornix foreshortening, symblepharons
2.
Trichiasis, entropion
3.
Tear deficiency
B.
Loss of epithelial barrier
C.
Microbial keratitis
D.
Corneal thinning or perforation
E.
Altered ocular surface and ocular surface disease resulting in
F.
VI.
Limbal stem cell replacement
1.
Corneal neovascularization and/or superficial scarring
2.
Corneal thinning

A.
Severe cases result in lifelong ocular morbidity
B.
Close monitoring for signs of infection and thinning
1.
2.
Foster CS. Immunologic disorders of the conjunctiva, cornea, and sclera. In: Albert DM, Jakobiec
207
AAO 2014-2016
FA, eds. Principles and Practice of Ophthalmology. Vol 2. 2nd ed. Philadelphia: Saunders;
2000:803-829.
3.
Holland EJ, Hardten DR. Stevens-Johnson syndrome. In: Pepose JS, Holland GN, Wilhelmus KR,
eds. Ocular Infection and Immunity. St Louis: Mosby; 1996:416-425.
4.
Hynes AY, Kafkala C, Daoud YJ, et al. Controversy in the use of high-dose systemic steroids in the
acute care of patients with Stevens-Johnson syndrome. Int Ophthalmol Clin 2005;45:25-48.
Review.
5.
6.
Gregory D. The ophthalmologic management of acute Stevens-Johnson syndrome. Ocular Surf

2008 6(1):87-95.
7.
Shammas MC, Lai EC, Sarkar JS et al. Management of acute Stevens-Johnson syndrome and
toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroid. Am J
Ophthalmol. 2010:149(2):203-213.
208
AAO 2014-2016
Ocular mucous membrane pemphigoid

I.

A.
Describe the etiology of this disease (also known as ocular cicatricial pemphigoid)
1.
B.
C.

1.
Chronic or recurrent blepharoconjunctivitis
2.
Use of glaucoma medications and other drugs associated with conjunctival scarring
3.
Skin rash or blisters
4.
Mucosal symptoms affecting mouth or gums, difficulty swallowing, hoarseness, obstructive sleep
apnea, dysuria, or anogenital lesions
5.
Can be exacerbated by ocular or adnexal surgery

1.
D.
II.
Autoimmune reaction to the conjunctival epithelial basement membrane
Conjunctival and ocular surface lesions, usually bilateral

a.
Inflammatory changes may include papillary conjunctivitis and conjunctival erosions
b.
Conjunctival subepithelial fibrosis, that may lead to progressive conjunctival shrinkage and
symblepharon
c.
Tear deficiency
d.
Lagophthalmos with exposure of the ocular surface and conjunctival keratinization
e.
Abnormal position of the eyelids and eyelashes, including entropion, trichiasis, and
distichiasis
2.
Skin lesions (uncommon): recurrent skin bullae of extremities or groin; and erythematous plaques
of the head
3.
Oral or respiratory lesions (uncommon): bullae of the mouth, nose, pharynx, or larynx;
desquamative gingivitis; and esophageal strictures

1.
Sequential examinations to evaluate progression of subconjunctival scarring, fornix foreshortening,

and symblepharon
2.
Conjunctival biopsy (See Conjunctival biopsy) to evaluate immunoglobulin linear deposits along
the basement membrane

A.
More common among patients older than 60 years
B.
Possible response to topical medication, such as glaucoma medication
209
AAO 2014-2016
III.
IV.

A.
Stevens-Johnson syndrome (erythema multiforme major)
B.
Medication toxicity or allergy, including drug-induced scarring (sometimes called

pseudopemphigoid)
C.
Residual scarring following chronic conjunctival inflammation

1.
2.
3.
Graft vs. host disease

A.

1.
2.
B.
V.
Agents to suppress inflammation and progressive cicatrization

a.
Dapsone
b.
Immunosuppressive agent, including cyclophosphamide, azathioprine, mycophenolate

mofetil, methotrexate, or cyclosporine
c.
Oral corticosteroid, often used as an adjunctive agent rather than as sole treatment
d.
Immunotherapy, such as intravenous immunoglobulin and rituximab
Lubricants and other means to control dry eye

1.
Punctal occlusion
2.
Correction of lid and lash malposition
3.
Fornix reconstruction
4.
Surgical repair of entropion and trichiasis
5.
Ocular surface reconstruction including:

a.
Amniotic membrane transplantation
b.
Limbal allografting
c.
Mucous membrane grafting
d.
Keratoplasty
e.
Keratoprosthesis

A.
Bone marrow suppression, including anemia, leukopenia, and thrombocytopenia
210
AAO 2014-2016
VI.
B.
Toxic effects on gastrointestinal tract, liver, or urinary tract
C.
Infection
D.
Dapsone should be used cautiously in patients with glucose-6-phosphate dehydrogenase

deficiency or sulfa allergy
E.
Corticosteroid-related effects, including osteoporosis, bone fracture, and weight change
F.
Prevention and management of treatment-related complications (See Scleritis)

A.
B.
C.
Progressive conjunctival scarring

1.
Conjunctival biopsy or other conjunctival surgery may exacerbate conjunctival scarring
2.
Symblepharon that may progress to obliterated conjunctival fornix and ankyloblepharon
Exposure and xerosis of the ocular surface

1.
Conjunctival keratinization
2.
Corneal neovascularization, opacification, ulceration, or perforation
3.
Secondary infection, including bacterial conjunctivitis and microbial keratitis
Manifestations affecting other mucous membranes, including oral mucosa or respiratory tract

A.
Awareness of symptoms that may represent secondary infection
B.
Need for monitoring systemic side effects of immunosuppressive therapy
C.
Methods to control dry eye syndrome (See Aqueous tear deficiency, Sjgren syndrome and
Mucin deficiency)
D.
Education regarding chronic nature of the disease with remission and exacerbation
1.
2.
Foster CS. Immunologic disorders of the conjunctiva, cornea, and sclera. In: Albert DM, Miller JW
et al, eds. Principles and Practice of Ophthalmology. 3rd ed. Philadelphia: Saunders; 2008
3.
Ross AH, Jaycocl P, Cook SD et al. The use of rituximab in refractory mucous membrane
pemphigoid with severe ocular involvement. Br J Ophthalmol 2009;93(4):421-2.
211
AAO 2014-2016

I.

A.
B.
C.
D.
II.
Describe the etiology of this disorder

1.
Unknown
2.
Although a viral immune response is suspected, an etiological agent has not been confirmed.
Describe the relevant epidemiology of the disorder

1.
Infrequent disorder
2.
No gender predilection
3.
Affects all age groups, probably most frequent in the second and third decades

1.
Intermittent photophobia
2.
Tearing
3.
Mild blurring of vision
4.
Burning, foreign body sensation
5.
Usually without ocular redness
6.
Spontaneously resolves to be followed by later exacerbations
7.
Usually bilateral
8.
Untreated episodes may last for weeks to 1-2 months

1.
Scattered clumps of fine epithelial lesions which are round, oval, or stellate
2.
Lesions are slightly elevated and may have mild punctate staining over them and subepithelial
infiltrates beneath them
3.
The lesions may be few or number up to 50 or more in each cornea
4.
Minimal or no conjunctival reaction
5.
Lesions change in location over time

A.
Staphylococcal toxic keratitis
B.
Rosacea
C.
D.
Dry eye
212
AAO 2014-2016
E.
Molluscum contagiosum
F.
1.
III.
May be confused but has florid conjunctival involvement

A.

1.
a.
B.
IV.
V.
VI.
Usually exquisitely sensitive to low dose steroids tapered over several days
2.
Topical cyclosporine tapered over many months may be of benefit
3.
Topical trifluridine has been suggested by some authors but others have been disappointed with
this treatment
4.
Bandage soft contact lenses provide temporary relief of symptoms and may lead to temporary
resolution of the lesions

1.
Scraping of the lesions is not beneficial
2.
Phototherapeutic keratectomy has been reported to decrease recurrences in the area of treatment
but has also been reported to induce recurrences
a.
Remains controversial
b.
Recurrence after laser assisted in situ keratomileusis (LASIK) has been reported.

A.
Corticosteroid toxicity and steroid dependence are significant risks with prolonged topical use,
so using the lowest dose for the shortest time that is effective is important in this chronic and
recurrent disease
B.
Corneal scarring generally is not seen with this disorder although anterior stromal haze may
occur but resolves over time

A.
Persistent or recurrent discomfort
B.
Blurred vision

A.
Use the lowest amount of corticosteroids for the shortest time necessary to relieve symptoms
B.
Seek ophthalmic care if symptoms persist despite treatment
213
AAO 2014-2016
1.
2.
AAO, Focal Points: Corneal Complications of Contact Lens, Module #2, 1993, p.4.
3.
Schwab IR, Thygeson P. Thygeson superficial punctate keratopathy. in: Pepose JS, Holland GN,
Wilhelmus KR, eds. Ocular Infection and Immunity. St. Louis: Mosby; 1996:403-407.
214
AAO 2014-2016
Marginal corneal infiltrates associated with

blepharoconjunctivitis
I.

A.

1.
B.
C.

1.
Acute onset
2.
Photophobia
3.
May have history of preexisting blepharitis, lid crusting, chalazia, but not essential
4.
Often history of prior episodes

1.
D.
Toxic/immune response to staphylococcal antigens from lid margin organisms
Usually round infiltrate in peripheral anterior stroma

a.
May at times be elongated concentric with the limbus
b.
Occur typically where lid margins cross the limbus at 2, 4, 8, and 10 o'clock
2.
Relative clear zone between lesion and the limbus
3.
Punctate overlying staining may develop and may become a frank epithelial defect that is usually
smaller than the infiltrate
4.
Conjunctival injection, diffuse or localized
5.
Often lid margins shows changes of staphylococcal blepharitis

1.
None for classic presentation

a.
II.
Define risk factors

A.
III.
By definition the lesion is not infected

A.
Microbial keratitis
1.
Bacterial
2.
215
AAO 2014-2016
IV.
B.
Contact lens associated peripheral corneal infiltrates
C.
Peripheral ulcerative keratitis associated with rheumatoid disease, Wegener granulomatosis
D.
Phlyctenulosis
E.
Rosacea keratitis
F.
G.
Toxic/ allergic reaction (e.g., marginal infiltrates due to Neosporin)
H.
Sterile limbal infiltrates during bacterial conjunctivitis

A.
V.
VI.

1.
Therapy of blepharitis with warm compresses, lid scrubs, antibiotic ointment to lid margins or
topical antibiotic
2.
Topical corticosteroids or corticosteroid/antibiotic combination
3.
Oral tetracyclines or erythromycin may be considered

A.
Exacerbation of active microbial keratitis if inaccurate diagnosis
B.
Culture of lids, conjunctiva or cornea may be considered if diagnosis is uncertain
C.
Photosensitivity of skin with oral tetracycline
D.
Corticosteroid-induced elevation of intraocular pressure

1.
Limit duration of treatment with corticosteroids
2.
Usually there is a rapid response and they may be tapered after 5 to 7 days

A.
Peripheral corneal scarring, occasionally thinning

A.
Warm compress to the lids (long-term, daily therapy)
B.
Lid scrubs
C.
Antibiotic ointment to lid margins after lid hygiene
D.
Consider long-term use of oral systemic tetracyclines as a prophylactic measure, although there
is limited evidence on their efficacy.
E.
Consider oral omega-3-fatty acids such as flaxseed oil, although there is limited evidence on their
efficacy.
216
AAO 2014-2016
F.
Advise patients to seek care if develop redness or pain in eye
G.
Patients should be advised not to self-treat with topical corticosteroids
H.
Patients should be aware that problem may reoccur
1.
217
AAO 2014-2016
Peripheral keratitis
I.

A.
Describe the etiology of these diseases

1.
The close anatomic relationship between the avascular peripheral cornea and the potentially
immune-responsive vascular limbal conjunctiva makes the peripheral cornea a common site for
inflammatory corneal disease
2.
Immune reactants from the limbus may react with antigens from the cornea in the corneal
periphery
3.
Nutrition to the peripheral cornea comes in part from the limbal vessels, and disorders involving
the limbal vessels may affect the peripheral cornea
4.
Substances may diffuse from the vascular system into the peripheral cornea where they may
accumulate or induce inflammation
5.
Limbal stem cells for the corneal epithelium reside along the margins of the cornea
a.
B.
Describe the relevant aspects of epidemiology of these diseases

1.
C.
D.
There are numerous disorders in this category ranging from the infrequent (neoplasms) to the
more common (staphylococcal marginal keratitis) (These individual entities are discussed in their
specific outlines)
List the pertinent elements of history

1.
Symptoms depend on the specific entity
2.
Complaints of ocular irritation and redness are most common
3.
Evaluate for systemic diseases, such as connective-tissue diseases

1.
E.
Abnormalities in these cells may lead to changes in the peripheral corneal surface.
Vary with the disorder, may include

a.
Ulceration
b.
Thinning
c.
Edema
d.
Vascularization
e.
Infiltration with inflammatory cells
f.
Lipid deposition
g.
Irregular epithelium and mucous plaques or filaments
h.
Elevated mass
218
AAO 2014-2016
1.
II.
Depends on the entity being considered

a.
Microbial or viral assays
b.
Serologic testing

A.
Infection-related conditions
1.
Microbial keratitis
2.
Stromal (interstitial) keratitis, including Herpes simplex virus (HSV) stromal keratitis and syphilitic
interstitial keratitis
B.
Marginal keratitis associated with blepharitis, including staphylococcal blepharitis and rosacea
C.
Collagen-vascular diseases
1.
2.
3.
4.
5.
Relapsing polychondritis
D.
Allergic keratoconjunctivitis including limbal vernal and drug reaction
E.
Degenerative and/or inflammatory disorders
F.
1.
Terrien marginal corneal degeneration
2.
Dellen
3.
4.
Mooren ulcer
5.
Contact lens peripheral infiltrate
Neoplastic
1.
G.
Corneal intraepithelial neoplasia may mimic peripheral keratitis

1.
2.
Congenital
a.
Aniridia
b.
Ectodermal dysplasia
Acquired
a.
Toxic
b.
Post-inflammatory
c.
Postsurgical
219
AAO 2014-2016
d.
Traumatic (i.e., contact lens-induced)
1.
220
AAO 2014-2016
Nonulcerative keratitis
I.

A.

1.
B.
C.
D.

1.
Previous ocular herpes, particularly previous herpes simplex virus (HSV) stromal keratitis
2.
Previous chickenpox or shingles (herpes zoster virus)
3.
Previous congenital syphilis with dental deformities, bone and cartilage deformities, or hearing loss
4.
Systemic illness including infectious mononucleosis, measles, and Lyme disease
5.
Recent upper respiratory infection with ear-related symptoms such as dizziness and reduced
hearing (Cogan syndrome)

1.
Stromal inflammation with stromal edema; may be focal or disciform, multifocal, or diffuse;
endothelial pseudoguttata
2.
Corneal epithelium intact
3.
Keratitis often accompanied by iritis and keratic precipitates: stromal keratouveitis/ endotheliitis
4.
Presence and extent of stromal neovascularization
5.
Presence and extent of corneal scarring
6.
Interstitial keratitis associated with infectious diseases
7.
Subepithelial infiltrates and multifocal posterior corneal nodular infiltrates associated with Cogan
syndrome

1.
II.
Humoral and cellular immune reaction to antigens (including viral glycoproteins and other
microbial substances) in the corneal stroma resulting in cellular infiltration and inflammation
Serological testing, depending upon history and clinical findings

a.
Fluorescent treponemal antibody absorption or similar treponemal test
b.
HSV antibody
c.
Varicella zoster virus (VZV) antibody
d.
Epstein-Barr virus (EBV) antibodies

A.
HSV stromal keratitis

1.
221
AAO 2014-2016
B.
C.
2.
3.
Virulent strain of HSV - 1
4.
Prior stromal keratitis is a strong predictor of recurrent disease
VZV stromal keratitis

1.
Increasing age
2.
Immunosuppression and malignancy
Interstitial keratitis associated with infectious diseases

1.
III.
Exposure to
a.
Treponema pallidum
b.
Mycobacterium tuberculosis
c.
Mycobacterium leprae
d.
Borrelia burgdorferi (Lyme disease)
e.
Rubeola (measles)
f.
EBV (infectious mononucleosis)
g.
Other systemic microorganisms

A.
Microbial keratitis
B.
Corneal transplant rejection
C.
Contact lens-related corneal infiltrate
D.
Diffuse lamellar keratitis following keratorefractive surgery
E.
Rosacea keratitis
F.
G.
Corneal edema
H.
Sterile keratitis following trauma
1.
2.
Kaufman SC. Peripheral Corneal Disease, In Cornea.Krachmer, Mannis, Holland, Editors. 3rd Ed.
2011, Elsevier inc.
222
AAO 2014-2016
Ulcerative keratitis
I.

A.
B.
Describe the etiology of the disease (corneal epithelial defect and stromal inflammation, without
or with stromal ulceration)
1.
Epithelial defect from delayed epithelial replication, migration, and/or adherence
2.
Stromal inflammation from innate immune response
3.
Stromal ulceration from keratocyte destruction and apoptosis and from proteolysis of stromal
collagen and proteoglycans
a.
Microbial enzymes (e.g., bacterial proteinases)
b.
Phagocyte (neutrophil) enzymes (e.g., lysosomal proteinases)
c.
Corneal degradative mechanisms, including matrix metalloproteinases and the

plasminogen-dependent pathway

1.
Onset and evolution of ocular inflammation

a.
2.
Contact lens wear

a.
3.
Exacerbating and alleviating factors
Contact lens care (e.g., products, frequency of cleansing and disinfection, and lens case)
Ocular trauma
a.
Foreign body
4.
Exposure to fluids (water and chemicals)
5.
Prior ocular surgery, including keratorefractive procedure
6.
Prior ocular disease
7.
a.
Recurrent erosion
b.
c.
Varicella zoster virus (VZV) keratitis
Recent topical ophthalmic medications

a.
Anesthetics
b.
Antibacterials
c.
Antivirals
d.
Corticosteroids
e.
Nonsteroidal anti-inflammatory drugs (NSAIDS)
f.
BAK preserved drops- frequent use
223
AAO 2014-2016
8.
a.
Diabetes mellitus
b.
Connective tissue disorder
c.
Immunosuppression
9.
Nutritional status, including alcohol use
10.
Recent exposure to others with "red eye"
11.
Effect of eye condition on quality of life, including level and duration of pain
12.
Duration and level of symptoms
13.
C.
Systemic disease
a.
Pain
b.
Redness
c.
Light sensitivity
d.
Tearing
e.
Decreased vision
General medical health

a.
Fever
b.
Fatigue
c.
Headache
d.
Weight change
e.
Appetite
f.
Upper respiratory tract symptoms
g.
Joint aches
h.
Reason for any recent hospitalization
i.
History of "fever blisters" or shingle

1.
Status of ocular adnexa, skin, and extremities
2.
Presence of palpable preauricular and other regional lymph node(s)
3.
Position of eyelids and eyelashes
4.
Presence of exposure
5.
Status of tear film and lacrimal system
6.
Status of conjunctiva, including presence of symblepharon and scarring
7.
Corneal sensation
8.
Size and shape of corneal epithelial defect
224
AAO 2014-2016
D.
II.
9.
Status of remaining corneal epithelium and corneal epithelial basement membrane
10.
Type of stromal inflammation: suppurative or nonsuppurative
11.
Area and depth of stromal inflammation, including location, number of separate infiltrates, and
appearance of border of any focal infiltrate
12.
Presence and extent of stromal thinning or ulceration
13.
Presence and extent of corneal vascularization
14.
Area and extent of corneal edema and pseudoguttata
15.
Presence or absence of iritis, including iris synechiae, inflammatory endothelial plaque, or

hypopyon
16.
Status of contralateral eye

1.
Infectious ulcerative keratitis (See Diagnostic techniques for infectious diseases of the cornea and
conjunctiva, including specimen collection methods for microbiologic testing and diagnostic
assessment of the normal ocular flora)
2.
Immune-mediated ulcerative keratitis

a.
Biopsy for suspected autoimmune disease
b.
Serological tests such as

i.
Rheumatoid factor
ii.
Antinuclear antibodies (ANA)
iii.
Anti-neutrophil cytoplastic antibodies (ANCA)
iv.
Hepatitis C antibodies

A.
Viral epithelial keratitis

1.
a.
2.
HSV epithelial keratitis

a.
3.
B.
Exposure to infected individual or contaminated fomite
Environmental triggers such as sun exposure, recent illness, or recent ocular surgery
VZV epithelial keratitis

a.
Increasing age
b.
Immunosuppression
c.
Malignancy
d.
Chemotherapy/radiotherapy
Suppurative microbial keratitis
225
AAO 2014-2016
C.
III.
1.
Contact lens use (especially extended-wear use)
2.
Ocular trauma (corneal foreign bodies, chemical and thermal injuries)
3.
Previous ocular and eyelid surgery
4.
Loose sutures
5.
Previous corneal surgery (including refractive surgery and penetrating keratoplasty)
6.
Medication toxicity (medicamentosa)
7.
Immunosuppression (systemic and local)
8.
Anesthetic abuse
9.
Ocular surface disease (trichiasis, exposure/lid abnormalities, tear film abnormalities)
10.
Adjacent infections (blepharitis, conjunctivitis, dacryocystitis, canaliculitis)
Nonsuppurative keratitis
1.
Ocular surface disorders (e.g., neurotrophic keratitis, recurrent erosion, previous corneal
infections, viral keratitis, bullous keratopathy, keratoconjunctivitis sicca, blepharoconjunctivitis)
2.
Systemic conditions (e.g., diabetes mellitus, malnourishment, connective-tissue disorders,

substance abuse, dermatological/mucous membrane disorders, Stevens-Johnson syndrome,
mucous membrane pemphigoid, immunocompromise, atopic dermatitis/ blepharoconjunctivitis,
vitamin A deficiency)

A.
Ulcerative keratitis (corneal epithelial defect and stromal inflammation)

1.
Punctate and dendritic epithelial keratitis and epithelial erosions with stromal infiltrate
a.
2.
Viral infections
i.
ii.
HSV epithelial keratitis
iii.
VZV epithelial keratitis
b.
c.
Toxicity
d.
Dry eye syndrome
e.
Contact lens reaction
Suppurative or necrotizing ulcerative keratitis

a.
Microbial infections
i.
Bacterial keratitis
ii.
Fungal keratitis
226
AAO 2014-2016
iii.
3.
B.
C.
D.
Acanthamebic keratitis
b.
Herpetic keratitis (persistent corneal epithelial defect with necrotizing herpes simplex virus
stromal keratitis)
c.
Zoster-associated neurotrophic keratopathy
Nonsuppurative ulcerative keratitis

a.
Marginal corneal infiltrate associated with blepharoconjunctivitis
b.
Sterile infiltrate due to contact lens wear or corneal trauma
c.
Peripheral ulcerative keratitis associated with systemic immune-mediated disease
d.
Mooren ulcer
Corneal epithelial defect without stromal inflammation

1.
Traumatic corneal abrasion
2.
Toxic keratopathy
3.
4.
Nonulcerative keratitis: stromal inflammation without epithelial defect

1.
Phlyctenulosis and rosacea keratitis
2.
Vernal and atopic keratoconjunctivitis
3.
Various forms of nonulcerative keratitis (HSV stromal keratitis, VZV stromal keratitis, Epstein-Barr
virus keratitis, interstitial keratitis associated with infectious diseases such as congenital syphilis,
Cogan syndrome)
Nonulcerative opacity: stromal opacification with corneal thinning but intact corneal epithelium
1.
Terrien marginal corneal degeneration
2.
Senile furrow degeneration
3.
Postinfectious and posttraumatic corneal scarring
1.
2.
AAO, Focal Points: Infectious Keratitis, Module #8, 1992, p.1-2.
227
AAO 2014-2016
Peripheral ulcerative keratitis associated

with systemic immune-mediated diseases
I.

A.
B.

1.
Vasculitis and immune complex deposition
2.
Contiguous with adjacent scleritis
Describe the relevant epidemiology of this disease

1.
C.
Epidemiology is that of the systemic disease

1.
2.
3.
4.
a.
History of erythematous, hot, tender, swollen joints
b.
May also have history of dry eyes, nose, and mouth
a.
May have history of pulmonary, sinus, ear, or renal disease
b.
Conjunctivitis or scleritis at presentation or in the past
c.
Ocular disease may be present alone (limited form) or prior to the onset of systemic disease

a.
Fatigue
b.
Fever
c.
Anorexia
d.
Weight loss
e.
Arthralgias and myalgias
f.
Skin rash and photosensitivity
g.
Renal disease
h.
Neurologic symptoms
i.
Pleuritis
Inflammatory bowel disease

a.
Rectal bleeding
b.
Diarrhea
c.
Abdominal pain
228
AAO 2014-2016
5.
D.
d.
Anorexia
e.
Weight loss
f.
Fever
g.
None may be present as ocular disease may precede symptomatic bowel disease
Ocular symptoms
a.
May vary
b.
c.
Tearing
d.
Pain may or may not be present.
e.
Photophobia
f.
Decreased vision
g.
Associated symptoms such as pain related to scleritis if present

1.
Peripheral ulcerative keratitis

a.
Peripheral epithelial defect, infiltration of the corneal stroma, and thinning
b.
c.
d.
i.
Peripheral stromal opacities with overlying epithelial defect, thinning, may be adjacent
to necrotizing scleritis
ii.
Stromal melting without clinical evidence of inflammation may occur peripherally or

centrally, more commonly in patients with concurrent keratoconjunctivitis sicca
i.
Peripheral corneal subepithelial infiltrates
ii.
Anterior grainy stromal opacities
iii.
Peripheral guttering with adjacent scleritis

i.
e.
II.
Corneal ulceration is uncommon
Inflammatory bowel disease

i.
Peripheral subepithelial infiltrates and nebulae
ii.
Malabsorption may lead to vitamin A deficiency and its corneal complications

A.

1.
Treat systemic disorder to suppress systemically mediated inflammation and vaso-occlusive
229
AAO 2014-2016
disease
B.
b.
Cytotoxic agents
c.
Immunosuppressive/immunomodulatory agents
d.
Tumor necrosis factors (TNF)-alpha antagonists
Maintain adequate lubrication of the ocular surface
3.
Promote corneal re-epithelialization

Perforation or impending perforation of the cornea may require treatment with tissue adhesive,
amniotic membrane graft, perilimbal conjunctival resection, and/or lamellar or penetrating
keratoplasty, often performed as a crescentic or circular peripheral graft. When possible,
intraocular surgery should be avoided until systemic immunosuppression has commenced

A.
B.
IV.
Systemic corticosteroids
2.
1.
III.
a.
Systemic side effects of corticosteroids, cytotoxic and immunosuppressive agents including

1.
Secondary infection
2.
Gastrointestinal symptoms
3.
Secondary neoplasms
Surgical complications
1.
Graft rejection
2.
Infection
3.
Recurrent corneal ulceration and perforation

A.
B.
Disease related complications are diverse and include

1.
Articular disease
2.
Pulmonary disease
3.
Renal disease
4.
Death
Ocular complications include

1.
Uveitis
2.
Dry eye
3.
Cataract
230
AAO 2014-2016
V.
4.
Retinal vasculitis
5.
Conjunctivitis
6.
Scleritis
7.
Eyelid involvement
8.
Corneal melt/perforation
9.
Loss of vision

A.
These patients must be managed in concert with the appropriate medical specialist, especially
the rheumatologist or gastroenterologist but at times also the nephrologist, pulmonologist, or
dermatologist
1.
Patients must be strongly impressed with the importance of maintaining these relationships
1.
2.
Virasch VV, Brasington RD, Lubniewski AJ. Corneal Disease in Rheumatoid Arthritis. In Cornea.
ed. Krachmer, Mannis, Holland, 3rd Ed. 2011, Elsevier inc.
3.
Sugar J, Cortina MS. Corneal Disease Associated with nonrheumatoid Collagen-Vascular

Disease, In Cornea. ed. Krachmer, Mannis, Holland, 3rd Ed. 2011, Elsevier inc.
231
AAO 2014-2016
Mooren ulcer
I.

A.

1.
B.
C.
D.
E.
Appears to be an immunologic disorder with autoimmunity to corneal antigens of unknown

etiology. Precipitating factors may include:
a.
Idiopathic
b.
Secondary to previous corneal insults such as trauma, chemical injury, surgery, or infection
c.
Hepatitis C, intestinal parasites, and other infections have been found in some patients, but
causal association remains uncertain

1.
Infrequent disorder
2.
Two populations have been described although some reports have disputed this:
a.
Older people with a more benign, often unilateral disease
b.
More aggressive bilateral painful disease, often in younger patients

1.
Pain, often severe, chronic, progressive
2.
3.
Photophobia
4.
Decreased visual acuity

1.
Peripheral gray to white stromal infiltrate, usually in the interpalpebral zone
2.
Overlying epithelial defect
3.
Associated stromal thinning
4.
Undermined leading edge progresses centrally and circumferentially
5.
Peripheral corneal reepithelialization as the ulcer moves centrally
6.
Injection and chemosis of adjacent conjunctiva

1.
Serologic testing to rule out collagen-vascular diseases (antinuclear antibody (ANA) panel,
perinuclear-staining anti-neutrophil cytoplasmic antibodies (p-ANCA), cytoplasmic-staining
anti-neutrophil cytoplasmic antibody (c-ANCA), rheumatoid factor)
2.
Hepatitis C antibodies
232
AAO 2014-2016
II.

A.
III.
Unknown, associated with some human leukocyte antigen subtypes, trauma, hepatitis C

A.
B.
Inflammatory
1.
Peripheral ulcerative keratitis and/or scleritis secondary to collagen vascular disease (rheumatoid
arthritis, Wegener granulomatosis, systemic lupus erythematosus, polyarteritis nodosa)
2.
Marginal keratitis (staphylococcal)
Infectious
1.
C.
IV.
Peripheral keratitis (bacterial, herpes simplex virus)
Degenerative
1.
Terrien marginal corneal degeneration - peripheral, more slowly progressive, usually intact
epithelium
2.
Senile furrow degeneration

A.

1.
Topical corticosteroids, especially in milder cases
2.
Systemic immunosuppression
a.
i.
b.
c.
d.
Antimetabolites
i.
Methotrexate
ii.
Azathioprine
Immunomodulatory agents
i.
Cyclosporine
ii.
Mycophenolate mofetil
Alkylating agents
i.
3.
B.
Prednisone
Cyclophosphamide
Systemic interferon (if associated with hepatitis c)

1.
Conjunctival resection - adjacent to ulcer
2.
Superficial keratectomy - for isolated de-epithelialized central corneal islands
233
AAO 2014-2016
V.
VI.
3.
Corneal/scleral patch grafting for perforations
4.
Corneal gluing may be helpful occasionally for very small perforations

A.
Side effects of systemic immunosuppressives including secondary infections, gastrointestinal

symptoms, secondary neoplasms
B.
Side effects of topical corticosteroids- glaucoma, cataract, secondary infection

A.
Corneal opacification
B.
Cataract
C.
Glaucoma
D.
Exacerbation of disease with surgical interventions
E.
Corneal Perforation
F.
Vision loss

A.
Disease may reactivate after periods of quiescence

1.
Patients must be warned to return promptly if there is any activation of symptoms
B.
For systemic immunosuppressive treatment, co-management with a medical specialist

(rheumatologist, etc.) is essential
C.
Avoid even minor trauma given the risk of perforation
1.
2.
Garg P, Sangwan VR. Mooren's Ulcer. In Cornea. ed. Krachmer, Mannis, Holland, 3rd Ed. 2011,
Elsevier inc.
3.
Gottsch JD, Stark WJ, Liu SH. Cloning and sequence analysis of human and bovine corneal
antigen (CO-Ag) cDNA: identification of host-parasite protein calgranulin C. Trans Am Ophthalmol
Soc. 1997;95:111-125.
234
AAO 2014-2016
Episcleritis
I.

A.

1.
Idiopathic (most common)
2.
Post-traumatic, post-surgical
3.
Associated with underlying systemic condition

a.
b.
Connective tissue disorders

i.
ii.
iii.
iv.
Sjgren syndrome
Infectious diseases
i.
ii.
c.
B.
C.
Bacteria
i)
Tuberculosis
ii)
Syphilis
Virus
i)
ii)
Miscellaneous
i.
Gout
ii.
Atopy
iii.
Rosacea
iv.
Inflammatory bowel diseases
v.
Sarcoidosis
List the pertinent elements of history

1.
Acute onset or recurrence of mild ocular discomfort
2.
Localized or diffuse conjunctival injection

1.
Localized injection of the bulbar conjunctival and episcleral vessels is more common than diffuse
involvement
2.
Blanching with topical (2.5% or 10%) phenylephrine
235
AAO 2014-2016
D.
II.
III.
3.
Excessive tearing
4.
Conjunctival nodule (in nodular form)
5.
Small peripheral corneal opacities
6.
Mild anterior chamber cell and flare
Describe the appropriate testing and evaluation for establishing the diagnosis
1.
If recurrent or if history suggests an underlying associated systemic disorder
2.
Serum uric acid
3.
Complete blood count with differential count
4.
Antinuclear antibody (ANA)
5.
Rheumatoid factor
6.
Erythrocyte sedimentation rate (ESR)
7.
Fluorescent treponemal antibody-absorption test, Venereal Disease Research Laboratory (VDRL)

test
8.
Chest X-ray

A.
B.
C.
Anterior scleritis
D.
Conjunctival abrasion
E.
F.
Pingueculitis
G.
Iritis
H.
Staphylococcal blepharoconjunctivitis

A.

1.
Treat underlying disorder, if present
2.
Judicious use of vasoconstrictors
3.
Mild
a.
4.
Artificial tears
Moderate
a.
Topical nonsteroidal anti-inflammatory drug (NSAID) or mild corticosteroid

236
AAO 2014-2016
5.
Severe, recalcitrant, or recurrent

a.
IV.
Stronger topical corticosteroid +/- oral NSAID

A.
1.
2.
Complications
a.
Potentiation of ocular infection
b.
Glaucoma
c.
Cataract
d.
Prolong time to natural resolution
Prevention
a.
3.
B.
Management
a.
Control intraocular pressure (IOP) with topical therapy/surgery if necessary
b.
Cataract surgery if indicated
Topical NSAID
1.
2.
Complications
a.
Corneal melt
b.
Medicamentosa
Prevention
a.
3.
C.
Limit use of topical corticosteroids (lowest effective potency for shortest duration)
Limit use
Management
a.
Cessation of use
b.
Topical lubricants (See Management of descemetocele and corneal perforation by bandage

contact lens, tissue adhesive or reconstructive graft)
Topical vasoconstrictors
1.
Complications
a.
2.
Prevention
a.
3.
Rebound vasoconstriction
Limit use
Treatment
a.
Cessation
237
AAO 2014-2016
V.
VI.

A.
No visually significant sequelae
B.
Persistent dilation of conjunctival or episcleral vessels may be of cosmetic concern

A.
Self-limiting disease
B.
Relapses may occur, in the same or contralateral eye
C.
No visually significant sequelae
D.
Use of topical corticosteroids should be limited to decrease incidence of associated side effects
1.
2.
3.
Williams CP, Browning AC, Sleep TJ, et al. A randomised, double-blind trial of topical ketorolac vs
artificial tears for the treatment of episcleritis. Eye 2005;19:739-42.
4.
Pearlstein ES. Episcleritis. In Cornea. ed. Krachmer, Mannis, Holland, 3rd Ed. 2011, Elsevier inc.
238
AAO 2014-2016
Scleritis
I.

A.
B.
C.

1.
50-75% idiopathic
2.
25-50% have underlying systemic disease

a.
More common: rheumatoid arthritis, Wegener granulomatosis, relapsing polychondritis
b.
Less common: ankylosing spondylitis, systemic lupus erythematosus, polyarteritis nodosa,

inflammatory bowel disease, gout, post-herpes zoster ophthalmicus, sarcoidosis, syphilis
3.
Deposition of immune complexes in vessel walls appears to be important
4.
Disordered immune response leads to tissue and blood vessel damage

1.
Severe eye pain, boring quality
2.
Red eye
3.
Pain on movement of eye
4.
Tearing
5.
Slow onset
6.
May be recurrent

1.
Classification
a.
b.
2.
Anterior
i.
Diffuse - most common presentation, least severe
ii.
Nodular
iii.
Necrotizing with inflammation- most severe, greatest potential for visual loss
iv.
Necrotizing without inflammation (scleromalacia perforans)- association with

rheumatoid arthritis
Posterior
Signs
a.
Anterior: pain on palpation, red-violet hue to sclera (seen best with natural lighting),
non-blanching with 10% phenylephrine drops, inflammation of sclera and episclera, scleral
nodules, uveitis, adjacent peripheral keratitis
b.
Posterior: hyperopia, proptosis, lid edema, ophthalmoplegia, disc edema, exudative retinal
detachment, macular edema, choroidal folds
239
AAO 2014-2016
D.

1.
II.
IV.
a.
Complete blood count (CBC)
b.
Erythrocyte sedimentation rate (ESR)
c.
rapid plasma reagin test or Venereal Disease Research Laboratory (VDRL) test
d.
Fluorescent treponemal antibody absorption test (FTA)
e.
Rheumatoid factor
f.
Antinuclear antibody (ANA) panel
g.
Angiotensin converting enzyme (ACE) test
h.
Cytoplasmic-staining anti-neutrophil cytoplasmic antibody (cANCA)
i.
Perinuclear-staining anti-neutrophil cytoplasmic antibody (pANCA)
j.
Chest radiograph
k.
Purified protein derivative (PPD) (tuberculosis skin test)
l.
Urinalysis
2.
Ultrasound (if posterior scleritis is suspected)
3.
Consider computed tomography scan (if posterior scleritis is suspected)

A.
Depends on etiology
B.
May be idiopathic
C.
Genetic factors
1.
III.
Medical workup
Certain major histocompatibility antigens may predispose some individuals

A.
Episcleritis
B.
Conjunctivitis

A.
Oral nonsteroidal anti-inflammatory drugs
B.
Systemic corticosteroids (start with 1 mg/kg/day and slowly taper)
C.
Systemic immunosuppressive agents in consultation with internist, oncologist, rheumatologist

1.
Cyclophosphamide particularly for systemic vasculitis, polyarteritis nodosa, Wegener

granulomatosis
240
AAO 2014-2016
V.
2.
Methotrexate
3.
Azathioprine
4.
Cyclosporine
5.
Tumor Necrosis Factor (TNF) inhibitors such as Infliximab (Remicade) and other
immunomodulators
D.
Consider periocular steroid injection if no evidence of infection
E.
Surgical management (i.e., scleral patch graft) may be required to maintain or re-establish the
integrity of the globe
F.

A.
B.
C.
Nonsteroidal anti-inflammatory drugs

1.
Gastrointestinal disturbance
2.
Impaired renal function
1.
Hypertension
2.
Elevated blood glucose
3.
Weight gain
4.
Cushingoid appearance
Systemic Immunosuppressive agents

1.
2.
3.
Cyclophosphamide
a.
b.
Hemorrhagic cystitis
c.
Secondary malignancies
Methotrexate
a.
Hepatoxicity
b.
Interstitial pneumonitis
c.
d.
e.
Alopecia
f.
Mouth sores
Azathioprine
a.
Bone marrow depression
241
AAO 2014-2016
4.
5.
D.
VI.
b.
Hepatotoxicity
c.
Cyclosporine
a.
Renal toxicity
b.
Hepatotoxicity
c.
Hypertension
d.
Secondary malignancy
e.
Increased risk of infection
f.
Growth of body hair
TNF inhibitors
a.
Secondary malignancies, including solid tumors
b.
Secondary infection

1.
2.
Know toxicities and monitor appropriately
3.
Combination therapy may allow for tapering of systemic corticosteroids
4.
Manage in concert with physician experienced in use of these medications (e.g., rheumatologist,
oncologist, primary care physician)

A.
Scleral melting
B.
Scleral perforation
C.
Cataract
D.
Glaucoma
E.
Cystoid macular edema
F.
Ocular pain

A.
Emphasize importance of close follow-up
B.
Discuss possible systemic side effects of medications
C.
Discuss natural history of disease
242
AAO 2014-2016
1.
2.
3.
Biber JM, Schwam B, Raizman MB. Scleritis. In Cornea. ed. Krachmer, Mannis, Holland, 3rd Ed.
2011, Elsevier inc.
243
AAO 2014-2016
Ocular surface squamous neoplasia:

corneal intraepithelial neoplasia,
conjunctival intraepithelial neoplasia, and
squamous cell carcinoma
I.

A.
B.

1.
Neoplasia of the epithelium of the limbal conjunctiva and/or cornea
2.
Varies from partial thickness dysplasia to full thickness disease to invasive squamous cell
carcinoma
3.
Human papillomavirus found in some cases of conjunctival intraepithelial neoplasia

1.
C.
D.
Higher prevalence with untreated acquired immune deficiency syndrome (AIDS)

1.
Duration of lesion
2.
Severity of foreign body sensation

1.
2.
3.
Conjunctival intraepithelial neoplasia

a.
Vascularized limbal lesion
b.
Keratinization (e.g., leukoplakia) and inflammation may indicate increased risk of dysplasia
c.
Conjunctiva may stain with Rose Bengal

a.
Gray epithelium, often with fimbriated margin usually contiguous with limbus although free
islands may occur
b.
May slowly change size and shape
c.
Adjacent limbus may appear clinically normal or corneal lesion may be associated with
signs of conjunctival intraepithelial neoplasia
Squamous cell carcinoma of the conjunctiva

a.
Limbal lesion may appear papilliform, gelatinous, or leukoplakic
b.
Most often occurs in the interpalpebral fissure
c.
Pigmentation of lesion may be present in dark-skinned individuals
244
AAO 2014-2016
d.
E.
II.
III.
May be affixed to the underlying tissue

1.
Histopathological examination of incisional or excisional biopsy
2.
Impression cytology

A.
Light complexion
B.
Advancing age
C.
Environmental risk factors such as cigarette smoking, sunlight exposure, and exposure to certain
chemicals such as pesticides and petroleum products
D.
Immunosuppression and human immunodeficiency virus (HIV) infection may increase incidence
of conjunctival squamous neoplasia and/or potential for growth
E.
Possible role of human papilloma virus 16 and 18

A.
B.
Conjunctival intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva

1.
Pterygium
2.
Pinguecula
3.
Nodular episcleritis or scleritis
4.
Foreign body reaction
5.
Pyogenic granuloma
6.
Epibulbar dermoid tumor or other choristoma
7.
Melanoma of the conjunctiva
8.
Sebaceous carcinoma of the conjunctiva
9.
Conjunctival primary localized amyloidosis
10.
Benign hereditary intraepithelial dyskeratosis

1.
Limbal stem-cell failure or deficiency
2.
3.
Vernal or atopic keratopathy
4.
Rosacea keratopathy
5.
Toxic epithelial keratopathy
6.
Corneal epithelial basement membrane dystrophy
245
AAO 2014-2016
7.
IV.

A.

1.
B.
V.
Topical interferon-alpha
a.
Topical interferon, usually administered until tumor disappearance
b.
Subconjunctival interferon-alpha, may be administered alone or as an adjunct with

excisional biopsy
2.
Topical mitomycin C (has risk to bare sclera)
3.
Topical 5 fluorouracil (least common option)

1.
Conjunctival intraepithelial neoplasia: excisional conjunctival biopsy (See Conjunctival biopsy) with
cryotherapy. and/or topical chemotherapy (interferon or antimetabolite)
2.
Corneal intraepithelial neoplasia: chemical or mechanical debridement (See Corneal epithelial

debridement) with limbal excision and cryotherapy.
3.
Squamous cell carcinoma: excisional biopsy, usually with lamellar sclerectomy and adjunctive
cryotherapy

A.
Incomplete removal and destruction of lesion, recurrence

1.
B.
C.
D.
Take wide excision at time of surgery, use cryotherapy as adjunctive therapy
1.
Use amniotic membrane or conjunctiva to reconstruct ocular surface
2.
Use symblepharon ring in eye post operatively for large excisions
Ulceration, inflammation, punctal stenosis, or other adverse effect due to topical mitomycin C or
other antimetabolite
1.
VI.
Spheroidal/Salzmann degeneration
Carefully monitor patients on topical antimetabolites
Limbal stem cell failure

1.
Limit limbal treatment to involved areas
2.
Treat with conservative measures if mild, amniotic membrane or limbal stem cell transplant when
severe

A.
Conjunctival intraepithelial neoplasia and corneal intraepithelial neoplasia
246
AAO 2014-2016
1.
B.
Recurrence
Squamous cell carcinoma of the conjunctiva

1.
Scleral and intraocular extension
2.
Orbital invasion
3.
Metastasis

A.
Awareness of possible recurrence, invasion, and metastasis that may lead to loss of vision, loss
of eye, or death
B.
Need for follow-up reevaluation
C.
Consult internist/oncologist for invasive carcinoma
1.
2.
AAO, Focal Points: Nonpigmented Lesions of the Ocular Surface, Module #9, 1996.
3.
Poothullil AM, Colby KA. Topical medical therapies for ocular surface tumors. Semin Ophthalmol
2006;21:161-9.
4.
Stone DU et al: Ocular surface squamous neoplasia: a standard of care survey. Cornea
2005;24:297.
5.
Pe'er J. Ocular surface squamous neoplasia. Ophthalmol Clin North Am 2005;18:1-13,vii.
6.
247
AAO 2014-2016
Sebaceous gland carcinoma of the eyelid

margin and conjunctiva
I.

A.

1.
B.
C.
D.
E.
II.
III.
Sebaceous gland carcinoma, also called sebaceous cell carcinoma, arises by malignant
transformation from one or more meibomian glands, or possibly from the glands of Zeis,
sebaceous glands of the caruncle, or pilosebaceous glands of the eyelid margin

1.
Less than 1% of eyelid tumors
2.
Can masquerade as chalazion

1.
Painless, slow-growing, firm nodule of the conjunctiva
2.
Chronic unilateral conjunctivitis/blepharitis
3.
Eyelid thickening and deformity, with focal loss of eyelashes (madarosis)

1.
Variable location, although upper lid more common than the lower
2.
Subepithelial spread, often multicentric and inflammatory, that may resemble chronic papillary
conjunctivitis
3.
Non-mobile yellowish nodule, that may have features overlapping with the spreading form
4.
Status of preauricular lymph node

1.
Biopsy, with attention to histopathologic characteristics, including presence of anaplastic cells,

multiple mitoses, and lipid
2.
Map biopsies to detect multicentric neoplasia

A.
Advancing age
B.
Prior radiation therapy

A.
Blepharitis, blepharoconjunctivitis, and chalazion
B.
Mucous membrane pemphigoid and other causes of cicatrizing conjunctivitis
248
AAO 2014-2016
IV.
V.
VI.
C.
Ocular surface squamous neoplasia, including papilloma and squamous cell carcinoma of the
conjunctiva
D.
Other neoplastic conditions, including basal cell carcinoma, lymphoma, and melanoma of the
conjunctiva

A.
Excision of lesion with tumor-free margins, that may be done with wide excision, map biopsies,
frozen-sections, or Mohs micrographic surgery
B.
Adjunctive cryotherapy, radiotherapy, or chemotherapy may be considered
C.
Know indications for orbital exenteration if invasive or recurrent neoplasia
D.
Follow for local recurrences and regional metastasis

A.
Local recurrence
B.
C.
Corneal exposure
D.
Need for eyelid reconstruction following excision

A.
Orbital invasion
B.
Metastasis to preauricular, parotid, or cervical lymph nodes
C.
Death from distant metastasis, especially if duration longer than 6 months, extensive tumor
invasion, or incomplete excision

A.
Be aware of possible complications, including local recurrence and metastases to other tissues
and organs
B.
Need for follow up
1.
2.
AAO, Focal Points: Management of Malignant Eyelid Tumors, Module #6, 1989.
3.
AAO, Focal Points: Periorbital Skin Cancers: The Dermatologist's Perspective, Module #1, 2006.
249
AAO 2014-2016
Primary acquired melanosis of the

conjunctiva
I.

A.

1.
B.
C.
D.

1.
Unilateral pigmentation in white race or light-skinned ethnicity more often affected
2.
Racial melanosis is seen bilaterally in pigmented individuals, but conjunctival melanoma can occur
in pigmented individuals

1.
Appearance may remain stable or progress
2.
Change in size or appearance may be associated with hormone changes such as puberty or
pregnancy
3.
Usually has little or no conjunctivitis

1.
Flat, brown lesion of the conjunctival epithelium
2.
Unilateral
3.
May be single or multiple
4.
Irregular margins
5.
Note asymmetry between two eyes
6.
Signs of malignant transformation
7.
E.
Neoplasia of conjunctival melanocytes
a.
Enlargement
b.
Increased pigmentation
c.
Nodularity
d.
Increased vascularity or inflammation
e.
Conjunctival feeder vessel
Rare pigmentary variations

a.
No visible pigmentation (amelanotic)
b.
Eyelid margin pigmentation
c.
Corneal epithelium may have fine pigmentation
250
AAO 2014-2016
II.
B.
a.
Large or progressive lesion of bulbar conjunctiva should be removed or do map biopsies if

inexciseable
b.
Darkly pigmented lesion of palpebral conjunctiva, fornix, or caruncle
c.
Multiple pigmented lesions
European ancestry
Congenital pigmented lesions of the conjunctiva or episclera

1.
Benign racial melanosis of conjunctiva (complexion-associated conjunctival pigmentation)
2.
Congenital conjunctival nevus
3.
Ocular melanosis (melanosis oculi) and oculodermal melanosis (nevus of Ota)
Acquired pigmentation of the conjunctiva (See Pigmentation of the conjunctiva and cornea)
1.
Acquired conjunctival nevus
2.
Secondary acquired melanosis of conjunctiva
3.
Melanoma of conjunctiva (See Melanoma of the conjunctiva)

1.
Excisional biopsy
2.
Adjunctive cryotherapy, such as double freeze-thaw at -20C
3.
Primary or adjunctive chemotherapy, such as mitomycin C for inexcisable disease

A.
VI.
Biopsy with histopathological examination to determine malignant potential

A.
V.
2.

A.
IV.
Periodic observation with photographic follow up

A.
III.
1.
Incomplete excision
1.
May justify further excisional surgery or adjunctive therapy
2.
Follow-up to check for local recurrence or spread to preauricular or other regional lymph nodes
251
AAO 2014-2016
A.

1.
2.
Lower melanoma risk if no histopathological atypia

a.
Hyperpigmentation and hyperplasia confined to basal epithelium
b.
No hyperchromaticity
Higher melanoma risk if histopathological features associated with atypia

a.
Intraepithelial spread
b.
Epithelioid cells
c.
Invasion into substantia propria

A.
Need for follow up
B.
Awareness of change in morphology of lesion
C.
Awareness of possible recurrence
D.
Awareness of possible malignant melanoma
1.
2.
AAO, Focal Points: Melanoma and Other Pigmented Lesions of the Ocular Surface, Module #11,
1996.
3.
Chalasani R, Giblin M, Conway RM. Role of topical chemotherapy for primary acquired melanosis
and malignant melanoma of the conjunctiva and cornea: review of the evidence and
recommendations for treatment. Clin Experiment Ophthalmol 2006;34:708-14.
4.
5.
Hu DN, Yu G, McCormick SA, Finger PT. Population-based incidence of conjunctival melanoma in

various races and ethnic groups and comparison with other melanomas. Am J Ophthalmol. 2008
Mar;145(3):418-423. Epub 2008 Jan 11.
252
AAO 2014-2016

I.

A.
B.
C.
D.

1.
Malignancy of conjunctival melanocytes
2.
Often arises from primary acquired melanosis of the conjunctiva, may evolve from preexisting
conjunctival nevus or may appear de novo

1.
Duration of lesion
2.
Course of lesion, including changes of pigmentation, size, and inflammation
3.
Bleeding from lesion
4.
Previous melanoma affecting skin or uvea
5.
Previous biopsy

1.
Location of lesion (bulbar versus palpebral conjunctiva vs forniceal)
2.
Size, thickness, number, and nodularity of lesion(s)
3.
Check whether lesion is attached to the underlying sclera or is freely movable
4.
Palpation of ipsilateral preauricular, submandibular, and cervical lymph nodes
5.
Rule out uveal melanoma with dilated fundus examination, transillumination, or ultrasonography
6.
Examine skin or recommend dermatology consult to look for cutaneous melanoma

1.
Excisional biopsy for suspicious lesion, such as large or nodular lesion or lesion having
progressive increase in size or thickness
2.
Histopathological examination to determine presence and severity of cellular atypia and prominent
cell type: epithelioid, spindle, or mixed.
3.
Consider ultrasonography for thick lesion or possible intraocular extension
4.
Obtain imaging (e.g., PET scan, computerized tomography (CT) or magnetic resonance imaging
(MRI)) of orbit and paranasal sinuses
5.
Consider roles of orbital or sinus surgery and radiotherapy
6.
Consider sentinel node biopsy although role of sentinel lymph node biopsy and
lymphoscintigraphy are unclear
7.
Consider screening for genetic testing for prognostic and therapeutic outcomes
8.
Consult with oncologist to detect metastasis, which tends to involve lung, liver, brain, or skin
253
AAO 2014-2016
II.

A.
B.
III.
IV.
Risk factors for lesion

1.
Middle-age or elderly
2.
White race or light-skinned ethnicity (e.g., European and Eurasian descent) more common, but
can rarely occur in darker-skinned races/ethnicities (Asian or African descent)
3.
Previous primary acquired melanosis of the conjunctiva or conjunctival acquired nevus
Risk factors influencing outcome

1.
Presence of cellular atypia on histopathology is primary association with progression to melanoma
2.
Site of lesion on conjunctiva (lesions of limbal and bulbar conjunctiva may have less risk of
post-excision recurrence than lesions of palpebral conjunctiva, fornix, or caruncle)
3.
Number of pigmented lesions
4.
Other histopathologic characteristics: tumor thickness, growth pattern and scleral invasion
5.
Metastases

A.
Conjunctival nevus
B.
Primary acquired melanosis
C.
Pigmented epithelial tumor, including squamous cell carcinoma
D.
Ocular melanocytosis
E.
Staphyloma
F.
Implantation of foreign substances: calcium, medications, cosmetics

A.

1.
Wide excisional biopsy
2.
Adjunctive therapy to destroy residual tumor cells
3.
a.
Cryotherapy of conjunctival margins
b.
Absolute alcohol to adjacent corneal epithelium (if limbal involvement) and scleral base
c.
Topical mitomycin may have a role in chemotherapy
Orbital exenteration or radiotherapy may be considered for diffuse, multifocal, or extended

melanoma
254
AAO 2014-2016
V.

A.
Local recurrence due to incomplete excision

1.
Prevention
a.
2.
Management
a.
B.
Prevention
a.
2.
Avoid excessive use of cryotherapy or mitomycin C
Management
a.
Reconstruct large defect with amniotic membrane graft or conjunctival autograft

1.
Prevention
a.
2.
Avoid excessive excision or mitomycin C
Management
a.
VI.
Repeat excision with wide surgical margins
Structural alteration of ocular surface

1.
C.
Perform complete excision
Reconstruct large defect with amniotic membrane graft or limbal stem cell transplant

A.
Subconjunctival invasion into orbit
B.
Lymphatic spread and distant metastasis with organ failure and death

A.
Knowledge of possible recurrence, local invasion, metastasis, loss of vision, and death
B.
Need for long-term follow up
1.
2.
Seregard S. Conjunctival melanoma. Surv Ophthalmol 1998;42:321-350.
3.
Shields CL, Shields JA, Gunduz K, et al. Conjunctival melanoma: risk factors for recurrence,
exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol
2000;118:1497-1507.
4.
1996.
255
AAO 2014-2016
5.
256
AAO 2014-2016
Conjunctival lymphoma
I.

A.

1.
B.
C.
D.
E.
Monoclonal proliferation of lymphocytes, most commonly B cells

1.
Usually young to middle aged adults
2.
Ocular involvement represents only 2% of extranodal lymphoma
3.
Lymphoid tumors of the conjunctiva associated with systemic lymphoma in up to 31% of patients
4.
Systemic lymphoma found more often in patients with forniceal or midbulbar conjunctival
involvement and those with multiple conjunctival tumors, and bilateral disease
5.
May have infectious etiology such as Chlamydia or H. pylori

1.
History of chronic redness
2.
Possible foreign body sensation
3.
Painless

1.
Diffuse; slightly elevated pink mass located in the stroma or deep to Tenon fascia
2.
Color similar to salmon, hence the term "salmon patch"
3.
Lesions are fleshy, often originate in fornix or adjacent to the limbus
4.
May also present as a chronic follicular conjunctivitis

1.
Biopsy of lesion for histopathologic diagnosis, must send fresh tissue for flow cytometry and gene
rearrangement
2.
Evaluation for systemic lymphoma in conjunction with oncologist or hematologist if biopsy is

positive
a.
II.
Tumor staging with complete blood count (CBC) and differential, imaging of the head, neck
and abdomen

A.
No specific risk factors except those associated with lymphomas in general including
1.
Prolonged antigen stimulation, leading to loss of regulation of B-lymphocyte proliferation and

differentiation
257
AAO 2014-2016
2.
III.
IV.
Human immunodeficiency virus (HIV)

A.
Benign lymphoid hyperplasia
B.
Scleritis and episcleritis
C.
Ectopic lacrimal gland
D.
Amyloid deposition
E.
Foreign body with pyogenic granuloma
F.
Lymphangiectasia
G.
Sarcoidosis
H.
Cat Scratch Disease
I.
Degenerative conjunctival changes (e.g., pinguecula, pterygium)
J.
Other ocular surface tumors

1.
Conjunctival intraepithelial neoplasia
2.
Squamous carcinoma
3.
Amelanotic melanoma
4.
Langerhans cell tumor

A.

1.
2.
B.
C.
Worse prognosis with

a.
Systemic disease
b.
Non-mucosal associated lymphoid tissue (MALT) lymphomas
Late manifestations of extra-ocular lymphoma occur up to 53 months after diagnosis, therefore

repeat systemic evaluation every 6 months for 5 years

1.
Complete systemic evaluation
2.
Treatment options depend on the presence of systemic disease

a.
Radiation considered for symptomatic lesions, especially if they threaten vision
b.
Intralesional interferon alpha-2b
c.
Chemotherapy for aggressive histological subtypes and for systemic diseased
d.
Anti CD 20 immunotherapy (intralesional or systemic)
258
AAO 2014-2016
1.
V.
Surgical biopsy for histopathologic diagnosis, rarely as a therapeutic modality

A.
Radiation therapy
1.
2.
Complications
a.
Xerophthalmia
b.
Keratitis
c.
Cataract formation
Prevention
a.
B.
Chemotherapy varies with agent

1.
VI.
Careful dosimetry by radiation oncologist
Administration and management by oncologist with training to manage these complications

A.
Isolated ocular disease

1.
B.
Usually minimal complications
Complications associated with systemic lymphoma

A.
Discuss association with systemic disease and importance of regular long-term follow-up and
medical surveillance for development of systemic lymphoma
1.
2.
Shields CL, Shields JA, Carvalho C, Rundle P, Smith AF. Conjunctival lymphoid tumors: clinical
analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology 2001
May;108(5):979-84.
3.
Ross JJ, Tu KL, Damato BE. Systemic remission of non-Hodgkin's lymphoma after intralesional
interferon alpha-2b to bilateral conjunctival lymphomas. Am J Ophthalmol 2004 Oct;138(4):672-3.
4.
Takahira M, Okumura H, Minato H, et al. Primary conjunctival follicular lymphoma treated with the
anti-CD20 antibody rituximab and low-dose involved-field radiotherapy. Jpn J Ophthalmol 2007
Mar-Apr;51(2):149-51.
259
AAO 2014-2016
Corneal epithelial basement membrane

dystrophy/degeneration
I.

A.
B.
C.
D.

1.
Abnormal corneal epithelial basement membrane, which is thickened, multilaminar, and

misdirected into the epithelium
2.
Altered epithelial turnover and maturation
3.
Ineffective hemidesmosome formation by epithelial cells, resulting in poor adhesion

1.
The most common anterior corneal dystrophy/degeneration
2.
Increasing frequency over 50 years of age

1.
Most patients are asymptomatic
2.
Blurred vision
3.
Monocular diplopia
4.
Glare
5.
6.
Photophobia
7.
Eye pain and epiphora during sleep or upon awakening

1.
Gray patches, microcysts, and/or fine lines in the central epithelial layer
2.
Fingerprint lines (or "putty marks")

a.
3.
Map lines
a.
4.
Thin, hair like lines, often arranged in a concentric pattern
Same as fingerprints but thicker, more irregular, surrounded by a faint haze, resembling
geographic borders
Dots or microcysts
a.
Intraepithelial spaces with debris of epithelial cells that have collapsed and degenerated
before reaching the epithelial surface
5.
Epithelial defects, loose epithelium or punctate epithelial erosions
6.
Subepithelial haze or scarring
260
AAO 2014-2016
E.
II.
III.
1.
Slit-lamp biomicroscopic exam including fluorescein staining and retroillumination
2.
Corneal topography
3.
Keratometry

A.
Corneal scarring secondary to injury
B.
Meesmann juvenile epithelial dystrophy
C.
Reis-Bucklers dystrophy
D.
Thiel-Behnke dystrophy
E.
F.
G.
H.
I.
Amiodarone deposits

A.
B.
IV.

1.
Antibiotic drops for acute recurrent erosion
2.
Patching for acute recurrent erosion
3.
Topical nonsteroidal anti-inflammatory drugs (NSAIDs)
4.
Loose soft bandage contact lens for recurrent erosion
5.
Hypertonic saline drops and ointment for maintenance
6.
Lubricating eyedrops and ointment for maintenance
7.
Rigid gas-permeable contact lens to improve vision if irregular astigmatism present

1.
Epithelial debridement for recurrent erosion (See Corneal epithelial debridement)
2.
Anterior stromal puncture for recurrent erosion especially in identifiable localized noncentral
disease in post-traumatic erosions.(See Anterior stromal puncture)
3.
Epithelial debridement for recurrent erosion with scraping or diamond burr polishing
4.
Excimer laser phototherapeutic keratectomy for recurrent erosion or scarring decreasing vision
261
AAO 2014-2016
V.
VI.
A.
Irritation from hypertonic saline eyedrops and ointment
B.
Corneal epithelial erosion or irritation related to bandage contact lenses
C.
Microbial keratitis secondary to bandage contact lens wear, patching, or surgical treatment
D.
Corneal scarring related to surgical treatment
E.
Irregular astigmatism related to surgical treatment

A.
Corneal erosion
B.
C.
Microbial keratitis
D.
Corneal scarring
E.
F.
Loss of best-corrected visual acuity

A.
Advise of recurrent or chronic nature of this condition
B.
Instruction on medications and side effects
C.
Instruction on patching and bandage soft contact lenses, if used
D.
Education on medical and surgical treatment options for recurrent erosions
E.
Instruction on proper follow-up
1.
2.
Weiss JS, Moller H, Lisch W, Kinoshita S, Aldave AJ, et al. The IC3D classification of the corneal
dystrophies. Cornea 2008; 27 Suppl 2:S1-83.
3.
.Aldave AJ, Kamal KM, Vo RC, and Yu F. Epithelial debridement and Bowman's layer polishing for
visually significant epithelial irregularity and recurrent corneal erosions. Cornea 2009; 28:1085-90.
4.
AAO, Ophthalmology Monographs 18. A Compendium of Inherited Disorders and the Eye, 2006.
262
AAO 2014-2016
Corneal dystrophy of Bowman layer I

(CDB I; Reis-Bcklers dystrophy) and
corneal dystrophy of Bowman layer II
(CDB II; Thiel-Behnke dystrophy)
I.

A.
B.
C.

1.
CDB 1 - Autosomal dominant; secondary to a mutation in the transforming growth factor

beta-induced gene (TGFBI). A spontaneous mutation has been reported in individuals without a
family history
2.
CDB 2 - Autosomal dominant; secondary to a mutation in TGFBI (different than the one that
causes CDB 1). A spontaneous mutation has been reported in individuals without a family history

1.
Uncommon dystrophy in countries in which prevalence of different corneal dystrophies has been
reported
2.
Clinical features and associated symptoms most commonly present in the first decade of life

1.
Slow progressive decrease in vision

a.
D.
E.
Progression is more rapid than other stromal dystrophies, affecting visual acuity by the
second to third decade
2.
Poor quality vision due to irregular astigmatism
3.
4.
Halos and glare at night
5.
Episodic pain from recurrent erosions developing in first or second decade, abating by third
decade of life

1.
Slit-lamp biomicroscopy: bilateral geographic or honeycomb, gray white, axially-distributed

opacification involving Bowman layer that spares the peripheral cornea.
2.
Anterior stromal scarring in advanced cases
3.

1.
Slit lamp evaluation
2.
Family history - One parent and 50% of siblings and offspring typically affected.
263
AAO 2014-2016
II.
IV.
Tissue diagnosis after corneal transplant or keratectomy
4.
Histopathology: deposits in Bowman's layer
5.
Molecular genetic analysis - Screening of TGFBI recommended in cases of atypical phenotype or

absence of family history.

A.
III.
3.
Positive family history

A.
Granular dystrophy
B.
Combined granular lattice corneal dystrophy (Avellino corneal dystrophy)
C.
Epithelial basement membrane corneal dystrophy

A.
B.

1.
Slow progressive decrease in vision
2.
Episodes of painful recurrent erosions

1.
Bandage contact lenses for recurrent erosions
2.
Lubricating ointment to decrease incidence of recurrent erosions
3.
Rigid contact lens wear to improve visual acuity

a.
C.
V.
Avoid in patients with recurrent erosions
Describe surgical therapy options (see separate outlines for each procedure)
1.
Superficial keratectomy (See Superficial keratectomy)
2.
Anterior lamellar keratoplasty (See Anterior lamellar keratoplasty)

a.
Shallow
b.
Deep
3.
Phototherapeutic keratectomy
4.
Penetrating keratoplasty (See Penetrating keratoplasty)

A.
Recurrence of disease after PTK, keratectomy, or corneal transplant
B.
Corneal infection from contact lens wear or recurrent erosions - prophylactic antibiotics reduce
264
AAO 2014-2016
risk
VI.
C.
Abrasion from rigid contact lens wear - discontinue if this occurs repeatedly
D.
Poor quality vision from lamellar keratoplasty
E.
Complications of phototherapeutic keratectomy
F.
Complications of lamellar, penetrating keratoplasty (See Anterior lamellar keratoplasty) (See

Penetrating keratoplasty)

A.
Painful recurrent erosions
B.
Corneal scarring
C.
Amblyopia from irregular astigmatism if present in early childhood

A.
Discuss progressive decrease in vision
B.
Discuss recurrent erosions, counsel on management
C.
Counsel regarding recurrence after surgical therapy
D.
Counsel patients regarding risk of transmission to offspring
1.
2.
265
AAO 2014-2016
Meesmann corneal dystrophy

I.

A.

1.
Autosomal dominant
2.
Causative mutations have been identified in two different genes on two different chromosomes
a.
B.
C.

1.
Mildly reduced vision
2.
Glare
3.
Foreign body sensation associated with infrequent epithelial erosion

1.
D.
II.
IV.
Minute intraepithelial cysts, typically bilateral and most densely concentrated in the interpalpebral
zone.

1.
Slit lamp evaluation
2.
3.
Tissue diagnosis after corneal transplant or keratectomy
4.
Transmission electron microscopy
5.
Intracytoplasmic inclusions, representing aggregated keratin filaments
6.
Molecular genetic analysis - Screening of the genes in which causative mutations have been
identified may be performed in cases of an atypical phenotype or absence of a family history.

A.
III.
The genes encode keratins that are expressed only in the cornea. This is why affected
patients do not experience extra corneal manifestations

A.
Band shaped, whorled microcystic corneal dystrophy
B.
Diffuse punctate epithelial keratopathy from various causes
266
AAO 2014-2016
A.
B.
C.

1.
Many patients remain asymptomatic
2.
Some patients may note persistent glare or mild visual disturbances

1.
Lubricating ointment may decrease incidence of recurrent erosions
2.
Bandage contact lenses for management of ocular irritation associated with epithelial erosions
Describe surgical therapy options (see separate outlines for each procedure)
1.
V.
VI.
Note: epithelial changes would be expected to recur following any of the following procedures.
Therefore, they should be reserved for the management of associated subepithelial fibrosis or
scarring
a.
b.
Superficial keratectomy (See Superficial keratectomy)
c.
Anterior lamellar keratoplasty (See Anterior lamellar keratoplasty)

A.
Recurrence of disease after PTK, superficial keratectomy, or anterior lamellar keratoplasty
B.
Complications of phototherapeutic keratectomy
C.
Complications of superficial keratectomy (See Superficial keratectomy)
D.
Complications of anterior lamellar keratoplasty (See Anterior lamellar keratoplasty)

A.
Painful recurrent erosions
B.
Glare symptoms
C.
Subepithelial corneal scarring

A.
Discuss implications of corneal epithelial adherence in terms of contact lens wear and refractive
surgery
B.
Counsel patients regarding risk of transmission to offspring
1.
2.
267
AAO 2014-2016
268
AAO 2014-2016
Granular and lattice corneal dystrophies

I.

A.

1.
2.
Granular corneal dystrophy type 1

a.
Autosomal dominant inheritance
b.
Secondary to a conserved mutation in the transforming growth factor beta-induced gene

(TGFBI)
Lattice corneal dystrophy

a.
b.
c.
d.
B.
C.
Classic (type 1; LCD1)

i.
ii.
Secondary to a conserved mutation in the transforming growth factor beta-induced

gene (TGFBI)
Variant
i.
ii.
Secondary to a a variety of rare mutations in the transforming growth factor

beta-induced gene (TGFBI)
Gelsolin (type 2; LCD2)

i.
ii.
Secondary to mutations in the gelsolin gene (GSN)
Granular corneal dystrophy type 2 (Avellino dystrophy; combined granular - lattice

dystrophy)
i.
ii.
Secondary to a conserved mutation in the transforming growth factor beta-induced

gene (TGFBI)
iii.
Initial reports of individuals with Italian ancestry but more commom in other
populations (Korea and Japan)

1.
Family history of corneal stromal dystrophy
2.
Progressive decrease of vision
3.
Photophobia is often the initial symptom
4.
Corneal epithelial recurrent erosions

1.
Granular corneal dystrophy
269
AAO 2014-2016
a.
Discrete deposits in the central cornea noted in the first 2 decades of life
i.
2.
Intervening stroma typically clear
b.
Decreased vision may result from stromal haze and epithelial surface irregularity
c.
Recurrent epithelial erosions
d.
Type I granular dystrophy

i.
Early age onset with crumb like opacities that broaden into a disciform appearance in
the teens
ii.
Clear peripheral 1-2 mm of cornea
iii.
Lesions can extend anteriorly through focal breaks in Bowman layer
iv.
Slowly progressive
v.
Vision rarely drops to 20/200 after age 40
vi.
Onset during childhood with superficial granular deposits
Lattice dystrophy
a.
Broad spectrum of corneal changes including:

i.
Refractile lines (lattice lines)
ii.
Central and subepithelial ovoid white dots
iii.
Diffuse anterior stromal haze
b.
Decreased vision may result from lattice lines, stromal haze (ground glass appearance) or
epithelial surface irregularity
c.
Frequent recurrent epithelial erosions
d.
Classic (type I) lattice corneal dystrophy
e.
f.
i.
Thin, branching anterior stromal lattice lines
ii.
Recurrent erosions and visual symptoms are common starting in the first decade but
significant visual disturbance does not develop typically until the third or fourth
decades
iii.
No systemic amyloid deposition
Variant lattice corneal dystrophy

i.
Significant phenotypic variability, with thicker and more posteriorly located lattice lines
ii.
Late-onset (fidth to seventh decade) and unilateral variants reported
Gelsolin type (type 2) lattice corneal dystrophy

i.
Associated with Meretoja syndrome (systemic amyloidosis with lattice dystrophy)
ii.
Presents in third or fourth decades
iii.
Characteristic facial mask (mask-like facies secondary to amyloid deposition in the

facial nerves)
270
AAO 2014-2016
3.
D.
2.
v.
Pendulous ears
vi.
Cranial and peripheral nerve palsies
vii.
Dry lax skin with amyloid deposition
viii.
Corneal lattice lines are less numerous and more peripheral
Granular dystrophy type 2 (Avellino dystrophy, combined granular and lattice corneal dystrophy)
a.
Often only granular phenotype observed; stellate deposits are characteristic
b.
Lattice lines may develop late in life, if ever
c.
Older patients have intervening stromal haze resulting in decreased visual acuity
Granular dystrophy
a.
Clinical diagnosis
b.
Masson trichome stain of corneal button to reveal bright red eosinophilic hyaline deposits
c.
Molecular genetic analysis (screening of TGFBI)
Lattice dystrophy
a.
Clinical diagnosis
b.
Congo red stain of corneal button to highlight orange-red deposits of amyloid
c.
Crystal violets stains amyloid metachromatically
d.
Amyloid exhibits dichroism and birefringence
e.
Molecular genetic analysis (screening of TGFBI)

A.
III.
Blepharochalasis

1.
II.
iv.
Family history of corresponding stromal dystrophy

A.
Corneal dystrophy of Bowmans I (Reis-Buckler dystrophy) and Corneal dystrophy of Bowmans II

(Thiel-Behnke dystrophy)
B.
Gelatinous droplike dystrophy (primary familial amyloidosis)
C.
Schnyder crystalline corneal dystrophy
D.
Fleck dystrophy
E.
Central cloudy dystrophy of Franois
F.
Corneal scar following stromal interstitial keratitis
G.
Corneal ghost vessels
271
AAO 2014-2016
IV.
H.
Corneal nerves
I.
Secondary, localized corneal amyloidosis
J.
Polymorphic amyloid degeneration
K.
Macular corneal dystrophy

A.

1.
B.
V.
VI.
Therapeutic contact lens, lubrication for recurrent erosions
Describe the surgical therapy options

1.
Phototherapeutic keratectomy, superficial keratectomy for recurrent erosions or visually significant

anterior stromal deposits
2.
Penetrating keratoplasty for reduction of visual acuity
3.
Possible lamellar keratoplasty if only anterior stroma is involved with dystrophy
List the complications of treatment

A.
Keratitis following superficial keratectomy, phototherapeutic keratectomy, or therapeutic contact

lens
B.
Corneal scarring following superficial keratectomy, phototherapeutic keratectomy, or therapeutic

contact lens
C.
Complications of penetrating keratoplasty (See Penetrating keratoplasty)
D.
Recurrence of disease process in graft after penetrating keratoplasty or anterior lamellar

keratoplasty

A.
B.
Recurrent erosions
C.
Keratitis
D.
Corneal scarring
E.
Recurrence after keratoplasty

A.
Use of appropriate drops for recurrent erosions
B.
Risks of penetrating keratoplasty
272
AAO 2014-2016
1.
2.
3.
273
AAO 2014-2016
Macular corneal dystrophy

I.

A.
B.
C.
D.
II.

1.
Autosomal recessive transmission, associated with different mutations in the carbohydrate

sulfotransferase gene located on chromosome 16q22
2.
Accumulation of non-sulfated keratan sulfate in endoplasmic reticulum of keratocytes and

endothelial cells, and extracellular stroma.

1.
Family history of corneal stromal dystrophy
2.
History of parental consanguinity
3.
Progressive decrease of vision
4.
Corneal epithelial recurrent erosions

1.
Clear corneas at birth, clouding begins in first decade
2.
Focal, gray-white superficial stromal opacities with indefinite edges, progress to involve full stromal
thickness and corneal periphery
3.
Intervening stroma is diffusely cloudy
4.
Involvement of Descemet membrane and endothelium with guttata
5.
Central corneal thinning in some
6.
Visual acuity affected in the second to fourth decades of life
7.
Type I more prevalent than type II but identical clinical presentation

1.
Clinical diagnosis
2.
Alcian blue or colloidal iron stain on pathology specimens delineates macular

mucopolysaccharides
3.
Molecular genetic analysis (screening of CHST6)
4.
Enzyme-linked immunosorbent assay (ELISA) to measure sulfated keratan sulfate in serum to

help diagnose in preclinical forms

A.
Family history of corresponding stromal dystrophy
274
AAO 2014-2016
III.
IV.

A.
Central cloudy dystrophy of Franois
B.
Fuchs endothelial dystrophy
C.
Corneal scar following stromal interstitial keratitis
D.
Secondary, localized corneal amyloidosis
E.
Granular corneal dystrophy
F.
Crocodile shagreen

A.
B.
V.
VI.

1.
Therapeutic contact lens, lubrication for recurrent erosions
2.
Tinted contact lens for photophobia

1.
Phototherapeutic keratectomy (PTK) for smoothing of anterior surface irregularities from

symptomatic anterior macular dystrophy
2.
Penetrating keratoplasty or deep anterior lamellar keratoplasty for reduction of visual acuity
3.
Anterior lamellar keratoplasty if only anterior stroma is involved with dystrophy

A.
Keratitis following therapeutic contact lens
B.
Corneal scarring following therapeutic contact lens
C.
Infection, scarring, astigmatism, loss of vision following PTK
D.
Complications of penetrating keratoplasty (See Penetrating keratoplasty)
E.
Recurrence of disease process in graft after penetrating keratoplasty

A.
B.
Recurrent erosion syndrome

A.
Use of appropriate drops for recurrent erosions
B.
Risks of penetrating keratoplasty
275
AAO 2014-2016
1.
2.
3.
2008;27:S1-S42.
4.
276
AAO 2014-2016

I.

A.
B.
C.
D.

1.
Probable autosomal dominant inheritance pattern
2.
Dysfunctional endothelial cell - primary etiology unknown

Abnormal production and thickening of Descemet membrane
b.
Later in course, progressive loss of endothelial cells with associated loss of Na+/K+ ATPase
endothelial pumps and subsequent corneal edema and decompensation

1.
Occurs more frequently in women than men
2.
Corneal decompensation more likely in females
3.
Common indication for endothelial and penetrating keratoplasty

1.
Family history of Fuchs dystrophy or corneal transplant
2.
Onset of symptoms typically after age 50
3.
Decreased vision - worse in the morning
4.
Photophobia, pain and tearing in later stages associated with epithelial edema and bullae
formation

1.
2.
II.
a.
Corneal guttae
a.
Nodular excrescences of Descemet membrane
b.
Mottled appearance - posterior corneal surface, with variable pigmentation
c.
Disrupt endothelial cell mosaic pattern
Corneal edema
a.
Stromal edema begins posteriorly, progresses to Descemet folds, then to mid- and anteriorstromal edema, with progressive increases in corneal thickness
b.
Subepithelial bullae and epithelial edema with progressive decompensation
c.
Epithelial erosions - ruptured bullae
d.
Subepithelial scarring secondary to repeated bulla formation and healing
277
AAO 2014-2016
III.
A.
Bullous keratopathy - aphakic or pseudophakic
B.
Herpetic disciform keratitis
C.
Chandler syndrome
D.
Pseudo guttae associated with infectious or inflammatory conditions

A.

1.
2.
Topical hyperosmotic agents (5% sodium chloride) - used primarily for epithelial edema
a.
Drops may be used during the day
b.
Ointment at night may reduce edema upon awakening
Hair dryer
a.
3.
B.
Bandage soft contact lens may be useful in the treatment of painful erosions and ruptured bullae,
and may improve blurring due to corneal irregularity from microcystic edema or bullae in the visual
axis

1.
2.
IV.
Cool setting applied to cornea may increase evaporation and temporarily improve vision
Visual rehabilitation
a.
Endothelial replacement (e.g., Descemet stripping with endothelial keratoplasty), with

cataract extraction as indicated
b.
Penetrating keratoplasty, with cataract extraction as indicated
c.
In presence of cataract, assess cornea for signs of decompensation including pachymetry

and endothelial cell count
d.
Cataract extraction could lead to corneal decompensation and patients should be informed
of this risk prior to surgery
Pain relief
a.
Penetrating keratoplasty with preservation of visual potential
b.
For patients with poor visual potential (e.g., retinal or optic nerve disease)
i.
Conjunctival flap
ii.
Amniotic membrane transplant
iii.
Corneal cauterization

A.
Complications of treatment (See Endothelial keratoplasty and Penetrating keratoplasty)

1.
Epithelial toxicity - secondary to topical agents
278
AAO 2014-2016
B.

1.
V.
VI.
Limit use of topical agents (See Endothelial keratoplasty and Penetrating keratoplasty)

A.
Corneal decompensation with progressive visual loss
B.
Corneal decompensation following cataract surgery
C.
Recurrent erosions
D.
Epithelial breakdown resulting in secondary stromal scarring and risk of infectious corneal ulcer
E.
Visual loss, glare, halos around lights from guttae without corneal edema, pain, or other
non-visual complications

A.
Stress education of disease process as well as implications of penetrating keratoplasty and

endothelial keratoplasty
B.
1.
2.
Anshu A, Price MO, Tan DTH, Price FW. Endothelial keratoplasty: a revolution in evolution
3.
Survey of Ophthalmology 2012;57:236-52.Aldave AJ, Sonmez B. Elucidating the molecular

genetic basis of the corneal dystrophies: are we there yet? Arch Ophthalmol. 2007
Feb;125(2):177-86.
4.
2008;27:S1-S42
5.
Price MO, Gorovoy M, Benetz BA, et al. Descemet's stripping automated endothelial keratoplasty
outcomes compared with penetrating keratoplasty from the cornea donor study. Ophthalmology.
2010; 117: 438-444.
279
AAO 2014-2016
Posterior polymorphous corneal dystrophy

I.

A.
B.
C.

1.
Autosomal dominant
2.
Mutations in genes on two different chromosomes are responsible for causing posterior
polymorphous corneal dystrophy

1.
Family history may or may not be present as many affected individuals are asymptomatic
2.
Blurred vision and painful bullae may be present in the minority of patients with corneal edema

1.
2.
D.
II.
Common features
a.
Isolated and/or grouped endothelial vesicles - often appear in clusters with surrounding gray
halo
b.
Geographic-shaped gray endothelial lesions
c.
Parallel endothelial bands with scalloped edges
Uncommon features
a.
Corneal stromal edema
b.
Iris abnormalities (corectopia, iridocorneal adhesions)
c.
Elevated intraocular pressure

1.
Slit lamp examination for typical endothelial lesions
2.
Specular microscopy: typical endothelial vesicles, bands
3.
Confocal microscopy: Descemet membrane abnormalities
4.
5.
Molecular genetic analysis - Genetic testing may be performed to confirm the diagnosis in cases of
an atypical phenotype or absence of a family history.

A.
Iridocorneal endothelial (ICE) syndrome
B.
Fuchs corneal dystrophy
C.
Congenital hereditary endothelial dystrophy
D.
Descemet membrane tear (secondary to trauma or congenital glaucoma)
280
AAO 2014-2016
III.

A.
B.

1.
Most patients remain asymptomatic
2.
Stromal edema may present at birth or later in life
3.
Elevated intraocular pressure may present at birth or later in life

1.
Corneal edema
a.
b.
Epithelial
i.
Topical hyperosmotic agents (5% sodium chloride)
ii.
Hair dryer - cool setting applied tangentially to cornea may increase evaporation and
temporarily improve vision
iii.
Bandage soft contact lens may relieve pain from ruptured bullae
Stromal
i.
C.

1.
2.
IV.
Reduction of elevated intraocular pressure may improve endothelial function
Visual rehabilitation
a.
Penetrating keratoplasty, with cataract extraction as indicated (See Penetrating

keratoplasty)
b.
Endothelial keratoplasty (e.g., Descemet stripping endothelial keratoplasty) (See

Endothelial keratoplasty)
c.
In presence of cataract, assess likelihood of corneal decompensation with pachymetry and

endothelial cell count prior to cataract surgery
Pain relief
a.
Penetrating or endothelial keratoplasty with preservation of visual potential
b.
For patients with poor visual potential (e.g., retinal or optic nerve disease)
i.
Conjunctival flap
ii.
Amniotic membrane transplant (See Amniotic membrane transplantation)
iii.
Anterior stromal micropuncture (See Anterior stromal puncture)

A.
Complications of treatment (See Anterior stromal puncture) (See Penetrating keratoplasty)

1.
Epithelial toxicity from topical hyperosmotics
281
AAO 2014-2016
2.
B.
V.
VI.
Potential of burning cornea or face from hair dryer
Prevention and management (See Anterior stromal puncture) (See Penetrating keratoplasty) (See
Endothelial keratoplasty)
1.
Cessation of topical hyperosmotics
2.
Keep hair dryer on cool, at appropriate distance from face

A.
B.
Corneal decompensation following cataract surgery
C.
Recurrent erosion symptoms from ruptured bullae
D.
Epithelial breakdown resulting in secondary stromal scarring and risk of infectious corneal ulcer
E.
Glaucoma

A.
Education of disease process, implications of penetrating keratoplasty and endothelial

keratoplasty
B.
1.
AAO Basic and Clinical Science Course. Section 8: External Disease and Cornea, 2013-2014.
2.
Anshu A, Price MO, Tan DTH, Price FW. Endothelial keratoplasty: a revolution in evolution. Survey
of Ophthalmology 2012;57:236-52.
3.
282
AAO 2014-2016
Keratoconus
I.

A.

1.
B.
C.
D.
Multifactorial/unknown

1.
Affects all races
2.
Onset in the second decade of life, but symptomatic at any age.
3.
Prevalence 1 per 2,000, but 1 to 5% of patients screened for refractive surgery are excluded due
to possible keratoconus
4.
Family history of keratoconus in up to 5-10% of cases
5.
Other family members may have known keratoconus or subclinical (forme fruste) keratoconus

1.
Blurred vision not fully correctable with eyeglasses
2.
Contact lenses can no longer be fit comfortably
3.
Progressive change in eyeglasses into adulthood

1.
Bilateral disease, may be highly asymmetric
2.
Irregular, high or progressive astigmatism
3.
Irregular retinoscopic reflex
4.
Central or paracentral corneal thinning
5.
Apical subepithelial cornea scarring
6.
Posterior corneal stromal striae (Vogt's striae)
7.
Descemet membrane breaks/ reduplication
8.
Fleischer iron ring outlining the cone
9.
Munson sign
a.
10.
Corneal hydrops
a.
E.
Bulging of the lower lid when the patient looks
Sudden loss of vision secondary to an acute tear in Descemet membrane resulting in the
rapid development of corneal stromal edema

1.
Computerized corneal topography
283
AAO 2014-2016
2.
3.
II.
III.
IV.
a.
High keratometry values
b.
Inferior or eccentric steepening
c.
Inferior-superior dioptric asymmetry
Keratometry
a.
High keratometry values- steeper in the periphery especially on upgaze
b.
Irregular mires - inability to superimpose central keratometric rings
Pachymetry - increasing thinning of the cornea as corneal thickness is measured from the center
to the inferior position of the cornea
Define risk factors

A.
Eye rubbing
B.
Allergic or atopic conjunctivitis
C.
Associated systemic diseases

1.
Down syndrome
2.
Marfan syndrome
3.
Mitral valve prolapse
4.
5.
Atopy
6.
Leber congenital hereditary optic neuropathy

A.
Pellucid marginal degeneration
B.
Keratoglobus
C.
Contact lens-induced irregular astigmatism
D.
Dry eye-induced epithelial hypertrophy

A.
B.

1.
Eyeglasses
2.
Rigid gas permeable contact lenses
3.
Scleral contact lens

1.
Superficial keratectomy may be used to remove superficial scars that prevent contact lens wear
284
AAO 2014-2016
V.
VI.
2.
Deep anterior lamellar keratoplasty or penetrating keratoplasty, if contact lens wear unsuccessful
3.
Intracorneal ring segments may improve acuity or contact lens tolerance and delay need for
keratoplasty
4.
Collagen cross linking performed for progression of corneal steepening

A.
Complications of contact lens wear (giant papillary conjunctivitis, microbial keratitis, etc)
B.
Complications of keratoplasty (rejection, microbial keratitis, etc)

A.
Hydrops
B.
Corneal scarring
C.
Corneal perforation (rare)

A.
Progressive nature of the disease
B.
Explain associated risk factors
C.
Importance of proper contact lens fit
D.
Instructions regarding follow-up, medications and rejection signs after penetrating keratoplasty
1.
2.
3.
2008;27:S1-S42
4.
Rabinowitz YS. Keratoconus. Surv Ophthalmol. 1998;42:297-319.
5.
Zadnik K, Barr JT, Edrington TB, et al. Baseline findings in the Collaborative Longitudinal
Evaluation of Keratoconus (CLEK) Study. Invest Ophthalmol Vis Sci. 1998;39:2537-2546.
6.
Seitz B, Langenbucher A, Nguyen NX, et al. Long-term follow-up of intraocular pressure after
penetrating keratoplasty for keratoconus and Fuchs' dystrophy: comparison of mechanical and
Excimer laser trephination. Cornea. 2002;21:368-73.
7.
Barr JT, Schechtman KB, Fink BA, et al. Corneal scarring in the Collaborative Longitudinal
Evaluation of Keratoconus (CLEK) Study: baseline prevalence and repeatability of detection.
Cornea. 1999;18:34-46.
285
AAO 2014-2016
Pellucid marginal corneal degeneration

I.

A.
B.
C.
D.
E.
II.
III.

1.
Unknown
2.
Very likely a variant of keratoconus
Describe the epidemiology of this disease

1.
Uncommon disorder
2.
May be seen in patients who also have more typical changes of keratoconus or relatives of
keratoconus patients
3.
Associated with allergy and atopy

1.
Increasing against-the-rule astigmatism
2.
Onset in the teens or later, may be seen in elderly patients
3.
Acuity initially often correctable with eyeglasses

1.
Corneal thinning and ectasia usually 1 to 2 mm central to the inferior limbus in an oval pattern from
4 to 8:00
2.
Corneal ectasia is most prominent just superior (central) to the area of thinning
3.
Usually no iron ring but there may be deep stromal striae
4.
High against-the-rule astigmatism
5.
Area of involvement is clear (pellucid) without vascularization or lipid deposition and with intact
epithelium

1.
Keratometry confirms against-the-rule astigmatism which is often regular
2.
Corneal topography shows peripheral steepening usually in or a crab's claw pattern
Define risk factors

A.
Unknown
B.
Atopy/allergy
C.
Association with eye rubbing in some patients
286
AAO 2014-2016
IV.
A.
Keratoconus
B.
Senile furrow degeneration - which is usually not ectatic and is closer to and more concentric
with the limbus
C.
Terrien marginal corneal degeneration - is often listed in the differential diagnosis but this is
associated with vascularization and lipid deposition as well as at times inflammatory episodes
D.
Post-laser assisted in-situ keratomileusis (LASIK) ectasia

A.

1.
B.
V.
Describe surgical therapy

1.
Large eccentric penetrating keratoplasty or deep anterior lamellar keratoplasty
2.
Lamellar keratoplasty - total or crescentic
3.
Excision of stroma overlying the thinned area with oversewing of the tissue (corneal imbrication)
4.
Intrastromal corneal ring segments

A.
VI.
Contact lens fitting, often with a large rigid gas-permeable lens (or scleral lens)
High rejection rate in large eccentric penetrating keratoplasty

A.
Decreased vision
B.
Hydrops may occur
C.
Corneal ectasia can occur after excimer laser refractive surgery, making these patients poor
candidates for this procedure

A.
Avoid eye rubbing
1.
2.
3.
Sridhar MS, Mahesh S, Bansal AK, Nutheti R, Rao GN. Pellucid marginal corneal degeneration.
Ophthalmology 2004, 111:1102-7.
287
AAO 2014-2016
Corneal congenital syndromes and

anomalies
I.

A.

1.
B.
C.
Anomalies of structure and clarity

a.
Anterior displaced border of Schwalbe line
b.
Absence of corneal endothelium and Descemet membrane
c.
Scleralization of the cornea
d.
Degeneration of endothelial cells
2.
Congenital infection
3.
Dysplasia of anterior chamber angle

1.
Genetics
2.
Laterality of ocular involvement
3.
Corneal opacification/edema/vascularization
4.
Epiphora
5.
Photophobia
6.
Blepharospasm
7.
Nystagmus

1.
2.
Posterior embryotoxon
a.
Inherited, autosomal dominant inheritance
b.
Bilateral
c.
Presence of irregular and opaque ring central to limbus
d.
May be associated with other anomalies including iris hypoplasia, attached iris strands, and
glaucoma
Peters anomaly
a.
Most occur sporadically, however both autosomal dominant and recessive inheritance has
been reported
b.
Mostly bilateral, in 60% of cases
c.
Central cornea opacity present since birth with iridocorneal adhesions
288
AAO 2014-2016
3.
4.
5.
6.
D.
d.
May be associated with other anomalies including keratolenticular touch, cataract,

congenital glaucoma, microcornea, aniridia, persistent fetal vasculature, and skeletal
anomalies
e.
Associated with skeletal anomalies
Congenital hereditary endothelial dystrophy (CHED)

a.
Inherited, autosomal dominant and recessive inheritance
b.
Bilateral
c.
Diffuse stromal edema
d.
May be associated with nystagmus
Sclerocornea
a.
Sporadic, however both autosomal dominant and recessive inheritance has been reported
b.
Bilateral, in 90% cases
c.
Noninflammatory scleralization of cornea with ill-defined limbus, and vascularization which

can affect partial or complete cornea
d.
Commonly associated with cornea plana and angle structure malformation
Intrauterine keratitis
a.
Sporadic
b.
c.
Posterior corneal defect, with corneal infiltrates, vascularization, keratic precipitates, iris
adhesions and uveitis
d.
May be associated with teratogenic effects with ocular malformation
Congenital glaucoma
a.
Sporadic or inherited
b.
c.
Buphthalmos, increased corneal diameter greater than 12mm, with corneal edema,
elevated intraocular pressure, and Haab striae (tears in Descemet membrane oriented
horizontally)
d.
No significant associated ocular anomalies

1.
Examination under anesthesia
2.
Slit lamp examination of corneal edema and anterior segment anomalies
3.
Measure intraocular pressure
4.
Serial corneal diameter measurements
5.
Immersion ultrasound
289
AAO 2014-2016
II.
III.
IV.
6.
Attempt gonioscopy, examination of anterior and posterior segment if epithelial edema can be
cleared with topical hyperosmotic agent (glycerin)
7.
Molecular genetic analysis when indicated

A.
B.
Genetic syndromes

A.
Birth trauma
B.
Sclerocornea
C.
Peter anomaly
D.
Cornea plana
E.
CHED
F.
Intrauterine keratitis
G.
Congenital glaucoma

A.
B.
C.

1.
Persistent edema if untreated
2.
Optic nerve cupping with severe visual loss if left untreated
3.
Amblyopia likely to develop

1.
Glaucoma medications
2.
Antibiotics for intrauterine infection
3.
Corneal edema
a.
May be lessened by topical hyperosmotic agents (5% sodium chloride)
b.
Stromal edema may be improved with reduction of intraocular pressure improving

endothelial function

1.
Trabeculotomy
2.
Goniotomy
3.
Trabeculectomy
290
AAO 2014-2016
V.
Glaucoma shunt surgery
5.
Penetrating keratoplasty if cornea is permanently damaged

A.
B.
VI.
4.
Glaucoma surgery
1.
Choroidal effusions
2.
Choroidal hemorrhage
3.
Hypotony
4.
Infection
Corneal transplant (See Penetrating keratoplasty) (See Allograft rejection)

A.
Progressive optic nerve damage and visual field loss
B.
Recurrent corneal edema (See Corneal edema)
C.
Permanent corneal opacification
D.
Amblyopia

A.
Need for compliance with medical therapy and regular follow-up visits
B.
Need for lifelong management
C.
Counsel parents regarding risk of transmission to additional offspring
1.
291
AAO 2014-2016
Pterygium and pinguecula

I.

A.
B.
C.

1.
Related to ultraviolet B exposure
2.
Microtrauma from a windy or sandy environment may play a role, in addition
Describe the relevant aspects of epidemiology of this disease

1.
Prevalence higher closer to the equator - in hot, dry climates
2.
Males and outdoor workers predominate

1.
Onset typically in the 20's to 40's
2.
Complaint of ocular redness, irritation
3.
May be asymptomatic
4.
Usually report childhood years in hot, dry climate
5.
Pterygium
6.
a.
May note visual distortion or decreased acuity
b.
May note diplopia, especially on lateral gaze
Pinguecula
a.
D.
May report yellowish elevated growth

1.
2.
Pterygium
a.
Fibrovascular triangular mass extending onto the cornea in the horizontal meridian, most
commonly nasally although may be nasal, temporal, or both
b.
Usually bilateral
c.
Lesion usually thick, vascular, has a leading edge (cap) with an iron line central to it on the
cornea, a fleshy head from the cap to the limbus, and a fleshy body in the conjunctiva with
discrete superior and inferior margins
d.
May be quiescent with less dilated vessels and little growth or "active" with dilated vessels
and progressive growth centrally on the cornea
e.
Punctate staining or dellen formation may be present central to the cap on the cornea
f.
Restriction of ocular mobility may occur, especially on lateral gaze with extensive lesions or
lesions recurrent after prior surgeries
Pinguecula
292
AAO 2014-2016
E.
II.
III.
a.
Yellow white conjunctival lesion
b.
Most commonly located nasally, may be temporal, in the interpalpebral space
c.
Adjacent to limbus
d.
Does not involve the cornea
e.
May be associated with an adjacent dellen

1.
Pterygium and pinguecula are clinically diagnosed
2.
May be confirmed by histopathology after excision

A.
Ultraviolet light exposure, especially in the early years of life
B.
Living closer to the equator
C.
Possibly wind and sand exposure
D.
Uncommonly familial

A.
Pterygium
1.
2.
Pseudopterygium
a.
Occurs after focal corneal trauma or inflammation
b.
May occur in any meridian and is non-adherent to the limbus so a probe can be passed
beneath it
Symblepharon and subconjunctival fibrosis associated with:

a.
b.
c.
Atopic disease
d.
Chemical injury
3.
Pinguecula
4.
Pannus
5.
a.
Usually does not involve the conjunctiva peripheral to the limbus
b.
Usually concentric with the limbus
Conjunctival/corneal intraepithelial neoplasia or other limbal tumors

a.
Usually appears morphologically different, lacks radial orientation and vascular straightening
associated with pterygium
293
AAO 2014-2016
B.
IV.
Pinguecula
1.
Dermoid
2.
Pterygium
3.
Nonpigmented nevus
4.
Conjunctival intraepithelial neoplasm

A.
B.
Describe medical therapy

1.
Artificial tears/ocular lubricants
2.
Vasoconstrictors intermittently for redness
3.
Topical corticosteroids briefly when lesion very inflamed
4.
Ultraviolet B blocking eyeglasses or sunglasses may have a role in reducing the likelihood of
progression or recurrence
Describe surgical therapy (See Pterygium excision)

1.
V.
Excision of pinguecula in rare cases when chronically inflamed, interfere with contact lens wear, or
for cosmetic reasons.

A.
Topical corticosteroid side effects
B.
Pterygium
1.
C.
Recurrence after surgical treatment

a.
This appears to be most frequent with simple excision leaving bare sclera, least frequent
with primary closure, conjunctival grafting, amniotic membrane transplantation and/or
mitomycin C application
b.
There is a higher rate of recurrence with subsequent resections
c.
Recurrence can be managed with post-operative 5-Fu or triamcinolone injections,

conjunctival autograft, amniotic membrane transplantation, or mitomycin C
2.
Fibrosis with restriction of ocular motility
3.
Dellen formation related to inadequate smoothing at limbus, too thick a conjunctival graft at the
limbus
4.
Pyogenic granuloma formation
5.
Irregular astigmatism - less likely with avulsion of the head from the cornea or blunt dissection
6.
Corneal and/or scleral melting with mitomycin C or radiation
Pinguecula
294
AAO 2014-2016
VI.
1.
Post-surgical recurrence
2.

A.
Avoidance of ultraviolet light

1.
Sunglasses, protective eyewear
2.
Brimmed hat
B.
Limit the use of topical corticosteroids
C.
Frequent use of artificial tears
D.
Discourage chronic vasoconstrictor use
1.
2.
AAO, Focal Points: Surgical Treatment of Pterygium, Module #12, 1996.
3.
Al Fayez MF. Limbal versus conjunctival autograft transplantation for advanced and recurrent
pterygium. Ophthalmology 2002;109:1752-5.
4.
Dadeya S, Malik KP, Gullian BP. Pterygium surgery: conjunctival rotation autograft versus
conjunctival autograft. Ophthalmic Surg Lasers 2002;33:269-74.
5.
Sharma A, Gupta A, Ram J, et al. Low-dose intraoperative mitomycin-C versus conjunctival

autograft in primary pterygium surgery: long term follow-up. Ophthalmic Surg Lasers
2000;31:301-7.
6.
Mutlu FM, Sobaci G, Tatar T, et al. A comparative study of recurrent pterygium surgery: limbal
conjunctival autograft transplantation versus mitomycin C with conjunctival flap. Ophthalmology
1999;106:817-21.
7.
Mahar PS. Conjunctival autograft versus topical mitomycin C in treatment of pterygium. Eye
1997;11:790-2.
8.
Panda A, Das GK, Tuli SW, et al. Randomized trial of intraoperative mitomycin C in surgery for
pterygium. Am J Ophthalmol 1998;125:59-63.
9.
Manning CA, Kloess PM, Diaz MD, et al. Intraoperative mitomycin in primary pterygium excision. A
prospective, randomized trial. Ophthalmology 1997;104:844-8.
10.
Hirst LW. The treatment of pterygium. Surv Ophthalmol 2003;48:145-180.
11.
Tsai YY, Chang KC, Lin CL, et al. Expression in pterygium by immunohistochemical analysis: a
series report of 127 cases and review of the literature. Cornea 2005;24:583-6.
295
AAO 2014-2016
Salzmann nodular degeneration

I.

A.
B.
C.
II.

1.
Postinflammatory fibrosis of subepithelial cornea
2.
Idiopathic, reason for nodule formation is often unclear

1.
History of corneal trauma
2.
History of trachoma
3.
Previous corneal surgery
4.
Recurrent corneal erosions
5.
Episodes of conjunctival injection/photophobia
6.
History of contact lens wear

1.
Gray-white/blue-white subepithelial nodules
2.
Adjacent to corneal scarring or corneal pannus, or vascularization
3.
Often localized to the midperiphery
4.
Often overlying incisions, subepithelial scarring (e.g., following recurrent corneal erosions)
5.
Surrounded by iron line or ring in some cases
6.
Can be unilateral or bilateral

A.
Any of the associated predisposing conditions listed above
B.
More commonly seen in women
C.
Fibrotic response following keratitis
D.
1.
Phlyctenulosis
2.
Trachoma
3.
Interstitial keratitis
Fibrotic response following epithelial disruption

1.

a.
Corneal epithelial basement membrane dystrophy
b.
Corneal dystrophy of Bowman's layer
296
AAO 2014-2016
c.
E.
III.
IV.
2.
3.
Fibrotic response at incision site following corneal surgery

1.
2.
Cataract extraction
3.
Laser in situ keratomileusis

A.
Calcific band keratopathy
B.
Spheroidal degeneration
C.
Gelatinous, droplike corneal dystrophy
D.
Corneal keloid

A.
B.
C.
V.
Pseudophakic bullous keratopathy
Indications for treatment

1.
Interference with contact lens wear
2.
Visual disturbance
a.
Direct obstruction of visual axis
b.
Associated tear film instability
c.
Associated irregular astigmatism

1.
Artificial tear replacement
2.
Punctal occlusion
3.
Bandage soft contact lens

1.
Epithelial debridement/superficial keratectomy/
2.

A.
Contact lens
1.
Predisposition to infection
297
AAO 2014-2016
a.
B.
Epithelial debridement/superficial keratectomy

1.
C.
Subepithelial corneal haze

a.
Judicious use of topical corticosteroids
b.
Possible use of anti-fibrotic agent mitomycin C
1.
2.
3.
a.
Minimize depth of ablation
b.
Use masking agent
Subepithelial corneal haze

a.
Judicious use of topical corticosteroids
b.
Possible use of anti-fibrotic agent mitomycin C
Hyperopic shift
a.
VI.
May decrease incidence with the use of prophylactic antibiotics
Minimize depth of ablation

A.
Visual disturbance, recurrent corneal erosions with secondary bacterial keratitis

A.
Treatment only indicated if one of the criteria listed above is met
1.
2.
3.
2008;27:S1-S42
298
AAO 2014-2016
Band keratopathy
I.

A.

1.
Calcium hydroxyapatite deposition

a.
2.
Uveitis in children
ii.
Phthisis bulbi
iii.
Prolonged corneal edema, including corneal graft failure
iv.
Silicone oil in an aphakic eye
v.
Chronic exposure to mercurial vapors or to mercurial preservatives in ophthalmic

medications
vi.
Prolonged superficial keratitis or keratopathy
Hyperphosphatemia, such as associated with renal failure
c.
Hypercalcemia, such as associated with sarcoidosis or hyperparathyroidism
Urate deposition
Brown urate deposits may be associated with hyperuricemia during gout

1.
C.
i.
b.
a.
B.
Chronic ocular disease
History of one of the etiologic conditions

a.
Chronic eye disease
b.
Chronic exposure to environmental irritants
c.
Systemic disorders
2.
3.
Ocular discomfort

1.
Early changes
a.
b.
2.
Fine, dust like deposits in Bowman layer in the horizontal interpalpebral fissure zone
i.
Deposits associated with ocular surface disease usually begin near the limbus
ii.
Deposits associated with anterior uveitis usually begin centrally
Peripheral clear zone between the limbus and the peripheral edge of the band keratopathy
Later changes
a.
Horizontal band of dense calcific plaque across interpalpebral zone of the cornea, varying in
299
AAO 2014-2016
color from beige-gray to chalky white

b.
D.

1.
II.
III.
IV.
Small holes or clear areas in the plaque
If no localized ocular cause identified

a.
Calcium, phosphorus, albumin, magnesium, blood urea nitrogen (BUN), and creatinine (if
renal disease or other systemic disease suspected)
b.
Uric acid (if gout suspected)

A.
Chronic ocular surface or corneal disorder
B.
Chronic anterior segment inflammation
C.
Abnormal level of serum calcium, phosphate, or uric acid

A.
Medication precipitation
B.
Epithelial disorders, including spheroidal degeneration
C.
Subepithelial corneal opacification

1.
Age-related changes such as limbal girdle of Vogt
2.
Posttraumatic changes such as Coats white ring
3.
Post-inflammatory lipid deposition
4.
Superficial stromal dystrophies such as corneal dystrophy of Bowman layer I and II

A.

1.
B.
Treatment of any precipitating ocular conditions

a.
Artificial tears in keratoconjunctivitis sicca
b.
Topical corticosteroids in chronic iritis
2.
Treatment of underlying systemic conditions
3.

1.
Indications
a.
Associated ocular discomfort
b.
Chronic overlying epithelial defect
300
AAO 2014-2016
2.
c.
d.
Recurrent infection
Scraping (debridement) and chelation for calcific band keratopathy

a.
Removal of overlying epithelium and loose calcium deposits with surgical blade
b.
Application of 0.4% - 3.0% ethylenediaminetetraacetic acid [EDTA]
c.
3.
V.
i.
Solution poured inside optical zone marker, trephine, or similar reservoir that is held
onto corneal surface, or applied to corneal surface with soaked cellulose sponge
ii.
Repeated until most calcium phosphate is removed
Bandage soft contact lens can be placed until epithelium has healed
a.
Considered for vision-limiting calcific deposits that remain after scraping and chelation
b.
Transepithelial ablation or ablation after epithelium has been removed (with a masking
agent)

A.
Scraping and chelation

1.
Bacterial keratitis
a.
b.
2.
i.
Use of antiseptic technique during surgical removal
ii.
Uncertain role of prophylactic antibiotics, although topical antibacterial agent could be

considered until epithelial defect has resolved
Management: (See Bacterial keratitis)
Incomplete removal or recurrence

a.
3.
Prevention
Management
i.
No further treatment
ii.
Additional debridement, chelation, or phototherapeutic keratectomy
Corneal scarring
a.
Prevention
i.
B.
Minimize scraping of Bowman layer
1.
Irregular corneal surface secondary to different rates of ablation between calcium and corneal
stroma
a.
Prevention
301
AAO 2014-2016
2.
Transepithelial ablation
ii.
Use of masking agent
iii.
Limiting depth of ablation
Corneal scarring
a.
VI.
i.
Prevention
i.
Limiting depth of ablation
ii.
Use of topical corticosteroids after treatment

A.
B.
Discomfort
C.
1.
Surface irregularity
2.
Undesirable cosmetic appearance

A.
Management of predisposing condition (if identified and if possible) important in prevention of

recurrences
B.
Serial treatments may be necessary

1.
Probability of recurrence and necessity for repeat removals
1.
2.
3.
2008;27:S1-S42.
302
AAO 2014-2016
Pigmentation of the conjunctiva and

cornea
I.

A.
B.
II.
Define the pertinent elements of the history

1.
Age of onset
2.
Duration and progression
3.
Medication use

1.
Color
2.
Location, distribution, and number of pigmented foci
3.
Depth
a.
Intraepithelial (conjunctival)
b.
Subepithelial (episcleral)
4.
Size, shape, and edges of lesion
5.
Thickness and consistency
6.
Growth and rate of change
7.
Presence or absence of cysts, inflammation, ulceration, or bleeding
8.
Status of cornea and adjacent tissues
9.
Status of regional lymph nodes
10.
Periocular skin pigmentation

A.
Conjunctival pigmentation
1.
Conjunctival pigmentation associated with skin complexion (also called benign epithelial melanosis
or racial melanosis)\
a.
2.
Typically bilateral
Conjunctival nevus
a.
Usually small
b.
Sometimes cystic
c.
Very frequently stable in color and size
303
AAO 2014-2016
d.
Congenital melanocytic nevus

i.
e.
3.
C.
Acquired melanocytic nevus
Primary acquired melanosis

a.
Multiple or diffuse
b.
Flat brown patches
4.
5.
Secondary acquired melanosis
6.
B.
Pigmentation may increase with puberty or pregnancy
a.
Postinflammatory melanosis, following chronic conjunctivitis
b.
Systemic conditions with flat pigmentary patches of conjunctiva:

i.
Addison disease
ii.
Peutz-Jeghers syndrome
iii.
Von Recklinghausen disease
Brown, black, or gray deposits

a.
Carbon or metal deposits
b.
Adrenochrome (oxidized epinephrine) deposits
c.
Argyrosis (silver deposition)
d.
Oral medications: tetracyclines or phenothiazines
Episcleral or scleral pigmentation

1.
Nerve loops of Axenfeld
2.
Ocular melanocytosis (melanosis oculi) and oculodermal melanocytosis (nevus of Ota)
3.
Extraocular extension of uveal melanoma
4.
Alkaptonuric ochronosis
5.
Senile scleral plaques
6.
Foreign body
Corneal epithelial pigmentation

1.
Striate melanokeratosis: melanin pigmentation extending from limbus
2.
Iron line associated with uneven corneal topography or with aging
3.
Pigmented band keratopathy
4.
Spheroidal degeneration
5.
Cornea verticillata
a.
Fabry disease (X-linked lysosomal storage disease)
304
AAO 2014-2016
b.
D.
Amiodarone medication use
Corneal stromal pigmentation

1.
Intrastromal melanin following perforating corneal trauma or surgery
2.
Deposits associated with systemic medications, such as phenothiazines or gold
3.
Foreign bodies, including ocular siderosis
4.
Corneal blood staining associated with hyphema
5.
Kayser-Fleischer ring associated with copper deposition in Wilson disease
1.
2.
1996.
3.
305
AAO 2014-2016
Postinflammatory, post-traumatic, and

postsurgical corneal opacity
I.

A.
B.

1.
History of previous ocular inflammation - "red eyes", "infection", or "keratitis"
2.
History of orofacial herpes simplex
3.
History of herpes zoster ophthalmicus
4.
History of sexually transmitted disease
5.
History of trauma including chemical injury
6.
History of ocular surgery - type of procedure and complications encountered
7.
Description of course and nature of visual loss and associated symptoms

1.
2.
II.
Location and depth of corneal opacification

a.
Bilateral versus unilateral
b.
Focal versus multifocal
c.
Central versus peripheral
Associated findings
a.
Neovascularization and ghost vessels
b.
Lipid deposition
c.
Corneal thinning
d.
Corneal edema
e.
Epithelial defect
f.
Corneal anesthesia
g.
Associated intraocular findings - e.g., posterior synechiae, peripheral anterior synechiae,

elevated intraocular pressure (IOP)

A.
Corneal dystrophy
B.
Congential corneal opacity
C.
Chronic stromal keratitis, such as herpes simplex virus (HSV) stromal keratitis or varicella zoster
virus (VZV) keratitis
306
AAO 2014-2016
III.
D.
Chronic microbial keratitis, including infectious crystalline keratopathy
E.
Corneal deposits

A.

1.
Work up and treat any underlying medical condition causing the opacification
2.
Improve visual function

a.
Contact lenses
i.
b.
Topical hypertonic agents

i.
3.
B.
Correct irregular astigmatism
Relieve superficial corneal edema
c.
Alleviate discomfort or pain
d.
Bandage contact lenses
e.
Lubricants
f.
Cycloplegic agents
Enhance cosmetic appearance

a.
Custom designed eyeglasses
b.
Cosmetic contact lens
c.
Scleral shell

1.
2.
Improve visual function

a.
Superficial keratectomy
b.
c.
Anterior lamellar keratoplasty
d.
e.
Rotational autograft
Alleviate discomfort or pain if persistent corneal edema or epithelial defect

a.
b.
Corneal cautery
c.
Conjunctival flap
d.
e.
307
AAO 2014-2016
f.
3.
Retrobulbar alcohol if poor visual potential
Enhance cosmetic appearance

a.
Penetrating or lamellar keratoplasty
b.
Corneal tattoo
1.
308
AAO 2014-2016
Chemical (alkali and acid) injury of the

conjunctiva and cornea
I.

A.

1.
Chemical agents alter the levels of highly reactive hydrogen and hydroxyl ions in affected tissues
2.
Alkalis
3.
B.
a.
Raise pH of tissues causing saponification of fatty acids in cell membranes and cellular
disruption
b.
Surface epithelial damage allows penetration of alkali into corneal stroma destroying
proteoglycan ground substance and collagen fibers of stroma matrix
c.
Leukocytic infiltration of corneal stroma
d.
Secondary protease expression by corneal cells and leukocytes and penetration into
anterior chamber can then occur causing tissue damage and inflammation
e.
Damage to limbal stem cells can lead to disruption of normal repopulation of corneal
epithelium, resulting in:
i.
Conjunctivalization of the cornea with vascularization
ii.
Goblet cells in the cornea
iii.
Poor epithelial adhesion
iv.
Recurrent epithelial breakdown
v.
Stromal thinning, worse with persistent epithelial defect
vi.
Chronic inflammation
Acids
a.
Lower pH of tissues and cause denaturing and precipitation of proteins in tissues
b.
Cause less injury than alkalis due to buffering capacity of tissues and barrier formed by
precipitated proteins
c.
Can cause severe inflammation leading to upregulation of protease expression resulting in

damage to corneal matrix

1.
Nature of the chemical substance
2.
Method of exposure and quantity of chemical substance
3.
Duration of exposure and time to treatment
4.
Immediate measures taken including irrigation, removal of particulate material
309
AAO 2014-2016
5.
C.
List the pertinent clinical features

1.
II.
Presence of a contact lens
Extent of ocular surface injury

a.
Amount of scleral and limbal ischemia or blanching (predictor of progression to limbal stem
cell failure)
b.
Percentage of epithelial defect
c.
Presence of corneal edema and haze
d.
Presence of stromal necrosis
e.
Presence of intraocular inflammation
2.
Presence and degree of skin and eyelid burns
3.
pH of offending substance and of ocular surface
4.
Residual chemical matter on the ocular surface

A.

1.
Minimize ongoing exposure to offending agent

a.
Immediate and copious irrigation of the ocular surface with water or normal saline or any
nontoxic solution that is not grossly contaminated
i.
b.
Irrigation should continue until pH of the conjunctival sac is normalized
c.
Removal of contact lenses
d.
Removal of particulate matter from the ocular surface with cotton-tip applicators and forceps
i.
2.
3.
Use of eyelid immobilization, topical anesthesia, and continuous irrigation with IV

tubing, irrigating lid speculum, or irrigating contact lens (e.g., Medi-flow)
Double eversion of lids to look for matter
Decrease inflammation
a.
Topical corticosteroids in the acute phase (inhibit leucocyte) (during first 2 weeks)
b.
Oral tetracyclines, citric acid (chelate calcium in the plasma membrane of leucocytes)
c.
Topical 1% medroxyprogesterone (suppresses collagen breakdown)
d.
Topical cycloplegics in patients with significant anterior chamber reaction
e.
Amniotic membrane grafts
f.
Control intraocular pressure

a.
Oral carbonic anhydrase inhibitor to prevent ocular surface toxicity

310
AAO 2014-2016
b.
4.
Topical therapies if epithelium is healing well
Promote healing
a.
Stroma
i.
b.
5.
Epithelium
i.
Intensive nonpreserved lubricants
ii.
Bandage contact lens with topical antibiotic broad-spectrum prophylaxis
Inhibit collagenolysis
a.
b.
B.
Oral vitamin C (high dose, approximately 2 g per day) (ascorbic acid is a cofactor in
collagen synthesis) (monitor renal status)
Topical agents
i.
Medroxyprogesterone
ii.
N-acetylcysteine
iii.
Na-citrate
iv.
Ethylenediaminetetraacetic acid (EDTA)
Oral agents
i.
Doxycycline/tetracycline
ii.
Vitamin C
iii.

1.
Normalize pH
2.
Promote healing
a.
3.
Tarsorrhaphy
Ocular surface reconstruction

a.
Early
i.
b.
Amniotic membrane grafting to ocular surface (sutured or self retained)
Late
i.
Autologous conjunctival or limbal transplant from the uninvolved eye
ii.
Limbal stem cell replacement (cadaveric keratolimbal or living-donor conjunctivallimbal allograft)
iii.
Amniotic membrane transplantation has limited effectiveness in the presence of

severe limbal stem cell deficiency)
iv.
Mucous membrane graft (reconstruct fornix)
v.
Corneal transplantation has very poor prognosis if eye inflamed or if stem cells
deficient
311
AAO 2014-2016
vi.
4.
Eyelid reconstruction
a.
III.
B.
Corticosteroids
1.
Infection
2.
Predisposition to stromal thinning and perforation
3.
Delayed reepithelialization

1.
C.
V.
Repair of ectropion, entropion, trichiasis, exposure

A.
IV.
Keratoprosthesis
Infection
Corneal transplantation
1.
Rejection (See Allograft rejection)
2.
Graft failure (See Penetrating keratoplasty)
3.
Persistent epithelial defect (See Persistent corneal epithelial defect)

a.
Stromal thinning
b.
Perforation

A.
Ocular surface disease/dry eye state
B.
Corneal stem cell deficiency
C.
Secondary super-infection
D.
Corneal stromal scarring and vascularization
E.
Corneal perforation
F.
Intraocular inflammation and synechiae formation
G.
Glaucoma
H.
Symblepharon formation and lid position abnormalities
I.
Phthisis bulbi

A.
Immediate copious irrigation
B.
Use of topical and oral medications to promote healing and prevent complications
C.
Chronicity of injury in severe burns
312
AAO 2014-2016
D.
Compliance with follow-up
1.
2.
Wagoner MD, Kenyon KR. Chemical injuries of the eye. In: Albert DM, Jakobiec FA, eds.
Principles and Practice of Ophthalmology. Vol 2. 2nd ed. Philadelphia: Saunders; 2000:943-959.
3.
Letko E, Stechschulte SU, Kenyon KR, et al. Amniotic membrane inlay and overlay grafting for
corneal epithelial defects and stromal ulcers. Arch Ophthalmol. 2001;119:659-663.
313
AAO 2014-2016
Toxic medication injury of the conjunctiva

I.

A.
B.
C.
II.
Provide mechanistic description

1.
Direct toxicity to cell membranes of conjunctival epithelium producing cell loss and secondary
inflammation
2.
Irritant effect of specific agents on conjunctiva -associated lymphoid tissue

1.
History of prolonged use of topical medication
2.
History of topical anesthetic abuse

1.
Generalized injection of the bulbar and tarsal conjunctiva
2.
Mild to severe papillary reaction of the tarsal conjunctiva
3.
Mucopurulent discharge
4.
Asymmetry between eyes
5.
Chronic follicular conjunctivitis, more prominent on the inferior tarsus and fornix
6.
Bulbar follicles
7.
Subconjunctival fibrosis
8.
Pseudopemphigoid or drug-induced mucous membrane pemphigoid (progressive fibrosis)

A.
Common topical therapeutic agents include

1.
Atropine
2.
Topical aminoglycosides
3.
Antiviral agents
4.
Miotics especially phospholine iodide
5.
Sulfonamides
6.
Epinephrine
7.
Apraclonidine
8.
Alpha2-adrenergic agonists
9.
Vasoconstrictors
10.
Topical antimetabolites
314
AAO 2014-2016
B.
III.
IV.

A.
B.
C.
D.
E.
Contact-lens induced conjunctivitis
F.
G.
Chlamydial conjunctivitis
H.
I.
Chemical injury
J.
Conjunctivochalasis
K.
Sequelae of Stevens-Johnson syndrome

A.
V.
VI.
Topical anesthetic agents

1.
Discontinuation of offending topical medications
2.
Topical lubricants
3.
Chemotherapy (dapsone, cyclophosphamide, corticosteroids) for drug-induced mucous membrane

pemphigoid
Describe the disease-related complications

A.
Symblepharon
B.
Trichiasis
C.
Entropion
D.
Superficial keratitis
E.
Corneal ulceration
F.
Corneal scarring

A.
Discontinuation of offending agents
B.
Resolution of signs and symptoms may take weeks to months
C.
Use of topical lubricants to optimize the ocular surface
315
AAO 2014-2016
1.
2.
Grant WM, Schuman JS. Toxicology of the Eye. 4th ed. Springfield, IL: Thomas; 1993.
3.
Liesegang TJ. Conjunctival changes associated with glaucoma therapy: implications for the
external disease consultant and the treatment of glaucoma. Cornea. 1998;17:574-583.
316
AAO 2014-2016
Toxic medication injury of the cornea

I.

A.

1.
Dose-dependent cytotoxicity involving the corneal epithelium and corneal stem cells in some
instances
2.
Epithelial loss and breakdown can lead to stromal scarring and thinning associated with
upregulation of matrix metalloproteinases
3.
Irritant effect on conjunctiva

a.
B.
C.
D.
II.
Associated lymphoid tissue hyperplasia may occur with specific agents
Describe the relevant aspects of epidemiology of the disease

1.
Prolonged use of topical medications
2.
Use of topical anesthetics
3.
Aqueous tear deficiency and delayed tear clearance with use of topical medications

1.
History of prolonged use of topical medication (common agents include anesthetics,

aminoglycosides, antivirals, diclofenac, mitomycin, and drops preserved with benzalkonium
chloride)
2.
History of topical anesthetic abuse

1.
Punctate epithelial erosions of the inferior cornea
2.
Diffuse punctate epitheliopathy
3.
Vortex or hurricane keratopathy
4.
Corneal epithelial defect of the inferior or central cornea
5.
Stromal opacification
6.
Dense stromal infiltrates or ring opacity
7.
Corneal thinning
8.
9.
Limbal stem-cell deficiency
10.
Peripheral corneal infiltrates with a limbal clear zone

A.
Prolonged use of topical medications or use of topical anesthetics
317
AAO 2014-2016
B.
III.
IV.

A.
Dry eye syndrome
B.
Microbial keratitis
C.
Viral keratoconjunctivitis
D.
E.
Amiodarone/Indomethacin vortex keratopathy
F.
G.
H.
Chronic blepharoconjunctivitis

A.
B.
V.

1.
Discontinuation of offending topical medications
2.
Topical preservative free lubricants
3.
Lateral tarsorrhaphy for severe cases

A.
VI.
Topical corticosteroids can cause cataract, glaucoma, and predispose to infection

A.
Microbial keratitis
B.
Corneal thinning with secondary irregular astigmatism
C.
Corneal perforation
D.
Corneal opacification

A.
Discontinuation of offending agents
B.
Resolution of signs and symptoms may take weeks to months
C.
Use of topical lubricants for comfort
318
AAO 2014-2016
1.
2.
Grant WM, Schuman JS. Toxicology of the Eye. 4th ed. Springfield, IL: Thomas; 1993.
3.
Liesegang TJ. Conjunctival changes associated with glaucoma therapy: implications for the
external disease consultant and the treatment of glaucoma. Cornea 1998;17:574-583.
319
AAO 2014-2016
Subconjunctival hemorrhage
I.

A.
B.
C.

1.
Direct injury to ocular surface
2.
Sudden venous congestion (Valsalva maneuver)

Vomiting
b.
Forceful coughing
c.
Weight lifting
d.
Straining to defecate or urinate
3.
Vascular fragility (e.g., conjunctival amyloid deposition)
4.
Thrombocytopenia and/or impaired clotting
5.
Medications
a.
Systemic (chemotherapy, anti-coagulants)
b.
Topical (corticosteroids)
6.
Uncontrolled hypertension
7.
Idiopathic

1.
Ocular or cranial trauma
2.
History of Valsalva maneuver
3.
History of hypertension
4.
Use of oral anticoagulants (medications or vitamins)

1.
D.
a.
Extravasated blood within and beneath the conjunctiva

a.
May be localized or diffuse
b.
Appearance not affected by vasoconstrictors

1.
If patient has a history of recurrent subconjunctival hemorrhages, as well as features of a bleeding

diathesis (easy bruising, bleeding from the gums, nose or bowels), may consider
a.
Bleeding time
b.
Complete blood count (CBC)
c.
Prothrombin time (PT) and INR derived from the PT if patient is on warfarin (Coumadin)
320
AAO 2014-2016
d.
2.
II.
III.
A.
Local trauma
B.
Increased venous or arterial blood pressure
C.
Bleeding diathesis
B.
1.
Episcleritis
2.
Pingueculitis
3.
Scleritis
4.
Conjunctival trauma
5.
Allergic or infectious conjunctivitis
6.
Localized corneal amyloid deposition

1.
No treatment needed in most cases
2.
Topical lubricants if necessary for localized drying
3.
Address underlying systemic condition, if present
Describe surgical therapy options in chronic recurrent disease

1.
Argon laser of feeding vessels if anatomic area is identified
2.
Conjunctival excision if anatomic area identified

A.
VI.
Focal or diffuse conjunctival injection

A.
V.
Blood pressure
A.
IV.
Activated partial thromboplastin time (aPTT)
No treatment needed

A.
No sequelae result from the subconjunctival hemorrhage itself
B.
Localized drying, dellen, or exposure keratopathy if large and protuberant
321
AAO 2014-2016

A.
Reassurance that no treatment is needed, and subconjunctival hemorrhage itself will not harm
the eye
B.
Spontaneous resolution expected in 7-14 days
C.
Hemorrhage may enlarge before it resolves, and may appear to change colors during its
resolution
1.
322
AAO 2014-2016
Conjunctival laceration
I.

A.

1.
B.
II.
History of trauma
a.
Timing
b.
Circumstances
i.
Likelihood of foreign body
ii.
Nature of foreign body
2.
Pain
3.
4.
Discomfort with blinking
5.
Tearing
6.
Loss of vision - suggestive of more extensive injury
7.
Purulent discharge - suggestive of infection

1.
Conjunctival erythema
2.
Subconjunctival hemorrhage
3.
Slit-lamp biomicroscopic examination with topical anesthesia (evaluate both eyes)

a.
Determine extent of laceration
b.
Explore margins, base with forceps or cotton-tip for

i.
Foreign body
ii.
Scleral laceration
c.
Assess anterior segment for signs of globe penetration
d.
Dilated fundus exam to examine for intraocular foreign body
e.
Imaging study may be indicated

i.
X-Ray and/or CT scan if intraorbital foreign body suspected
ii.
Anterior segment ultrasound biomicroscopy if occult anterior segment foreign body

suspected

A.
323
AAO 2014-2016
B.
III.
1.
Topical antibiotic prophylaxis until laceration healed
2.
Topical corticosteroids to control inflammation as needed
3.
Topical lubricants for comfort as needed
4.
Oral analgesics as needed
5.
Regular follow-up until healed

1.
Peritomy for further exploration if possibility of globe penetration can not be ruled out with office
examination
2.
Foreign body removal that can not be accomplished at slit-lamp biomicroscope
3.
Suture closure of laceration - rarely necessary, unless large flap of conjunctiva is dislocated and
then close for patient comfort

A.
Allergy to topical medications

1.
Prevention
a.
2.
B.
Management
a.
Cessation of medication
b.
Consider use of topical corticosteroids if clean and healing
Infection
1.
Prevention
a.
2.
IV.
V.
History
Antibiotic prophylaxis
Management
a.
Culture and sensitivity
b.
More intensive topical antibiotic therapy, directed at specific organisms once known
c.
Systemic antibiotics if infectious scleritis develops

A.
Infection
B.
Retained foreign body
C.
Associated scleral laceration, globe penetration
324
AAO 2014-2016
A.
Proper use of topical medications
B.
1.
325
AAO 2014-2016
Conjunctival foreign body

I.

A.

1.
B.
History of trauma
a.
Timing
b.
Nature of injury, possible alkali exposure (e.g., cement)
2.
3.
4.
Tearing
5.
Photophobia
6.
Blurred vision

1.
Conjunctival erythema and/or hemorrhage
2.
Lid edema may be present
3.
Visible foreign body
4.
Secondary epithelial erosions

a.
II.
Linear pattern of fluorescein staining is highly suggestive of foreign body on corresponding

tarsal conjunctiva

A.
B.

1.
Topical antibiotic prophylaxis, drops or ointments
2.
Follow-up to evaluate healing if epithelial keratopathy or abrasion present

1.
Removal usually possible with slit lamp biomicroscope in office

a.
Apply topical anesthesia
b.
Always evert upper lids. May use Desmarres retractor or bent paper clip to visualize foreign
body
c.
Double-evert lid if multiple foreign bodies or particulate matter suspected
d.
Wipe away superficial foreign body(ies) with cotton-tipped applicator
e.
Remove embedded foreign body(ies) with jewelers forceps or needle tip
326
AAO 2014-2016
f.
III.
2.
Patients with multiple, extensive foreign bodies or who are uncooperative may need exploration in
operating room
3.
Take meticulous care in removal of all foreign bodies, particularly in cases of wet cement or other
alkali-containing materials
4.
Topical antibiotic prophylaxis, drops or ointments following removal

A.

1.
Prevention
a.
2.
B.
Cessation of medication, consider use of topical corticosteroids if clean and healing
Infection
1.
Prevention
a.
2.
V.
History
Management
a.
IV.
If no foreign body visualized, or if multiple foreign bodies present or suggested by history,

irrigate fornix and sweep with cotton-tipped applicator
Management
a.
Culture and sensitivity
b.
More intensive topical antibiotic therapy, directed at specific organisms once known
c.
Systemic antibiotics if infectious scleritis develops

A.
Secondary epithelial erosion
B.
Microbial keratitis
C.
D.
Chemical burn if significant acid or alkali content

A.
B.
327
AAO 2014-2016
1.
328
AAO 2014-2016
Corneal foreign body

I.

A.

1.
2.
B.
II.
History of trauma
a.
Timing
b.
High- or low-velocity injury
c.
Nature of material

1.
Visualize foreign body location and depth
2.
Evaluate chamber depth and perform Seidel test if deep corneal foreign body extends into inner
eye

A.
B.

1.
Topical antibiotic prophylaxis
2.
Systemic antibiotics for extension into anterior chamber
3.
Topical cycloplegics for relief of ciliary spasm
4.
Embedded glass foreign bodies without surface exposure are often inert and may be left in place,
but must be followed carefully for evidence of infection or inflammation
5.
Pressure patching or topical nonsteroidal anti-inflammatory drugs (NSAIDs) may aid in comfort
6.
Initially, frequent evaluation for microbial keratitis, endophthalmitis, aqueous leak
7.
Evaluate both eyes

1.
2.
Remove all accessible foreign bodies

a.
Topical anesthesia
b.
Jeweler's forceps or needle tip to remove foreign body
c.
Battery-powered drill with sterile dental burr for removal of rust resistant to removal with
needle tip
Indications for sterile operating room environment

a.
Foreign body inaccessible from corneal surface
329
AAO 2014-2016
3.
III.
b.
Extension into anterior chamber present or suspected
c.
Multiple, extensive foreign bodies
d.
Uncooperative patient
Surgical technique for deep, embedded foreign bodies

a.
Topical or peribulbar anesthesia, sedation as needed
b.
Surgical "cut-down" or placement of needle through uninvolved cornea at obtuse angle to

foreign body, with manipulation to push foreign body back along entry track
c.
Paracentesis, ophthalmic viscosurgical device (viscoelastic) if extension into anterior

chamber
d.
Corneal sutures if necessary (See Corneal and corneoscleral laceration)

A.
Penetration into anterior chamber with aqueous leakage

1.
Prevention
a.
2.
IV.
Avoid overly aggressive attempts to remove embedded foreign bodies at the slit-lamp
biomicroscope
Management
a.
Therapeutic contact lens
b.
Tissue adhesive (See Application of corneal tissue adhesive, Corneal and corneoscleral
laceration)
c.
Surgical repair

A.
Microbial keratitis
B.
Sterile keratitis
1.
Immune
2.
Chemical
a.
Plant
b.
Animal (e.g., envenomations)
C.
Corneal scarring
D.
Regular and irregular astigmatism
E.
Endophthalmitis
1.
Prevention
a.
Avoid penetration of anterior chamber

330
AAO 2014-2016
b.
V.

A.
B.
Avoid postoperative exposure to non-sterile tap water
C.
Hand-washing, proper wound care as applied to ocular surface
D.
Additional Resource
1.
2.
Goyal R, Shankar J, Fone DL, et al. Randomised controlled trial of ketorolac in the management of
corneal abrasions. Acta Ophthalmol Scand. 2001;79:177-9.
3.
Kaiser PK. A comparison of pressure patching versus no patching for corneal abrasions due to
trauma or foreign body removal. Corneal Abrasion Patching Study Group. Ophthalmology.
1995;102:1936-42.
331
AAO 2014-2016

I.

A.

1.
B.
a.
Timing
b.
Circumstances
i.
Nature of injury
ii.
Contact lens wear
c.
Absence of symptoms suggestive of recurrent erosion or herpes simplex virus (HSV)
d.
Work history (construction, plumbing, welder)
e.
History of recent general anesthesia
2.
Pain
3.
4.
5.
Tearing
6.
Photophobia
7.
Blurred vision if visual axis involved

1.
II.
History of trauma
Epithelial defect on slit-lamp biomicroscopic examination

a.
Positive fluorescein staining
b.
Size of defect may be measured to follow healing
2.
Presence or absence of stromal edema or infiltrate
3.
Loose epithelial tissue
4.
Presence or absence of corneal or tarsal conjunctival foreign body
5.
Note opacification or signs of infection

A.

1.
Topical anti-infective drop or ointment often used
2.
Pressure patching
332
AAO 2014-2016
a.
Does not accelerate healing, though theoretically reduces repetitive lid trauma from blinking
b.
May be more comfortable for patients with large abrasion
c.
Potential risk of exacerbating microbial keratitis in abrasions associated with contact lens
wear
d.
Patients unable to assess if vision worsens
3.
Therapeutic contact lens for comfort
4.
Topical cycloplegic agent for comfort
5.
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) for comfort
6.
Use 5% NaCl ointment q hs in cases of trauma from organic material to prevent recurrent erosions
7.
Frequent follow-up to evaluate for microbial keratitis

a.
B.
i.
Large abrasion
ii.
Associated with contact lens
iii.
Secondary to trauma with dirty or organic material

1.
2.
III.
Initial follow up may be daily if:
Rarely necessary, unless corneal abrasion is associated with:

a.
Persistent corneal epithelial defect (See Persistent corneal epithelial defect)
b.
Recurrent corneal erosion (See Recurrent erosion)
c.
Tear deficiency (See Aqueous tear deficiency, Sjgren syndrome and Mucin deficiency)
d.
Neurotrophic keratopathy (See Neurotrophic keratopathy)
e.
Exposure keratopathy (See Exposure keratopathy)
f.
Corneal melting or perforation (See Corneal perforation)
May include
a.
Punctal occlusion
b.
Corneal epithelial and/or basement membrane debridement
c.
Anterior stromal puncture
d.
e.
Tarsorrhaphy

A.

1.
Prevention
333
AAO 2014-2016
a.
2.
B.
Management
a.
Cessation of medication
b.
Consider use of topical antihistamine, mast cell stabilizer, NSAID, and/or corticosteroid if
abrasion clean and healing
Epithelial toxicity, delayed healing (especially NSAIDs)

1.
Prevention
a.
2.
Minimize use of topical medications
Management
a.
C.
History
Cessation or dose reduction

1.
Tight lens syndrome

a.
Prevention
i.
b.
2.
D.
IV.
V.
Management
i.
Discontinue lens
ii.
Looser fit
Bacterial keratitis (See Bacterial keratitis)
Recurrent erosion
a.
E.
Good fit
Management
i.
Lubricants and hypertonic solutions
ii.
Stromal puncture/superficial keratectomy (see Recurrent erosion section)
Superficial corneal scarring associated with delayed epithelial healing

A.
Microbial keratitis
B.
Recurrent erosions especially in those caused by fingernail or paper cut injury, or by vegetative
trauma
C.
D.
Corneal scarring

A.
334
AAO 2014-2016
B.
1.
2.
AAO, Focal Points: Corneal Complications of Contact Lens, Module #2, 1993.
3.
Goyal R, Shankar J, Fone DL, et al. Randomised controlled trial of ketorolac in the management of
corneal abrasions. Acta Ophthalmol Scand. 2001;79:177-9.
4.
Eke T, Morrison DA, Austin DJ. Recurrent symptoms following traumatic corneal abrasion:
prevalence, severity, and the effect of a simple regimen of prophylaxis. Eye 1999;13:345-7.
5.
Morrison D, Eke T, Austin DJ. High prevalence of recurrent symptoms following uncomplicated
traumatic corneal abrasion. Br J Ophthalmol. 1998;76:108-11.
6.
Kaiser PK, Pineda R 2nd. A study of topical non steroidal anti-inflammatory drops and no pressure
patching in the treatment of corneal abrasions. Corneal Abrasion Patching Study Group.
Ophthalmology. 1997;104:1353-9.
7.
Kaiser PK. A comparison of pressure patching versus no patching for corneal abrasions due to
trauma or foreign body removal. Corneal Abrasion Patching Study Group. Ophthalmology.
1995;102:1936-42.
335
AAO 2014-2016
Corneal and corneoscleral laceration

I.

A.

1.
B.

1.
C.
D.
E.
Occurs due to blunt or penetrating globe trauma
Incidence is common in industrial and farm workers, and in young males

1.
Mechanism and nature of injury (specifically time and circumstances of injury, suspected
composition of intraocular foreign body, high or low-velocity injury, use of eye protection)
2.
Previous history of ocular trauma or surgery
3.
Level of acuity prior to injury
4.
Medications
5.
Time of last oral intake
6.
Status of tetanus prophylaxis

1.
Clinically evident corneal, corneoscleral, or scleral laceration
2.
Uveal prolapse
3.
Flat or shallow anterior chamber
4.
Hypotony
5.
Aqueous humor efflux as detected by Seidel test
6.
Iris defect, irregular pupil, or unilateral cataract after trauma may indicate occult corneal or scleral
laceration and possibly an intraocular foreign body
7.
Blood in anterior chamber (hypopyon)
8.
Subconjunctival hemorrhage may hide underlying scleral laceration

1.
Assess extent of injury to formulate medical or surgical management

a.
Partial thickness versus full thickness
b.
Seidel testing for smaller lacerations
c.
Length and depth of laceration
d.
Iris prolapse
e.
Lens injury
336
AAO 2014-2016
II.
2.
Perform ophthalmic evaluation to rule out concomitant ocular injury (e.g., traumatic optic
neuropathy, intraocular foreign body)
3.
Evaluate other eye
4.
Determine need for radiologic imaging (x-ray or CT scan; MRI if metallic foreign body not
suspected)
Describe patient management in terms of treatment

A.
B.
C.

1.
Use protective shield
2.
Bandage soft contact lens for small lacerations with minimal wound gape
3.
Aqueous suppressant (e.g. carbonic anhydrase inhibitor)
4.
Application of tissue adhesive has a role for pinpoint perforations
Define surgical therapy options:

1.
Use protective shield
2.
Avoid eating or drinking by patient during preoperative period
3.
Consider facial nerve anesthesia to reduce eyelid squeezing until definitive repair
4.
Consider obtaining cultures of external eye (See Repair of corneal laceration and suture closure of
corneal wound)
5.
Possible need for corneal tissue if portion of cornea is missing from wound
Medications
1.
Consider systemic and/or subconjunctival and/or topical antimicrobial prophylaxis
2.
Pain medication
3.
Tetanus prophylaxis may be applicable depending on mechanism of laceration
III.
List the complications of treatment, their prevention and management (See Repair
of corneal laceration and suture closure of corneal wound)
IV.

A.
Wound leak
B.
Infectious corneal ulcer
C.
Endophthalmitis
D.
Corneal scarring
E.
F.
Retinal detachment
337
AAO 2014-2016
V.
G.
Cataract
H.
Iris damage

A.
Stress importance of compliance with medications
B.
Recommend physical restrictions, importance of eye protection, and plans for further care
C.
Discuss expectations for post-operative recovery and visual rehabilitation depending on nature
and extent of the injury
1.
2.
AAO, Focal Points: Repair of the Traumatized Anterior Segment, Module #1, 1992.
338
AAO 2014-2016
Corneal perforation
I.

A.

1.
2.
Injury
a.
Direct tissue destruction from mechanical or chemical trauma
b.
Perforating foreign body
Ocular surface disorder

a.
B.
C.
D.
II.
Breakdown of corneal epithelium with decreased barrier protection
3.
Immune-mediated corneal ulceration
4.
Corneal inflammation and necrosis

a.
Microbial invasion and exotoxins
b.
Infiltration of leukocytes
c.
Corneal proteinases

1.
Recent change in symptoms with "gush of fluid" or increased tearing
2.
Presence and type of preexisting corneal or ocular surface disorder
3.
Recent ocular trauma
4.
Current ophthalmic and systemic medications

1.
Flat or shallow anterior chamber (compare with other eye)
2.
Low intraocular pressure
3.
Positive Seidel test
4.
Size, configuration, and topographic location of corneal perforation
5.
Folds in Descemet membrane emanating from the thinned area
6.
Iris prolapse or plugging
7.
Status of crystalline lens or intraocular lens
1.
If suspect corneal infection, consider obtaining corneal specimen for cultures
2.
If suspect systemic disease, obtain serological assessment for connective-tissue disease
339
AAO 2014-2016
A.
III.
IV.
Infection (bacteria, fungi, protozoa, or viruses) is the most common cause of corneal perforation
1.
Bacterial keratitis is most common infectious etiology, such as Pseudomonas aeruginosa
2.
Fungal keratitis may lead to corneal perforation by rapid progression (e.g., Fusarium solani) or
slow necrosis (e.g., Scedosporium apiospermum)
3.
Corneal perforation may complicate course of Acanthamoeba keratitis
4.
Corneal perforation may occur during progressive herpes simplex virus stromal keratitis or
following zoster keratitis with loss of corneal sensation
B.
Trauma (blunt, sharp, surgical, chemical, thermal)
C.
Connective-tissue disorder or systemic ischemic vasculitis (rheumatoid arthritis, systemic lupus

erythematosus, rosacea, atopic disease, Wegener granulomatosis)
D.
Xerosis (Sjgren syndrome, Stevens-Johnson syndrome, mucous membrane pemphigoid,

vitamin A deficiency)
E.
Exposure keratopathy (cranial nerve (CN) VII palsy, thyroid ophthalmopathy, ectropion,
lagophthalmos)
F.
G.
Cornea degeneration (Terrien marginal degeneration, keratoconus, keratoglobus, pellucid

marginal degeneration)
H.
Mooren ulcer
I.
Medication (topical corticosteroids, topical nonsteroidal antiinflammatory drugs, anesthetic)

A.
Descemetocele
B.
Impending corneal perforation
C.
Corneal melt
D.
Corneal ulceration
E.
Partial thickness defect in cornea
F.
Dellen

A.
B.

1.
Aqueous humor suppression
2.
Patch eye and shield orbit
3.
Bandage (therapeutic) soft contact lens
4.
Cycloplegia and mydriasis

1.
Application of tissue cyanoacrylate glue to cornea
340
AAO 2014-2016
C.
2.
Corneal sutures
3.
Corneal patch graft

b.
Lamellar keratoplasty
4.
Tarsorrhaphy for impending perforation associated with non-healing epithelial defects
5.
Amniotic membrane patch graft (small perforation)
Patient follow-up
1.
V.
a.
Follow patient closely until the integrity of the globe is re-established

A.
Disease-related complication
1.
Failure to seal wound
2.
Progression of thinning
3.
Progression or development of corneal infiltrate or endophthalmitis

a.
B.
C.
Patients should receive antibiotic prophylaxis to prevent infection

1.
Corneal pannus formation
2.
Corneal edema
3.
Development of corneal infiltrate
Tissue adhesive
1.
Loosening of glue
2.
3.
4.
Effects of glue on adjacent ocular structures

a.
Toxicity to endothelium
b.
Toxicity to lens- cataract formation
c.
Symblepharon
5.
Corneal sutures
6.
Loosening of sutures
7.
8.
Vascularization
9.
Induced astigmatism
341
AAO 2014-2016
D.
E.
VI.
1.
Graft rejection (epithelial rejection, subepithelial infiltrates, stromal rejection)
2.
Interface opacities
3.
Vascularization of the interface
4.
5.
Inflammatory necrosis of the flap
Penetrating keratoplasty- tectonic or optical, patch grafts

1.
Graft rejection
2.
Graft failure
3.
4.
5.
Glaucoma

A.
Loss of vision
B.
Corneal scarring
C.
D.
Increasing size of the perforation
E.
Endophthalmitis
F.
Choroidal detachment
G.
Cataract

A.
Close follow-up until the tectonic integrity of the globe is re-established
B.
Advise patients to call as soon as possible should they develop increasing pain, loss of vision,
increasing tearing, increased redness or a gush of fluid
C.
Shield/eye protection at all times
D.
No eye rubbing
E.
Minimize sneezing or coughing
F.
Limited activity
G.
Topical antibiotics may be considered
1.
342
AAO 2014-2016
2.
AAO, Focal Points: Scleritis and Episcleritis: Diagnosis and Management, Module #9, 1995, p.9.
343
AAO 2014-2016
Corneal edema
I.

A.

1.
Decreased corneal endothelial pump and/or barrier function

a.
b.
Trauma
i.
Surgical (See Postsurgical corneal edema) (See Surgical injury of Descemet

membrane and corneal endothelium)
ii.
Nonsurgical
iii.
Birth trauma
Infection
i.
c.
d.
e.
Keratitis
i)
Viral
ii)
Bacterial
iii)
Acanthamoeba
iv)
Fungal
ii.
Endotheliitis (Herpes simplex)
iii.
Endophthalmitis
Immune-mediated
i.
Anterior uveitis
ii.
Corneal endothelial graft rejection
Hypoxia
i.
Contact lens wear
ii.
Anterior segment ischemia
Spontaneous tears in Descemet membrane

i.
Keratoconus with hydrops
ii.
Congenital glaucoma
iii.
(Haab striae)
f.
Toxicity of topical or intraocular pharmacologic agents
g.
Endothelial dystrophies and dysgeneses
i.
Fuchs dystrophy
ii.
Posterior polymorphous dystrophy

344
AAO 2014-2016
h.
2.
3.
B.
iii.
Congenital hereditary endothelial dystrophy
iv.
Iridocorneal endothelial syndrome
Systemic medications (e.g., Amantadine)
Disrupted corneal epithelial barrier function

a.
b.
Recurrent erosion
c.
Chronic corneal epithelial defect secondary to neurotrophic, exposure keratopathy
d.
Chemical injury
e.
Thermal injury
Increased intraocular pressure (IOP)

1.

a.
Duration
b.
Laterality
i.
c.
Timing
i.
2.
C.
Worse in morning in early stages of endothelial dysfunction, related to sleep hypoxia

and decreased surface evaporation
Pain and foreign body sensation related to epithelial edema, bulla(e)

a.
3.
Dystrophies, dysgeneses usually bilateral, except iridocorneal endothelial syndrome
May subside over time with development of subepithelial fibrosis
Other specific symptoms vary with etiology

1.
Corneal edema, with increasing corneal thickness

a.
Endothelial dysfunction
i.
b.
Epithelial barrier disruption

i.
c.
Edema is first evident in the posterior stroma with Descemet folds, progresses to
full-thickness stromal edema, then microcystic epithelial edema, and finally epithelial
bullae
Edema develops first in the anterior stroma, may be full-thickness with large epithelial
defects or in the presence of toxins or inflammatory mediators
Increased intraocular pressure (IOP)

i.
Epithelial edema develops, stroma remains compact if endothelial function is intact
2.
Epithelial bullae
3.
Subepithelial opacification, fibrosis may develop secondary to chronic epithelial edema
345
AAO 2014-2016
4.
D.
Other specific findings vary with specific etiology

1.
Specular microscopy
a.
b.
c.
2.
II.
III.
Fuchs dystrophy
i.
Cornea guttae
ii.
Pleomorphism
iii.
Polymegathism

i.
Dark/light cell border/body reversal
ii.
Abrupt border between normal and abnormal areas

i.
Vesicles
ii.
Linear parallel tracks
Corneal pachymetry

A.
Increased IOP
B.
Intraocular inflammation
C.
Other risk factors vary according to etiology

A.
Corneal stromal scarring

1.
B.
C.
Prior trauma, infection, inflammation
Corneal stromal inflammation, infiltrates

1.
Microbial keratitis
2.
Immune-mediated keratitis
Congenital corneal opacification

1.
Peters anomaly
2.
Sclerocornea
3.
Congenital hereditary stromal dystrophy
4.
Intrauterine infection
5.
Inborn errors of metabolism
346
AAO 2014-2016
IV.
a.
Mucopolysaccharidoses
b.
Hyperlipoproteinemias
c.
Mucolipidoses

A.

1.
a.
Topical hyperosmotic agents

i.
B.
b.
Gentle use of hair dryer to increase evaporation
c.
Low water-content therapeutic contact lens for epithelial edema
d.
Lowering IOP may reduce edema when endothelial dysfunction is the cause of corneal
edema
2.
Epithelial defects (See Traumatic corneal abrasion) (See Neurotrophic keratopathy) (See
Exposure keratopathy)
3.
Increased intraocular pressure - treat accordingly

1.
a.
Repair Descemet's detachment if present (See Surgical injury of Descemet membrane and
corneal endothelium)
i.
b.
V.
2% or 5% NaCl ointment at bedtime, drops during day (ointment during day if severe
edema)
Endothelial keratoplasty
Pain relief without restoration of optical quality

i.
Conjunctival flap
ii.
iii.
Cautery of corneal surface
iv.
Anterior stromal micropuncture
2.
Epithelial defects (See Traumatic corneal abrasion) (See Neurotrophic keratopathy) (See
Exposure keratopathy) (See Amniotic membrane transplantation)
3.
Increased IOP - treat accordingly

A.
Endothelial replacement (See Penetrating keratoplasty)
B.
Conjunctival flap
347
AAO 2014-2016
C.
VI.
1.
Microbial keratitis
2.
Flap or graft retraction

a.
Prevention via careful suturing
b.
Treatment via re-grafting or re-suturing

1.
Microbial keratitis
2.
Corneal melting
3.
Corneal perforation (See Corneal perforation)

A.
Secondary infection, melting due to loss of epithelial barrier
B.
Corneal scarring

A.
B.
Proper use of hairdryer to reduce corneal edema
C.
1.
2.
AAO, Corneal Dystrophies & Degenerations: A Molecular Genetics Approach, 2003.
348
AAO 2014-2016
Postsurgical corneal edema

I.

A.

1.
Intraoperative compromise of endothelial pump and/or barrier function

a.
2.
i.
Surgical instruments
ii.
Crystalline lens fragments
iii.
Intraocular lens or haptics
iv.
Phacoemulsification tip
v.
Iris hooks
vi.
Capsular tension rings (CTR)
b.
Descemet's membrane detachment
c.
Ultrasonic energy from phacoemulsification tip
d.
Thermal burn from phacoemulsification tip
e.
Hydrostatic pressure from copious irrigating solution or elevated bottle
f.
Toxicity of pharmacologic agents, capsule staining solutions, irrigating solutions (toxic

anterior segment syndrome) (TASS)
g.
Gas bubble
h.
Primary graft failure in corneal transplant recipients
Postoperative compromise of endothelial pump and barrier functions

a.
3.
Mechanical trauma - contact between endothelium and:
Mechanical trauma - contact between endothelium and:

i.
Vitreous
ii.
Intraocular lens (IOL)
b.
c.
Endophthalmitis
d.
Anterior segment ischemia after retina, strabismus surgery
e.
Endothelial rejection in corneal transplant recipients
f.
Preoperative history Fuchs' endothelial dystrophy
g.
Preoperative history low endothelial cell count
Disrupted corneal epithelial barrier function

a.
Intraoperative corneal abrasion

349
AAO 2014-2016
b.
4.
B.
C.
Toxicity of irrigating solutions, pharmacologic agents
Increased intraocular pressure

a.
Pupillary block
b.
Retained ophthalmic viscosurgical device (OVD) (viscoelastic)
c.
Retained lens material

1.
Post-cataract surgery edema remains the leading indication for corneal transplant surgery in the
United States
2.
Infrequent clusters due to:

a.
Toxicity of irrigating solutions, pharmacologic agents
b.
Introduction of new surgical techniques, technologies
3.
Diabetic patients may be more prone than non-diabetic patients to develop postsurgical corneal
edema following vitrectomy surgery
4.
Complicated cataract extraction

1.
Pre-existing corneal endothelial disease or compromise
2.
History of diabetes mellitus
3.
Procedure performed
4.
a.
Length of procedure, phacoemulsification time and power
b.
Density of lens nucleus
c.
Type and volume of irrigating solution used
d.
Topical and intracameral pharmacologic agents used
e.
OVD use and removal technique
f.
Re-usable cannulas or tubing
g.
Iris hooks, CTRs
h.
Complications encountered
i.
Endothelial contact with instruments, IOL
ii.
Vitrectomy
iii.
Retained lens material
Postoperative course
a.
Onset of edema
i.
Immediate
i)
Typical after cataract surgery

350
AAO 2014-2016
ii)
ii.
D.
Delayed
i)
May occur after cataract surgery in patients with previous endothelial

compromise or relatively mild intraoperative cell loss
ii)
Endothelial rejection or late failure after corneal transplant
b.
Intraocular pressure (IOP)
c.

1.
2.
3.
a.
Posterior stromal edema and Descemet folds in mild cases
b.
Full-thickness stromal edema with increasing severity
c.
Microcystic epithelial edema with greater severity
d.
Epithelial bullae in most severe cases
Epithelial barrier disruption

a.
Edema develops first in the anterior stroma
b.
May be full-thickness with large epithelial defects or in the presence of toxins or

inflammatory mediators
Increased IOP
a.
4.
II.
Typical following corneal transplant; may also indicate primary graft failure
Epithelial edema develops, stroma remains compact if endothelial function is intact
Findings specific to other possible etiologies listed above:

a.
Descemet membrane detachment
b.
Retained lens fragments
c.
Pupillary block
d.
Elevated IOP
e.
Marked intraocular inflammation
f.
Epithelial defect
g.
Presence of thermal burn at site of incision
h.
Iris atrophy or pupillary abnormalities (TASS)
i.
Endophthalmitis - profound visual loss, hypopyon, pain

A.
Preoperative
1.
Preexisting endothelial disease or compromise
351
AAO 2014-2016
B.
b.
c.
Prior intraocular surgery
d.
e.
Nonsurgical trauma
f.
History of severe intraocular inflammation
Dense nuclear sclerosis
3.
Narrow anterior chamber depth
4.
Glaucoma
5.
Diabetes mellitus
Intraoperative
1.
Irrigating solution additives
2.
Intraocular delivery of pharmacologic agents
3.
Reuse of cannulas, especially for OVD
4.
Reuse of irrigation tubing
5.
Mechanical trauma to endothelium
7.
III.
Fuchs endothelial dystrophy or endothelial guttae
2.
6.
C.
a.
a.
Inadequate OVD use
b.
Prolonged ultrasound time during phacoemulsification
c.
Significant air bubbles in anterior chamber during phacoemulsification
d.
Contact with instruments, lens fragments, or IOL
Thermal burn during phacoemulsification

a.
Tight incision
b.
Inadequate irrigation fluid flow
Incomplete OVD removal
Postoperative
1.
Excessive intraocular inflammation
2.
Marked IOP elevation

A.

1.
Treat epithelial defects
2.
Control inflammation with topical, rarely systemic, corticosteroids
352
AAO 2014-2016
B.
3.
Control IOP with topical and systemic pressure lowering agents
4.
Topical 5% NaCl ointment at bedtime, drops during day (for epithelial edema)
5.
Drying of ocular surface (hair dryer) for epithelial edema
6.
Low water-content therapeutic contact lens for epithelial edema
7.
Watchful waiting to see if edema clears over 3-4 months

1.
a.
Aqueous release via paracentesis (plus medications)
b.
Filtering surgery if necessary
c.
Peripheral iridotomy or iridectomy for pupillary block
d.
YAG laser of vitreous face or pars plana vitrectomy for aqueous misdirection
2.
Vitrectomy for broad-based vitreous/endothelial contact and retained lens material
3.
Repair Descemet membrane detachment (See Surgical injury of Descemet membrane and
corneal endothelium)
4.
Endothelial replacement for optical correction of persistent edema
5.
IV.
Control IOP
a.
b.
Endothelial Keratoplasty (See Endothelial keratoplasty)
Pain relief without restoration of optical clarity

a.
Conjunctival flap
b.
Amniotic membrane graft (oriented basement membrane side up) or patch (oriented
basement membrane side down) may provide temporary relief of pain (See Amniotic
membrane transplantation)
c.

A.
Endothelial replacement (See Penetrating keratoplasty)
B.
Conjunctival flap, amniotic membrane graft
C.
1.
Microbial keratitis
2.
Flap or graft retraction

a.
Prevention via careful suturing
b.
Treatment via re-grafting or re-suturing

1.
Microbial keratitis
353
AAO 2014-2016
2.
V.
VI.
Corneal melting, perforation (See Corneal perforation)

A.
Secondary infection, melting due to loss of epithelial barrier
B.
Pain secondary to ruptured bullae
C.
Corneal scarring

A.
B.
Proper use of hairdryer to reduce corneal edema
C.
1.
2.
AAO, Focal Points: Penetrating Keratoplasty, Module #6, 1992.
354
AAO 2014-2016
Surgical injury of Descemet membrane

and corneal endothelium
I.

A.

1.
2.
B.

a.
Traumatic injury associated with tear and separation of Descemet membrane
b.
Often associated with manipulation of wound

i.
Injection of balanced salt solution
ii.
Ophthalmic viscosurgical device (OVD) (viscoelastic)
iii.
Insertion of instruments into the anterior chamber,
iv.
Lens implantation
Endothelial damage
a.
Mechanical trauma secondary to surgical instruments, lens fragments, and intraocular lens
(IOL)
b.
Ultrasonic energy from phacoemulsification tip
c.
d.
Toxicity from pharmacologic agents and irrigating solutions

1.
Preexisting corneal endothelial disease or compromise
2.
Details of surgery
3.
a.
Length of procedure, phacoemulsification time and power
b.
Density of lens nucleus
c.
Type and volume of irrigating solution
d.
Type and placement of IOL
e.
Topical and intracameral pharmacologic agents
f.
OVD use and removal technique
g.
Reusable cannulas or tubing
h.
Complications including endothelial contact with instruments or intraocular lens, vitrectomy,

or retained lens material
Postoperative course
a.
Immediate onset of edema

355
AAO 2014-2016
b.
C.

1.
2.
3.

a.
Sharply demarcated area of edema
b.
Descemet scroll or tear often visible
c.
Often found near entrance wound
d.
Diagnosis and determining extent of detachment may be aided by UBM or OCT
Endothelial injury and dysfunction

a.
Posterior stromal edema and Descemet folds in mild cases
b.
Full-thickness stromal edema with increasing severity
c.
Microcystic epithelial edema with greater severity
d.
Epithelial bullae in most severe cases
Decreased vision
a.
II.
May have pain, tearing, and light sensitivity

A.
B.
III.
Associated visual loss if central cornea involved
Findings which may contribute to complicated cataract extraction

1.
Shallow anterior chamber
2.
Dense nuclear sclerosis
Surgical technique - mechanical trauma to Descemet membrane and endothelium

1.
Inadequate OVD use
2.
Prolonged phacoemulsification time
3.
Contact with instruments, lens fragments, or IOL
4.

A.
B.
Toxic anterior segment syndrome (TASS)

1.
Intense inflammatory reaction which may result in marked corneal edema
2.
Often secondary to toxins or chemical residue on instruments or in irrigating solutions
3.
Specific etiology should be established to avoid other cases
Corneal edema secondary to other factors

1.
Elevated intraocular pressure (IOP)
356
AAO 2014-2016
2.
IV.
Keratouveitis (i.e., herpetic disciform endotheliitis)

A.

1.
Observation
a.
B.
2.
Small 1-2 mm peripheral detachments can be observed and typically do not progress to involve
the central cornea
3.
Trial with intensive topical corticosteroids
4.
Symptomatic trial of hypertonic saline drops (Muro 128 2% or 5%)

1.
2.
V.

a.
Injection of air or gas (sulfur hexafluoride SF6 or C3F8 perfluoropropane) to tamponade

detachment and reposition membrane to the posterior corneal stroma
b.
Face up positioning (lay on back)
c.
Suture Descemet membrane - full-thickness suture
d.
Penetrating keratoplasty or endothelial keratoplasty for recalcitrant detachments
Endothelial injury with subsequent persistent corneal edema and decompensation

a.
b.

A.
1.
B.
VI.
May resolve spontaneously
Injection of gas
a.
Elevated IOP from large bubble resulting from pupillary block
b.
Minimal risk of endophthalmitis

1.
Limit size of gas bubble (60% fill)
2.
Mydriasis (See Penetrating keratoplasty and Endothelial keratoplasty)

A.
B.
Subepithelial bullae with advanced corneal decompensation with secondary erosions and
357
AAO 2014-2016
epithelial breakdown resulting in secondary stromal scarring and risk of infectious corneal ulcer
C.
Chronic pain

A.
Stress education of disease process as well implications of treatment options including

intracameral gas injection and penetrating keratoplasty
B.
1.
2.
AAO, Focal Points: Clinical Evaluation of the Corneal Endothelium, Module #8, 1986.
358
AAO 2014-2016
Punctal occlusion
I.

A.
Indications
1.
2.
II.
III.
IV.
Treat ocular surface disorders associated with abnormal tear film

a.
b.
c.
d.
Contact lens intolerance related to tear insufficiency
Prolong retention and reduce systemic absorption of topically administered drugs

A.
Slit-lamp biomicroscopic examination with dye staining
B.
Schirmer testing (optional)

A.
Topical therapy: lubricants and/or cyclosporine
B.
Increase humidity: room humidifier, moisture shields, occlusive goggles
C.
D.
Tarsorrhaphy
Describe the instrumentation, anesthesia and technique

A.
Temporary
1.
B.
Temporary intracanalicular plug

a.
Dissolvable collagen plugs can be inserted into one or more puncta
b.
Used to determine whether bothersome epiphora might occur in a patient with mild to
moderate aqueous tear deficiency before proceeding to a non-dissolving plug or to punctal
cauterization
Permanent
1.
Reversible
a.
Topical anesthesia
b.
Insert silicone or polymer plugs into punctum with inserter
359
AAO 2014-2016
2.
c.
Plug diameter should be judged according to the size of the punctum
d.
Used to treat aqueous tear deficiency and other chronic ocular surface disorders
Irreversible
a.
V.
Punctal cauterization
i.
Topical anesthesia and/or infiltrative anesthesia
ii.
Canaliculus and punctum cauterized with thermal cautery or radiofrequency unit
iii.
Used to treat severe aqueous tear deficiency

A.
Epiphora
1.
2.
Prevention
a.
Reversible procedure prior to permanent occlusion
b.
Occlude 1 punctum at a time in each eye
Treatment
a.
B.
Punctum re-opens
1.
2.
C.
Prevention
a.
Use of largest plug that will fit
b.
Intracanicular plugs
c.
Avoidance of laser to occlude punctum (high failure rate)
Treatment
a.
Larger plug
b.
Cauterize punctum
Inflammation
1.
Treatment
a.
D.
Removal of plug
Removal of plug
Canaliculitis or dacryocystitis
1.
Prevention
a.
2.
Risk of lacrimal sac infection may be higher with intracanicular plug or occlusion of both
puncta but still uncommon
Treatment
a.
Removal of plug
b.
Topical and/or oral antibiotics
360
AAO 2014-2016
VI.
Describe the follow-up care

A.
Slit-lamp biomicroscopic evaluation several weeks after procedure
VII. Describe appropriate patient instructions (post-op care, vision rehabilitation)

A.
Avoid rubbing inner canthus (if silicone plug with exposed head)
B.
Instructions on continued lubrication use
C.
Describe expectations for improved comfort
D.
Instructions regarding contact lens use, if appropriate
1.
2.
AAO, Ophthalmic Technology Assessment: Punctal Occlusion for the Dry Eye. Ophthalmology
1997;104:1521-1524.
3.
Hamano T. Lacrimal duct occlusion for the treatment of dry eye. Semin Ophthalmol 2005;20:71-4.
Review.
4.
Altan-Yaycioglu R, Gencoglu EA, Akova YA, et al. Silicone versus collagen plugs for treating dry
eye: results of a prospective randomized trial including lacrimal scintigraphy. Am J Ophthalmol
2005;140:88-93.
5.
361
AAO 2014-2016
Tarsorrhaphy
I.

A.
Indications
1.
B.
III.
a.
Neurogenic exposure keratopathy (Cranial Nerve (CN) VII palsy)
b.
Neurotrophic corneal ulceration (CN V deficit, herpes simplex virus (HSV) or varicella zoster
virus (VZV) keratitis)
c.
Severe keratitis sicca
d.
Progressive corneal thinning or descemetocele
e.
f.
Eyelid abnormalities (e.g., trauma, previous eyelid surgery, cicatricial disease, ectropion and
floppy eyelid syndrome)
g.
Exposure (thyroid eye disease, orbital tumors)
Contraindications
1.
II.
Severe, recalcitrant keratopathy, persistent epithelial defect, or corneal thinning resulting from:
Active microbial (bacterial or fungal) keratitis (although tarsorrhaphy may be necessary in some
cases after the infection is controlled)
Describe the pre procedure evaluation

A.
Visual acuity testing to document vision
B.

1.
Documenting keratopathy location
2.
Examining palpebral conjunctiva for foreign bodies or keratinization

a.
External examination to document eyelid abnormalities (e.g., lagophthalmos, eyelid

retraction, and proptosis)
b.
Assessment of corneal sensitivity
c.
Determination of what type of tarsorrhaphy is necessary (permanent vs. temporary) and

extent of tarsorrhaphy (lateral vs. medial vs. central vs. total)
List the alternatives to the procedure

A.
Frequent lubrication with ointments and artificial tears
B.
C.
Amniotic membrane grafting
362
AAO 2014-2016
IV.
D.
Temporary eyelid taping
E.
Botulinum toxin injection to induce a temporary ptosis
F.
Moisture chambers or cellophane eye patching
G.
Other eyelid surgery as indicated to correct ectropion, lagophthalmos, or eyelid retraction,

including tarsal strip procedure and gold eyelid weights

A.
B.
C.
V.
Temporary suture
1.
Local anesthesia
2.
Place horizontal mattress sutures (at least 2) through upper and lower lids and tie over bolsters on
skin
Temporary glue
1.
Topical anesthesia
2.
Manually oppose upper and lower eyelids with slight eversion and apply cyanoacrylate glue to lid
margin and lashes
Permanent
1.
Local anesthesia
2.
De-epithelialize portion of eyelid margin for adherence
3.
Place vertical incision in upper and lower tarsus
4.
Place absorbable sutures in horizontal mattress fashion joining upper and lower lid tarsal grooves
5.
Advanced tarsorrhaphy techniques (Oculoplastics referral): e.g. mobilization of tarsoconjunctival

flaps
List the complications of the procedure, their prevention, and management

A.
Temporary
1.
Premature loosening of sutures
2.
Suture infection
a.
Prevention
i.
B.
Antibiotic ointment
Permanent
1.
Tarsorrhaphy dehiscence (prevention: leave sutures for longer or use nonabsorbable sutures)
2.
Wound infection
a.
Prevention
i.
363
AAO 2014-2016
3.
Trichiasis or eyelid abnormalities after tarsorrhaphy is severed

a.
Prevention
i.
4.
Corneal epithelial defects or corneal ulceration from loose or inappropriately placed sutures or
from misdirected eyelashes resulting from the procedure
a.
VI.
Meticulous technique when performing tarsorrhaphy
Prevention
i.
Removal of loose sutures
ii.
Epilation of eyelashes
Describe follow up care

A.
Regular follow-up to monitor corneal and tarsorrhaphy status

A.
Instructions on the use of antibiotic ointment to the eyelids following tarsorrhaphy
B.
Instruction on the use of lubricants and/or topical antibiotics, depending on the underlying
problem
C.
Instruction on importance of regular follow-up
1.
2.
AAO, Focal Points: Management of Eyelid Burns, Module #2, 1990, p.3, 8.
364
AAO 2014-2016
Conjunctival biopsy
I.
List the indications

A.
For diagnosis not achieved by another means

1.
2.
Neoplasia affecting the conjunctiva

a.
Ocular surface squamous neoplasia
b.
Sebaceous carcinoma
c.
Lymphoma or leukemia
d.
Metastatic tumor
Chronic cicatrizing or ulcerative conjunctivitis

a.
3.
4.
5.
B.
II.
Conjunctival nodule or inflammation

a.
Sarcoidosis
b.
Foreign-body granuloma
c.
Fungal or parasitic lesion
d.
Cat scratch disease
e.
Microsporidiosis
Abnormal conjunctival pigmentation

a.
Primary acquired melanosis in Caucasians
b.
Primary acquired melanosis in any individual with suspicious characteristics (See Primary
acquired melanosis of the conjunctiva)
c.
Melanoma (See Melanoma of the conjunctiva)
Inherited metabolic disorder

a.
Fabry disease and other lysosomal storage disorders
b.
Cystinosis
For management
1.
Excisional biopsy of conjunctival lesion
2.
Management of chronic conjunctivitis

a.
b.
Conjunctivochalasis
365
AAO 2014-2016
III.
IV.
V.
VI.
A.
Record conjunctival abnormalities, including dimensions of conjunctival mass
B.
Review available tests and radiographs if systemic disease is a reason to perform conjunctival
biopsy

A.
Conjunctival scraping (exfoliative cytology) or impression cytology
B.
Biopsy of another site for systemic disorder
C.
Medical rather than surgical therapy for ocular surface lesion

A.
Consider preoperative antiseptic or antibiotic
B.
Provide topical or infiltrative anesthesia of planned biopsy site
C.
Use forceps and scissors to resect portion of conjunctiva that incorporates lesion, generally
acquiring at least 3 mm2
D.
Place biopsy specimen in appropriate transport medium or fixative

A.
Damage to adjacent tissues
B.
Conjunctival scarring or symblepharon
Describe the considerations of interpretation of this diagnostic procedure

A.
Conjunctival tissue is thin and flimsy, often curling when placed into liquid, so lay specimen flat
by placement onto absorbent paper and transfer mounted specimen into fixative
B.
If orientation is important, then identify margin and explain which edge is tagged
C.
Give laboratory sufficient information to determine the appropriate examination method
1.
2.
1996, p. 6, 10-11.
3.
AAO, Focal Points: Nonpigmented Lesions of the Ocular Surface, Module #9, 1996, p.8-10, 12.
366
AAO 2014-2016
Pterygium excision
I.

A.
Indications
1.
II.
III.
IV.
Decreased vision secondary to pterygium

a.
Due to the lesion approaching the visual axis
b.
Due to induced regular or irregular astigmatism
c.
Due to disrupted tear film
2.
Visual side effects such as glare and halos around lights or difficulty driving at night
3.
Progression of the lesion toward the visual axis
4.
Restriction of motility/diplopia
5.
Persistent discomfort
6.
Persistent/recurrent inflammation
7.
Cosmesis
8.
9.
To rule out malignant process if suspicious features are present

A.
Refraction
B.
Assessment of tear film
C.
Motility evaluation
D.
Slit-lamp biomicroscopy
E.
Consider corneal topography

A.
Observation
B.
Ocular lubricants and anti-inflammatory agents to reduce discomfort and erythema

A.
Instrumentation
1.
Standard anterior segment instruments are used under the operating microscope
367
AAO 2014-2016
2.
B.
C.
A diamond burr may be of benefit in smoothing a rough corneal surface after lesion removal
Anesthesia
1.
Anesthesia is partially dependent on the procedure chosen.
2.
For simple excision with bare sclera (not recommended) or with conjunctival closure, topical
and/or subconjunctival anesthetic may be sufficient
3.
Peribulbar anesthetic injection helpful to reduce blepharospasm
Technique
1.
The pterygium is resected by incising the body of the lesion and dissecting it at the limbus and by
avulsion or superficial dissection of the head from the cornea
a.
This can also be carried out in the reverse order by removing the corneal portion of the
lesion first
b.
Dissection should remove subconjunctival fibrovascular tissue while sparing as much of the
conjunctiva as possible.
c.
Repair of the defect left in the conjunctiva is the area of greatest variability. Options include:
i.
Free conjunctival autograft

i)
A thin free conjunctival piece is dissected from the superior bulbar area where
it has been protected from sunlight exposure
ii)
The dissection may be extended to include limbal tissue
iii)
The free graft is then placed over the area of the resection of the body of the
lesion and sutured in place
(i)
iv)
ii.
2.
V.
Suture repair of donor site is not necessary
Sliding conjunctival pedicle flap

i)
d.
Fibrin adhesive may be used to fixate the graft instead of sutures
A thin flap of conjunctiva may be dissected from above the resected area and
moved as a pedicle flap to the area of resection and sutured in place
Amniotic membrane may be used instead of conjunctiva although recurrence is more likely
At the time of the procedure, MMC may be placed over the resected area prior to covering with
conjunctival tissue
a.
Local beta irradiation has been used but has a significant risk of late scleral necrosis
b.
The appropriate concentration and duration of MMC should be used to avoid complications
of toxicity
c.
The MMC should be irrigated off thoroughly
List the complications of the therapy

A.
Recurrence
368
AAO 2014-2016
1.
Most frequent complication is recurrence of pterygium

a.
VI.
Frequency may range from over 50% for bare sclera techniques to 5 to 20% or more with
conjunctival flaps and grafts
B.
C.
Infection and necrosis of the corneoscleral bed
D.
Diplopia, strabismus
E.
Dellen associated with swollen or excessively thick conjunctival or amniotic membrane graft at
limbus
F.
Corneal and/or scleral melting with MMC or radiation
G.
Excision or lysis of medial rectus tendon if dissection of tenons is not performed carefully

A.
Postoperatively, topical corticosteroid-antibiotic combinations are used frequently and tapered

over several weeks to months
B.
Follow-up visits allow suture removal as grafted tissue becomes adherent
C.
Observation for recurrence is carried out over progressively extended periods of time
D.
Antibiotics can be discontinued once epithelial integrity has been re-established
E.
Topical corticosteroids are often continued for a few months to reduce the risk of recurrence
F.
Ocular lubrication
G.
Protection of the eye from UV exposure with sunglasses

A.
The eye may remain patched for the first day after surgery
B.
Topical medications are then begun and slowly tapered
1.
2.
AAO, Focal Points: Surgical Treatment of Pterygium, Module #12, 1996.
3.
Hirst LW. The treatment of pterygium. Surv Ophthalmol 2003;48:145-180.
4.
Mutlu FM, Sobaci G, Tatar T, et al. A comparative study of recurrent pterygium surgery: limbal
conjunctival autograft transplantation versus mitomycin C with conjunctival flap. Ophthalmology
1999;106:817-21.
5.
Chen PP, Ariyasu RG, Kaza V, et al. A randomized trial comparing mitomycin C and conjunctival
autograft after excision of primary pterygium. Am J Ophthalmol 1995 Aug;120:151-60.
6.
Frucht-Pery J, Siganos CS, Ilsar M. Intraoperative application of topical mitomycin C for pterygium
surgery. Ophthalmology 1996 Apr;103:674-7.
369
AAO 2014-2016
7.
Kucukerdonmez C, Akova YA, Altinors DD. Vascularization is more delayed in amniotic membrane
graft than conjunctival autograft after pterygium excision. Am J Ophthalmol 2007;143:245-249.
8.
Luanratanakorn P, Ratanapakorn T, Suwan-Apichon O, et al. Randomised controlled study of

conjunctival autograft versus amniotic membrane graft in pterygium excision. Br J Ophthalmol
2006;90:1476-80.
9.
Prabhasawat P, Tesavibul N, Leelapatranura K, et al. Efficacy of subconjunctival 5-fluorouracil and

triamcinolone injection in impending recurrent pterygium. Ophthalmology 2006;113:1102-9.
10.
Frucht-Pery J, Raiskup F, Ilsar M, et al. Conjunctival autografting combined with low-dose

mitomycin C for prevention of primary pterygium recurrence. Am J Ophthalmol
2006;141:1044-1050.
370
AAO 2014-2016

I.

A.
Indications
1.
2.
B.
II.
Therapeutic
a.
Pain relief
b.
Promote epithelial healing
c.
Act as a splint in the treatment of lacerations, perforations and ulcerations
d.
Protect the cornea from mechanical damage secondary to abnormalities of the eyelid
e.
Improve visual acuity by correcting irregular corneal surface
f.
Deliver medications
Clinical
a.
Corneal edema
b.
Persistent epithelial defects
c.
Noninfectious corneal ulcerations or small perforations especially those requiring

cyanoacrylate glue
d.
e.
Filamentary keratitis
f.
Keratitis sicca
g.
Neurologic conditions leading to exposure
h.
Irregular corneal surfaces secondary to anterior corneal dystrophies
i.
Corneal scars or opacities
j.
Cosmetic tinted and painted lenses
k.
Post surgical (such as after Boston Keratoprosthesis)
Relative contraindications
1.
Anatomical considerations leading to an inability to place or center a contact lens
2.
Poor patient tolerance
3.
Poor patient hygiene and lens care
Describe the pre-therapy evaluation

A.
Complete comprehensive eye examination (including lids)
B.
Determination of etiology of corneal pathology
371
AAO 2014-2016
III.
C.
Fluorescein/rose bengal staining when appropriate
D.
Evaluation of contact lens fit
List the alternatives to this therapy

A.
B.
IV.
Non-surgical
1.
Patching
2.
Lubrication
Surgical
1.
Suture tarsorrhaphy
2.
Botox tarsorrhaphy
3.
Amniotic membrane
4.
Gunderson conjunctival flap
5.
Corneal cautery for painful bullous keratopathy in blind eyes
Describe the instrumentation, anesthesia and technique- fitting considerations

A.
Base curves
1.
Flatter fit- larger base curve
B.
Lens thickness
C.
Lens diameter
1.
D.
E.
Bigger lens more stable but increases the area of tissue that depends on exchange of metabolic
nutrients through the lens
Lens materials
1.
Hydrogel
2.
Silicone
3.
Collagen
Dk/oxygen permeability and water content in Silicone Hydrogel lenses

1.
Are important considerations for therapeutic contact lenses
2.
The higher the Dk the more oxygen permeability yet the stiffer the contact lens.
F.
Expense
G.
Examples of some available lenses

1.
Food and Drug Administration (FDA) approved - (examples)

a.
Permalens Therapeutic (Cooper Vision)
b.
Acuvue Oasys (Vistakon)
372
AAO 2014-2016
2.
c.
Air Optix (Night & Day) (CIBA Vision)
d.
Purevision (Bausch & Lomb)
e.
Softform-55 EW (Unilens Corp.)
Non Food and Drug Administration (FDA) approved

a.
V.
VI.
Disposable lenses
i.
Many examples
ii.
Readily available
iii.
Inexpensive
List the complications of the therapy, their prevention and management

A.
Infection (prophylactic antibiotics often prescribed)
B.
Decentration
C.
Loss of contact lens

A.
The patient seen at slit-lamp biomicroscope within the first 24-48 hours after placement
B.
Seen at slit-lamp biomicroscope thereafter on a 1 to 2-week basis
C.
D.
Proper lens lubrication with preservative-free artificial tear drops and ointments
E.
Lens replacement schedule

A.
Therapeutic modality with possible complications
B.
If lens dislodges from eye, do not attempt to replace
C.
If lens decenters, seek proper care
D.
Use medications as directed
E.
Lens replacement on a regular basis
1.
2.
AAO, Focal Points: Postoperative Management of the PRK Patient, Module #10, 1998.
3.
373
AAO 2014-2016
Application of corneal tissue adhesive

I.

A.
B.
II.
IV.
1.
Small corneal perforation - impending or frank (less than 1-2 mm)
2.
Corneal thinning
3.
Corneal melt
4.
Wound leaks
Contraindications
1.
Large corneal perforations (over 3 mm)
2.
Severe corneal ulceration or corneal melting
3.
Inability to re-establish anterior chamber

A.
III.
Indications

1.
Measure degree of corneal thinning
2.
Assess size of corneal perforation
3.
Evaluation of corneal ulceration
4.
Anterior chamber depth

A.
Observation
B.
C.
Sutures
D.
E.
Tectonic penetrating keratoplasty

A.
Topical anesthesia
B.
Lid speculum
C.
Remove loose epithelium, necrotic tissue
D.
Keep corneal surface dry with micro-sponges
374
AAO 2014-2016
E.
F.
Available cyanoacrylate glue preparations

1.
Indermil, butyl-2-cyanoacrylate, Sherwood, Davis, and Geck, St. Louis, MO
2.
Histoacryl
3.
Nexacryl, N-butyl-cyanoacrylate, Closure Medical, Raleigh, NC
4.
Dermabond, 2-octyl-cyanoacrylate,Closure Medical, Raleigh, NC
Application of corneal glue

1.
V.
Device for delivery of appropriately small quantity of glue (e.g. tuberculin syringe with 25-30 gauge
needle, butterfly needle, lacrimal probe, plastic micro-dropper
G.
Two or three mm disc punched from plastic surgical drape may be used along with glue as
corneal patch for larger perforations
H.
Application of adhesive then await polymerization
I.

A.
B.
C.
Progression or development of corneal infiltrate
D.
Pain
E.
Decreased vision
F.
Corneal scarring
G.
Loosening of glue
H.
I.
J.

1.
2.
Toxicity to lens
a.
VI.
butyl-2-cyanoacrylate, Braun, Melsungen, Germany
Cataract formation
3.
Symblepharon
4.
Adherent leukoma between iris and cornea

A.
Monitor status of glue
B.
Monitor status of cornea
C.
Monitor for corneal ulceration
375
AAO 2014-2016
D.
Remove glue when healed or allow it to fall off as epithelialization occurs under glue
A.
Re-glue if indicated

A.
Not a Food and Drug Administration approved use
B.
No eye rubbing
C.
Protective eye shield
D.
Call if pain increases, contact lens falls out or a gush of fluid is noted
1.
376
AAO 2014-2016
Anterior stromal puncture

I.

A.
B.
Indications
1.
Post-traumatic localized corneal recurrent erosions
2.
Recurrent erosions secondary to corneal epithelial basement membrane dystrophy
3.
Chronic, painful corneal edema when corneal transplant is not indicated
Contraindications
1.
II.
Use with caution in the visual axis

A.
History
1.
Symptoms of recurrent corneal erosions (sudden onset of eye pain, usually at night or upon first
awakening, with redness, photophobia, and tearing)
a.
2.
History of previous traumatic corneal abrasion, usually secondary to a sudden sharp, shearing
injury (fingernail, paper cut, tree branch)
a.
B.
Interval from injury to recurrent erosions can vary from days to years
1.
Often intact epithelial surface at time of exam

a.
2.
May have pooling of fluorescein over affected area
If erosion present, epithelium in involved area appears heaped up and edematous

a.
III.
Episodes lasting from 30 minutes to several days depending on severity
Epithelium is loosely attached to underlying Bowman layer
3.
Retroillumination may reveal subtle corneal abnormalities
4.
Corneal epithelial dots or "microcysts" in the other eye suggest a degenerative or dystrophic cause

A.
B.
Conservative therapy
1.
Acute phase: frequent lubrication, antibiotic ointments, cycloplegia
2.
Chronic phase: nonpreserved lubricants, hypertonic saline (5% NaCl) ointments; topical
corticosteroids combined with systemic tetracyclines
Therapeutic bandage contact lens
377
AAO 2014-2016
IV.
V.
C.
Epithelial debridement with or without polishing with burr/drill
D.
Excimer laser phototherapeutic keratectomy
E.
Neodymium: yttrium argon garnet (Nd:YAG) laser reinforcement
F.
Thermal cautery

A.
A bent (usually 21,23, or 25 gauge) needle tip (to reduce the risk of full-thickness penetration of
the cornea) is used to make numerous superficial puncture wounds in the involved area and
extending slightly beyond the borders of the previously observed erosions, allowing a firm
adhesion to develop as the epithelium heals, under topical anesthesia at the slit-lamp
biomicroscope
B.
Sterile precautions

A.
B.
C.
Significant scarring, with increased risk from more aggressive/deeper punctures, may reduce
best corrected visual acuity
1.
Caution should be used if working in the visual axis
2.
If scarring begins to appear, topical corticosteroids may help to decrease severity
Infection
1.
Prophylactic antibiotic drops should be used postoperatively
2.
If microbial keratitis develops, cultures and scrapings should be performed and broad-spectrum
topical antibiotic therapy should be initiated pending culture results
Inadequate treatment of affected area

1.
VI.
Treatment may need to be repeated

A.
Topical antibiotic prophylaxis to prevent infection
B.
Topical hyperosmotics and lubricants to promote healing
C.
Possible bandage contact lens for pain control
D.
Topical non-steroidal anti-inflammatory drugs (NSAIDs) for pain control

A.
Postoperative medications and follow-up
B.
Discomfort similar to recurrent erosions may be experienced
C.
Explanation as to likelihood of the procedure to be effective and the possible need for
retreatment
378
AAO 2014-2016
1.
2.
3.
2008;27:S1-S42
4.
AAO, Focal Points: Therapy of Recurrent Erosion and Persistent Defects of the Corneal
Epithelium, Module #9, 1991, p.4.
379
AAO 2014-2016
Corneal epithelial debridement

I.

A.
B.
Indications
1.
Recurrent erosions (See Recurrent erosion)
2.
Corneal epithelial basement membrane dystrophy (for decreased vision due to epithelial
irregularities) (See Corneal epithelial basement membrane dystrophy/degeneration)
3.
Microbial keratitis (to decrease pathogen load in fungal and acanthamoeba keratitis and to enhance
corneal penetration of the topical medications)
4.
Ocular surface disease (debridement of necrotic epithelium in chemical corneal burns, corneal
intraepithelial neoplasia)
5.
Irregular or heaped-up traumatic corneal abrasion (See Traumatic corneal abrasion)
6.
Phototherapeutic keratectomy and photorefractive keratectomy
Contraindications/cautions
1.
II.
III.
Conditions predisposing to persistent epithelial defects

a.
b.
c.
Ocular surface disease

A.
Assess for risk factors for poor epithelial healing
B.
Slit-lamp biomicroscopic examination with vital dye staining
C.
Corneal topography or keratometry (to detect irregular astigmatism in some cases)
D.
Identify areas of epithelial and subepithelial involvement

A.
Hypertonic saline or lubricating ointment for recurrent erosions
B.
Pressure patch, bandage contact lens, lubrication, topical antibiotic for recurrent erosion or
traumatic corneal abrasion
C.
Anterior stromal puncture for recurrent erosions
D.
Superficial keratectomy with or without the use of diamond burr for recurrent erosions
E.
Phototherapeutic keratectomy for recurrent erosions or visual disturbance secondary to epithelial

irregularity associated with corneal epithelial basement membrane dystrophy
380
AAO 2014-2016
IV.
V.

A.
Performed at the slit-lamp biomicroscope or under the operating microscope
B.
Topical anesthesia
C.
Insert eyelid speculum, if needed
D.
Remove the loosely adherent epithelium using a cotton swab, surgical sponge, spatula, blade, or
forceps while avoiding trauma to Bowmans layer
E.
Leave the perilimbal cells intact
F.
Instill antibiotic, nonsteroidal anti-inflammatory drug, and cycloplegic eyedrops. Limit use of topical
NSAIDs to 1-3 days due to possible delay in reepithelialization
G.
Patch the eye or place a bandage contact lens
H.
Oral analgesics (over the counter and/or narcotics)

A.
Microbial keratitis
1.
Prevention
a.
2.
Treatment
a.
B.
Culture the infiltrate and treat with the appropriate topical antibiotics
Non-healing epithelial defect

1.
Prevention
a.
2.
C.
Follow sterile technique and maintain the patient on topical antibiotic until epithelium heals
Screen patients for dry eyes and other predisposing conditions such as neurotrophic
keratopathy
Treatment
a.
Increased lubrication
b.
c.
Patching of the eye
d.
Autologous serum drops
e.
Tarsorrhaphy
Corneal scarring
1.
Prevention
a.
2.
Avoid traumatizing Bowman layer when using a surgical blade to perform debridement
Treatment
a.
Topical corticosteroids may limit amount of scarring
381
AAO 2014-2016
VI.

A.
Slit-lamp biomicroscopic evaluation frequently until epithelium heals and later as needed
depending on the underlying condition

A.
Instructions on topical medication use
B.
Instructions regarding contact lens use, if appropriate
C.
Instructions on importance of follow-up
D.
Describe expectations for postoperative pain and slow, gradual improvement of comfort and visual
acuity
1.
2.
AAO, Focal Points: Therapy of Recurrent Erosion and Persistent Defects of the Corneal Epithelium,
Module #9, 1991, p.2.
382
AAO 2014-2016
Corneal biopsy
I.

A.
Indications
1.
Infectious corneal processes

a.
Deep suppurative stromal keratitis without involvement of anterior stroma
b.
Sight-threatening or progressive corneal infiltrate exhibiting one or more of the following:
c.
2.
II.
ii.
Culture negative on superficial scrapings
iii.
An atypical clinical course
Infectious crystalline keratopathy if cultures not easily obtained with superficial scraping
Suspected conjunctival neoplasms with corneal extension
Contraindications
a.
Corneal infiltrate in a region of the cornea that is very thin, making risk of perforation during
biopsy excessively high
b.
Intracameral infiltrate that is located on posterior aspect of the cornea, without posterior
stromal involvement

A.
B.
III.
Inadequate response to appropriate antimicrobial therapy
Neoplastic limbal processes

a.
B.
i.

1.
Depth of the infiltrate and overlying corneal thickness should be evaluated (pachymetry may be
useful)
2.
Confocal microscopic examination, if strongly suggestive of the presence or absence of infectious

organisms, may obviate the need for a corneal biopsy
Topically applied antimicrobial should be stopped approximately 24 hours prior to performance

of the biopsy if culture is planned

A.
Continued empiric broad-spectrum antimicrobial therapy
B.
Superficial corneal scrapings for culture and/or cytology
C.
Anterior chamber paracentesis and aspiration of infiltrate on posterior surface of the cornea
D.
Corneal imaging, including confocal microscopy or confocal scanning laser ophthalmoscopy
383
AAO 2014-2016
IV.

A.
B.
C.
Setting
1.
Patient lying supine under operating microscope
2.
If patient is very cooperative, all techniques except trap door may be performed with patient
seated at the slit-lamp biomicroscope
3.
Operative eye can be prepared and draped in sterile fashion for ocular surgery
4.
Speculum inserted into operative eye if necessary
Anesthesia
1.
Preservative-free tetracaine drops or similar anesthetic agent
2.
If needed, a cotton tip applicator soaked in lidocaine may be held at limbal position where forceps
fixation performed
Techniques for collecting material for microbial culture

1.
Cut-down
a.
2.
Suture
a.
3.
4.
D.
Supersharp blade may be used to create a vertical or oblique incision to allow sampling
using sterile needle or spatula
Braided silk suture can be passed through the infiltrate; then cut into pieces for inoculation
Trap door
a.
A flap (either triangular or rectangular) of anterior stroma is created overlying the active
edge of the deep stromal infiltrate with a supersharp or #69 blade, reflected, and the
underlying tissue is excised using forceps and a surgical blade
b.
The flap is then sutured into position with an interrupted 10-0 nylon suture
Trephination
a.
A 2 or 3 mm corneal or dermatologic trephine is used to perform a partial-thickness

trephination overlying the active edge of the deep stromal infiltrate
b.
The edge of the partially trephinated disc is carefully grasped with .12 forceps, and the base
is undermined using a blade or microscissors
c.
The stromal base may be scraped and plated onto culture media
Specimen handling and processing

1.
Corneal scrapings plated onto culture media as well as glass slides for staining
2.
Corneal tissue specimens divided and sent in fixative to histopathology laboratory and in sterile
saline to microbiology laboratory
3.
Discuss case with pathology laboratory prior to submitting specimen to alert them as to small
specimen size and to ensure use of proper container
384
AAO 2014-2016
V.

A.
Complications and management

1.
Perforation
a.
May result in aqueous humor leakage and/or introduction of infectious organisms into
anterior chamber
i.
Cut-down technique
i)
ii.
Suture technique
i)
iii.
iv.
B.
A simple incision made in cornea, should be closed with single 10-0 nylon
suture
Should not require suture closure
Trap door technique

i)
Additional 10-0 nylon sutures may be placed in flap
ii)
If not able to maintain deep anterior chamber, may place thin application of
cyanoacrylate tissue adhesive over flap, followed by bandage contact lens
placement
Trephination technique
i)
If perforation occurs during trephination, trephinated tissue can be secured to

surrounding stroma with 10-0 nylon sutures
ii)
If perforation occurs during lamellar dissection of base, may either secure

trephinated tissue to surrounding stroma or perform more superficial lamellar
dissection, and apply tissue adhesive to base after trephinated tissue removed
iii)
If tissue is necrotic and closure is not possible with sutures and/or tissue
adhesive, a corneal or scleral patch graft or Tutoplast may be needed for
closure
iv)
If no tissue is immediately available, temporary closure of the globe may be

performed using a piece of sterile material, such as the surgical drape,
v)
The material may be cut with a trephine, placed over the defect, and secured
to the globe using tissue adhesive or sutures
Prevention of perforation
1.
Perform thorough slit-lamp biomicroscopic examination prior to procedure to estimate local corneal
thickness and depth of infiltrate
2.
Ultrasonic corneal pachymetry when possible before lamellar dissection
3.
Corneal imaging with optical coherence tomography or ultrasonography to determine depth of

lesion and corneal thickness prior to dissection
385
AAO 2014-2016
VI.

A.
Antimicrobial therapy restarted after the biopsy
B.
Treatment modified according to results of microbiologic and histopathologic investigations

A.
Precautions against rubbing the operated eye
B.
Need for medical therapy
1.
386
AAO 2014-2016
I.

A.
Indications
1.
2.
3.
4.
5.
B.
b.
Chronic inflammation
c.
d.
Rule out malignant process
Anterior corneal dystrophies, either primary or recurrent after penetrating keratoplasty, (corneal
epithelial basement membrane dystrophy, corneal dystrophy of Bowman layers I and II, etc.)
a.
b.
Anterior corneal degenerations (Salzmann nodular degeneration, band keratopathy, etc.)

a.
b.
Discomfort
Pannus
a.
b.
Conjunctival neoplasm with superficial corneal involvement
Corneal dystrophy or degeneration producing visual loss via stromal opacification

A.
Complete slit-lamp biomicroscopic examination to ensure:

1.
III.
a.
Contraindications
1.
II.
Pterygium/pseudopterygium
Opacification epithelial/subepithelial (amenable to treatment with superficial keratectomy)

A.
Observation
B.
Fitting with a rigid contact lens (for visually significant corneal epithelial irregularity)
C.
D.
387
AAO 2014-2016
IV.

A.
B.
C.
Setting
1.
Minor procedure room with patient lying supine under operating microscope
2.
May be performed at the slit lamp with a cooperative patient.
3.
Preparation
4.
Operative eye prepped and draped in standard sterile fashion for ocular surgery
5.
Speculum inserted into operative eye
Anesthesia (for all techniques)

1.
Proparacaine or preservative free tetracaine drops
2.
If needed, a cotton tip applicator soaked in 4% lidocaine may be held to limbal positions where
forceps fixation performed
Technique
1.
Fixation of the globe at the limbus with .12 forceps
2.
Removal of corneal epithelium over involved area with Weck-cel sponge or surgical blade
3.
Dissection of abnormal tissue from Bowman layer using:
4.
D.
Forceps to peel tissue
b.
Surgical blade to dissect abnormal tissue
Diamond-dusted burr may be used to polish Bowman layer to:

a.
Decrease incidence of recurrent erosions
b.
Produce smoother ocular surface
Specimen handling and processing

1.
V.
a.
Excised tissue placed on a piece of paper and then placed in formalin and submitted for
histopathologic examination

A.

1.
Management
a.
B.
Treat with bandage soft contact lens, lubricating ointment and drops, tarsorrhaphy, amniotic
membrane graft/patch
Microbial keratitis
1.
Prevention
a.
Topical antibiotics while bandage soft contact lens in place, or until epithelial defect has
resolved
388
AAO 2014-2016
2.
Management
a.
C.
Corneal scarring
1.
Prevention
a.
2.
D.
Management
a.
b.
Optical keratoplasty if visually limiting
Prevention
a.
2.
Treat underlying disease process (if possible) that led to need for superficial keratectomy
Management
a.
Repeat superficial keratectomy
a.
Corneal perforation
1.
2.
VI.
Avoid lamellar dissection into Bowman layer or anterior stroma
Recurrence of the primary disease process

1.
E.
Corneal cultures/smears and intensive topical antibiotic therapy
Prevention
a.
Evaluate corneal thickness carefully preoperatively
b.
Consider penetrating keratoplasty in cases of very thin, scarred corneas
Management
a.
Tissue adhesive or suture closure of defect if small or linear
b.
Corneal graft for perforations not amenable to closure with sutures or glue

A.
Bandage soft contact lens while epithelium is healing
B.
Topical antibiotics and corticosteroids

A.
Compliance with postoperative topical medication regimen
1.
389
AAO 2014-2016

I.

A.
B.
General indications
1.
Cover defects of ocular surface
2.
Amniotic membrane may be used as a substrate for epithelial growth on the ocular surface
3.
It may reduce inflammation and scarring.
Specific indications
1.
Covering ocular surface defects

a.
b.
Conjunctival loss
i.
Surgery (pterygium, tumors, lysis of symblepharon)
ii.
Chemical injuries
Cornea
i.
2.
3.
II.
Descemetocele or small corneal perforation (Layered approach)
Substrate for epithelial growth

a.
For persistent corneal epithelial defects
b.
Limbus- may be of benefit in conjunction with limbal stem cell grafts or to allow limbal stem
cell expansion in partial limbal stem cell deficiency
Decreasing Inflammation and scarring

a.
Acute Stevens Johnson Syndrome/Toxic Epidermal Necrolysis with significant ocular

involvement
b.
Acute chemical injuries

A.
History and slit-lamp biomicroscopic examination to determine

1.
2.
Prognosis, based on preexisting conditions and underlying disease

a.
Etiology
b.
Extent
c.
Stability
Surgical planning
B.
Identify and correct anatomical abnormalities of lids (may occur simultaneously with amniotic
membrane transplantation)
C.
Identify and treat systemic conditions contributing to ocular disease
390
AAO 2014-2016
D.
III.
IV.
Identify and treat keratoconjunctivitis sicca and Meibomian gland disease (blepharitis, rosacea)
1.
Lubricants
2.
Punctal occlusion
3.
Tetracyclines, azithromycin

A.
Alternatives to amniotic membrane transplantation may be indicated or contraindicated

depending on the underlying disease.
B.
Medical therapy of underlying disease
C.
Therapeutic bandage contact lens
D.
Conjunctival flap or free graft
E.
Limbal stem cell graft(s)

1.
Conjunctival limbal autograft(s)
2.
Keratolimbal allograft(s) (cadaveric or living related)
3.
Ex-vivo expanded auto- or allograft(s)
F.
Mucous membrane graft(s)
G.
Temporary or permanent tarsorrhaphy
H.

A.
Operating room with operating microscope.
B.
Standard sterile preparation and draping for ocular surgery
C.
Topical, sub-Tenons, peri- or retrobulbar, or general anesthesia depending on extent of

accompanying surgical procedures and American Society of Anesthesiology classification
D.
Instruments
E.
1.
Lid speculum
2.
0.12 mm forceps for globe fixation
3.
Smooth tying forceps for handling amniotic membrane
4.
10-0 nylon suture for cornea
5.
8-0 or 9-0 absorbable suture for conjunctiva, sclera
Preparation of ocular surface based on underlying disease

1.
Pterygium excision (See Pterygium excision)
2.
Tumor excision with adjunctive therapy as indicated
3.
Symblepharon release
391
AAO 2014-2016
4.
F.
Amniotic membrane may be obtained fresh, frozen on a filter paper sheet with the stromal side
adherent to the sheet, or in a lyophilized form
1.
G.
V.
Corneal epithelial debridement
The best preparation has not yet been established in comparative studies
Placement and fixation

1.
When used as a graft to promote epithelialization, it is placed with the basement membrane
(non-sticky) side up
2.
As a patch, it is placed with the stromal (sticky) side up or in multiple layers
3.
The tissue is trimmed to fit the area to be covered and sutured in place with interrupted or
continuous sutures
H.
The placement of a bandage lens and/or use of temporary tarsorrhaphy (depending on the
clinical situation) may be useful in preventing early dehiscence of the amniotic membrane graft
I.
Amniotic membrane fused to symblepharon ring is alternative and can be placed outside the
operating room

A.
Failure to suppress underlying disease process with resultant corneal scarring, thinning,
perforation, or progressive conjunctival scarring and forniceal shrinkage
B.
Early dissolution of amniotic membrane transplant (less than 1 week)

1.
2.
Prevention
a.
Adequate suture fixation of graft
b.
Preoperative treatment of exposure and dry eye
c.
Treat exposure prior to or at time of amniotic membrane grafting
Management
a.
VI.
Correct exposure and treat tear insufficiency

i.
Lubricants, autologous serum
ii.
Punctum plugs
iii.
iv.
Tarsorrhaphy

A.
Topical antibiotics and corticosteroids
B.
Therapeutic soft contact lens is optional in some cases
C.
Weekly follow-up
D.
Consider removal of amniotic membrane if it is still present after underlying disease process
392
AAO 2014-2016
resolved
E.
Suture removal once amniotic membrane has dissolved

A.
Compliance with postoperative topical medication regimen
B.
Avoid eye rubbing
C.
1.
2.
Tseng SC. Amniotic Membrane Transplantation for Ocular Surface Reconstruction. Biosci Rep.
2001 Aug;21(4):481-9. Mannis, Springer, New York, 2002.
3.
4.
2008;27:S1-S42.
5.
Gruterich M, Espana EM, Tseng SC. Ex vivo expansion of limbal epithelial stem cells: amniotic
membrane serving as stem cell niche. Surv Ophthalmol 2003;48:631-46.
6.
393
AAO 2014-2016
Repair of corneal laceration and suture

closure of corneal wound
I.

A.
B.
Indications
1.
Penetrating injury
2.
Perforating injury
Contraindications
1.
II.
Perforations with significant tissue loss

a.
Perforation from microbial keratitis
b.
Perforation from immune melt
c.
Perforation with traumatic tissue avulsion
d.
These conditions may not be amenable to primary closure and often require removal of
adjacent involved tissue and corneal grafting

A.
B.
Complete history
1.
Mechanism and nature of injury
2.
Previous history of ocular trauma and surgery
3.
Level of visual acuity prior to injury
4.
Medications
5.
Time of last food intake
6.
Status of tetanus prophylaxis
Physical examination
1.
Visual acuity of both eyes
2.
External examination to assess orbital trauma with inspection of involved eye and other eye
3.
Pupils
a.
4.
Check for afferent pupillary defect
Slit-lamp biomicroscopic examination with Seidel testing if indicated

a.
Partial vs. full-thickness injury
b.
The presence of foreign bodies in cornea, anterior chamber (AC) angle (which may require
gonioscopy)
394
AAO 2014-2016
c.
5.
C.
III.
IV.
Lens status (i.e. presence of cataract or anterior capsule rupture)
Dilated fundus examination unless iris plugging the wound, foreign body in or extending into the
anterior chamber from the cornea, or complete hyphema
Diagnostic imaging - localization of foreign body if suspected

1.
Plain film
2.
Computed tomography
3.
Ultrasound

A.
Application of tissue adhesive for perforations less than 2 mm diameter
B.
Bandage soft contact lens for small partial-thickness lacerations with minimal wound gape or
shelved, self-sealing lacerations

A.
General anesthesia (avoid agents that cause contraction of the extra-ocular muscle such as
succinylcholine, use nondepolarizing muscle relaxants instead) and perioperative antibiotics
B.
Prep, drape, and insert eyelid speculum avoiding pressure to the globe
C.
Inspect for iris prolapse and incarceration

1.
D.
May need to excise necrotic or epithelialized tissue
Ophthalmic viscosurgical device (viscoelastic) introduced via a paracentesis

1.
Can be used to deepen the chamber and relieve iris incarceration
E.
Align wound at limbus first
F.
Use 9-0 nylon for limbus and 10-0 nylon for clear cornea with spatulated needle
G.
Use large, compressive sutures to close the peripheral aspects of the wound and smaller bites to
close the central cornea
1.
This flattens the peripheral cornea and steepens the central cornea, resulting in some reduction of
astigmatism
2.
Suture placement should avoid posterior wound gape
H.
Orient suture bites 90 degrees to wound with 90% stromal thickness s
I.
Stellate lacerations may require a purse string suture for closure
J.
Remove the lens if anterior capsule disrupted
K.
Anterior vitrectomy if indicated
L.
Conjunctival peritomy when scleral laceration suspected
M.
Inspect carefully to insure watertight globe
N.
Subconjunctival antibiotics
395
AAO 2014-2016
V.
O.
Topical antibiotics, corticosteroids, and cycloplegics
P.
Consider cephalosporin, fluoroquinolone, aminoglycoside
Q.
Pain medications

A.
Post-operative infection including keratitis and endophthalmitis

1.
2.
Prevention
a.
Follow sterile technique
b.
Maintain the patient on topical antibiotics and systemic antibiotics as indicated
Treatment
a.
B.
Wound leak
1.
2.
C.
Prevention
a.
Careful inspection of wound intra-operatively to insure watertight globe
b.
Apply mild pressure on wound edges and look for leak
c.
Seidel testing
Treatment
a.
Return to operating room for closure of large leaks (flat chamber). If fistula suspected,
remove epithelium from inner aspect of wound.
b.
Trial with pressure patching or bandage soft contact lens and aqueous suppressants if leak
is minimal

1.
D.
Treat as indicated with topical agents
Hyphema
1.
Corticosteroids and cycloplegics

a.
E.
May need wash-out
Corneal scarring and opacification

1.
Prevention
a.
2.
Minimize suture placement in central visual axis
Treatment
a.
F.
Culture and treat with the appropriate antibiotics
May require penetrating or rotational keratoplasty
Postoperative irregular astigmatism

1.
Prevention
396
AAO 2014-2016
G.
Difficult
b.
Attempt to maintain corneal architecture
Treatment
1.
VI.
a.
Rigid gas permeable lens may be indicated
H.
I.
Frequency of postoperative visits is a function of epithelial healing and control of intraocular

pressure and inflammation
J.
Essential components of the postoperative exam include:

1.
Interval history
2.
Measurement of visual acuity
3.
4.
IOP assessment
K.
Discontinue antibiotics as epithelium heals
L.
Taper corticosteroids as inflammation resolves
M.
Sequential suture removal in 6-12 weeks before sutures vascularize and loosen
Describe appropriate patient instructions (post-op care, vision rehabilitation)

A.
Stress importance of compliance with medications and need for regular postoperative care to
ensure optimum visual rehabilitation
B.
Discuss physical restrictions, importance of eye protection, and details for emergency care
C.
Discuss expectations for postoperative recovery depending on the nature and extent of the injury
1.
2.
AAO, Focal Points: Repair of the Traumatized Anterior Segment, Module #1, 1992.
397
AAO 2014-2016
Management of descemetocele and

corneal perforation by bandage contact
lens, tissue adhesive or reconstructive
graft
I.

A.
II.
Indications
1.
Corneal perforation - impending or frank
2.
Descemetocele
3.
Corneal thinning
4.
Corneal melt
5.
Wound leaks
6.
Contraindications
7.
Severe corneal ulceration or corneal melting in an eye with no or very limited visual potential
8.
Blind, painful eye

A.
B.

1.
Measure degree of corneal thinning (pathology)
2.
Seidel test
3.
Assess size of corneal perforation
4.
Evaluate wound configuration
5.
Evaluation of corneal ulceration
6.
Evaluate whether any tissue was lost
7.
Anterior chamber depth
8.
Determine reason for descemetocele or corneal thinning
9.
Evaluate lens status
Identify and correct any anatomical abnormalities leading to corneal thinning (exposure,
entropion, ectropion, trichiasis, etc.)
1.
C.
May occur simultaneously with corneal intervention
Identify and treat any contributing systemic conditions
398
AAO 2014-2016
1.
D.
Consider tetanus prophylaxis
E.
Consider systemic antibiotics
F.
Optimize the ocular surface

1.
III.
May occur simultaneously with corneal intervention

a.
Treat keratoconjunctivitis sicca (i.e. preservative free lubricants)
b.
Treat any lid disease (rosacea, blepharitis)
c.
Punctal occlusion

A.
Observation
B.
Lubrication
C.
Patching
D.
Pharmacological aqueous suppression
E.
Bandage contact lens for small leaks with well opposed wound margins
F.
Tarsorrhaphy (temporary or permanent) as adjuvant therapy or for descemetoceles due to

exposure or neurotrophic disease
G.
Cyanoacrylate adhesive for small wounds (under 2 mm)
H.
Corneal sutures (if no loss of tissue)
I.
Amniotic membrane (small perforation or descemetocele)
J.
Ophthalmic viscosurgical device (viscoelastic) injection for reforming the anterior chamber if
indicated (especially if patient is phakic)
K.
The use of collagenase inhibitors (i.e., acetylcysteine, medroxyprogesterone)
L.
Lamellar keratoplasty (if wound is not full-thickness)
M.
N.
IV.
May occur simultaneously with corneal intervention (i.e., rheumatoid arthritis, Wegener
granulomatosis, systemic lupus erythematosus, gout, Crohn disease)
1.
Full size graft may have to be large and eccentric, depending on the size and location of the
thinned area
2.
Patch graft (under 5 mm)
Enucleation or evisceration

A.

1.
B.
Topical antibacterial prophylaxis
Tarsorrhaphy
399
AAO 2014-2016
Lidocaine 1% or 2% with epinephrine injected subcutaneously into the upper and lower eyelids
2.
Apposition of the eyelid margins using one of the following: Frost suture, tarsal pillar,
cyanoacrylate adhesive, intermarginal adhesion, Botox tarsorrhaphy
C.
Cyanoacrylate adhesive - (See Application of corneal tissue adhesive)
D.
Corneal sutures - (See Repair of corneal laceration and suture closure of corneal wound)
E.
Amniotic membrane- requires multiple layers
F.
G.
H.
V.
1.
1.
Recipient cornea is dissected first (may be necessary to convert to full thickness penetrating
keratoplasty)
2.
Donor lamellar graft from whole globe or from donor cornea-scleral rim of 16 mm or more (with
use of an artificial anterior chamber)
3.
Microkeratome may be helpful with the dissection
4.
Remove Descemet membrane from donor button
5.
Meticulous irrigation, cleaning, and smoothing of the interface (See Penetrating keratoplasty)
Patch graft
1.
Even if the area to be repaired is small, if the patch graft would interfere with vision, full-sized
penetrating keratoplasty is preferable
2.
Full-size graft may have to be large and eccentric, depending on the size and location of the
thinned area
3.
Ulcerated (or thinned) area is outlined with a small trephine (See Penetrating keratoplasty)

A.
Common to all
1.
2.
3.
Progression or development of corneal infiltrate
4.
Pain
5.
Decreased vision
6.
Corneal scarring
7.
8.
Endophthalmitis
9.
10.
Shallow/flat anterior chamber
400
AAO 2014-2016
B.
C.
D.
E.
F.
G.
11.
Cataract formation
12.
Anterior synechiae formation leading to glaucoma

1.
2.
Corneal edema
3.
Tarsorrhaphy
1.
Trichiasis
2.
Entropion
3.
Corneal abrasion
Cyanoacrylate adhesive
1.
Loosening of glue
2.
3.

a.
b.
Toxicity to lens - cataract formation
c.
Symblepharon
Corneal sutures
1.
Loosening of sutures
2.
Development of corneal infiltrate/suture abscess
3.
Induced astigmatism
1.
Graft rejection (epithelial rejection, subepithelial infiltrates, stromal rejection)
2.
Interface opacities
3.
Vascularization of the interface
4.
Inflammatory necrosis of the flap
5.
Corneal perforation
Penetrating keratoplasty - tectonic or optical, patch grafts

1.
Graft rejection
2.
Graft failure
3.
4.
5.
Glaucoma
401
AAO 2014-2016
H.
VI.

1.
Select appropriate therapy for situation
2.
Careful surgical technique
3.
Careful follow-up

A.
Monitor status of glue or sutures or transplant
B.
Monitor status of cornea
C.
Monitor for the development of new corneal ulceration or progression of corneal ulceration
D.
Remove glue or sutures when healing noted
E.
Use topical antibiotics to prevent superinfection
F.
Follow-up every 1-3 days depending on clinical response

A.
No eye rubbing
B.
Eye protection at all times/eye shield
C.
No coughing or sneezing
D.
Limited activities
E.
Use medications as directed (topical antibiotics, aqueous suppressants, cycloplegics,

collagenase inhibitors)
F.
Call physician if pain increases, vision changes, increased tearing, or a gush of fluid is noted
1.
402
AAO 2014-2016
Donor selection criteria contraindicating

donor cornea use for corneal
transplantation
I.
List the contraindications

A.
Donor evaluation must include

1.
Serologic testing for hepatitis B (hepatitis B surface antigen (HBsAg), hepatitis C (anti-HCV), and
human immunodeficiency virus (anti-HIV1, anti-HIV2 [or combination test])
2.
Physical assessment of the donor
3.
4.
B.
a.
Physical signs of human immunodeficiency virus (HIV) disease
b.
Infectious hepatitis
c.
Injection drug use
Tissue evaluation
a.
Gross evaluation
b.
Slit-lamp biomicroscopic evaluation
c.
Specular microscopy
i.
Generally, corneas with endothelial cell counts of <2000cells/mm2 are not used for
endothelial keratoplasty or penetrating keratoplasty
ii.
Lower cell counts are acceptable for lamellar keratoplasty
d.
Death to preservation time (optimal range <12 hours)
e.
Donor age (more important indicator of tissue elasticity than graft survival)
Donor history evaluation including donor's name and donor information obtained from at least one
of the following
a.
Pathologist or medical examiner physical assessment of death report
b.
Police investigation report
c.
Medical examiner's investigative report
d.
Family interview
e.
Medical record or hospital chart
f.
Treating physician interview
Contraindications for human transplantation

1.
a.
Death of unknown cause

403
AAO 2014-2016
b.
Creutzfeldt-Jakob disease, variant Creutzfeldt-Jakob disease, or family member with

Creutzfeldt-Jakob disease
c.
Death with neurologic disease of unestablished diagnosis
d.
Dementia, unless due to cerebrovascular disease, brain tumor, or head trauma

i.
Donor with toxic or metabolic-induced dementia may be acceptable pending

documentation of consultation with the medical director. The approval of the medical
director is required
e.
Subacute sclerosing panencephalitis
f.
Progressive multifocal leukoencephalopathy
g.
Congenital rubella
h.
Reyes syndrome
i.
Active viral encephalitis or encephalitis of unknown origin or progressive encephalopathy
j.
Active septicemia (bacteremia, fungemia, viremia)
k.
Active bacterial or fungal endocarditis
l.
Active viral hepatitis
m.
Rabies
n.
Intrinsic eye disease

i.
Retinoblastoma
ii.
Malignant tumors of the anterior segment or known adenocarcinoma in the eye of

primary or metastatic origin
iii.
Active ocular or intraocular inflammation: conjunctivitis, keratitis, scleritis, iritis,

uveitis, vitritis, choroiditis, retinitis
iv.
Congenital or acquired disorders of the eye that would preclude a successful

outcome for the intended use
i)
v.
Central donor corneal scar for an intended penetrating keratoplasty,

keratoconus and keratoglobus
Pterygia or other superficial disorders of the conjunctiva or corneal surface involving

the central optical area of the corneal button that would preclude a successful
outcome for penetrating keratoplasty.
i)
May be used for posterior lamellar grafts
o.
Prior intraocular or anterior segment surgery is a relative contraindication depending on the

use of the tissue. Donor's status post LASIK and PRK are acceptable for DMEK. Eyes that
have had prior cataract surgery can be used for all grafts if the cell count is adequate and
the wounds do not enter the area of the planned trephination
p.
Leukemias
q.
Active disseminated lymphomas
404
AAO 2014-2016
r.
Hepatitis B surface antigen positive donors
s.
Recipients of human pituitary-derived growth hormone (pit-hGH) during the years from
1963-1985
t.
Human T-Lymphotrophic virus (HTLV)-I or HTLV-II infection.
u.
Recipients of non-synthetic dura mater graft

v.
w.
HIV or high risk for HIV, HIV seropositive donors

x.
2.
Criteria are the same as listed for penetrating keratoplasty

i.
Except that the endothelial cell count does not matter as long as the corneal tissue is
clear
a.
4.
Positive syphilis serology as defined as a contraindication by Food and Drug

Administration (FDA) guidance
Lamellar or patch grafts

a.
3.
Hepatitis C seropositive donors
Criteria are the same as listed for penetrating keratoplasty

i.
Except that tissue with non-infectious anterior pathology that does not affect the
posterior stroma and endothelium is acceptable.
ii.
Surgeons must be notified of any prior pathology prior to placing tissue for transplant
Scleral tissue
a.
Criteria are the same as for penetrating keratoplasty except that tissue with local eye
disease affecting the cornea is acceptable for use. Death to preservation time may be
extended
1.
2.
Eye Bank Association of America Medical Standards. June 2012. EBAA. Washington D.C.
3.
AAO, Focal Points: Penetrating Keratoplasty, Module #6, 1992, p.1-2.
405
AAO 2014-2016
I.

A.
B.
Indications
1.
Pseudophakic or aphakic corneal edema
2.
Endothelial dystrophies: Fuchs and posterior polymorphous corneal dystrophy
3.
Regraft related to allograft rejection
4.
Regraft unrelated to allograft rejection
5.
Stromal dystrophies: lattice, granular, Avellino,
6.
Keratoconus and other ectasias
7.
Viral/postviral keratitis/keratopathy
8.
Microbial/post microbial keratitis/keratopathy
9.
Noninfectious ulcerative keratitis or perforation
10.
Corneal degenerations
11.
Chemical injury
12.
Mechanical trauma, nonsurgical
13.
Congenital opacity
14.
15.
Corneal degeneration
16.
Other causes of corneal opacification or distortion, including surgical trauma
Contraindications
1.
Active uveitis
2.
Active keratitis, except when necessary for tectonic support or for removal of infectious material in
progressive microbial keratitis
3.
Severe ocular surface disease
4.
a.
Marked 360 degrees, limbal stem cell deficiency
b.
Neurotrophic cornea
Preexisting conditions that limit visual potential, including amblyopia, macular or retinal disease
and optic nerve damage
a.
Surgery may be considered in this situation if visualization of the posterior pole is necessary
and as a means of treating pain from bullous keratopathy
b.
Penetrating keratoplasty is contraindicated in individuals with complete loss of vision
406
AAO 2014-2016
5.
Multiple graft rejections
6.
Stromal neovascularization
a.
7.
Poorly controlled glaucoma

a.
8.
9.
May benefit from combined glaucoma filtering procedure or placement of tube
Eyelid abnormality
a.
Address lid malposition first
b.
May benefit from combined tarsorrhaphy

i.
Poor blink due to facial nerve paresis
ii.
Lagophthalmos
iii.
Ectropion
iv.
Entropion
Dry eye
a.
II.
If not severe, transplantation may be successful with intensive steroid treatments, but
prognosis is more guarded
Address prior to surgery

i.
ii.
Punctal plugs
iii.
Aggressive lubrication

A.
Performing a complete ophthalmic history and examination is essential to assess whether the
corneal abnormality is a cause of decreased visual acuity and whether a corneal graft would be
expected to survive in the recipient's ocular environment
B.
Patient history
C.
1.
Assessment of past ocular history including previous vision and disorders of the involved eye
2.
Cause and course of visual loss
3.
Other medical conditions
4.
Previous and current medications
1.
Best corrected visual acuity including rigid contact lens over-refraction if indicated
2.
External examination of ocular adnexa
3.
Ocular surface, including eyelids, conjunctiva, tears, and corneal sensation
4.
Corneal and anterior segment status, including extent of corneal vascularization, inflammation,
and thinning
407
AAO 2014-2016
D.
5.
Intraocular pressure (IOP) assessment
6.
Evaluation of the lens to determine need for combined cataract extraction
7.
Posterior segment evaluation and/or B-scan ultrasound
Preoperative assessment
1.
III.
a.
Identify and counsel individuals at greater risk for allograft rejection
b.
May benefit from intensive topical corticosteroids (See Allograft rejection)
2.
Aim for stable medical health, including conditions such as diabetes mellitus, hypertension,
cardiopulmonary disease, and endocrine disorders
3.
Control abnormal IOP
4.
Suppress ocular inflammation and treat ocular surface disease
1.
Interface with eye bank and evaluate donor cornea
5.
Consider perioperative antimicrobial or antiseptic prophylaxis
6.
Consider systemic immunosuppression in the preoperative assessment (especially for high risk
grafts)

A.
IV.
Evaluate prognosis of corneal graft based on history and examination
Based on depth of corneal opacity and visual potential

1.
Endothelial keratoplasty for endothelial dysfunction
2.
Ethylenediaminetetraacetic acid (EDTA) chelation for band keratopathy
3.
4.
5.
Lamellar keratectomy
6.
7.
Keratoprosthesis
8.
Thermocautery
9.
Conjunctival flap

A.
General versus retrobulbar anesthesia
B.
Donor cornea
C.
Donor corneal trephine
D.
Flieringa ring for scleral support
408
AAO 2014-2016
V.
E.
Recipient corneal trephine
F.
Corneal scissors and knife
G.
Instruments for cataract extraction, intraocular lens exchange or insertion, anterior vitrectomy,
and/or iridectomy, as indicated
H.
Suturing techniques: interrupted, continuous, and combined

A.
B.
Intraoperative
1.
Damage to the lens or iris
2.
Vitreous loss
3.
Retained Descemet membrane
4.
Poor graft centration
5.
Poor tissue apposition and wound leak
6.
Suturing problems
7.
Problems reforming the anterior chamber
8.
Hyphema
9.
Choroidal hemorrhage or effusion and suprachoroidal hemorrhage
Postoperative
1.
2.
3.
Wound leak
a.
Patching
b.
c.
Aqueous suppressants
d.
May need resuturing
Flat chamber/iris incarceration

a.
Indicative of poor wound integrity or posterior pressure
b.
Early surgical intervention often necessary
Elevated IOP
a.
4.
Endophthalmitis
a.
5.
Treat with medical, laser surgery, or surgical intervention as indicated
Urgent, aggressive intervention with consultation with retina specialist for anterior chamber
tap, vitreous biopsy and intravitreal antibiotics
Severe inflammation including formation of fibrin

a.
Treat aggressively with corticosteroids
409
AAO 2014-2016
b.
6.
7.
8.
Microbial or viral keratitis

a.
Scrape and culture as indicated
b.
Initiate treatment promptly as indicated

a.
Identify and treat concomitant ocular surface disease
b.
Aggressive lubrication, patching, bandage soft contact lens, autologous serum, and
tarsorrhaphy may be indicated
Primary endothelial failure

a.
9.
10.
11.
12.
13.
14.
16.
Consider regraft if edema is significant and fails to resolve after several weeks
Recurrence of primary disease

a.
Treat as indicated in cases of microbial keratitis
b.
Regraft may be required for recurrent dystrophy
Suture-related problems
a.
Remove broken or loose sutures
b.
Treat suture abscesses aggressively
Postoperative astigmatism
a.
Selective suture removal based on corneal topography
b.
Consider relaxing incisions and placement of additional sutures
Allograft rejection
a.
Recognize early and treat aggressively with corticosteroids
b.
Cyclosporine may have a role an adjuvant therapy in the prevention and treatment of
allograft rejection (See Allograft rejection)
Anterior synechiae
a.
Release existing synechiae during surgery
b.
Aggressive control of inflammation
Posterior synechiae
a.
15.
Tissue plasminogen activator may have a role in fibrinolysis
Use postoperative mydriatics
Pupillary block
a.
Attempt medical management
b.
Will likely need peripheral iridotomy
Choroidal detachment
a.
Likely due to choroidal effusion

410
AAO 2014-2016
b.
17.
18.
a.
Remove adjacent sutures
b.
Associated with increased risk of graft rejection
Epithelial ingrowth
a.
VI.
Usually self-limiting, observe closely for resolution
Treat aggressively with complete surgical excision and cryotherapy
19.
Transmission of donor disease
20.
Traumatic wound rupture
21.
Graft failure
a.
Higher probability in eyes with tube shunts
b.
Patients should be advised of higher likelihood of re graft within 5 years if a tube is present
c.
Management of failed penetrating keratoplasty

i.
Determine cause of graft failure (e.g. ocular surface disease, immunologic graft
refection, graft failure without rejection, uncontrolled glaucoma, etc)
ii.
Assess if regrafting would be helpful and have realistic chance of success
iii.
If chance of success poor, consider conjunctival flap, cautery to corneal surface, or

keratoprosthesis
iv.
If realistic chance of success, address problems that led to graft failure (e.g. ocular
surface disease, glaucoma, etc)
v.
If replacing graft and previous refractive result acceptable, and graft-host interface
well apposed posteriorly, consider endothelial keratoplasty as it provides more rapid
visual recovery and maintains ocular surface.
vi.
If refractive results was not acceptable prior to failed PK, proceed with repeat PK

A.
Frequency of postoperative visits is a function of epithelial healing and control of IOP and
inflammation
B.
Visits are indicated more frequently in the first 90 days
C.

1.
Interval history
2.
3.
4.
IOP assessment
D.
Topical corticosteroid and other ophthalmic medications
E.
Suture removal
411
AAO 2014-2016

A.
ensure optimum visual rehabilitation, which may take up to a year
B.
Discuss symptoms of corneal transplant rejection and need for immediate attention (redness,
sensitivity to light, visual changes, pain)
C.
1.
2.
AAO, Focal Points: Penetrating Keratoplasty, Module #6, 1992.
3.
AAO, Preferred Practice Patterns Committee, Cornea and External Disease Panel. Corneal
Opacification and Ectasia Preferred Practice Patterns, 2000.
4.
Shimazaki J, Shimmura S, Ishioka M, et al. Randomized clinical trial of deep lamellar keratoplasty
vs penetrating keratoplasty. Am J Ophthalmol 2002;134:159-65.
5.
Karabatsas CH, Cook SD, Figueiredo FC, et al. Combined interrupted and continuous versus
single continuous adjustable suturing in penetrating keratoplasty: a prospective, randomized study
of induced astigmatism during the first postoperative year. Ophthalmology 1998;105:1991-8.
6.
Frueh BE, Bohnke M. Prospective, randomized clinical evaluation of Optisol vs organ culture
corneal storage media. Arch Ophthalmol 2000 Jun;118:757-60.
7.
Karabatsas CH, Cook SD, Figueiredo FC. Surgical control of late postkeratoplasty astigmatism
with or without the use of computerized video keratography: a prospective, randomized study.
Ophthalmology 1998;105:1999-2006.
8.
Frost NA, Wu J, Lai TF, et al. A review of randomized controlled trials of penetrating keratoplasty
techniques. Ophthalmology 2006;113:942-9.
9.
Anshu A, Price MO, Price FW. Descemet's Stripping Endothelial Keratoplasty Under Failed
Penetrating Keratoplasty: Visual Rehabilitation and Graft Survival Rate. Ophthalmology 2011;
118:2155-60.
10.
Anshu A, Price MO, Richardson MR, Segu ZM, Lai X, Yoder MC, Price FW. Alterations in the
aqueous humor proteome in patients with a glaucoma shunt device. (http://www.ncbi.nlm.nih.gov
/pubmed/21850163) Molecular Vision 2011;17:1891-1900. http://www.molvis.org/molvis/v17/a206
(http://www.molvis.org/molvis/v17/a206)
412
AAO 2014-2016
I.

A.
Indications
1.
B.
II.
Persistent corneal endothelial dysfunction, with corneal surgery aiming to improve vision, to
alleviate bullous keratopathy or to allow visualization of posterior pole
a.
Pseudophakic or aphakic corneal edema
b.
c.
Corneal graft failure
d.
Other endothelial disorders e.g. posterior polymorphous corneal dystrophy, iridocorneal

endothelial syndrome, congenital hereditary endothelial dystrophy, post traumatic
endothelial failure
Relative Contraindications
1.
Limited visual potential from amblyopia, macular disease or optic nerve damage, unless
visualization of the posterior pole is necessary or surgery is needed to control pain from bullous
keratopathy
2.
Active keratitis
3.
Active uveitis
4.
Corneal stromal scarring
5.
Resolved keratitis with significant irregular astigmatism
6.
Multiple graft rejections
7.
Uncontrolled glaucoma
8.
Shallow anterior chamber with significant peripheral anterior synechiae and/or anterior chamber
intraocular lens (ACIOL)

A.
Performing a complete ophthalmic history and examination is essential to assess whether the
guttae and corneal edema from endothelial dysfunction are the cause of decreased visual acuity
and whether the graft would offer visual rehabilitation and/or patient comfort from bullous
keratopathy
B.
Patient history
1.
Assessment of past ocular history including previous vision and disorders of the involved eye
2.
Cause and course of visual loss
3.
Assessment of pain level with current condition
4.
Other medical conditions
413
AAO 2014-2016
5.
C.
D.
1.
Best corrected visual acuity including contact lens over-refraction if indicated
2.
3.
Status of ocular surface, including eyelids, conjunctiva, and tear film
4.
Corneal and anterior segment status, including extent of corneal decompensation and presence of
corneal scarring
5.
6.
Evaluation of the lens to determine need for cataract extraction
7.
Posterior segment evaluation, possibly including B-scan ultrasound if inadequate visualization
1.
III.
Evaluate patient and identify contraindications and risk factors which may affect the prognosis and
long term viability of corneal graft
a.
Presence of AC IOL
b.
Presence of glaucoma drainage device
c.
Shallow anterior chamber and/or PAS
d.
Aphakia
2.
Counsel individuals at greater risk for allograft rejection (See Allograft rejection)
3.
Consider cataract removal prior to endothelial keratoplasty (EK) (staged procedure) or at time of
EK (combined procedure).
4.
If ACIOL, consider IOL exchange (either staged or combined procedure) prior to EK. Note
presence and location of peripheral iridectomy
5.
Note presence of peripheral anterior synechiae, and if extensive, counsel against EK
6.
Achieve control of abnormal IOP
7.
8.
Interface with eye bank to discuss plans for endothelial graft that may be pre-cut by eye bank or
prepared by surgeon

A.
1.
Advantages
a.
2.
In cases of subepithelial haze with chronic bullous changes, this will be removed
Disadvantages
a.
Higher risk of intraoperative vision loss

414
AAO 2014-2016
B.
IV.
b.
Longer healing and time for suture removal, therefore longer time for visual rehabilitation
c.
Potential for high surgically-induced postoperative astigmatism and ametropia
d.
Higher potential for suture related complications and/or infection
e.
Theoretical higher risk of rejection
f.
Less tectonic strength of globe long-term
Other treatments of symptomatic endothelial dysfunction in an eye with poor visual potential
1.
Bandage contact lens application
2.
Anterior stromal micropuncture +/- amniotic membrane transplantation
3.
Conjunctival (Gunderson) flap for painful bullous keratopathy

A.
Anesthesia
1.
B.
Topical, peribulbar, or retrobulbar with monitored intravenous anesthesia
Techniques and instrumentation for EK

1.
Size and centration of donor disc determined
2.
Incision is either clear corneal or scleral tunnel ranging from 3-5mm in diameter for DSEK or
2.8mm clear corneal incision for DMEK
3.
Donor tissue can be pre-cut or donor preparation carried out on back bench by surgeon utilizing
artificial anterior chamber and microkeratome
4.
Appropriate trephine punch used to create posterior lamellar graft
5.
Descemet membrane is scored
6.
Descemet membrane may be stripped under viscoelastic or under balanced salt solution.. If
viscoelastic is used, it must be completely removed following this step
7.
Peripheral recipient full-thickness venting incisions and/or peripheral stromal roughening to

increase chance of graft adherence in DSEK cases
8.
In DSEK cases, the posterior lamellar graft can be inserted with tissue insertion forceps, or a
tissue inserter such as a glide or retractable platform inserter, or the suture pull through technique.
In DMEK, the donor membrane is inserted with a glass pipette or IOL injector.
9.
Anterior chamber is filled with a 100% air bubble to allow for proper centration and adherence of
posterior lamellar graft
10.
After adherence in OR, air bubble is partially removed to allow for a mobile air bubble over the
pupil, and cycloplegic drops placed (unless inferior peripheral iridotomy is present)
11.
The patient remains supine for a period of time so that the air bubble ensures that the endothelial
graft stays in position
415
AAO 2014-2016
V.

A.
B.
Intraoperative
1.
Damage to the lens or iris
2.
Damage to the donor cornea during preparation
Postoperative
1.
Dislocation of endothelial graft

a.
2.
i.
Reposition graft with air bubble
ii.
Caution patient to avoid eye rubbing post operatively
Pupillary block from air bubble

a.
3.
Management
Management
i.
Remove air via paracentesis
ii.
Consider pre-op laser PI or intra-op peripheral iridectomy
Elevated IOP
a.
Management
i.
4.
Wound leak
a.
5.
Management
i.
Suture
ii.
Patching
iii.
iv.
Aqueous suppressants
Endophthalmitis
a.
Management
i.
6.
Urgent, aggressive intervention with consultation with retina specialist for anterior
chamber tap, vitreous biopsy and intravitreal antibiotics
Primary endothelial failure

a.
Management
i.
7.
Treat with medical, laser surgery, or surgical intervention as indicated
Consider re graft if edema is significant and fails to resolve after several weeks
Allograft rejection
a.
Management
i.
Treat aggressively with corticosteroids. (See Allograft rejection)
416
AAO 2014-2016
8.
VI.
Late interface infectious keratitis

A.
B.
C.
Frequency of postoperative visits related to graft attachment and control of intraocular pressure
and inflammation
1.
Patients are often seen the next day, at one week and at one month, then regularly
2.
In DMEK cases, patients are often also seen 4-5 days post-operatively before air bubble is totally
gone to see if reinjection of air to push up detaching areas is indicated

1.
Interval history
2.
3.
4.
IOP assessment
5.
Manifest refraction is typically stable 4-6 weeks post-op

1.
Topical corticosteroids in endothelial keratoplasty are administered similarly to those given after
penetrating keratoplasty

A.
ensure visual rehabilitation.
B.
Discuss symptoms of graft rejection and need for immediate attention (redness, sensitivity to
light, visual changes, pain)
C.
Discuss physical restrictions, importance of eye protection, avoid eye rubbing and details for
emergency care
D.
Patients can achieve good visual acuity although interface haze may occur between the recipient
cornea and the donor endothelial graft
1.
2.
Price FW Jr, Price MO. Descemet's stripping with endothelial keratoplasty in 200 eyes: Early
challenges and techniques to enhance donor adherence. J Cat Refract Surg 2006;32:411.
3.
Gorovoy MS. Descemet-stripping automated endothelial keratoplasty. Cornea 2006;25:886.
4.
Terry MA, Ousley PJ. Deep lamellar endothelial keratoplasty: early complications and their
management. Cornea 2006;25:37.
5.
Culbertson WW. Descemet stripping endothelial keratoplasty. Int Ophthalmol Clin 2006;46:155.
417
AAO 2014-2016
6.
7.
2008;27:S1-S42
8.
Anshu A, Planchard B, Price MO, Pereira CDR, Price FW. A Cause of Reticular Interface Haze
and its Management After Descemet Stripping Endothelial Keratoplasty.
(http://www.ncbi.nlm.nih.gov/pubmed/22751144) Cornea 2012;31:1365-1368
9.
Anshu A, Price MO, Tan DTH, Price FW. Endothelial keratoplasty: a revolution in evolution
(http://www.ncbi.nlm.nih.gov/pubmed/22516537). Survey of Ophthalmology 2012;57:236-52.
418
AAO 2014-2016
Anterior lamellar keratoplasty

I.

A.
Indications
1.
2.
3.
B.
Corneal stromal opacities with healthy endothelium

a.
Corneal stromal dystrophies
b.
Corneal stromal degenerations
c.
Corneal opacities from non-perforating trauma
d.
Corneal opacities from resolved infectious keratitis
e.
Corneal opacities from resolved inflammatory/immunologic conditions
f.
Alternative to penetrating keratectomy (PK) in high risk patients

i.
Atopy
ii.
Herpes simplex
iii.
Down syndrome
Corneal irregular astigmatism with healthy endothelium

a.
Keratoconus with contact lens intolerance
b.
Pellucid marginal degeneration with contact lens intolerance
c.
Resolved infectious keratitis (Herpes simplex, Herpes zoster, bacterial, fungal) with surface
scar and irregular astigmatism
d.
Post-refractive surgery (photo refractive keratectomy (PRK), laser in situ keratomileusis

(LASIK)) with irregular astigmatism and/or ectasia
e.
Resolved ulcerative keratopathy from autoimmune or neurotrophic corneal melting
Tectonic reconstruction of the cornea

a.
Corneal thinning disorders such as Terrien marginal degeneration, pellucid marginal

degeneration, Mooren ulcer, or any ulcerative disorder from autoimmune or resolved
infectious etiology
b.
Thinned corneas following trauma or surgical excision of dermoids, pterygium, or neoplasm
c.
Non-infectious corneal descemetoceles
d.
Corneal perforations less than 2 mm in size
Contraindications
1.
Optical rehabilitation
a.
Abnormal endothelium
b.
Limited visual potential from amblyopia, macular disease or optic nerve damage, unless
419
AAO 2014-2016
visualization of the posterior pole is necessary or surgery is needed to control pain

c.
2.
II.
Tectonic rehabilitation
a.
Abnormal endothelium, unless surgery in an emergency setting to preserve the globe
b.
Corneal perforations greater than 3 mm in size

A.
B.
C.
Patient history
1.
Assessment of past ocular history including previous vision and disorders of the involved eye,
especially previous ocular surgery history
2.
Cause and course of visual loss; chronic or acute
3.
Assessment of pain level with current condition
4.
Other medical conditions, especially autoimmune disorders
5.
Family history of eye disease
6.
1.
Best corrected visual acuity including contact lens over-refraction if indicated
2.
3.
Status of ocular surface, including eyelids, conjunctiva, and tear film
4.
Corneal and anterior segment status, including extent and location of any corneal thinning, degree
of any corneal opacity, depth of opacity
5.
Corneal topography assessment to determine location and extent of irregular astigmatism
6.
Corneal endothelial health assessment by slit lamp examination, pachymetry, and specular
microscopy if possible
7.
Determination of depth, location and area of any corneal melt and decision making as to urgency
of any tectonic repair
8.
9.
Evaluation of the lens to determine need for later cataract extraction
10.
Posterior segment evaluation, possibly including B-scan ultrasound if inadequate visualization
1.
Evaluate patient and identify contraindications and risk factors which may affect the prognosis and
long term viability of corneal graft
2.
Assess whether the patient is a candidate for an anterior lamellar keratoplasty, endothelial
keratoplasty, or penetrating keratoplasty
420
AAO 2014-2016
III.
3.
Treat and eliminate acute infectious keratitis prior to surgery
4.
Achieve control of abnormal IOP
5.
6.
Treat autoimmune causes of corneal melting (e.g. rheumatoid disease) with systemic
immunosuppression
7.
Consult with internal medicine colleagues (e.g. rheumatologist) for management of acute and long
term systemic immunosuppression of appropriate autoimmune diseases
8.
Counsel individuals at greater risk for continued melting due to systemic disease, inform them of
imperfect visual outcome even in ideal circumstances due to interface image degradation
9.
Determine additional procedures that may need to be done at time of anterior lamellar keratoplasty
such as: amniotic membrane overlay, tarsorrhaphy, punctal cautery, lid reconstruction, bandage
contact lens application, etc.
List the alternatives to this procedure (based on presence of corneal opacification

and visual potential)
A.
1.
Advantages
a.
2.
B.
Disadvantages
a.
Higher risk of rejections
b.
Higher short and long term endothelial cell loss
c.
Higher risk of intra-operative vision loss (e.g. suprachoroidal hemorrhage, retinal

detachment)
d.
Longer time to suture removal, visual rehabilitation
e.
Longer exposure to topical steroids and their potential complications
f.
Less tectonic strength of globe long-term
Laser phototherapeutic keratoplasty (PTK)

1.
Advantages
a.
2.
C.
Potential for better acuity due to lack of interface irregularity
Surface ablation for superficial opacities and irregular astigmatism is faster, easier and less
traumatic
Disadvantages
a.
Potential for ectasia
b.
Induced hyperopia, residual irregular astigmatism or opacities
Intrastromal corneal rings

1.
May reduce irregular astigmatism, stabilize topography, defer corneal transplantation in cases of
421
AAO 2014-2016
keratoconus, post-LASIK ectasia and other corneal warpage conditions

D.
IV.
Other treatments for corneal melting, Descemetocele, and perforations

1.
Corneal glue with bandage contact lens application for small perforations and Descemetoceles
2.
Conjunctival flaps for neurotrophic ulcerations and melts
3.
Amniotic membrane placement for neurotrophic ulcerations and melts
4.
Tarsorrhaphy for stabilized neurotrophic ulcerations

A.
B.
Anesthesia
1.
Usually retrobulbar, may be topical if using femtosecond laser or microkeratome for anterior
lamellar grafts
2.
General anesthesia if perforation or uncooperative patient
Techniques and instrumentation

1.
2.
3.
Standard anterior lamellar keratoplasty - Optical procedure

a.
Central trephination performed down to desired depth
b.
Lamellar dissection performed to remove anterior stromal tissue
c.
Donor prepared to similar thickness stabilized on artificial anterior chamber or sutured to

gauze-wrapped sphere
d.
Donor sutured into recipient bed
e.
Suture tension adjusted for astigmatism
Standard anterior lamellar keratoplasty - tectonic

a.
Area of melt and/or perforation determined
b.
Anterior chamber filled with viscoelastic to stabilize anatomy and pressure
c.
Smallest possible diameter trephine used to encompass area of thinning, and trephination
taken to 80% depth or more, anterior tissue removed, and donor prepared and placed as
described above
d.
If melt cannot be surrounded by trephine (e.g. limbal area and extensive), then freehand
keratotomy performed (preferably with diamond knife) in adjacent healthy tissue
surrounding thinned area to depth of 80% and the anterior tissue removed. Filter paper can
be placed over the recipient bed and then cut to form and used as a template for
preparation of the proper shape for the donor tissue. The donor can then be prepared and
placed as described above
Automated lamellar therapeutic keratoplasty (ALTK)

a.
Microkeratome cuts pre-set depth and diameter of recipient and donor, utilizing artificial
anterior chamber for preparation of the donor
b.
Donor tissue secured with sutures or fibrin glue
422
AAO 2014-2016
c.
4.
5.
6.
No sutures required if graft less than 200 microns thick (place bandage contact lens over
graft)
Femtosecond laser assisted lamellar keratoplasty

a.
Femtosecond laser cuts pre-set depth and diameter of recipient and donor utilizing artificial
anterior chamber for preparation of the donor
b.
Donor tissue secured with sutures or fibrin glue
c.
Superficial dissections can be secured with a bandage contact lens
Deep anterior lamellar keratoplasty (DALK) - Limbal approach (Melles technique)

a.
Incision , usually 5 mm in length, is made at the scleral limbus
b.
An air bubble in anterior chamber used to judge the depth of stromal dissection by using the
reflection of the tip of the dissection instrument seen on the air bubble. Maximum depth is
desirable without perforation
c.
Specialized stromal dissectors are used to create a total stromal pocket, limbus to limbus,
just above Descemet membrane
d.
Intraocular pressure lowered as much as possible by air-fluid exchange through

paracentesis
e.
Cohesive viscoelastic is injected into the pocket to detach Descemet membrane into
anterior chamber
f.
Trephination from corneal surface down into the viscoelastic pocket
g.
Anterior tissue removed, leaving bare Descemet or Descemet and minimal posterior stromal
fibers
h.
The viscoelastic thoroughly washed off the recipient bed
i.
Remove Descemet membrane from donor with forceps or sponge
j.
Donor is sutured into position, sutures adjusted for astigmatism
DALK - corneal surface approach (big bubble technique)

a.
Trephination of central cornea performed to 80% depth
b.
Descemet membrane detached from the stroma into the anterior chamber using forced
injection of either air (Anwar Big Bubble technique) or fluid (hydrodissection technique of
Sugita) using a 27 gauge needle with bevel down or a rounded cannula. Tip needs to be
deeper than 80% depth, but does not need to be immediately above Descemet membrane
to achieve detachment
c.
Limbal paracentesis made to reduce pressure and allow room for intrastromal air bubble or
fluid to expand and further detach Descemet membrane
d.
Anterior 80% of stromal tissue removed
e.
Cohesive viscoelastic placed into space between detached Descemet membrane and
overlying residual posterior stromal tissue
f.
Blunt spatula placed into space and blade used to cut down from surface to spatula to enter
423
AAO 2014-2016
space and divide posterior tissue into halves or quadrants
7.
V.
g.
Standard corneal scissors used to cut a trephination circle and excise posterior tissue,
leaving 8.0 mm diameter or larger area of bare Descemet
h.
Viscoelastic thoroughly washed off recipient bed
i.
Remove Descemet membrane from donor with forceps or sponge
j.
DALK anterior surface approach with manual dissection

a.
Used in cases where a big bubble cannot be attained or do not want to attempt due to
scarring involving Descemet's membrane (risk of perforation)
b.
Trephination of central cornea performed to 80% depth
c.
Create deep dissection plane 50-80 microns above Descemet's membrane and dissect
across corneal surface by peeling back stroma and excising at base. Multiple layers may be
excised in this manner going deeper each time. Scissors are used to excise stroma along
trephination edge.
d.
Remove Descemet's membrane from donor with forceps or sponge
e.

A.
B.
Intraoperative
1.
Perforation of Descemet membrane with loss of chamber
2.
Inadequate depth of dissection
3.
Inability to achieve "Big Bubble" or detachment of Descemet in DALK
4.
Damage to intraocular structures with collapse of chamber
Postoperative
1.
Interface fluid ("double anterior chamber") due to break in Descemet membrane with separation of
recipient Descemet membrane from overlying swollen graft
a.
Management: place large enough air bubble into anterior chamber to cover defect in
Descemet membrane and position head to allow contact of air bubble with defect
2.
Pupillary block from residual air bubble: remove air via paracentesis, or place inferior iridotomy to
prevent pupillary block
3.
Elevated IOP: treat with medical therapy, laser surgery, or surgical intervention as indicated
4.
Interface haze
a.
In DALK surgery: usually resolves over several months. If vision unacceptable at 1 year,
perform PK
b.
In traditional anterior lamellar keratoplasty, ALTK and femtosecond laser assisted anterior
424
AAO 2014-2016
lamellar keratoplasty: interface haze is variable and can get better or worsen over time.
Increased risk of vascularization compared to DALK. If vision unacceptable at 1 year,
perform PK
5.
Interface infection: if suspected interface bacterial or fungal infection, treat aggressively with
topical antibiotics and schedule PK as urgent case. Alternatively, graft could be removed, infection
cleared, and then new graft placed after the eye no longer inflamed.
6.
Endophthalmitis: urgent, aggressive intervention with consultation with retina specialist for anterior
chamber tap, vitreous biopsy and intravitreal antibiotics
7.
Irregular corneal surface due to poor epithelial healing and dry eye
a.
8.
High degrees of surgically induced regular or irregular astigmatism, hyperopia, or myopia

a.
VI.
Treat with aggressive lubrication with drops and ointment, punctal plugs, autologous serum
and topical cyclosporine.
Treat in same manner as penetrating keratoplasty with selective suture removal or

adjustment, relaxing incisions, laser refractive surgery, etc.

A.
Frequency of postoperative visits related to Descemet membrane attachment, interface haze,

surface topography and control of intraocular pressure and inflammation
1.
B.
C.
Patients routinely seen one day, one week and one month, and then every 2 months until sutures
are removed and/or topography is stable for glasses or contacts

1.
Interval history
2.
3.
4.
IOP assessment
5.
Suture removal may begin as early as 1 to 2 months

1.
Topical prednisolone acetate 1% 4 times a day initially, tapered over 3-6 months, and discontinued
2.
Stromal rejection and vascular invasion of the stroma and/or interface is less likely with steroid
therapy

A.
ensure visual rehabilitation
B.
Discuss symptoms of infection and need for immediate attention (redness, sensitivity to light,
visual changes, pain)
C.
425
AAO 2014-2016
D.
Patients can achieve good visual acuity although interface haze may occur between the recipient
cornea and the donor tissue
1.
2.
Krachmer J, Mannis M, Holland E, eds. Cornea: Surgery of the Cornea and Conjunctiva. St. Louis:
2nd edition, Elsevier Mosby; 2005
3.
Terry MA. The evolution of lamellar grafting techniques over twenty-five years. Cornea
2000;19:611-6.
4.
Shimmura S, Tsubota K. Deep anterior lamellar keratoplasty. Curr Opin Ophthalmol.

2006;17:349-55.
5.
Melles GR, Lander F, Rietveld FJ, et al. A new surgical technique for deep stromal, anterior
lamellar keratoplasty. Br J Ophthalmol 1999;83:327-33.
6.
Anwar M, Teichmann KD. Big-bubble technique to bare Descemet membrane in anterior lamellar
keratoplasty. J Cataract Refract Surg 2002;12:2067-68.
426
AAO 2014-2016
Allograft rejection
I.

A.
B.
C.
D.

1.
Complex cascade of events initiated by recognition of foreign donor corneal antigens by the
recipient
2.
Cell surface markers - human leukocyte antigens present on donor corneal epithelial, stromal, and
endothelial cells interact with recipient cytotoxic T cells resulting in local inflammation, cellular
destruction and corneal graft rejection

1.
Leading cause of secondary graft failure
2.
2 year cumulative fraction of eyes with a rejection episode:

a.
DMEK: <1%
b.
DSEK: 10-14%
c.
PKP: 18%

1.
History of previous graft rejection and failure
2.
Visual loss, photophobia, conjunctival hyperemia, and may experience pain
3.
Patients may be asymptomatic

1.
2.
Epithelial rejection
a.
Linear rejection line - stains with fluorescein
b.
Progresses across corneal surface over several days
c.
Typically self limited
Stromal rejection
a.
b.
c.
Subepithelial infiltrates (rare)

i.
Small focal areas of leukocyte aggregation
ii.
Similar in appearance to adenoviral keratitis
Corneal thickening and focal inflammation

i.
Usually in conjunction with endothelial rejection
ii.
May appear similar to herpes simplex keratitis
iii.
May be associated with neovascularization
Predisposing factors (broken suture, focal corneal neovascularization, suture infiltrate)

427
AAO 2014-2016
3.
II.
III.
a.
Focal or generalized corneal edema
b.
Keratic precipitates - may aggregate to form endothelial rejection line (Khodadoust line)
c.
Progresses across graft with subsequent endothelial cell destruction
d.
Associated anterior chamber cellular reaction (may be very mild and unnoticed)
e.
Predisposing factors (broken suture, focal corneal neovascularization, suture infiltrate)

A.
Previous graft failure
B.
C.
Large or eccentric grafts
D.
Active ocular inflammation
E.
Active microbial keratitis
F.
In EK, transplanting stroma

A.
Herpetic keratouveitis (herpes simplex virus (HSV), varicella zoster virus (VZV))
B.
Epithelial downgrowth
1.
C.
D.
Fungal or infectious crystalline keratopathy
Early graft failure

1.
E.
May mimic endothelial rejection line
Indolent microbial keratitis

1.
IV.
Endothelial rejection (most common type of rejection in PKP)
May result in focal edema, nonresponsive to topical corticosteroids
Endothelial decompensation secondary to low endothelial cell count
Describe patient management of endothelial rejection in terms of treatment and

follow-up
A.

1.
Corticosteroids
a.
Prompt and frequent (e.g., hourly) administration of topical corticosteroid (e.g. prednisolone
acetate 1% or difluprednate)
b.
Periocular injections or oral corticosteroids may have a role in severe rejection episodes or
in patients with poor compliance
c.
IV corticosteroids may be of benefit when administered early in the course of a rejection
428
AAO 2014-2016
episode
V.
Removal of loose suture if present
3.
Treatment of coexistent microbial keratitis, if present
4.
Central corneal pachymetry measurements allow detection of early immunologic reactions as well
as gradual return to normal function after treating rejection episodes.
5.
Initially followed weekly or more and decreased based on clinical response

A.
B.
VI.
2.
Complications of corticosteroid treatment

1.
2.
Cataract development with prolonged corticosteroid use
3.
Worsening of underlying condition (e.g., herpetic keratitis)

1.
Follow closely to monitor inflammatory response and assess IOP
2.
Taper corticosteroids as indicated
3.
Prophylactic oral antiviral in individuals with history of herpetic keratitis
4.
Consider topical cyclosporine 2% (in patients who are steroid responders or patients grafted for
recent fungal keratitis)

A.
Secondary corneal graft failure (See Postsurgical corneal edema)
B.
Corneal endothelial cell compromise with secondary corneal edema (ranging from visually
insignificant to significant stromal and epithelial edema with microcyst and bullae formation)

A.
B.
C.
African-Americans have been shown to have 5 times the risk of immunologic graft rejection
compared to Caucasians after DSEK
1.
2.
Chiou AG, Kaufman SC, Kaz K. Characterization of epithelial downgrowth by confocal microscopy.
J Cataract Refract Surg 1999;25:1172-4.
429
AAO 2014-2016
3.
Daneshvar H, Brownstein S, Mintsioulis G. Epithelial ingrowth following penetrating keratoplasty: a

clinical, ultrasound biomicroscopic and histopathological correlation. Can J Ophthalmol
2000;35:222-4.
4.
Karabatsas CH, Hoh HB, Easty DL. Epithelial downgrowth following penetrating keratoplasty with
a running adjustable suture. J Cataract Refract Surg 1996;22:1242-4.
5.
Groh MJ, Naumann GO. Cystic epithelial growth after penetrating keratoplasty: successful curative
treatment by block excision. Br J Ophthalmol 2001;85:240.
6.
Wearne MJ, Buckley RJ, Cree IA,. Cystic epithelial ingrowth as a late complication of penetrating
keratoplasty. Arch Ophthalmol 1999;117:1444-5.
7.
Kamp MT, Fink NE, Enger C, et al. Patient-reported symptoms associated with graft reactions in
high-risk patients in the collaborative corneal transplantation studies. Collaborative Corneal
Transplantation Studies Research Group. Cornea 1995;14:43-8.
8.
Coster DJ, Williams KA. The impact of corneal allograft rejection on the long-term outcome of
corneal transplantation. Am J Ophthalmol 2005;140:1112-22. Review.
9.
10.
Anshu A, Price MO, Price FW. Risk of Corneal Transplant Rejection Significantly Reduced with
Descemet's Membrane Endothelial Keratoplasty. (http://www.ncbi.nlm.nih.gov/pubmed/22218143)
Ophthalmology 2012 Mar;119(3):536-40.
11.
Price MO, Jordan CS, Moore G, Price FW. Graft Rejection Episodes after Descemet's Stripping
with Endothelial Keratoplasty: Part Two: the Statistical Analysis of Probability and Risk Factors. Br
J Ophthalmology 2009;93:391-5.
12.
Jordan CS, Price MO, Trespalacios R, Price FW. Graft Rejection Episodes after Descemet's
Stripping with Endothelial Keratoplasty: Part One: Clinical Signs and Symptoms. Br J Ophthalmol
2009;93:387-90.
430
AAO 2014-2016
Conjunctival limbal autograft

I.

A.
Indications
1.
B.
II.
III.
Stem cell deficiency

a.
Alkali burn
b.
Chemotherapeutic burn
c.
Thermal burn
d.
Ultraviolet exposure/pterygium
e.
Asymmetric contact lens keratopathy
f.
Postcryodestructive therapy or lesional excision with stem cell depletion
Contraindications
1.
Pemphigoid (frequently bilateral, asymmetric)
2.
Bilateral surface burns (risks both eyes)
3.
Borderline stem cell supply or early deficiency in donor eye
Describe the pre procedure evaluation

A.
Determine laterality and degree of stem cell deficiency
B.
Decide if donor needs to cover single or multiple recipient sites

1.
Large areas may require a donor to be split to supply four quadrants
2.
Proportionately less sites for smaller areas of deficiency
List the alternatives to the procedure

A.
Aggressive supportive care

1.
Tear replacement
2.
Withdrawal of preservatives
3.
Topical nonpreserved corticosteroids
4.
Amniotic membrane transplant
5.
Tarsorrhaphy
6.
7.
Topical retinoic acid
431
AAO 2014-2016
B.
IV.
V.
1.
Last resort due to need for lifelong systemic/topical immunosuppression
2.
Generally only to save a monocular individual

A.
Prepare the recipient bed by dissecting the conjunctiva, use minimal cautery (allows better
vascularization, reduces inflammation)
B.
Measure/mark/dissect a trapezoid of conjunctival tissue with a short side of the trapezoid at the
limbus
C.
Make a scratch incision just anterior to the vascular arcade/palisades of Vogt
D.
Carry a lamellar dissection from the underside of the conjunctiva to the limbus
E.
Divide the graft if necessary
F.
Use tissue adhesive or suture to fixate the donor graft(s)
G.
Consider the use of amniotic membrane as a substrate for the graft or as a bandage covering to
promote healing, or both
List the complications of the procedure, their prevention, and management

A.
B.
VI.
Conjunctival allograft
Graft loss
1.
Due to poor fixation
2.
Suture more securely, assure glue adherence, have patient wear shield continuously to avoid
rubbing graft off
3.
Re-graft if necessary
Recurrence of pathology (e.g., pterygium)

1.
Decide if size of graft inadequate or pathology too aggressive for autograft
2.
Consider regrafting
3.
Consider regrafting with chemoadjunctive therapy (mitomycin), amniotic membrane and/or more
aggressive postoperative corticosteroid therapy in cases of recurrent pterygium (not limbal stem
cell dysfunction).
Describe follow up care

A.
Observe for recurrence of pathology
1.
2.
Kim JY, Djalilian AR, Schwartz GS, Holland EJ. Ocular surface reconstruction: limbal stem cell
432
AAO 2014-2016
transplantation. Ophthalmol Clin North Am 2003;16(1):67-77.
433
AAO 2014-2016
Keratolimbal allograft (KLAL) - cadaveric

donor, living-related conjunctival limbal
allograft (lr-CLAL) - living related donor
I.
List the indications and contraindications

A.
B.
Indications
1.
Bilateral total corneal limbal stem cell deficiency
2.
Unilateral total corneal limbal stem cell deficiency and partial corneal stem cell deficiency in the
fellow eye
3.
Unilateral total corneal stem cell deficiency and normal fellow eye where the patient does not want
any surgical procedure on the good eye
Contraindications
1.
2.
II.
Ocular contraindications
a.
Total corneal and conjunctival cell failure with complete keratinization of the ocular surface
b.
Poor visual potential secondary to posterior segment pathology such as total chronic retinal
detachment, etc.
c.
Uncontrolled or poorly controlled glaucoma
d.
Severe tear film insufficiency
Non-ocular contraindications
a.
Any systemic disease precluding systemic immunosuppression such as liver, and renal
disease.
b.
Other chronic poorly controlled systemic disease which can be worsened by postoperative
systemic immunosuppression such as poorly controlled diabetes mellitus
c.
Lack of ability for regular follow-up for management of immunosuppressive therapy

A.
B.
Thorough and detailed history to establish the etiology of the disease such as
1.
External etiology (e.g., chemical and thermal burns)
2.
Intrinsic etiologies (e.g. ocular mucous membrane pemphigoid, Stevens Johnson syndrome,
aniridia)
Complete ocular examination with emphasis on

1.
Anterior segment examination
2.
Measurement of tear production
434
AAO 2014-2016
C.
III.
Intraocular pressure measurement
4.
Examination of the posterior segment when possible by ophthalmoscopy and, if not possible, by
performing ultrasound
Establish the diagnosis of stem cell deficiency

1.
Dull and irregular reflex of the corneal epithelium which varies in thickness and transparency
2.
Ingrowth of thickened fibrovascular pannus
3.
Chronic keratitis
4.
Scarring and calcification
5.
Stippled late staining pattern with fluorescein
6.
Impression cytology which can detect goblet cells containing conjunctival epithelium on the
corneal surface
D.
Determination of patient's expectations and ability for chronic follow-up
E.
Determination of any living relatives who may be willing to donate tissue
F.
Consultation with rheumatologist, hematologist/oncologist or transplant service for preoperative

evaluation of general health as well the management of postoperative immunosuppression

A.
Keratoprosthesis
B.
Use of ex-vivo expanded corneal stem cells
C.
IV.
3.
1.
Ex vivo cultivated limbal autograft (EVLAU) if stem cells are from recipient eye
2.
Ex vivo cultivated cadaveric limbal allograft (EVc-LAL) if stem cells are from cadaver
3.
Ex vivo cultivated living-related limbal allograft (EVlr-LAL) if source of donor cells is living relative
4.
Ex vivo cultivated living nonrelated limbal allograft (EVlnr-LAL) if donor is living nonrelative
Use of patient's own buccal mucosa as a source of stem cells (experimental): Ex vivo cultivated
oral mucosa autograft (EVOMAU)

A.
Instrumentation
1.
B.
Anesthesia
1.
C.
Instrumentation includes standard instruments normally used for corneal transplantation including
trephines, fine needle holders, etc.
General or retrobulbar
Technique
1.
Variable techniques depending on whether a cadaver eye is used or cells from a living related
donor tissue is utilized
435
AAO 2014-2016
a.
Living related donor

i.
If living relatives are potential donors, an HLA-matched tissue is preferred if possible
ii.
Donor
iii.
b.
V.
i)
Harvest two conjunctival corneal scleral specimens of approximately two clock

hours each, in circumferential length, from the superior and inferior limbal
zones of the donor eye
ii)
Each graft extending approximately 2 mm into bulbar conjunctiva, 1 mm into

limbus, and 2 mm into peripheral clear cornea
Recipient
i)
Strip off abnormal corneal epithelium and superficial vascularized scar by blunt
dissection
ii)
Incise conjunctiva to expose limbus and perilimbal sclera where donor tissue
will be grafted
iii)
Prepare bed to receive donor tissue
iv)
Suture donor tissue to recipient site with interrupted 10-0 nylon sutures at
corneal and scleral margin
Stem cell transplant from cadaveric tissue

i.
Fresh eyes preferred because success depends on the transplantation of healthy

limbal stem cells
ii.
Tissue is harvested from whole globe or donor corneoscleral rim
iii.
Recipient bed is prepared as described above 360 degrees
iv.
360 cadaveric donor cornea-limbal ring graft trephined from a corneoscleral button
v.
Secure harvested ring to surrounding conjunctival edge with 9-0 or 10-0 interrupted
absorbable sutures and to the denuded corneal surface with a running 10-0 nylon
suture

A.
Intraoperative
1.
B.
Perforation of globe with potential for

a.
Endophthalmitis
b.
Suprachoroidal hemorrhage
c.
Damage to intraocular structures
Postoperative
1.
Possible complications to the living related donor

a.
Relative stem cell deficiency

436
AAO 2014-2016
b.
2.
Infection
Complications related to the recipient

a.
b.
Ocular complications
i.
Areas of epithelial loss at donor site
ii.
Conjunctival epithelial growth over the graft and onto the corneal surface
iii.
Delayed epithelial healing
iv.
Immunological destruction of the transplanted limbal stem cells
Systemic complications
i.
C.
Prevention of complications
1.
2.
D.
VI.
Complications related to systemic immunosuppression such as susceptibility to

infections, renal, and hepatic toxicity
Living related donor

a.
Careful examination of the donor for any signs of ocular disease and any signs of stem cell
disease
b.
Harvesting the minimal amount of tissue possible; no more than 4 clock hours of tissue
Recipient related complications

a.
Careful surgical technique
b.
Careful patient selection (e.g., prognosis better for aniridia than for bilateral severe chemical
burns)
c.
Management of inflammation and immunological response with immune modulating agents
Management of complications
1.
Management of ocular surface complications includes aggressive lubrication with preservative free
artificial tears, possible autologous serum, application of amniotic membrane, and aggressive
topical and systemic immunosuppression
2.
Management of systemic complications related to systemic immunosuppression should be

handled by the appropriate specialist and not the ophthalmologist

A.
Topical antibiotics until corneal epithelial defect completely healed
B.
C.
Preservative free artificial tears
D.
Consider autologous serum in selected patients
E.
Effective systemic immunosuppression is considered essential for at least 12 months after

surgery when non HLA matched limbal allografts are used
1.
In some instances, permanent systemic immunosuppression may be needed
437
AAO 2014-2016
VII. Describe appropriate patient instructions (post-operative care)

A.
Management of patient expectations
B.
Chronic nature of the disease with limited success rate of allografts
C.
Importance of follow-up with both ophthalmologist and physician monitoring systemic

immunosuppression needs to be emphasized
1.
2.
Dua HS, Saini JS, Azuara-Blanco A, Gupta P. Limbal stem cell deficiency: concept, etiology,
clinical presentation, diagnosis and management. Indian J Ophthalmol 2000 Jun;48(2):83-92.
Review.
3.
Holland EJ, Djalilian AR, Schwartz GS. Management of aniridic keratopathy with keratolimbal
allograft: a limbal stem cell transplantation technique. Ophthalmology 2003 Jan;110(1):125-30.
4.
Schwab IR. Cultured corneal epithelia for ocular surface disease. Trans Am Ophthalmol Soc
1999;97:891-986.
5.
Holland EJ. Epithelial transplantation for the management of severe ocular surface disease. Trans
Am Ophthalmol Soc 1996;94:677-743.
6.
Solomon A, Ellies P, Anderson DF, et al. Long-term outcome of keratolimbal allograft with or
without penetrating keratoplasty for total limbal stem cell deficiency. Ophthalmology 2002
Jun;109(6):1159-66.
438
AAO 2014-2016
Keratoprosthesis
I.
Indications and contraindications

A.
Indications
1.
Boston keratoprosthesis type I(must have adequate eyelid and tear function)
a.
Repeated allograft rejection
b.
Corneal opacity with significant corneal vascularization after
c.
d.
2.
3.
B.
i.
ii.
Varicella zoster virus reactivation (shingles)
iii.
Microbial keratitis
iv.
Trauma
Limbal stem cell failure

i.
Multiple ophthalmic surgeries
ii.
Aniridia
iii.
Moderate chemical injury
iv.
Others
Congenital corneal opacity
Boston keratoprosthesis type II

a.
Stevens Johnson syndrome
b.
c.
Severe autoimmune dry eye
d.
Severe chemical injury
Osteo-odonto-keratoprosthesis (OOKP)
a.
Stevens Johnson syndrome
b.
c.
Severe autoimmune dry eye
d.
Severe chemical injury
Contraindications
1.
Boston keratoprosthesis type I

a.
b.
Severe ocular inflammation
439
AAO 2014-2016
c.
2.
3.
II.
Severe dry eye syndrome (associated with keratinization of the ocular surface)

a.
Low likelihood of compliance with medications and follow-up care
b.
Any condition that can be safely treated with Boston keratoprosthesis type I
c.
d.
Sighted contralateral eye
e.
Phthisis
a.
Children
b.
Low likelihood of compliance with medications and follow-up care
c.
Any condition that can be safely treated with Boston keratoprosthesis type I
d.
e.
Sighted contralateral eye
f.
Phthisis

A.
B.
Visual potential
1.
Acuity
2.
Visual field
3.
Color perception
4.
Light projection
Pupil responses
1.
C.
Afferent papillary defect
Eyelids
1.
Closure
2.
Blepharitis
D.
Intraocular pressure
E.
Slit lamp examination

1.
Cornea
2.
Conjunctival fornices
3.
Lens status (phakic, pseudophakic, aphakic)
F.
Schirmer test
G.
Fundus
440
AAO 2014-2016
III.
IV.
1.
Macula
2.
Optic nerve
3.
B scan if necessary
H.
Axial length (Boston keratoprosthesis, if aphakic, and all patients with OOKP)
I.
Psychological assessment (Boston keratoprosthesis type II and OOKP)

A.
B.
Limbal stem cell transplant

A.
Instrumentation
1.
2.
3.
B.

a.
Request either pseudophakic or aphakic version (need axial length for latter)
b.
Standard instrumentation for corneal transplantation and lateral tarsorrhaphy

a.
Boston keratoprosthesis type II device (pseudophakic or aphakic)
b.
Standard instrumentation for corneal transplantation and lateral tarsorrhaphy
a.
OOKP optical cylinder
b.
Instrumentation for dental procedure
c.
Instrumentation for oral mucous membrane graft
d.
Instrumentation for automated vitrectomy
Anesthesia
1.

a.
2.

a.
3.
General
a.
C.
Local or general
General
Technique
1.
441
AAO 2014-2016
a.
2.
3.
Prosthesis is constructed around a corneal donor or the patient's own cornea

i.
3 mm trephination of center of donor cornea
ii.
8.5 mm (or greater) trephination of corneal donor to accommodate 8.5 mm back plate
(regular size), or 7.0 mm (or greater) trephination of corneal donor to accommodate
7.0 mm back plate (pediatric size)
iii.
Insertion of optic stem with attached front plate through hole in cornea
iv.
Snap in back plate secured
v.
Titanium locking ring secured
b.
Trephination and removal of host cornea at 0.5 mm smaller than donor cornea (8 mm if
donor cornea is 8.5mm)
c.
Extracapsular lens extraction if phakic
d.
Corneal donor / prosthesis construct sutured to the eye as with any corneal transplant
e.
Bandage contact lens placed at conclusion of surgery

a.
Construction around donor cornea and implantation same as with type I
b.
Division of any symblepharon
c.
Removal of all conjunctiva and limbus
d.
Excision of eyelid margins
e.
Construction of lateral and medial tarsorraphies to completely close lids around the stem of
the device
f.
No contact lens
a.
b.
Stage 1
i.
Removal of tooth and anchoring bone in conjunction with oral surgeon
ii.
Placement of keratoprosthesis optic through drilled hole in tooth
iii.
Implantation of OOKP in tooth in submuscular layer of lower eyelid
iv.
Oral mucous membrane graft to ocular surface
Stage 2 (2-4 months later)

i.
Removal of OOKP from implantation site
ii.
Lifting of mucous membrane ocular surface graft as a flap
iii.
5.5 mm Trephination of cornea to accommodate the posterior aspect of OOKP optic
iv.
Total iridodialysis, lensectomy subtotal vitrectomy
v.
Placement of keratoprosthesis optic through the cornea with tooth and lamina sutured
to surface of the eye
442
AAO 2014-2016
V.
vi.
Replacement of mucous membrane graft over the device
vii.
Opening of central hole in mucous membrane graft to accommodate OOKP optic

A.
Intraoperative
1.
2.
3.
B.

a.
Same as with corneal transplant
b.
Inability to construct the device around the corneal donor

a.
b.
Inability to construct the device around the corneal donor
a.
Jaw injury, oral infection
b.
Postoperative
1.
2.
3.

a.
Glaucoma
b.
Microbial infection
i.
Keratitis
ii.
Endophthalmitis
c.
Difficulty with contact lens retention
d.
Sterile vitritis
e.
Retroprosthetic membrane

a.
Same as type I (except no contact lens related complications)
b.
Corneal melt and extrusion of device
c.
Retinal detachment
a.
Glaucoma
b.
Extrusion of device
c.
Endophthalmitis
d.
Retinal detachment
443
AAO 2014-2016
e.
C.
Prevention of complications
1.
2.
3.
D.

a.
Close observation of all patients
b.
Annual visual field examination
c.
Timely replacement of contact lens
d.
Topical antibiotics
i.
Fluoroquinolone
ii.
Vancomycin

a.
Same as for type I
b.
Oral carbonic anhydrase inhibitor if history of glaucoma
a.
Close observation of all patients
b.
Antibiotic ointment
c.
Oral carbonic anhydrase inhibitor if history of glaucoma
d.
Chlorhexidine mouth wash
Management of complications
1.
Extrusion: revision or replacement of device
2.
Glaucoma
3.
4.
a.
Topical aqueous suppressants and outflow facilitators
b.
Drainage tube device (may be considered before keratoprosthesis or concurrent to

keratoprosthesis implantation in patients with pre-existing glaucoma)
c.
Cyclophotocoagulation
d.
Cyclodialysis
Microbial infection
a.
Topical antibiotics or antifungals
b.
Subconjunctival antibiotics or antifungals
c.
Systemic antibiotics or antifungals
d.
Replacement if recalcitrant to medical therapy
e.
Pars plana vitreous aspiration for smear, culture, and sensitivities followed by injection of
intraocular antibiotics if endophthalmitis suspected
Sterile vitritis
444
AAO 2014-2016
5.
6.
VI.
a.
Assume infectious if any external or orbital signs of infection
b.
Sub-tenons triamcinolone
a.
Yag laser capsulotomy
b.
Surgical excision if too thick for laser capsulotomy or if vascularized
Retinal detachment treated with pars plana vitrectomy

A.
B.
C.

1.
Topical prednisolone acetate 1% tapered from 4 times a day to once a day over 4-6 weeks after
surgery
2.
Topical fluoroquinolone tapered from 4 times a day to once a day over 4-6 weeks after surgery,
(can be replaced by other broad-spectrum topical antibiotic such as polymyxin B/trimethoprim)
3.
Topical vancomycin 14 mg/ml with benzalkonium chloride preservative once a day in selected
patients (autoimmune, monocular, chemical burns)
4.
Topical glaucoma medications as necessary

1.
same as for type I
2.
oral carbonic anhydrase inhibitor if needed
1.
Requires hospital admission and multiple medications
VII. Describe appropriate patient instructions (post-operative care)

A.

1.
B.
Call and be seen immediately for

a.
Change in vision
b.
Redness
c.
Discharge
d.
Pain
e.
Lost contact lens

1.

a.
Change in vision
445
AAO 2014-2016
C.
b.
Redness or swelling of eyelids
c.
Discharge
d.
Clear fluid from eye
e.
Pain
1.

a.
Change in vision
b.
Discharge
c.
Pain
1.
2.
Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston Type I keratoprosthesis Improving Outcomes and
Expanding Indications. Ophthalmology. 2009;116:640-651.
3.
Khan BF, Harissi-Dagher M, Khan DM, Dohlman CH. Advances in Boston keratoprosthesis:
enhancing retention and prevention of infection and inflammation. Int Ophthalmol Clin. 2007
Spring;47:61-71.
4.
Liu C, Hille K, Tan D, Hicks C, Herold J. keratoprosthesis surgery. Dev Ophthalmol.

2008;41:171-86.
5.
Liu C, Okera S, Tandon R, Herold J, Hull C, Thorp S. Visual rehabilitation in end-stage

inflammatory ocular surface disease with the osteo-odonto-keratoprosthesis: results from the UK.
Br J Ophthalmol. 2008;92:1211-7.
6.
Liu C, Paul B, Tandon R, Lee E, Fong K, Mavrikakis I, Herold J, Thorp S, Brittain P, Francis I,
Ferrett C, Hull C, Lloyd A, Green D, Franklin V, Tighe B, Fukuda M, Hamada S. The osteo-odontokeratoprosthesis (OOKP). Semin Ophthalmol. 2005;20:113-28.
7.
Sayegh RR, Ang LP, Foster CS, Dohlman CH. The Boston keratoprosthesis in Stevens-Johnson
syndrome. Am J Ophthalmol. 2008;145:438-44.
8.
Zerbe BL, Belin MW, Ciolino JB; Boston Type 1 keratoprosthesis Study Group. Results from the
multicenter Boston Type 1 keratoprosthesis Study. Ophthalmology. 2006;113:1779-1784.
446
AAO 2014-2016
Clinical trials in cornea external disease

I.
Multi-centered randomized controlled trials

A.
Herpetic Eye Disease Study I (HEDS-I)

1.
Purpose
a.
2.
To assess the efficacy of topical corticosteroids and oral Acyclovir in treating HSV stromal
keratitis and iridocyclitis
Trials: Three randomized, placebo-controlled studies

a.
b.
c.
d.
Herpes Stromal Keratitis, Not on Steroid Trial (HEDS-SKN):

i.
Treatment Group: 106 patients treated with topical steroids and topical trifluridine
were followed for 26 weeks
ii.
Control Group: Topical trifluridine only
iii.
Results: Treatment group had faster resolution of the stromal keratitis and fewer
treatment failures. However, delaying the initiation of corticosteroid treatment did not
affect the eventual outcome of the disease, in that visual acuity was similar in the two
groups at 26 weeks
Herpes Stromal Keratitis, on Steroid Treatment (HEDS-SKS):

i.
Treatment Group: 104 patients were treated with topical steroids, topical trifluridine
and oral Acyclovir
ii.
Control Group: Topical trifluridine and topical steroids only
iii.
Results: There was no difference in the rate of treatment failure between the two
groups so no apparent benefit from adding acyclovir. However, visual acuity improved
in more patients in the treatment group at 6 months but was not statistically
significant
Herpes Simplex Virus Iridocyclitis, Receiving Topical Steroids (HEDS-IRT):

i.
Treatment Group: Only 50 of the planned 104 patients could be recruited over 4
years and were treated with topical steroids, topical trifluridine and oral Acyclovir
ii.
Control Group: Topical trifluridine and topical steroids only
iii.
Results: Recruitment was too low to achieve statistical significance but there was a
trend towards lower treatment failures in Acyclovir group
Meta-analysis of the three trials to determine the risk of epithelial disease in patients with
stromal keratitis
i.
Groups compared
i)
Trifluridine alone
ii)
Trifluridine and steroids
447
AAO 2014-2016
iii)
ii.
B.
Results:
i)
No difference in risk of epithelial disease between groups
ii)
Previous epithelial disease or non-whites were at increased risk
Herpetic Eye Disease Study II (HEDS-II)

1.
2.
Purpose
a.
To assess the role of oral Acyclovir in the management of HSV keratitis
b.
To investigate risk factors, including stress, for the development of ocular recurrences of the
disease
Trials: Two randomized, placebo-controlled trials and one epidemiologic study

a.
b.
c.
C.
Trifluridine, steroids and acyclovir
Herpes Simplex Virus Epithelial Keratitis Trial (HEDS-EKT):

i.
Recruitment ended November 1995
ii.
Treatment Group: 287 patients were treated with topical trifluridine and oral Acyclovir
iii.
Control Group: Topical trifluridine only
iv.
Results: in the treatment of acute HSV epithelial keratitis, there was no benefit from
the addition of oral acyclovir to treatment with topical trifluridine in preventing the
development of stromal keratitis or iritis. Incidentally, the risk was lower than
published literature
Acyclovir Prevention Trial (HEDS-APT):

i.
Recruitment began September 1992 and was completed December 1996
ii.
Treatment Group: 357 patients were treated with oral Acyclovir at 400 mg twice a day
for one year and followed for an additional six months
iii.
Control Group: 346 patients were treated with a placebo
iv.
Results: Oral acyclovir reduced the recurrence rate of HSV epithelial keratitis by 41
percent and a reduction in the recurrence rate of stromal keratitis by 50 percent in
patients who had an infection with epithelial or stromal keratitis, respectively, in the
previous year. However, the effect did not persist after discontinuing the Acyclovir
Ocular HSV Recurrence Factor Study (HEDS-RFS):

i.
Cohort: 308 immunocompetent adults, aged 18 years or older, with a documented

history of ocular HSV disease in the prior year and observed for up to 15 months.
ii.
Exposure variables: Psychological stress, systemic infection, sunlight exposure,

menstrual period, contact lens wear, and eye injury were recorded on a weekly log.
iii.
Results: No association was found between any of the exposure variables and
recurrence
Cornea Donor Study (CDS)

1.
Purpose
448
AAO 2014-2016
2.
a.
To determine whether the graft-failure rate over a 5-year follow-up period following corneal
transplantation is the same when using corneal tissue from donors older than 65 years of
age compared with tissue from younger donors.
b.
To assess the relationship between donor/recipient ABO blood type compatibility and graft
failure due to rejection.
c.
To assess corneal endothelial cell density as an indicator of the health of the cornea and as
a surrogate outcome measure
Design
a.
3.
4.
D.
Multi-center prospective, double-masked, controlled clinical trial
Participants
a.
Recruitment began in January 2000 and was completed August 2002
b.
1090 subjects undergoing corneal transplantation for moderate risk conditions (principally
Fuchs dystrophy or pseudophakic corneal edema) were enrolled by 105 surgeons at 80
sites
c.
Donors were in the age range of 12 to 75 year old with endothelial cell densities of 2300 to
3300 cells/mm2
Results
a.
Five-year survival was similar using corneas from donors > 66 years or < 66 years and
there was no difference in the causes of graft failure
b.
The five-year incidence for a rejection episode, irrespective of whether graft failure
ultimately occurred, was 12% for ABO compatible compared with 8% for ABO incompatible
cases and the percent loss of endothelial cells was similar in the two groups
c.
There was a substantial loss of endothelial cells 5 years after corneal transplantation in all
participants. The median cell loss in corneas from donors < 66 years was 69% compared to
75% in corneas from donors > 66 years. Additionally, there was a weak negative correlation
between donor age and endothelial cell density at 5 years
Collaborative Corneal Transplantation Studies (CCTS)

1.
Purpose
a.
2.
To determine whether histocompatibility matching of corneal transplant donors and

recipients can reduce the incidence of graft rejection in high-risk patients
Design
a.
Two controlled, double-masked studies

i.
The Antigen Matching Study (AMS) was a prospective, double-masked, observational

study of the effectiveness of HLA-A, -B, and -DR donor-recipient matching in high-risk
corneal transplants
ii.
The Crossmatch Study (CMS) was a randomized study assessing the effectiveness
of crossmatching in preventing graft rejection among high-risk patients with
lymphocytotoxic antibodies
449
AAO 2014-2016
3.
4.
E.
Participants
a.
Recruitment began in May 1986 and was completed September 1989
b.
AMS: 419 patients with no lymphocytotoxic antibodies were allocated corneas with varying
degrees of HLA matching and followed for 3 years. ABO blood group compatibility was
determined but not used for recipient selection
c.
CMS: 37 patients with lymphotoxic antibodies were randomly assigned to receive a cornea
from either a positively or negatively crossmatched donor and followed for 3 years
Results
a.
Matching for HLA-A, -B and -DR antigens had no effect on overall graft survival, the
incidence of irreversible rejection, or the incidence of rejection episodes
b.
The positively crossmatched group in the CMS had fewer graft failures, rejection failures,
and rejection episodes than the negatively crossmatched group; however, these differences
were not statistically significant
c.
Patients with ABO compatibility had lower rates of graft failure and rejection than those with
ABO incompatibility
d.
Incidentally noted that the rate of rejection was lower than reported and concluded that it
likely was related to aggressive steroid use in the postoperative period, good patient
compliance with medication, and close patient follow-up
Mycotic Ulcer Treatment Trial I (MUTT I)

1.
Purpose
a.
2.
Design
a.
3.
4.
F.
To compare topical natamycin vs topical voriconazole in the treatment of fungal keratitis
Randomized, active comparator-controlled, double-masked, multicenter clinical trial
Participants
a.
Recruitment began April 2010 and was completed December 2011
b.
323 patients with a smear and/or culture positive fungal corneal ulcers with visual acuity
between 20/40 and 20/400 were randomized to receive either topical 5% Natamycin or 1%
Voriconazole and followed for 3 months
Results
a.
Natamycin treated cases had significantly better 3-month best spectacle-corrected visual
acuity than voriconazole-treated cases
b.
Natamycin-treated cases were significantly less likely to have perforation or require

therapeutic penetrating keratoplasty compared to voriconazole-treated cases
c.
The difference between the treatment groups was secondary to improved outcomes in
Fusarium keratitis; other fungal organisms had comparable outcomes with the two
medications
Steroids for Corneal Ulcers Trial (SCUT)
450
AAO 2014-2016
1.
2.
Purpose
a.
To determine whether there is a benefit in clinical outcomes with the use of topical
corticosteroids as adjunctive therapy in the treatment of bacterial corneal ulcers.
b.
Primary outcome was best corrected visual acuity at 3 months from enrollment
c.
Secondary outcomes include BSCVA at 3 weeks from enrollment; infiltrate/scar size at 3

weeks and 3 months, and rate of adverse events, including corneal perforation and time to
re-epithelialization
Design
a.
3.
Randomized, placebo-controlled, double-masked, multicenter clinical trial
Participants
a.
Recruitment began in September 2006 and was completed February 2010
b.
500 patients with a culture-positive bacterial corneal ulcer who received topical moxifloxacin
for at least 48 hours were randomized to receive either prednisolone sodium phosphate
1.0% or placebo and followed for 3 months
c.
Results
d.
There was no difference overall in the visual acuity at 3 months (primary outcome variable),
scar size, time to re-epithelialization, or rate of perforation
e.
In patients with presenting vision of Count Fingers or worse, or with central ulcers at
baseline, the steroid group had significantly greater improvement in vision at 3 months
compared to the control group
f.
Subgroup analysis of pseudomonas ulcers showed that there was no difference between
the response of these ulcers to steroids compared to other bacterial ulcers
1.
Herpetic Eye Disease Study Group: A controlled trial of oral acyclovir for iridocyclitis caused by
herpes simplex virus. Arch Ophthalmol 114: 1065-1072, 1996.
2.
Wilhelmus KR, Dawson CR, Barron BA, Bacchetti P, Gee L, Jones DB, Kaufman HE, Sugar J,
Hyndiuk RA, Laibson PR, Stulting RD, Asbell PA: Risk factors for herpes simplex virus epithelial
keratitis recurring during treatment of stromal keratitis or iridocyclitis. Br J Ophthalmol 80: 969-972,
1996.
3.
Barron BA, Gee L, Hauck WW, Herpetic Eye Disease Study: A controlled trial of oral acyclovir for
herpes simplex stromal keratitis. Ophthalmology 101: 1871-1882, 1994.
4.
Wilhelmus KR, Gee L, Hauck WW, Herpetic Eye Disease Study: A controlled trial of topical
corticosteroids for herpes simplex stromal keratitis. Ophthalmology 101: 1883-1896, 1994.
5.
Dawson CR, Jones DB, Kaufman HE, Barron BA, Hauck WW, Wilhelmus KR: Design and
organization of the Herpetic Eye Disease Study Group (HEDS). Curr Eye Res 10: 105-110, 1991.
6.
The Herpetic Eye Disease Study Group: Acyclovir for the prevention of recurrent herpes simplex
virus eye disease. N Engl J Med 339: 300-306, 1998.
451
AAO 2014-2016
7.
Herpetic Eye Disease Study Group: A controlled trial of oral acyclovir for the prevention of stromal
keratitis or iritis in patients with herpes simplex virus epithelial keratitis. Arch Ophthalmol 115:
703-712, 1997.
8.
Herpetic Eye Disease Study Group. Psychological stress and other potential triggers for
recurrences of herpes simplex virus eye infections. Arch Ophthalmol. 2000 Dec;118(12):1617-25.
9.
Cornea Donor Study Investigator Group. The effect of donor age on corneal transplantation
outcome results of the cornea donor study. Ophthalmology. 2008 Apr;115(4):620-626.
10.
Cornea Donor Study Investigator Group. The effect of ABO blood incompatibility on corneal
transplant failure in conditions with low-risk of graft rejection. Am J Ophthalmol. 2009
Mar;147(3):432-438.
11.
The Collaborative Corneal Transplantation Studies Research Group. The collaborative corneal
transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal
transplantation. Arch Ophthalmol. 1992 Oct;110(10):1392-403.
12.
The Mycotic Ulcer Treatment Trial Group. The Mycotic Ulcer Treatment Trial: A Randomized Trial
Comparing Natamycin vs Voriconazole. Arch Ophthalmol. 2012 Dec 10:1-8.
13.
Steroids for Corneal Ulcers Trial Group. Corticosteroids for bacterial keratitis: the Steroids for
Corneal Ulcers Trial (SCUT). Arch Ophthalmol. 2012 Feb;130(2):143-50.
14.
Sy A, Srinivasan M, Mascarenhas J, Lalitha P, Rajaraman R, Ravindran M, Oldenburg CE, Ray

KJ, Glidden D, Zegans ME, McLeod SD, Lietman TM, Acharya NR. Pseudomonas aeruginosa
keratitis: outcomes and response to corticosteroid treatment. Invest Ophthalmol Vis Sci. 2012 Jan
25;53(1):267-72.
452
AAO 2014-2016

Cornea

Uploaded by

Copyright:

Available Formats

Cornea

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Cornea

Uploaded by

Copyright:

Available Formats

PRACTICING OPHTHALMOLOGISTS

Practicing Ophthalmologists Curriculum

Practicing Ophthalmologists Curriculum

Background on Maintenance of Certification (MOC)

Neuro-Ophthalmology and Orbit

Oculoplastics and Orbit

The FDA issues a drug/device warning

Industry issues a warning

Ocular Surface Disorders

19. Meibomian gland dysfunction, rosacea, and seborrheic blepharitis........................................... 62

43. Adult chlamydial keratoconjunctivitis.......................................................................................... 161

66. Primary acquired melanosis of the conjunctiva........................................................................... 250

Toxic and Traumatic Injuries

87. Subconjunctival hemorrhage ....................................................................................................... 320

Procedures for the Cornea and Ocular Surface

111. Penetrating keratoplasty ........................................................................................................... 406

Anatomy and embryology of the cornea

Describe relevant aspects of corneal embryology

Week 5 of gestation: surface ectoderm forms corneal and conjunctival epithelium

At birth, infant's globe is 80% of adult size

Describe relevant aspects of corneal anatomy

11-12mm horizontally, 10-11mm vertically

Stratified squamous epithelial cells optically smooth

Basement membrane is secreted by basal epithelial cells

Water content 78%

Basement membrane of the corneal endothelium

Increases in thickness from 3 microns at birth to 10-12 microns in adults

Closely interdigitated cells arranged in a mosaic pattern of mostly hexagonal shapes

Cell density is typically 2400-3200 cells/mm2 in adults

Human endothelial cells do not proliferate in vivo

Slit-lamp biomicroscopy: performance and

Describe the instrumentation and technique

Viewing arm (corneal microscope)

Magnification depends on eyepieces and objective lens changer settings

Magnification numbers on knob apply to one set of oculars

For higher power oculars, magnification increases by proportionate amount

Adjust dioptric power to compensate for observer's refractive error and/or

Eyepiece settings and calibration can be confirmed using focusing rod

Arresting lock or lever for stabilization

Patient positioning frame

Diffuse and direct illumination

Gives overview of eyelids, ocular surface, and anterior segment of eye

Use full height and broad width

Light diffuser may be used for photography

Direct focal illumination and slit illumination

Allows detection and localization of structures, including differences in refractive

Use medium to narrow beam width to illuminate a parallelepiped of transparent tissue

Shine light across anatomical surface, such as cornea or iris

Observe shadowing effects

Indirect illumination, retroillumination, and sclerotic scatter

Indirect, proximal illumination and lateral illumination

Useful to highlight abnormalities that have a refractive index similar to their

Abnormalities visualized by light scattered from its irregular surface or glowing by

Three-dimensionality may be enhanced by oscillatory movements of light beam

Used to examine illuminated abnormalities against a darkened background

Used to examine darkened abnormalities against an illuminated background

Used to examine darkened (e.g., posterior subcapsular cataract), illuminated

Detect scattering of light while shining light onto limbus

Estimate endothelial cell density, evaluate endothelial cell pleomorphism and